CCB-CRISIS-02 
STUDY PROTOCOL  
The CRISIS2 Study: A phase 2, randomized, double blind, placebo -controlled, multi -center 
study assessing the safety and anti-coronavirus r esponse of suppression of host nucleot ide 
synthe sis in out -patient adults with SARS- CoV-[ADDRESS_883563] 04575038 
Original Protoc
ol Date: 08/20/20 V1  
Amendment 01 Date: 09/15/2020 V2 
Amendment 02 Date: 09/23/2020 V3 
Amendment 03 Date: 10/01 /2020 V4 
Amendment 04 Date: 11/19/2020 V5 
Table of Contents
STUDY PROTOCOL COVER PAGE .........................................................................................
TABLE OF CONTENTS..............................................................................................................
CCB-CRISIS-02 Protocol v1.0 20AUG020 .................................................................................
2 SYNOPSIS.....................................................................................................................
3 INTRODUCTION..........................................................................................................
3.1 Coronavirus-19 (COVID-19) ........................................................................
3.1.[ADDRESS_883564] Nucleotide Synthesis .............................................................................
3.3  Dihydroorotate dehydrogenase (DHODH) ..................................................
3.4  Brequinar........................................................................................................
3.5  Rationale for the Planned Trial ......................................................................
3.5.1 Brequinar Dose Selection.................................................................
3.5.2    Risk/Benefit of Brequinar .............................................................
3.6  Risks Associated with Participation in the Clinical Study.............................
3.7  Possible Interactions with Concomitant Medical Treatments........................
3.7.1 CYP Interactions ..............................................................................
3.8 Steps to be Taken to Control or Mitigate Risks ..............................................
4 TRIAL OBJECTIVES....................................................................................................
4.1 Primary Objective ...........................................................................................
4.2 Secondary Objectives......................................................................................
4.3 EXPLORATORY OBJECTIVES...................................................................
5 TRIAL DESIGN ............................................................................................................
6 TRIAL ENDPOINTS.....................................................................................................
6.1 Primary Endpoint ............................................................................................
6.2 Secondary Endpoints.......................................................................................
6.3 Exploratory Endpoints.....................................................................................
7 TRIAL POPULATION..................................................................................................
7.1 Number of Subjects.........................................................................................
7.2 Inclusion criteria..............................................................................................
7.3 Exclusion Criteria............................................................................................
8 STUDY TREATMENTS ...............................................................................................
8.1 Description of Study Medications...................................................................
8.1.1 Brequinar..........................................................................................
8.2 Treatment Administration ...............................................................................
8.2.1 Safety/Tolerability............................................................................01
02
16
24
31
31
31
31
31
32
32
33
33
34
34
34
34
35
35
35
35
36
37
37
37
37
38
38
38
38
40
40
40
40
40
8.3 Study Discontinuation.....................................................................................
8.4 Stoppi[INVESTIGATOR_2121] .............................................................................................
8.4.1 Individual Stoppi[INVESTIGATOR_2121].............................................................
8.4.2 Study-Level Stoppi[INVESTIGATOR_2121] .........................................................
8.5 Concomitant Medication/Treatment ...............................................................
8.6 Treatment Compliance ....................................................................................
8.7 Storage, Stability, Labeling and Packaging ....................................................
8.7.1 Storage and Stability ........................................................................
8.7.2 Labeling and Packaging ...................................................................
8.7.3 Blinding and Randomization............................................................
8.7.4 Unblinding/Expectedness.................................................................
8.7.[ADDRESS_883565].................................................................................................
9.5.1 Unscheduled Visits...........................................................................
9.6 Compliance with Study Procedures ................................................................
9.7 Early Withdrawal from the Study ...................................................................
9.8 Early Termination of the Study.......................................................................
9.9 Non-Childbearing Potential.............................................................................
10 ADVERSE EVENT REPORTING..............................................................................
10.1 Follow Up of Grade 3 or 4 Toxicities ...........................................................
10.2 Infection Follow Up ......................................................................................
10.3 Classification of Causality ............................................................................
10.4 Classification of Severity ..............................................................................
10.5 Serious Adverse Event (SAE) Reporting ....................................................
10.6 Suspected Unexpected Serious Adverse Reactions (S[LOCATION_003]Rs) ..................
10.7 Pregnancies....................................................................................................
10.8 Safety Monitoring for Hematologic Toxicities .............................................
10.9 Data Monitoring Committee .........................................................................
10.9.1 DMC Safety Review Schedule.......................................................
11 STATISTICAL CONSIDERATIONS.........................................................................41
41
41
41
41
42
42
42
42
42
42
42
43
43
44
44
44
45
46
46
46
46
47
47
47
48
49
49
49
50
50
51
52
52
53
54
55
11.1 Study Populations for Analysis.....................................................................
11.2 Safety Analyses.............................................................................................
11.3 Efficacy Analyses..........................................................................................
11.4 Sample Size Considerations..........................................................................
11.5 Randomization ..............................................................................................
11.6 Pooling of Study Centers ..............................................................................
11.7 Interim Analysis ............................................................................................
12 INVESTIGATOR RESPONSIBILITIES ....................................................................
12.1 Investigator's Performance ............................................................................
12.2 Confidentiality...............................................................................................
12.3 Source Documentation ..................................................................................
12.4 Data Collection..............................................................................................
12.5 Case Report Forms, Investigator's Site File and Record Retention ..............
12.6 Non-Protocol Research .................................................................................
12.7 Publication.....................................................................................................
13 SPONSOR RESPONSIBILITIES................................................................................
13.1 General ..........................................................................................................
13.2  Indemnity .....................................................................................................
13.3  Data Monitoring ...........................................................................................
13.4  Audit.............................................................................................................
13.5  Confidentiality..............................................................................................
13.6  Finance .........................................................................................................
14 REFERENCES.............................................................................................................
15 APPENDICES..............................................................................................................
15.1 Appendix A:  CCB-CRISIS-02 Schedule of Events .....................................
15.2 Appendix B: Investigator's Statement and Agreement .................................
15.3 Appendix C: WHO Ordinal Scale.................................................................
CCB-CRISIS-02_Protocol_v2.0 15SEPT2020-V2-FINAL.pdf ...................................................
2 SYNOPSIS.....................................................................................................................
3 INTRODUCTION..........................................................................................................
3.1 Coronavirus-19 (COVID-19) ........................................................................
3.1.[ADDRESS_883566] Nucleotide Synthesis .............................................................................
3.3  Dihydroorotate dehydrogenase (DHODH) ..................................................
3.4  Brequinar........................................................................................................
3.5  Rationale for the Planned Trial ......................................................................
3.5.1 Brequinar Dose Selection.................................................................55
55
55
55
55
56
56
57
57
57
57
58
58
59
59
60
60
60
60
60
61
61
62
63
63
64
65
66
74
81
81
81
81
81
82
82
83
3.5.2    Risk/Benefit of Brequinar .............................................................
3.6  Risks Associated with Participation in the Clinical Study.............................
3.7  Possible Interactions with Concomitant Medical Treatments........................
3.7.1 CYP Interactions ..............................................................................
3.8 Steps to be Taken to Control or Mitigate Risks ..............................................
4 TRIAL OBJECTIVES....................................................................................................
4.1 Primary Objective ...........................................................................................
4.2 Secondary Objectives......................................................................................
4.3 EXPLORATORY OBJECTIVES...................................................................
5 TRIAL DESIGN ............................................................................................................
6 TRIAL ENDPOINTS.....................................................................................................
6.1 Primary Endpoint ............................................................................................
6.2 Secondary Endpoints.......................................................................................
6.3 Exploratory Endpoints.....................................................................................
7 TRIAL POPULATION..................................................................................................
7.1 Number of Subjects.........................................................................................
7.2 Inclusion criteria..............................................................................................
7.3 Exclusion Criteria............................................................................................
8 STUDY TREATMENTS ...............................................................................................
8.1 Description of Study Medications...................................................................
8.1.1 Brequinar..........................................................................................
8.2 Treatment Administration ...............................................................................
8.2.1 Safety/Tolerability............................................................................
8.3 Study Discontinuation.....................................................................................
8.4 Stoppi[INVESTIGATOR_2121] .............................................................................................
8.4.1 Individual Stoppi[INVESTIGATOR_2121].............................................................
8.4.2 Study-Level Stoppi[INVESTIGATOR_2121] .........................................................
8.5 Concomitant Medication/Treatment ...............................................................
8.6 Treatment Compliance ....................................................................................
8.7 Storage, Stability, Labeling and Packaging ....................................................
8.7.1 Storage and Stability ........................................................................
8.7.2 Labeling and Packaging ...................................................................
8.7.3 Blinding and Randomization............................................................
8.7.4 Unblinding/Expectedness.................................................................
8.7.[ADDRESS_883567].................................................................................................
9.5.1 Unscheduled Visits...........................................................................
9.6 Compliance with Study Procedures ................................................................
9.7 Early Withdrawal from the Study ...................................................................
9.8 Early Termination of the Study.......................................................................
9.9 Non-Childbearing Potential.............................................................................
10 ADVERSE EVENT REPORTING..............................................................................
10.1 Follow Up of Grade 3 or 4 Toxicities ...........................................................
10.2 Infection Follow Up ......................................................................................
10.3 Classification of Causality ............................................................................
10.4 Classification of Severity ..............................................................................
10.5 Serious Adverse Event (SAE) Reporting ....................................................
10.6 Suspected Unexpected Serious Adverse Reactions (S[LOCATION_003]Rs) ..................
10.7 Pregnancies....................................................................................................
10.8 Safety Monitoring for Hematologic Toxicities .............................................
10.9 Data Monitoring Committee .........................................................................
10.9.1 DMC Safety Review Schedule.......................................................
11 STATISTICAL CONSIDERATIONS.........................................................................
11.1 Study Populations for Analysis.....................................................................
11.2 Safety Analyses.............................................................................................
11.3 Efficacy Analyses..........................................................................................
11.4 Sample Size Considerations..........................................................................
11.5 Randomization ..............................................................................................
11.6 Pooling of Study Centers ..............................................................................
11.7 Interim Analysis ............................................................................................
12 INVESTIGATOR RESPONSIBILITIES ....................................................................
12.1 Investigator's Performance ............................................................................
12.2 Confidentiality...............................................................................................
12.3 Source Documentation ..................................................................................
12.4 Data Collection..............................................................................................
12.5 Case Report Forms, Investigator's Site File and Record Retention ..............
12.6 Non-Protocol Research .................................................................................94
94
94
95
95
96
96
97
97
97
98
99
100
100
100
101
101
102
103
103
104
105
106
106
106
106
106
106
107
107
108
108
108
108
109
109
110
12.7 Publication.....................................................................................................
13 SPONSOR RESPONSIBILITIES................................................................................
13.1 General ..........................................................................................................
13.2  Indemnity .....................................................................................................
13.3  Data Monitoring ...........................................................................................
13.4  Audit.............................................................................................................
13.5  Confidentiality..............................................................................................
13.6  Finance .........................................................................................................
14 REFERENCES.............................................................................................................
15 APPENDICES..............................................................................................................
15.1 Appendix A:  CCB-CRISIS-02 Schedule of Events .....................................
15.2 Appendix B: Investigator's Statement and Agreement .................................
15.3 Appendix C: WHO Ordinal Scale.................................................................
CCB-CRISIS-02 Protocol v3.0 23SEPT2020...............................................................................
2 SYNOPSIS.....................................................................................................................
3 INTRODUCTION..........................................................................................................
3.1 Coronavirus-19 (COVID-19) ........................................................................
3.1.[ADDRESS_883568] Nucleotide Synthesis .............................................................................
3.3  Dihydroorotate dehydrogenase (DHODH) ..................................................
3.4  Brequinar........................................................................................................
3.5  Rationale for the Planned Trial ......................................................................
3.5.1 Brequinar Dose Selection.................................................................
3.5.2    Risk/Benefit of Brequinar .............................................................
3.6  Risks Associated with Participation in the Clinical Study.............................
3.7  Possible Interactions with Concomitant Medical Treatments........................
3.7.1 CYP Interactions ..............................................................................
3.8 Steps to be Taken to Control or Mitigate Risks ..............................................
4 TRIAL OBJECTIVES....................................................................................................
4.1 Primary Objective ...........................................................................................
4.2 Secondary Objectives......................................................................................
4.3 EXPLORATORY OBJECTIVES...................................................................
5 TRIAL DESIGN ............................................................................................................
6 TRIAL ENDPOINTS.....................................................................................................
6.1 Primary Endpoint ............................................................................................
6.2 Secondary Endpoints.......................................................................................
6.3 Exploratory Endpoints.....................................................................................110
111
111
111
111
111
112
112
113
114
114
115
116
117
125
132
132
132
132
132
133
133
134
134
135
135
135
135
136
136
136
136
137
138
138
138
138
7 TRIAL POPULATION..................................................................................................
7.1 Number of Subjects.........................................................................................
7.2 Inclusion criteria..............................................................................................
7.3 Exclusion Criteria............................................................................................
8 STUDY TREATMENTS ...............................................................................................
8.1 Description of Study Medications...................................................................
8.1.1 Brequinar..........................................................................................
8.2 Treatment Administration ...............................................................................
8.2.1 Safety/Tolerability............................................................................
8.3 Study Discontinuation.....................................................................................
8.4 Stoppi[INVESTIGATOR_2121] .............................................................................................
8.4.1 Individual Stoppi[INVESTIGATOR_2121].............................................................
8.4.2 Study-Level Stoppi[INVESTIGATOR_2121] .........................................................
8.5 Concomitant Medication/Treatment ...............................................................
8.6 Treatment Compliance ....................................................................................
8.7 Storage, Stability, Labeling and Packaging ....................................................
8.7.1 Storage and Stability ........................................................................
8.7.2 Labeling and Packaging ...................................................................
8.7.3 Blinding and Randomization............................................................
8.7.4 Unblinding/Expectedness.................................................................
8.7.[ADDRESS_883569].................................................................................................
9.5.1 Unscheduled Visits...........................................................................
9.6 Compliance with Study Procedures ................................................................
9.7 Early Withdrawal from the Study ...................................................................
9.8 Early Termination of the Study.......................................................................
9.9 Non-Childbearing Potential.............................................................................
10 ADVERSE EVENT REPORTING..............................................................................
10.1 Follow Up of Grade 3 or 4 Toxicities ...........................................................
10.2 Infection Follow Up ......................................................................................139
139
139
139
141
141
141
141
141
142
142
142
142
142
142
143
143
143
143
143
143
144
144
145
145
145
146
146
147
148
148
148
148
149
150
151
151
10.3 Classification of Causality ............................................................................
10.4 Classification of Severity ..............................................................................
10.5 Serious Adverse Event (SAE) Reporting ....................................................
10.6 Suspected Unexpected Serious Adverse Reactions (S[LOCATION_003]Rs) ..................
10.7 Pregnancies....................................................................................................
10.8 Safety Monitoring for Hematologic Toxicities .............................................
10.9 Data Monitoring Committee .........................................................................
10.9.1 DMC Safety Review Schedule.......................................................
11 STATISTICAL CONSIDERATIONS.........................................................................
11.1 Study Populations for Analysis.....................................................................
11.2 Safety Analyses.............................................................................................
11.3 Efficacy Analyses..........................................................................................
11.4 Sample Size Considerations..........................................................................
11.5 Randomization ..............................................................................................
11.6 Pooling of Study Centers ..............................................................................
11.7 Interim Analysis ............................................................................................
12 INVESTIGATOR RESPONSIBILITIES ....................................................................
12.1 Investigator's Performance ............................................................................
12.2 Confidentiality...............................................................................................
12.3 Source Documentation ..................................................................................
12.4 Data Collection..............................................................................................
12.5 Case Report Forms, Investigator's Site File and Record Retention ..............
12.6 Non-Protocol Research .................................................................................
12.7 Publication.....................................................................................................
13 SPONSOR RESPONSIBILITIES................................................................................
13.1 General ..........................................................................................................
13.2  Indemnity .....................................................................................................
13.3  Data Monitoring ...........................................................................................
13.4  Audit.............................................................................................................
13.5  Confidentiality..............................................................................................
13.6  Finance .........................................................................................................
14 REFERENCES.............................................................................................................
15 APPENDICES..............................................................................................................
15.1 Appendix A:  CCB-CRISIS-02 Schedule of Events .....................................
15.2 Appendix B: Investigator's Statement and Agreement .................................
15.3 Appendix C: WHO Ordinal Scale.................................................................
CCB-CRISIS-02_Protocol v4.0 01OCT2020 ...............................................................................151
152
152
153
154
154
155
156
157
157
157
157
157
157
158
158
159
159
159
159
160
160
161
161
162
162
162
162
162
163
163
164
165
165
166
167
168
2 SYNOPSIS.....................................................................................................................
3 INTRODUCTION..........................................................................................................
3.1 Coronavirus-19 (COVID-19) ........................................................................
3.1.[ADDRESS_883570] Nucleotide Synthesis .............................................................................
3.3  Dihydroorotate dehydrogenase (DHODH) ..................................................
3.4  Brequinar........................................................................................................
3.5  Rationale for the Planned Trial ......................................................................
3.5.1 Brequinar Dose Selection.................................................................
3.5.2    Risk/Benefit of Brequinar .............................................................
3.6  Risks Associated with Participation in the Clinical Study.............................
3.7  Possible Interactions with Concomitant Medical Treatments........................
3.7.1 CYP Interactions ..............................................................................
3.8 Steps to be Taken to Control or Mitigate Risks ..............................................
4 TRIAL OBJECTIVES....................................................................................................
4.1 Primary Objective ...........................................................................................
4.2 Secondary Objectives......................................................................................
4.3 EXPLORATORY OBJECTIVES...................................................................
5 TRIAL DESIGN ............................................................................................................
6 TRIAL ENDPOINTS.....................................................................................................
6.1 Primary Endpoint ............................................................................................
6.2 Secondary Endpoints.......................................................................................
6.3 Exploratory Endpoints.....................................................................................
7 TRIAL POPULATION..................................................................................................
7.1 Number of Subjects.........................................................................................
7.2 Inclusion criteria..............................................................................................
7.3 Exclusion Criteria............................................................................................
8 STUDY TREATMENTS ...............................................................................................
8.1 Description of Study Medications...................................................................
8.1.1 Brequinar..........................................................................................
8.2 Treatment Administration ...............................................................................
8.2.1 Safety/Tolerability............................................................................
8.3 Study Discontinuation.....................................................................................
8.4 Stoppi[INVESTIGATOR_2121] .............................................................................................
8.4.1 Individual Stoppi[INVESTIGATOR_2121].............................................................
8.4.2 Study-Level Stoppi[INVESTIGATOR_2121] .........................................................
8.5 Concomitant Medication/Treatment ...............................................................176
183
183
183
183
184
184
185
186
186
186
187
187
187
188
188
188
188
189
190
190
190
190
191
191
191
191
193
193
193
193
193
194
194
194
194
194
8.6 Treatment Compliance ....................................................................................
8.7 Storage, Stability, Labeling and Packaging ....................................................
8.7.1 Storage and Stability ........................................................................
8.7.2 Labeling and Packaging ...................................................................
8.7.3 Blinding and Randomization............................................................
8.7.4 Unblinding/Expectedness.................................................................
8.7.[ADDRESS_883571].................................................................................................
9.5.1 Unscheduled Visits...........................................................................
9.6 Compliance with Study Procedures ................................................................
9.7 Early Withdrawal from the Study ...................................................................
9.8 Early Termination of the Study.......................................................................
9.9 Non-Childbearing Potential.............................................................................
10 ADVERSE EVENT REPORTING..............................................................................
10.1 Follow Up of Grade 3 or 4 Toxicities ...........................................................
10.2 Infection Follow Up ......................................................................................
10.3 Classification of Causality ............................................................................
10.4 Classification of Severity ..............................................................................
10.5 Serious Adverse Event (SAE) Reporting ....................................................
10.6 Suspected Unexpected Serious Adverse Reactions (S[LOCATION_003]Rs) ..................
10.7 Pregnancies....................................................................................................
10.8 Safety Monitoring for Hematologic Toxicities .............................................
10.9 Data Monitoring Committee .........................................................................
10.9.1 DMC Safety Review Schedule.......................................................
11 STATISTICAL CONSIDERATIONS.........................................................................
11.1 Study Populations for Analysis.....................................................................
11.2 Safety Analyses.............................................................................................
11.3 Efficacy Analyses..........................................................................................
11.4 Sample Size Considerations..........................................................................
11.5 Randomization ..............................................................................................194
195
195
195
195
195
195
196
196
197
197
197
198
198
199
200
200
200
200
201
202
203
203
203
204
204
205
206
206
207
208
209
209
209
209
209
209
11.6 Pooling of Study Centers ..............................................................................
11.7 Interim Analysis ............................................................................................
12 INVESTIGATOR RESPONSIBILITIES ....................................................................
12.1 Investigator's Performance ............................................................................
12.2 Confidentiality...............................................................................................
12.3 Source Documentation ..................................................................................
12.4 Data Collection..............................................................................................
12.5 Case Report Forms, Investigator's Site File and Record Retention ..............
12.6 Non-Protocol Research .................................................................................
12.7 Publication.....................................................................................................
13 SPONSOR RESPONSIBILITIES................................................................................
13.1 General ..........................................................................................................
13.2  Indemnity .....................................................................................................
13.3  Data Monitoring ...........................................................................................
13.4  Audit.............................................................................................................
13.5  Confidentiality..............................................................................................
13.6  Finance .........................................................................................................
14 REFERENCES.............................................................................................................
15 APPENDICES..............................................................................................................
15.1 Appendix A:  CCB-CRISIS-02 Schedule of Events .....................................
15.2 Appendix B: Investigator's Statement and Agreement .................................
15.3 Appendix C: WHO Ordinal Scale.................................................................
CCB-CRISIS-02 Protocol v5.0 19NOV2020 ...............................................................................
2 SYNOPSIS.....................................................................................................................
3 INTRODUCTION..........................................................................................................
3.1 Coronavirus-19 (COVID-19) ........................................................................
3.1.[ADDRESS_883572] Nucleotide Synthesis .............................................................................
3.3  Dihydroorotate dehydrogenase (DHODH) ..................................................
3.4  Brequinar........................................................................................................
3.5  Rationale for the Planned Trial ......................................................................
3.5.1 Brequinar Dose Selection.................................................................
3.5.2    Risk/Benefit of Brequinar .............................................................
3.6  Risks Associated with Participation in the Clinical Study.............................
3.7  Possible Interactions with Concomitant Medical Treatments........................
3.7.1 CYP Interactions ..............................................................................
3.8 Steps to be Taken to Control or Mitigate Risks ..............................................210
210
211
211
211
211
212
212
213
213
214
214
214
214
214
215
215
216
217
217
218
219
220
228
236
236
236
236
237
237
238
239
239
239
240
240
240
4 TRIAL OBJECTIVES....................................................................................................
4.1 Primary Objective ...........................................................................................
4.2 Secondary Objectives......................................................................................
4.3 EXPLORATORY OBJECTIVES...................................................................
5 TRIAL DESIGN ............................................................................................................
6 TRIAL ENDPOINTS.....................................................................................................
6.1 Primary Endpoint ............................................................................................
6.2 Secondary Endpoints.......................................................................................
6.3 Exploratory Endpoints.....................................................................................
7 TRIAL POPULATION..................................................................................................
7.1 Number of Subjects.........................................................................................
7.2 Inclusion criteria..............................................................................................
7.3 Exclusion Criteria............................................................................................
8 STUDY TREATMENTS ...............................................................................................
8.1 Description of Study Medications...................................................................
8.1.1 Brequinar..........................................................................................
8.2 Treatment Administration ...............................................................................
8.2.1 Safety/Tolerability............................................................................
8.3 Study Discontinuation.....................................................................................
8.4 Stoppi[INVESTIGATOR_2121] .............................................................................................
8.4.1 Individual Stoppi[INVESTIGATOR_2121].............................................................
8.4.2 Study-Level Stoppi[INVESTIGATOR_2121] .........................................................
8.5 Concomitant Medication/Treatment ...............................................................
8.6 Treatment Compliance ....................................................................................
8.7 Storage, Stability, Labeling and Packaging ....................................................
8.7.1 Storage and Stability ........................................................................
8.7.2 Labeling and Packaging ...................................................................
8.7.3 Blinding and Randomization............................................................
8.7.4 Unblinding/Expectedness.................................................................
8.7.[ADDRESS_883573].................................................................................................
9.5.1 Unscheduled Visits...........................................................................
9.6 Compliance with Study Procedures ................................................................
9.7 Early Withdrawal from the Study ...................................................................
9.8 Early Termination of the Study.......................................................................
9.9 Non-Childbearing Potential.............................................................................
10 ADVERSE EVENT REPORTING..............................................................................
10.1 Follow Up of Grade 3 or 4 Toxicities ...........................................................
10.2 Infection Follow Up ......................................................................................
10.3 Classification of Causality ............................................................................
10.4 Classification of Severity ..............................................................................
10.5 Serious Adverse Event (SAE) Reporting ....................................................
10.6 Suspected Unexpected Serious Adverse Reactions (S[LOCATION_003]Rs) ..................
10.7 Pregnancies....................................................................................................
10.8 Safety Monitoring for Hematologic Toxicities .............................................
10.9 Data Monitoring Committee .........................................................................
10.9.1 DMC Safety Review Schedule.......................................................
11 STATISTICAL CONSIDERATIONS.........................................................................
11.1 Study Populations for Analysis.....................................................................
11.2 Safety Analyses.............................................................................................
11.3 Efficacy Analyses..........................................................................................
11.4 Sample Size Considerations..........................................................................
11.5 Randomization ..............................................................................................
11.6 Pooling of Study Centers ..............................................................................
11.7 Interim Analysis ............................................................................................
12 INVESTIGATOR RESPONSIBILITIES ....................................................................
12.1 Investigator's Performance ............................................................................
12.2 Confidentiality...............................................................................................
12.3 Source Documentation ..................................................................................
12.4 Data Collection..............................................................................................
12.5 Case Report Forms, Investigator's Site File and Record Retention ..............
12.6 Non-Protocol Research .................................................................................
12.7 Publication.....................................................................................................
13 SPONSOR RESPONSIBILITIES................................................................................
13.1 General ..........................................................................................................
13.2  Indemnity .....................................................................................................
13.3  Data Monitoring ...........................................................................................252
253
253
253
253
254
255
256
256
256
257
257
258
259
259
260
261
262
262
262
262
262
262
263
263
264
264
264
264
265
265
266
266
267
267
267
267
13.4  Audit.............................................................................................................
13.5  Confidentiality..............................................................................................
13.6  Finance .........................................................................................................
14 REFERENCES.............................................................................................................
15 APPENDICES..............................................................................................................
15.1 Appendix A:  CCB-CRISIS-02 Schedule of Events .....................................
15.2 Appendix B: Investigator's Statement and Agreement .................................
15.3 Appendix C: WHO Ordinal Scale.................................................................267
268
268
269
270
270
271
272
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 1 of 50 
PROTOCOL VERSION  1.0 DATE:  [ADDRESS_883574] 2020  
 
STUDY PROTOCOL  
The CRISIS 2 Study: A phase 2, randomized , double blind, placebo -controlled, multi -center 
study  assessing the safety and anti -coronavirus response of suppression of host nucleot ide 
synthe sis in out-patient adults with SARS -CoV -2  
 
Study No: CCB -CRISIS -02 
Version: 1.0 
 Version Date:  [ADDRESS_883575] 2020   
 
Sponsor:  
Clear Creek Bio, Inc.  
[ADDRESS_883576], 4th Floor,  
Cambridge MA [ZIP_CODE]  
 
Sponsor Telephone: ([PHONE_13583]  
Sponsor Facsimile: ([PHONE_13584]  
 
IND Number: 149291  
 
 
 
 
This confidential document is the property of Clear Creek Bio, Inc .  No unpublished information contained herein 
may be disclosed without the prior written approval of Clear Creek Bio, Inc. This trial will be conducted in 
accordance with the ICH Note for Guidance on Good Clinical Practice (CPMP/ICH/135/95, Jan.97), the De claration 
of Helsinki (1964, 1975, 1983, 1989, 1996, 2000 (Note for Clarification 2002 & 2004) and 2008), FDA Regulations 
and locally applicable regulations.   
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 2 of 50 
PROTOCOL VERSION  1.0 DATE:  [ADDRESS_883577] 2020  
 
TABLE OF CONTENTS  
2 SYNOPSIS  ................................ ................................ ................................ ............................  9 
3 INTRODUCTION  ................................ ................................ ................................ ..............  16 
3.1 Coronavirus -19 (COVID -19) ................................ ................................ .....................  [ADDRESS_883578] Nucleotide Synthesis  ................................ ................................ .........................  16 
3.3 Dihydroorotate dehydrogenase (DHODH)  ................................ ................................  16 
3.4 Brequinar  ................................ ................................ ................................ ....................  17 
3.5 Rationale for the Planned Trial  ................................ ................................ ..................  17 
3.5.1  Brequinar Dose Selection  ................................ ................................ .............................  18 
3.5.2  Risk/Benefit of Brequinar  ................................ ................................ ............................  18 
3.6 Risks Associated with Participation in the Clinical Study  ................................ .........  19 
3.7 Possible Interactions with Concomitant Medical Treatments  ................................ .... 19 
3.7.1  CYP Interactions  ................................ ................................ ................................ ..........  19 
3.8 Steps to be Taken to Control or Mitigate Risks  ................................ .........................  19 
4 TRIAL OBJECTIVES  ................................ ................................ ................................ ........  20 
4.1 Primary Objective  ................................ ................................ ................................ ...... 20 
4.2 Secondar y Objectives  ................................ ................................ ................................ . 20 
4.3 EXPLORATORY OBJECTIVES  ................................ ................................ ..............  20 
5 TRIAL DESIGN  ................................ ................................ ................................ .................  21 
6 TRIAL ENDPOINTS ................................ ................................ ................................ ..........  22 
6.1 Primary Endpoint  ................................ ................................ ................................ ....... 22 
6.2 Secondary Endpoints  ................................ ................................ ................................ .. 22 
6.3 Explor atory Endpoints ................................ ................................ ................................  22 
7 TRIAL POPULATION  ................................ ................................ ................................ ....... 23 
7.1 Number of Subjects  ................................ ................................ ................................ .... 23 
7.2 Inclus ion criteria  ................................ ................................ ................................ .........  23 
7.3 Exclusion Criteria  ................................ ................................ ................................ ....... 23 
8 STUDY TREATMENTS  ................................ ................................ ................................ .... 25 
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 3 of 50 
PROTOCOL VERSION  1.0 DATE:  [ADDRESS_883579] 2020  
 
8.1 Descriptio n of Study Medications  ................................ ................................ ..............  25 
8.1.1  Brequinar  ................................ ................................ ................................ ......................  25 
8.2 Treatment Administration  ................................ ................................ ..........................  25 
8.2.1 Safety/Tolerability  ................................ ................................ ................................ ........  25 
8.3 Study Discontinuation  ................................ ................................ ................................  26 
8.4 Stoppi[INVESTIGATOR_2121]  ................................ ................................ ................................ ........  26 
8.4.1  Indivi dual Stoppi[INVESTIGATOR_2121]  ................................ ................................ .........................  26 
8.4.2  Study -Level Stoppi[INVESTIGATOR_2121] ................................ ................................ ......................  26 
8.5 Concomitant Medication/Treatment  ................................ ................................ ..........  26 
8.6 Treatment Compliance  ................................ ................................ ...............................  27 
8.7 Storage, Stability, Labeling and Packaging  ................................ ...............................  27 
8.7.1  Storage and Stability  ................................ ................................ ................................ .... 27 
8.7.2  Labeling and Packaging  ................................ ................................ ...............................  27 
8.7.3  Blinding and Randomization  ................................ ................................ ........................  27 
8.7.4  Unblinding/Expectedness  ................................ ................................ .............................  [ADDRESS_883580]  ................................ ................................ ................................ ............  31 
9.5.1  Unschedule d Visits  ................................ ................................ ................................ ....... 31 
9.6 Compliance with Study Procedures  ................................ ................................ ...........  31 
9.7 Early Withdrawal from the Study  ................................ ................................ ..............  32 
9.8 Early Termination of the Study  ................................ ................................ ..................  32 
9.9 Non-Childbearing Potential ................................ ................................ ........................  32 
10 ADVERSE EVENT REPORTING ................................ ................................ .....................  33 
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 4 of 50 
PROTOCOL VERSION  1.0 DATE:  [ADDRESS_883581] 2020  
 
10.1  Follow Up of Grade 3 or 4 Toxicities  ................................ ................................ ........  34 
10.2  Infection Follow Up  ................................ ................................ ................................ ... 34 
10.3  Classification of Causality  ................................ ................................ .........................  34 
10.4  Classification of Severity  ................................ ................................ ...........................  35 
10.5  Serious Adverse Event (SAE) Reporting  ................................ ................................ ... 35 
10.6  Suspected Unexpected Serious Adverse Reactions (S[LOCATION_003]Rs)  ................................ . 36 
10.7  Pregnancies ................................ ................................ ................................ .................  37 
10.8  Safety Monitoring for Hematologic Toxicities  ................................ ..........................  37 
10.9  Data Monitoring Committee  ................................ ................................ ......................  38 
10.9.1  DMC Safety Review Schedule  ................................ ................................ ...............  39 
11 STATISTICAL CONSIDERATIONS ................................ ................................ ................  40 
11.1  Study Populations for Analysis  ................................ ................................ ..................  40 
11.2  Safety Analyses  ................................ ................................ ................................ ..........  40 
11.3  Efficacy Analyses  ................................ ................................ ................................ ....... 40 
11.4  Sample Size Considerations  ................................ ................................ .......................  40 
11.5 Randomization  ................................ ................................ ................................ ...........  40 
11.6  Pooling of Study Centers ................................ ................................ ............................  41 
11.7  Interim Analysis  ................................ ................................ ................................ .........  41 
12 INVESTIGA TOR RESPONSIBILITIES  ................................ ................................ ...........  42 
12.1  Investigators Performance  ................................ ................................ ........................  42 
12.2  Confidentiality  ................................ ................................ ................................ ............  42 
12.3  Source Documentation  ................................ ................................ ...............................  42 
12.4  Data Collection  ................................ ................................ ................................ ...........  43 
12.5  Case Report Forms, Investigators Site File and Record Retention  ...........................  43 
12.6  Non-Protocol Research  ................................ ................................ ..............................  44 
12.7  Publication  ................................ ................................ ................................ ..................  44 
13 SPONSOR RESPONSIBILITIES  ................................ ................................ ......................  45 
13.1  General  ................................ ................................ ................................ .......................  45 
13.2  Indemnity  ................................ ................................ ................................ ...................  45 
13.3  Data Monitoring  ................................ ................................ ................................ .........  45 
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 5 of 50 
PROTOCOL VERSION  1.0 DATE:  [ADDRESS_883582] 2020  
 
13.4  Audit  ................................ ................................ ................................ ...........................  45 
13.5  Confidentiality  ................................ ................................ ................................ ............  46 
13.6  Finance  ................................ ................................ ................................ .......................  46 
14 REFERENCES  ................................ ................................ ................................ ...................  47 
15 APPENDICES  ................................ ................................ ................................ ....................  48 
15.1  Appendix A:  CCB -CRISIS -02 Schedule of Events  ................................ ..................  48 
15.2  Appendix B: Investigators Statement and Agreement  ................................ ..............  49 
15.3  Appendix C: WHO Ordinal Scale  ................................ ................................ ..............  50 
 
 
  
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 6 of 50 
PROTOCOL VERSION  1.0 DATE:  [ADDRESS_883583] OF FIGURES   
Figure 3 -1. DHODH is a mitochondrial enzyme that catalyzes the 4th step of pyrimidine synthesis; 
it is completely essential for the generation of UMP . ................................ ...............  16 
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 7 of 50 
PROTOCOL VERSION  1.0 DATE:  [ADDRESS_883584]  
ESR Erythrocyte Sedimentation Rate  
EUA  Emergency Use Authorization  
FDA  [LOCATION_002] Food and Drug Administration  
GCP  Good Clinical Practice  
HIV Human immunodeficiency virus  
IB Investigator Brochure  
ICF Informed consent form  
ICH International Council on Harmonization  
ICU Intensive care unit  
IMP Inosine -5 phosphate  
IP Investigational product  
IRB Institutional Review Board  
LDH  Lactate dehydrogenase  
MedDRA  Medical Dictionary for Regulatory Activities  
NCI National Cancer Institute  
NEWS2  National Early Warning System (NEWS) [ADDRESS_883585] of Care  
S[LOCATION_003]R  Suspected unexpected serious adverse reaction  
UMP  Uridine 5 -monophosphatase  
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 8 of 50 
PROTOCOL VERSION  1.0 DATE:  [ADDRESS_883586] 2020  
 
Abbreviation  Definition  
US [LOCATION_002]  
XMP  Xanthosine -5 phosphate  
WHO  World Health Organization  
WOCBP  Women of childbearing potential  
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 9 of 50 
PROTOCOL VERSION  1.0 DATE:  [ADDRESS_883587] 2020  
 
2 SYNOPSIS  
CCB -CRISIS -02 SYNOPSIS  
IND 149291  
Title  The CRISIS2 Study: A phase 2, randomized, double blind, placebo -controlled, 
multi -center study assessing the safety and anti -coronavirus response of 
suppression of host nucleotide synthesis in out-patient adults with SARS -CoV -[ADDRESS_883588] SARS -CoV -2 is likely 
due to DHODH inhibitio n and shows  nanomolar potency and a high selectivity 
index in inhibiting viral replica tion in  in vitro  studies.    
The CRISIS2 trial will study out-patients ( non-hospi[INVESTIGATOR_9643] ) who have  a 
positive SARS -CoV -[ADDRESS_883589] of care (SOC)  + 5 days of brequinar or SOC + [ADDRESS_883590] and 
Dosage  Subjects will be randomized in a 1:[ADDRESS_883591] of care (SOC) + 5 days 
of brequinar  100 mg or SOC + [ADDRESS_883592] will be supplied as either b requinar 100 mg oral capsules  
or placebo capsules . The subjects are to self -administer one capsule on  Study Days 
1  5.  
Treatment assignment will be randomized, double -blind.   
Primary 
Objective s  To demonstrate a change from baseline in quantitative SARS -CoV -2 viral load 
for brequinar -treated subjects compared to placebo -treated subjects through 
Day 29. 
Secondary 
Objectives  Through Day 29:  
 To characterize  the safety and tolerability of brequinar i n out-patient COVID -
19 subjects  as measured by [CONTACT_656340] 3 and 4 AEs and SAEs ; 
 To demonstrate a shorter duration of viral shedding in subjects treated with 
brequinar compared to  subjects who received placebo ;  
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 10 of 50 
PROTOCOL VERSION  1.0 DATE:  [ADDRESS_883593] 2020  
 
 To reduce the percentage of subject s requiring hospi[INVESTIGATOR_656300] -
patient for > 24 hours  for brequinar subjects compared to  subjects who received 
placebo ; 
 To reduce mortality through Day 29  for brequinar subjects compared to  
subjects who received placebo.  
Exploratory 
Objective s  To determine time to viral clearance (two consecutive negative tests) ;  
 To determine time to resolution of new onset COVID -19-related clinical 
symptoms and pre -existing non-COVID -19 symptoms returned to baseline ; 
 To reduce disease severity  as me asured by [CONTACT_656341] [ADDRESS_883594] a Screening Visit followed as soon as possible with Study Day 
1. Study procedures are presented in detail in the Schedule of Events . Study visits 
(virtual or in person) will take place at Screening and on Study Da ys 1, 8, 15, 22, 
and 29. The visits that include bloodwork must be conducted at the study site or 
arrangements made for sample collection at the subjects home or other appropriate 
location. Other visits /visit activities for that visit  may be conducted rem otely using 
telemedicine  or other remote technique . Subjects are to self -collect a viral load 
sample , obtain their respi[INVESTIGATOR_697], heart rate, body temperature and pO2, and 
complete a symptom assessment on Days 1, 4, 8, 12, 15, 22, and 29 . 
Sample Size:  Approximately 100 subjects will be randomized to 5 days of either SOC  + 
brequinar 100 mg or SOC + placebo in a 1:1 ratio (approximately 50 subjects 
assigned to brequinar 100 mg and 50 subjects to placebo ).  
Number of Sites:  Approximately 15 
Study Period:  An enrollment period of 3 months is expected.  
Inclusion 
Criteria:  
 1. Willing and able to provide informed consent for the trial, written, 
electronic, verbal or other method deemed acceptable by [CONTACT_656342].  
2. 18 years of age or older.  
3. Laboratory -confirmed SARS -CoV -2 infection as determined by [CONTACT_656343] (RT -PCR) or other FDA -approved commercial 
or public health assay  within 14 days of randomization . 
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 11 of 50 
PROTOCOL VERSION  1.0 DATE:  [ADDRESS_883595] 2020  
 
4. Out-patient (not currently hospi[INVESTIGATOR_656301] < 
24 hours) . 
5. The effects of brequinar on the developi[INVESTIGATOR_19241] . For 
this reason, women of child -bearing potential and men must agree to use 
adequate contraception (hormonal or barrier method of birth control; 
abstinence) prior to study entry and for the duration of study participation. 
Should a woman become pregnant or suspect she is pregnant while she or 
her partner is participating in this study, she should inform her treating 
physician immediately. Men and women treated or enrol led on this protocol 
must also agree to use adequate contraception for the duration of study 
participation, and for [ADDRESS_883596] one COVID -19 symptom including bu t not limited to 
fever, cough, sore throat, malaise, headache, muscle pain, gastrointestinal 
symptoms, shortness of breath , dyspnea , ansomia , dysgeusia, or other 
symptom commonly associated with COVID -19.  
8. Able to swallow capsules.  
Exclusion 
Criteria:  1. Any physical examination findings and/or history of any illness that, in the 
opi[INVESTIGATOR_103160], might confound the results of the study 
or pose an additional risk to the patient  
2. Nursing women or women of childbearing potential (WO CBP) with a 
positive pregnancy test  
3. Treatment with another DHODH inhibitor  (e.g., leflunomide , 
teriflunomide ) or other agents known to cause bone marrow suppression 
leading to thrombocytopenia  
4. Platelets 150,000 cell/mm3 
5. Hemoglobin < 10 gm/dL for menstruating women and < 12 gm/dL for all 
other subjects  
6. Absolute neutrophil count < 1500 cells/mm3 
7. Renal dysfunction, i.e., creatinine clearance < 30 mL/min  
8. AST and/or ALT > [ADDRESS_883597], or total bilirubin > ULN . Gilberts Syndrome 
is allowed.  
9. Bleeding disord ers or blood loss requiring transfusion  in the six weeks 
preceding enrollment  
10. Ongoing  gastrointestinal ulcer, or gastrointestinal bleeding  within 6 weeks 
of randomization . 
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 12 of 50 
PROTOCOL VERSION  1.0 DATE:  [ADDRESS_883598] 2020  
 
11. Chronic  hepatitis B  infection , active hepatitis C infection, active liver 
disease an d/or cirrhosis  per subject report.  
12. Heart failure, current uncontrolled cardiovascular disease, including 
unstable angina, uncontrolled arrhythmias, major adverse cardiac event 
within 6 months (e.g. stroke, myocardial infarction, hospi[INVESTIGATOR_656302], or revascularization procedure).   
Treatment  All subjects will receive standard of care (SOC)  including symptomatic care. 
Subjects will be randomly assigned to SOC + brequinar 100 mg daily x 5 or SOC 
+ placebo daily x 5. Study encounters will be conducted remotely whenever 
possible.  
DMC A Data Monitoring Committee  (DM C) will meet periodically to review the safety 
and scientific conduct of the study. At a minimum, the DMC  is to review adverse 
events and safety laboratory assessm ents after the first [ADDRESS_883599] 40 subjects complete Day 8.  
Procedures  Study procedures are outlined in the Schedule of Events.  
Study completion or the reason for study discontinuation will be recorded in the 
source document and the eCRF.  
Safety/  
Tolerability  Safety/Tolerability  
Adverse events will be collected from the time of informed consent through Day 
29. After Day 29, collect/record only Serious Adverse Events (SAEs) or those 
judged by [CONTACT_656344]. 
Treatment -emergent  adverse events will be those with an onset after the date and 
time of first treatment . 
Subjects who  develop Grade 3 or 4 toxicities or SAEs are to be re -evaluated every 
2 days, as feasible, until the toxicity returns to Grade  2 severity.  
Stoppi[INVESTIGATOR_656303]:  
 Participants who develop a Grade 3 toxicity that is assessed by [CONTACT_656345].  
 Participants who develop a Grade 4 toxicity, regardless of relatedness to 
study drug, are to be permanently discontinued from study treatment.  
Study -Level  Stoppi[INVESTIGATOR_2121]:  
Study enrollment is to be paused  if any of the below criteria are met:  
 If  [ADDRESS_883600] s develop the same  related Grade 4 (life -threatening) adverse 
event or laboratory abnormality;  
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 13 of 50 
PROTOCOL VERSION  1.0 DATE:  [ADDRESS_883601] 2020  
 
 If  5 subjects develop the same  related Grade 3 or 4 adverse event or 
laboratory abnormality ; 
 If  10 subjects develop any related Grade 3 or 4 adverse event or 
laboratory abnormality .  
Following assessment by [CONTACT_1578] (DMC), the DMC will 
determine whether to stop the study, amend the protocol, or continue the study per 
protocol.  
Statistical 
Analysis  A separate, detailed statistical analysis plan (SAP) will be finalized prior to locking 
the database. All analyses of safety and efficacy for this study will be descriptive 
in nature and p resented by [CONTACT_19313]. Subject demographics and baseline 
characteristics will be summarized. Subject data listings will also be provided.  
Summaries for quantitative variables will include the mean, median, quartiles, 
standard error, minimum, and maximum. For qualitative variables, the summaries 
will include the number and percentage of subjects for each outcome, and the 95% 
CI, when appropriate.  Any statistical testing will be considered exploratory and 
descriptive. All computations will be performed using SA S (Version 9.4 or 
higher). Safety and tolerability will be assessed in terms of AEs, SAEs, and safety 
laboratory data.  
Adverse event data will be descriptively evaluated. All AEs will be reported in data 
listings. The incidence of treatment -emergent  adverse events, defined as TEAEs 
occurring after randomization will be tabulated by [CONTACT_656346] (MedDRA) preferred term and system organ class, and by 
[CONTACT_78621]. All laboratory results and other 
clinical measures will be summarized using appropriate descriptive statistics.  
 
  
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 14 of 50 
PROTOCOL VERSION  1.0 DATE:  [ADDRESS_883602] 2020  
 
CCB -CRISIS -02 Schedule of Events  
CCB -CRISIS -02  
Schedule of Events  
 
Procedures  Screen  D1 D2, 3  
( 8 
hr) D4 
( 8 
hrs) D5 
( 8 
hrs) D8 
( 1 
day)  D12 
( 1 
day)  D15 
( 1 
day) D22 
(1 
day) Final Visit   
D29 
( 2 days)  
Informed Consent (note Date and 
Time)  X          
AE/Concomitant Medications 
(dose, route, duration or 
ongoing)  X X  X  X X X X X 
Medical history (relevant within 
one year or ongoing)/ History of 
current illness (date of symptom 
onset or change in baseline co -
morbidity thought to be due to 
COVID -19 infection)  X          
Demographics (subject reported 
height and weight, date of birth, 
gender, race, ethnicity)  X          
Check for Physical Exam 
abnormalities (subject self -
reported)  X          
Pregnancy Test (WOCBP)  X 
(serum)          X 
(urine)  
Hematology/Chemistrya X X     X  X   
Vital Signsb X X  X  X X X X X 
Symptom Assessmentc X X  X  X X X X X 
Viral load  sampled X X   X  X X X X X 
Hospi[INVESTIGATOR_656304]       X  X X X 
WHO Ordinal Scale Assessment   X    X  X X X 
Randomize subject and dispense 
Study Medication   X         
Study drug administratione  X X X X      
Drug Accountability       X     
aDo not repeat if within 48h of Day 1 visit.  Send to Covance Central Laboratory Services (CCLS) for analysis.  
bVital signs include heart rate, respi[INVESTIGATOR_697], body temperature, pO2.  
cSymptom Assessment will be using a checklist provided to the subject with symptoms such as sore throat, cough, GI 
symptoms (vomting, diarrhea), ansomia, dysgeusia, other (specify), etc.  
dSample Day [ADDRESS_883603] using an Oragene collection system or similar. These samples are to be sent to CCLS for analysis.  The 
viral load sample may also be used to perform viral cultures (sample can be spl it, no additional sample required).  
eSubject will self -administer study drug once daily Days 1  [ADDRESS_883604] doses in a medication diary.  
Note that any visits/visit activities may be conducted via telephone, telemedicine , or digital media other than serum 
pregnancy test and chemistry/hematology sample collection. These l abs may be collected at the clinical site or another 
designated out -patient facility/laboratory or collected via home visit.  Arrangements for shippi[INVESTIGATOR_656305].  
 
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 15 of 50 
PROTOCOL VERSION  1.0 DATE:  [ADDRESS_883605]  
Name:  [CONTACT_656462], MSN, Ph.D.  
Title:  Clinical Operations  
Address:  Clear Creek Bio, Inc.  
[ADDRESS_883606], 4th Floor,  
Cambridge, MA [ZIP_CODE]  
Telephone No.:  [PHONE_13585]  
Fax No.:  [PHONE_13586]  
E-mail:  [EMAIL_12502]   
 
MEDICAL MONITOR  
Name:  [CONTACT_656463], MD  
Title:  Senior Medical Director  
Telephone No.:  ([PHONE_13587]  
E-mail:  [EMAIL_12503]  
 
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 16 of 50 
PROTOCOL VERSION  1.0 DATE:  [ADDRESS_883607] 2020  
 
3 INTRODUCTION  
3.1 Coronavirus -19 (COVID -19) 
Beginning in December  2019, Chinese scientists isolated a novel coronavirus, severe acute 
respi[INVESTIGATOR_6507]  2 (SARS -CoV -2) from patients with virus -infected pneumonia 
which was later designated as coronavirus disease 2019 (COVID -19) by [CONTACT_656347] (WHO) ( Zhou et al., 2020  [2]; Phelan et al., 2020  [3]).  
Approximately 14% of those affected with this virus will develop severe disease requiring 
hospi[INVESTIGATOR_656306]; 5% will require admission to the intensive care unit ( Handel 
et al. , 2020  [4]). Severe cases ma y be complicated by [CONTACT_171958][INVESTIGATOR_656307] (ARDS), 
sepsis and septic shock, and multi -organ failure, including acute kidney injury and cardiac injury. 
Risk factors for death include older age and co -morbid disease such as hypertension and diabe tes 
(Zhou, et al., 2020  [2]). This means that most  patients will be treated as out -patients. Reducing 
viral load in this environment is critically important for both the subjects themselves by [CONTACT_656348][INVESTIGATOR_059], but also to reduce the transmission 
of the disease to others in the patients households and their communities.  
3.1.[ADDRESS_883608] RNA building blocks, and without these building blocks they are 
unable to replicate.  The SARS -CoV -2 is a single -stranded (positive sense) RNA virus with a 
genome that is 29,811 nucleotides long, quite a lot larger than other RNA -based viruses (e.g. the 
hepatitis C geno me comprises only 9600 nucleotides). The nucleotide composition is broken down 
as: 29.9% adenosines, 18.4% cytosines, 19.6% guanines, and 
32.1% uridines  (Sah et al., 2020  [12]). 
3.[ADDRESS_883609] de novo  pyrimidine synthesis generates uridine 
monophosphate (UMP) as the building block for all pyrimidine 
ribonucleotides and deoxyribonucleotides  (Figure 3-1). There 
exists no salvage pathway for the synthesis of UMP, the 
fundamental building block  of pyrimidines . Inhibition of 
enzymatic steps upstream of UMP  (Figure 3 -1) leads to a rapid  
and profound  depletion of intracellular pyrimidines.   
3.3  Dihydroorotate dehydrogenase (DHODH)  
The enzyme dihydroorotate dehydrogenase ( DHODH ) catalyzes 
the 4th step of de novo  pyrimidine synthesis  and inhibition of 
DHODH completely halts all pyrimidine production. As shown in  
Figure 3 -1, DHODH  is located on the inner mitochondrial 
membrane and transfers electrons between DHO and complex III  
Figure 3-1. DHODH is a 
mitochondrial enzyme that 
catalyzes the 4th step of pyrimidine 
synthesis; it is completely essential 
for the generation of UMP.    

PROTOCOL NUMBER:  CCB -CRISIS -02      Page 17 of 50 
PROTOCOL VERSION  1.0 DATE:  [ADDRESS_883610] 2020  
 
of the electron -transport chain via the reduction of its ubiquinone (coenzyme Q10) cofactor.  
DHODH is a clear therapeutic target for the inhibition of host pyrimidine synthes is. The chemical 
inhibition of DHODH in vitro  or in vivo  leads to the rapid depletion of UMP and subsequent 
depletion of downstream products thymine and cytosine.  This forces a cell to rely on the salvage 
of extracellular pyrimidine nucleotides and this ex tracellular salvage is not capable of maintaining 
the cells normal nucleotide pool  (Sykes et al., 2016) [ 1]).    
3.[ADDRESS_883611] -targeting 
antiviral. It is an orally available and potent inhibitor of dihydroorotate dehydrogenase (DHODH) , 
the enzyme that  catalyzes the fourth step in pyrimidine synthesis, namely the conversion of 
dihydroorotate (DHO) to orotate.  DHODH inhibitors, including brequinar, inhibit de novo  
pyrimidine synthesis thereby [CONTACT_331577] a depletion of a cells pool of uridine, cytidine and 
thymidine ribonucleotides and deoxyribonucleotides.  
The anti viral acti vity of brequinar has been demonstrated  in studies  of rotavirus replication in 
human intestinal Caco -2 cell s as well as in human primary intestinal organoids  (Chen et al., 2019  
[6]). Treatment with teriflunomide , another DHODHi,  has been effective in vitro  and in vivo  in a 
murine model of foot and mouth disease virus (Mei-Jian et al., 2019  [7]). DHODH inhibition 
(DHODHi) also inhibited the growth of dengue virus in vitro  (Wang et al., 2011  [8]). DHODHi 
also showed antiviral effects against RNA viruses including influenza A, Zika, Ebola and 
coronavirus SARS -CoV -2 (Xiong et al., 2020  [11]). Brequinar has also been shown to inhibit the 
replication of Ebola virus , vesicular stomatitis virus and Zika virus in vitro (Luthra et al., 2018  
[9]). Brequinar inhibits the replication of human immunodeficiency virus ( HIV) in vitro  (Andersen 
et al., 2019  [10]). When considering brequinar as an antiviral for treatment of SARS -CoV-2, oral 
brequinar is highly bioavailable (>95%) and has good penetration of lung tissue  with an average 
tissue:blood ratio of 0.5 following a single dose of brequinar in the rat . It is therefore expected to 
achieve a similar period of DHODH inhibition i n lung tissue  (Brequinar IB  [5]). 
3.5  Rationale for the Planned Trial  
DHODH inhibition has been extensively studied as a potential therapeutic target in the treatment 
of RNA -based viruses. The inhibition of DHODH is effective in inhibiting viral replication in pre -
clinical models involving many RNA -based viruses with nanomolar potency and a high selectivity 
index (see the Brequinar IB [5], Section 5 ). In these pre -clinical models, the benefit of DHODH 
inhibition can be reversed by [CONTACT_656349], confirming that the 
on-target effect of host pyrimidine depletion is key to the anti -viral activity .  
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 18 of 50 
PROTOCOL VERSION  1.0 DATE:  [ADDRESS_883612] of care (SOC) with 5 days of brequinar (DHODH 
inhibition) compared to SOC with [ADDRESS_883613] pyrimidine nucleotides, thereby [CONTACT_534828]. A 
recent publication demonstrated that inhibitors of DHODH could potentiate the activity of 
inhibitors of RNA -dependent RNA pol ymerase (RdRp) in the treatment of dengue virus, another 
single -stranded RNA virus  similar to SARS -CoV -2 (Liu et al., 2020 [13]). This inhibition of viral 
replication may restore the balance in favor of the host immune system for the clearance of SARS -
CoV -2. 
Marketed DHODHi medications are available, includ ing lefluno mide or teriflunomide, however 
these are very weak inhibitors of DHODH with cellular potency ~[ADDRESS_883614] that 5 days of daily doses of 100 mg  p.o. will be safe and well tolerated. A dose of 
brequinar 100 mg achieves plasma concentrations of approximately 1 uM (0.4 ug/ml)  that should 
result in sufficient suppression of nucleotide synthesis . When given over 5  days, these plasma 
concentrations are achieved on a daily basis without accumulation, also assur ing the safety of this 
regimen  (see Brequinar IB  [5]).  
3.5.2    Risk/Benefit of Brequinar  
As presented in the Brequinar IB  [5], an extensive safety and pharmacokinetic database exists with 
more than 1,000 patients treated with brequinar. Cancer patients (N = 806) have been exposed to 
this compound for treatment of a variety of solid tumors  at various  treatment regimens, doses, and 
routes  including a single dose, once weekly, twice weekly, single dose every [ADDRESS_883615]  also been utilized for patients with  psoriasis and organ transplant. The maximum 
intravenous dose given was 2,250 mg/m2 every 3 weeks, and the maximum oral dose was 100 
mg/m2 daily for 21 days. There has been limited testing of DHODHi to date in the clinic for 
infection with SARS -CoV -2. DHODHi therapy at relatively high doses in the context of trials for 
patients with cancer has the expected safety side-effects of mucositis and bone marrow 
suppre ssion.  Importantly, h owever, the prior clinical experience in 39 subjects who received daily 
brequinar for 5 consecutive days at or lower than 100 mg/day show no cases of mucositis and only 
1 (2.6%) epi[INVESTIGATOR_656308]. Based on these data the  [ADDRESS_883616] .  
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 19 of 50 
PROTOCOL VERSION  1.0 DATE:  [ADDRESS_883617] been the primary dose -limiting toxicities. In addition, skin rash, nausea/vomiting, 
fatigue, and leukopenia have been dose -limiting in trials utilizing other schedules of brequinar 
administration. However , these effects were self -limiting, transient, required treatment in few 
cases,  and resolved following discontinuation of dosing . These adverse effects have been 
associated  with higher doses of brequinar given via the intravenous route and for longer durations 
than the 100 mg dose and 5 -day regimen proposed for this study .  
In addition to studying a higher risk population  with symptomatic COVID -19, a comprehensive 
safety monitor ing plan will be utilized in this study to assess the ongoing safety and well -being of 
participants (see Section 10.8).  
3.[ADDRESS_883618] been no 
apparent hepat otoxic  effects in the clini cal studies. Brequinar itself does not appear to be a 
substrate for metabolism by [CONTACT_9058] P450 enzymes when tested under a variety of conditions. 
(See Brequinar IB [5]; nonclinical d ata on file with Clear Creek).   
3.8 Steps to be Taken to Control or Mitigate Risks  
All subjects will be treated  by [CONTACT_656350] d clinicians  familiar with the treatment of viral 
infections and their complications .  
 
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 20 of 50 
PROTOCOL VERSION  1.0 DATE:  [ADDRESS_883619] 2020  
 
4 TRIAL OBJECTIVES  
4.1 Primary Objective  
To demonstrate a change from baseline in quantitative SARS -CoV -2 viral load for brequinar -
treated subjects compared to placebo -treated subjects through Day  29. 
4.2 Secondary Objectives  
The secondary objectives of this study are:  
Through Day 29:  
 To characterize  the safety and tolerability of brequinar in  out-patient  COVID -19 subjects  as 
measured by [CONTACT_656340] 3 and 4 AEs and SAEs ; 
 To demonstrate a shorter duration of viral shedding in subjects treated with brequinar 
compa red to  subjects who received placebo ;  
 To reduce the percentage of subjects  requiring hospi[INVESTIGATOR_656309]  >24 hours  
for brequinar subjects compared to  subjects who received placebo ; 
 To improve survival status through Day 29  for brequinar subjects compared to  subjects who 
received placebo . 
4.3 EXPLORATORY OBJECTIVES  
 To determine time to viral clearance (two consecutive negative tests) ;  
 To determine time to resolution of new onset COVID -19-related clinical symptoms and pre -
existing  non-COVID -19 symptoms returned to baseline ; 
 To reduce disease severity as measured by [CONTACT_656351] 2  for brequinar subjects compared to  subjects 
who received placebo . 
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 21 of 50 
PROTOCOL VERSION  1.0 DATE:  [ADDRESS_883620] of care per (SOC) institutional 
guidelines for treatment of patients with COVID -[ADDRESS_883621] a Screening Visit followed as soon as possible with Study Day 1. Study 
procedures are presented in detail in the Schedule of Events (Appendix 15.1). Study visits (virtual 
or in person) will take place at Screening and on Study Days 1, 8, 15, 22, and 29. The visits that 
include bloodwork must be conducted at the study site or arrangements made for sample collection 
at the subjects home or other appropriate location. Other visits/visit activities for that visit may 
be conducted remotely using telemedicine  or other remote technique . Subjects are to self -collect a 
viral load sample, obtain their respi[INVESTIGATOR_697], heart rate, body temperature and pO2, and complete 
a symptom assessment checklist on Days 1, 4, 8, 12, 15, 22, and 29.    
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 22 of 50 
PROTOCOL VERSION  1.0 DATE:  [ADDRESS_883622] 2020  
 
6 TRIAL EN DPOINTS  
6.1 Primary Endpoint  
Quantitative SARS -CoV -2 viral load  through Day  29. 
6.2 Secondary Endpoints  
The secondary endpoints  of this study are:  
Through Day 29:  
 Rates of AEs and SAEs including laboratory assessments ; 
 Duration of viral shedding ;  
 Percentage of subjects requiring admission as an inpatient for  >24 hours . 
6.3 Exploratory Endpoints  
 Time to viral clearance (two consecutive negative tests) ;  
 Time to resolution of new onset COVID -19-related clinical symptoms and pre -existing non-
COVID -19 symp toms returned to baseline ; 
 Disease severity as measured by [CONTACT_656352] 2;  
 
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 23 of 50 
PROTOCOL VERSION  1.0 DATE:  [ADDRESS_883623] of care plus placebo in a 1:1 ratio 
(approximately [ADDRESS_883624] of care  plus placebo ).  
7.2 Inclusion criteria  
1. Willing and able to provide informed consent for the trial, written, electron ic, verbal or 
other method deemed acceptable by [CONTACT_656353].  
2. 18 years of age or older.  
3. Laboratory -confirmed SARS -CoV -2 infection as determined by [CONTACT_656354] (RT -PCR) or other FDA -approved commercial or public health assay  within 
14 days of randomization . 
4. Out-patient (not currently hospi[INVESTIGATOR_656310] < 24 hours)  
5. The effects of brequinar on the developi[INVESTIGATOR_19241] . For this reason, 
women of child -bearing potential and me n must agree to use adequate contraception 
(hormonal or barrier method of birth control; abstinence) prior to study entry and for the 
duration of study participation. Should a woman become pregnant or suspect she is 
pregnant while she or her partner is par ticipating in this study, she should inform her 
treating physician immediately. Men and women treated or enrolled on this protocol must 
also agree to use adequate contraception for the duration of study participation, and for [ADDRESS_883625] one COVID -19 sympt om including but not limited to fever, cough, sore throat, 
malaise, headache, muscle pain, gastrointestinal  symptoms, shortness of breath, dyspnea, 
anosmia , dysgeusia, or other symptom commonly associated with COVID -19. 
8. Able to swallow capsules.  
7.3 Exclusion Criteria  
1. Any physical examination findings and/or history of any illness that, in the opi[INVESTIGATOR_50395], might confound the results of the study or pose an additional risk to the 
patient  
2. Nursing women or women of childbearing potential (WOCBP) with a positive pregnancy 
test 
3. Treatment with another DHODH inhibitor (e.g., leflunomide, teriflunomide) or other 
agents known to cause bone marrow suppression leading to thrombocytopenia  
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 24 of 50 
PROTOCOL VERSION  1.0 DATE:  [ADDRESS_883626] 2020  
 
4. Platelets 150,000 cell/mm3  
5. Hemoglobin < 10 gm/dL for menstruating women and < 12 gm/dL for all other subjects  
6. Absolute neutrophil count < 1500 cells/mm3  
7. Renal dysfunction, i.e., creatinine clearance < 30 mL/min  
8. AST and/or ALT > [ADDRESS_883627], or total bilirubin > ULN . Gilberts Syndrome is allowed.  
9. Bleeding di sorders or blood loss requiring transfusion in the six weeks preceding 
enrollment  
10. Ongoing  gastrointestinal ulcer, or gastrointestinal bleeding  within 6 weeks of 
randomization . 
11. Chronic  hepatitis B  infection , active hepatitis  C infection, active liver diseas e and/or 
cirrhosis  per subject report.  
12. Heart failure, current uncontrolled cardiovascular disease, including unstable angina, 
uncontrolled arrhythmias, major adverse cardiac event within 6 months (e.g. stroke, 
myocardial infarction, hospi[INVESTIGATOR_144651], or revascularization procedure).  
 
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 25 of 50 
PROTOCOL VERSION  1.0 DATE:  [ADDRESS_883628] of care (SOC) for COV ID-19 
infection. Subjects will be randomly assigned in a 1: [ADDRESS_883629] of care plus  placebo . 
8.2.1 Safety/Tolerability  
Safety/tolerability is assessed for each s ubject at each study visit . The NIH Division of AIDS 
(DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Corrected Version 2.1 
(July 2017)  will be utilized for AE reporting. All appropriate treatment areas should have access to 
a copy of the criteria .  
Adverse events (AEs) commonly observed in patients treated with brequinar are provided in the 
Investigators Brochure  (IB) and include thrombocytopenia, nausea, anemia, diarrhea, vomiting, 
leukopenia, stomatitis, rash, granulocytopen ia, fatigue,  and infection . In a study of 209 cancer 
subjects treated once -weekly  (DuP 785 -012, see Brequinar IB  [5]), the deaths of three patients 
were attributed to study drug toxicity (two to hemorrhage , one following acute renal failure). 
Severe toxicities grades (Grades 3 to 4) which typi[INVESTIGATOR_656311] (anemia , thrombocytopenia, leukopenia , granulocytopenia ), 
digestive  system toxicity (nausea, vomiting, stomatitis , others  including gastric hemorrhage) and 
mucositis.  
In three oncology studies with five consecutive days of intravenous (IV) brequinar dosing in 168 
subjects (Study 785 -001 [14], 785-003 [15], and 785-005 [16]) there were no toxic deaths . For 
subjects from these three studies who were treated with a daily dose of 100 mg or below  (as will 
be dosed in CCB -CRISIS -02), AEs through 21 days showed that 2 of 39 subjects (5.1%) had a 
severe (Grades 3 or 4) AE related to study drug ([ADDRESS_883630] each with hyperbilirubinemia and 
hyperglycemia), and no subjects discontinued from the study due to a study drug -related AE. The 
few study drug related AEs through [ADDRESS_883631] each 
with thrombocytopenia and diarrhea. When only studies with oral dosing  were considered at this 
dose level (Studies 785 -022 [17], 785 -031 [18] , and  785-034 [19]), the study drug related AEs 
through 21 days (each observed in one subject only) included diarrhea, headache, nausea, 
pruritus, abdominal pain, anorexia, chest pain, dry mouth, fatigue, keratosis, stomatitis, and 
vomiting. See brequinar IB [5]. 
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 26 of 50 
PROTOCOL VERSION  1.0 DATE:  [ADDRESS_883632] Study Day 29 (or longer if needed to follow up 
study drug-related adverse events).  Participants may discontinue  from the study by [CONTACT_656355] 9.7. 
8.4 Stoppi[INVESTIGATOR_2121]  
8.4.1 Individual Stoppi[INVESTIGATOR_2121]  
 Participants who develop a Grade 3 toxicity that is as sessed by [CONTACT_656356].  
 Participants who develop a Grade 4 toxicity, regardless of relatedness to study drug, are to  
be permanently discontinued from study treatmen t. 
 Subjects who develop Grade 3 or 4 toxicities are to be followed by [INVESTIGATOR_1312] -evaluation every 2 
days, as feasible, until the toxicity returns to  Grade 2 severity.  
8.4.2 Study -Level Stoppi[INVESTIGATOR_656312] : 
 If  [ADDRESS_883633] s develop the same  related Grade 4 (life -threatening) adverse event or 
laboratory abnormality ; 
 If  5 subjects develop the same  related Grade 3 or 4 adverse event or laboratory 
abnormality ; 
 If  10 subjects develo p any related Grade 3 or 4 adverse event or laboratory abnormality .  
Following assessment by [CONTACT_1578] (DMC, see Section 10.9), the DMC 
will deter mine whether to stop the study, amend the protocol, or continue the study per 
protocol.  
8.5 Concomitant Medication/Treatment  
Record t he name, dose, start/stop  date, indication for use , route, and whether ongoing or stopped 
for medications/treatments taken within two weeks prior to study entry  as well as any medications 
taken during the study  are to be recorded . Prohibited medications are identified in Section 8.8.  
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 27 of 50 
PROTOCOL VERSION  1.0 DATE:  [ADDRESS_883634]s medication diary and study records as 
appropriate.  
8.[ADDRESS_883635] of care plus  placebo . The brequinar and placebo 
capsules will be provided to each participating institution  in pre -number ed bottles intended for 
individual subjects to be dispensed by [CONTACT_8236]s pharmacist  or designated person . 
Randomization assignments will be provided by [CONTACT_656357] . The pharmacist/designated person will  dispense the next number in sequence to the next 
patient who qualifies for the study at an individual site.  
8.7.4 Unblinding/ Expectedness  
Contact [CONTACT_656358] (AE) . Each site will be provided with a sealed envelope containing 
individual sealed envelopes for subject numbers assigned to that site. Each individual subject 
number sealed  envelope will have the treatment (brequinar or placebo) randomly assigned to that 
subject number. Do not open the outer envelope or the individual sealed envelope unless it has 
been agreed with the Medical Monitor and the Sponsor that unblinding is necess ary for that 
particular AE. Unblinding must be documented in the study records. Envelope seals are to be 
checked to ensure they remain intact during drug accountability monitoring.  
If after a discussion with the Medical Monitor, the investigator or treatin g clinician believes the 
AE leading to unblinding to be related to the study drug, no further doses of drug should be 
administered  to that subject .  
Expectedness will be determined by [CONTACT_656359] -19 or 
similar severe viral illnesses  and their complications .   
8.7.5 Study Drug Accountability  
The study drug provided is for use only as directed in this protocol.  
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 28 of 50 
PROTOCOL VERSION  1.0 DATE:  [ADDRESS_883636]/ staff member  responsible for drug accountability is to document t he date and time  
of dispensing  and for what subject the study drug was intended (i.e., record subject initials and 
birth date or other unique identifier). A pharmacy manual will be provided by [CONTACT_1034].   
At the end of the study any unused study drug  will be returned to the Sponsor for  destruction or 
may be destroyed locally; disposition of study drug  will be documented .   
The Sponsor will be permitted access to the trial supplies at any time within usual business hours 
and with appropriate notice during or after completion of the study  to perform drug accountability 
reconciliation.  Records may be electronic or paper and may be accessed remotely for 
monitoring/drug accountability purposes.  
Each subject will be provided with one bottle with five brequinar or five placebo capsules for the 
five days of dosing.  
8.8 Prohibited Medications  
Treatment is prohibited with another DHODH inhibitor (e.g., leflunomide and teriflunomide ). 
Treatment is prohibited with agents known to cause bone marrow suppression leading to 
thrombocytopenia.  
8.[ADDRESS_883637] of care is 
expected to change as additional information, such as that from randomized controlled trials, 
emerges, and the Sponsor and the treating clinicians will need to address anticipated off -label use 
of any other drugs, devices, or interventions that might be used to manage COVID -19 (e.g. 
anticoagulants).  
The Sponsor and treating clinicians are to consider changes in SOC over time, for example, 
overlappi[INVESTIGATOR_656313] a SOC treatment expected to be widely used is to be 
considered. The availability of new standard of care treatment may change over time and vary 
from one clinical trial site to another. The Sponsor will discuss these issues with FDA should  the 
need arise.  
 
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 29 of 50 
PROTOCOL VERSION  1.0 DATE:  [ADDRESS_883638] OF THE TRIAL  
9.1 Ethical and Regulatory Considerations  
The trial will be performed in accordance with the Declaration of Helsinki (1964)  as revised in 
Tokyo (1975), Venice (1983), Hong Kong (1989), South Africa (1996), Scotland (2000, Note of 
Clarification 2002 & 2004) and Seoul 2008 (Appendix A), and Fortaleza (Brazil) (2013), and with 
the International Council on Harmonization ( ICH) Tripartite Guideline on Good Clinical Practice 
(CPMP/ICH/135/95, Jan.97) and [LOCATION_002] ( US) FDA Regulations.  
9.[ADDRESS_883639] be obtained i n accordance with US Code of Federal Regulations (21 CFR Part 50) ,  
the FDA Guidance on Conduct of Clinical Trials of Medical Products during the COVID -19 Public 
Health Emergency (March 2020, Updated April 16, 2020)  [20], as well as local and national 
regulations. Information should be given in both oral and written form whenever possible and 
deemed app ropriate by  [CONTACT_4707] ( IRB). Subjects  and their relatives, if 
necessary, must be given ample opportunity to inquire about details of the study.  
The Investigator  or qualified designated person  will verbally inform subjects as to the nature, 
expect ed duration and purpose of the trial, the administration of the Investigational Product ( IP), 
and the hazards involved, as well as the potential benefits that may come from treatment with this 
IP. The trial procedures will be explained in lay language and any questions will be answered.  The 
subjects will be given an IRB-approved consent form. The subjects will be given appropriate time 
to consider their participation in the trial and have any questions answered prior to signing the 
consent form. If a subject agrees to participate, he/she will sign and date an informed consent form 
and be provided with a copy of the signed consent. All subjects who sign a n informed consent 
form are to be recorded on the applicable screening log . If the subject is u nable to consent for any 
reason, a designated family member or healthcare power of attorney or other person may consent 
per institutional policy.   
The subject will be informed that his/her  medical records will be subject to review by [CONTACT_1034], 
Sponsors  representatives , and possibly by a representative of the FDA  and other relevant 
regulatory authorities. Subjects will be informed that they are free to refuse participation in this 
clinical investigation, and if they should participate, it will be made cl ear to them that they may 
withdraw from the trial at any time without prejudicing further  medical  care they may require . The 
subject will receive a copy of the consent form as well as an information sheet about the trial.  
Informed consent must be obtained  from every subject  prior to any study -specific procedures . 
Standard procedures carried out prior to completing  the informed consent process but within the 
time constraints of the protocol may be used for baseline evaluation; they need not be repeated. 
Documentation of c onsent will be subject to review by [CONTACT_1034]; if in writing, a copy will be 
given to the subject  and a copy will be filed with the subjects medical notes.  Verbal consents will 
be documented by [CONTACT_656360].  
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 30 of 50 
PROTOCOL VERSION  1.0 DATE:  [ADDRESS_883640] been affected by [CONTACT_4113] -19, and the study staff may 
use any consent method that has been approved by [CONTACT_1201] (e.g., phone consent, verbal consent 
with witness, e -consent, etc.)  of the local institution . In-person consent, w ritten consent signatures 
and providing hard copi[INVESTIGATOR_656314].  
The study should be discussed with the potential participant only a fter an initial review of his/her 
clinical status and appropriateness for participation have been evaluated to determine if he/she  
meets the subject selection criteria.  
A sample subject  information sheet and consent form are available from Clear Creek .  The final 
version at each institution may differ  depending on institutional requirement s and standard 
format s. This protocol will not be amended for site specific changes  as such changes are to be 
made to the sites consent when required . 
9.[ADDRESS_883641]  
It is the responsibility of the Investigator to submit the protocol, consent form a nd information 
sheet to the IRB . An IB will be available for review by [CONTACT_1201]. The protocol and informed consent 
form  (ICF) must be approved by [CONTACT_656361] e recruitment of the first  subject . The template 
consent form may be revised in accordance with site -specific requirements with Sponsor review 
and approval.  A copy of the IRB written approval must be provided  to the Sponsor and investigator 
before the tria l may start  at that institution . Written approval from the IRB is also required for 
substantial protocol amendments prior to their implementation.    
A substantial amendment may arise from changes to the protocol or from new information relating 
to the sci entific documents in support of the trial.  Amendments are substantial  when they are 
likely to have an impact on:  
 the safety or physical or mental integrity of the subjects ; 
 the scientific value of the trial;  
 the conduct or management of the trial; or  
 the quality or safety of any IP used in the trial.  
If it is necessary to change or deviate from the protocol to eliminate an immediate hazard to the 
subjects, the Investigator will notify the Sponsor and the IRB of the new events and the measures 
taken as soon as possible.   
The Investigator will report promptly to the Sponsor and IRB any new information that may 
adversely affect the safety of the subjects or the conduct of the trial. On completion of the trial, the 
Investigator will inform the applicable IRB as per local IRB requirements that the trial has ended. 
If the study is terminated for any reason , the investigator will return all clinical supplies and study -
related equipment supplied by [CONTACT_656362].  
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 31 of 50 
PROTOCOL VERSION  1.0 DATE:  [ADDRESS_883642] of study assessments and timings.   
Blood chemistry tests include blood urea nitrogen (BUN), creatinine, alkaline phosphatase (AL K), 
alanine amino transferase (ALT), aspartate amino transferase (AST), total bilirubin, total protein, 
albumin, glucose, serum electroly tes (sodium, potassium, chloride, carbon dioxide/bicarbonate, 
and calcium ), lactate dehydrogenase (LDH) . 
Hematology tests include hemoglobin, hematocrit, complete blood count with full differential , and 
platelet count.  
Viral load sampling  is to be carried out on Days [ADDRESS_883643] saliva samples with appropriate training  for this analysis . Samples may be banked for future 
retrospective analyses.  
Hospi[INVESTIGATOR_656315] -patient with admission > [ADDRESS_883644]  
The study visits are to be conducted as shown in the Schedule of Events, Appendix 15.1. 
Study completion or the reason for study discontinuation will be recorded in the source document 
and the eCRF.  
9.5.1 Unscheduled Visits  
Unscheduled visits and tests  are permitted as needed  to assess AEs /SAEs  throughout t he study. 
Unscheduled visits and tests  are also permitted as needed to assess  AEs/  SAE s with onset within 
two (2) weeks after the final study  visit providing the AE is considered related to study drug  
9.[ADDRESS_883645] as 
much information as possible remotely. A home visit or return to the clinical site or an out -patient 
laboratory may be arranged for safety labs or other assessments, when required.  Telemedicine  or 
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 32 of 50 
PROTOCOL VERSION  1.0 DATE:  [ADDRESS_883646]s study participation  after 
discussion with the other party if  it is believe d it would be unsafe for the subject to continue in the 
study .   
Subjects must discontinue study medication  if any of the following events occur:  
 Significant protocol violation or non -compliance, either on the part of the subject or the 
investigator or other site personnel;  
 Decision of the Investigator or Sponsor that removal is in the subject's best interest;  
 Severe unrelated medical illness or complication;  
 Safety reasons/ significant adverse event;  
 Subject request (withdrawal of consent);  
 Sponsor decision.  
Collect/co nduct  all scheduled evaluations  even for subjects who discontinue study medication  
prior to co mpleting the treatment  period  unless consent is withdrawn . 
9.8 Early Termination of the Study  
If the Sponsor or an Investigator believes it would be unsafe to continue the study, or for any 
reason at the Sponsors request, the study may be terminated at that s ite or the entire study 
terminated after discussion with the other part ies. 
The Sponsor will provide a written statement to the IRB and the relevant regulatory authority with 
the reasons for termination of the study. This will be conducted within 15 days o f the decision to 
terminate the study.  
If the study is terminated, a close out monitoring visit will be performed and applicable procedures 
will be carried out to close the trial site(s).  
9.[ADDRESS_883647] had a hysterectomy or tubal ligation. A woman is also presumed to be 
infertile due to natural causes if she has been amenorrheic for greater than 12 months and has an 
FSH greater than 40 IU/L.  In the absence of such  documentation, a negative serum pregnancy test  
is required for inclusion into the study.  
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 33 of 50 
PROTOCOL VERSION  1.0 DATE:  [ADDRESS_883648] a causal relationship with 
this treatment. An AE can therefore be any unfavorable and unintended sign (including an 
abnormal laboratory finding), symptom, or disease temporally associated with the use of the 
medicinal product, whether or  not considered related to the medicinal product.  
Events that occur prior to informed consent  will be entered as medical history; AEs that occur after 
informed consent  will be ente red on the AE form.  
Subjects will be questioned and observed for evidence of AEs, whether or not judged by [CONTACT_656363] . All AEs will be documented in the 
subject's medical record and CRF. For any pre -existing condition or abnormal laboratory finding 
that changes in severity after dosing, this change should be recorded as an AE. New abnormal 
laboratory findings that are clinically significant are considered AEs. 
All adverse events  will be collected  from the time of informed consent  through  Day 29. After Day 
29, collect/record only Serious Adverse Events (SAEs) which are  assessed  by [CONTACT_656364].  AE details are to be documented including start and 
stop date and times, whether continuous or intermittent, severity, any intervention utilized to 
correct the event  (e.g., medication, surgery , or other therapy) , outcome and the relationship to the 
study drug.   
AEs identified in the protocol as critical to the evaluation of sa fety must be reported to the Sponsor 
by [CONTACT_656365].  
AEs determined by [CONTACT_656366] [ADDRESS_883649] results occurring after study enrollment constitute AEs only if 
they induce clinical signs or symptoms, are considered clinically sig nificant, are Grades 3 or 4, or 
require therapy.  
If a death occurs during the SAE reporting period, the cause of death such as pneumonia, ARDS, 
or respi[INVESTIGATOR_1399], is considered as the AE and the death is considered its outcome. Death should 
be conside red an outcome, not an event. The event or condition leading to death should be recorded 
and reported as a single medical concept on the AE eCRF. Generally, only one such event should 
be reported. Fatal will be recorded as the outcome of this respective event; death due to an 
outcome of an AE will not be recorded as separate event. If the primary cause of death is disease 
progression, the cause of death should be clearly identified as COVID -19. 
In cases of surgical or diagnostic procedures, the condition leading to the procedure is considered 
as the AE instead of the procedure itself. Each AE will be coded by [CONTACT_656367] a preferred term using a thesaurus based on the Medical Dictionary for Regulatory Activities 
(MedDRA) . For exam ple, record appendicitis, not appendectomy.  
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 34 of 50 
PROTOCOL VERSION  1.0 DATE:  [ADDRESS_883650] start date is unknown, month and year or year may be used as the start 
date of the baseline even t. 
2. Adverse events occurring after signing consent are to be recorded in the eCRF using the AE 
form.  
3. Serious adverse events will be reported to the local IRB according to institutional policy.  
The NIH Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse 
Events, Corrected Version 2.1 (July 2017) 
(https://rsc.niaid.nih.gov/sites/def ault/files/daidsgradingcorrectedv21.pdf ) will be used for 
adverse event reporting.    
10.1 Follow Up of Grade 3 or 4 Toxicities  
Grade 3 or 4 toxicities are to be followed by [INVESTIGATOR_1312] -evaluation every 2 days, as feasible, until the 
toxicity returns to Grade  2 severit y. 
10.2 Infection Follow Up  
Any new infection that occurs on study regardless of infecting agent (i.e., viral or non -viral) should 
be captured. Additionally, the site of infection and source of culture (BAL, tracheal aspi[INVESTIGATOR_337], 
sputum, blood, urine, etc.) should  also be recorded.  
10.3 Classification of Causality  
Attribution is the relationship between an adverse event or serious adverse event  
and the study treatment. Attribution will be assigned as follows:  
 Definite  The AE is clearly related to the study treatment.  
 Probable  The AE is likely related to the study treatment  
 Possible  The AE may be related to the study treatment.  
 Unlikely - The AE is doubtfully related to the study treatment.  
 Unrelated - The AE is clearly NOT related to the study treatment  
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 35 of 50 
PROTOCOL VERSION  1.0 DATE:  [ADDRESS_883651] 2020  
 
Guidance fo r assessing causality:  
The Investigator will need to determine whether an AE is considered related to ( caused by) the 
study drug rather than some underlying condition , for example, COVID -19.   
For the purposes of this study, drug related shall mean Definite, Probable and Possible 
relationship to drug as determined by [CONTACT_737] . 
10.4 Classification of Severity  
The NIH Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse 
Events, Corrected Version 2.1 (July 2017)  will be utilized for AE reporting. All appropriate 
treatment areas should have access to a copy of the criteria.  
AEs that are expected are subject to expedited reporting only if the adverse event varies in nature, 
intensity or frequency from the expected toxicity information that is provided in the Investigator 
Brochure . 
10.5 Serious Adverse Event (SAE) Reporting  
The regulatory definition of a n SAE  is any untoward medical occurrence or effect that  at any dose  
fulfills one or more of these criteria : 
 results in death ; 
 is life threatening (at the time of the event) ; 
 requires in -patient hospi[INVESTIGATOR_1081] ; 
 results in persistent or significant disability / incapa city 
 is a congenital anomaly / birth defect ; 
 or is an  event considered medically serious by [CONTACT_737].  
 
Disability  is defined as a substantial disruption of a persons ability to conduct normal life 
functions.  
A life -threatening adverse event  is one that places the patient /subject , in the view of the 
Investigator, at immediate risk of death from the event as it occurr ed.  It does not include an event 
that, had it occurred in a more severe form, might have caused death.   
An unexpected adverse event  is any adverse drug event, the nature or severity of which is not 
consistent with the applicable product information (e.g.  IB for an unauthorized  investigational 
product or summary of product characteristics for an authorized  product).  
Enter only one event as the reason for the SAE on the SAE form.  Other non -serious events which 
did not directly result in the SAE should be d etailed in the description section on the SAE form 
and listed separately as AEs if necessary.  For fatal SAEs, report the cause of death as an SAE with 
a fatal outcome rather than reporting death as the SAE term.  
Note that hospi[INVESTIGATOR_656316]:  
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 36 of 50 
PROTOCOL VERSION  1.0 DATE:  [ADDRESS_883652] 2020  
 
 Routine treatment or monitoring of COVID -19 infection , not associated with any 
deterioration in condition ;  
 Elective or pre -planned treatment for a pre -existing condition that is unrelated to the 
indication under s tudy and has not worsened since signing the informed consent ;  
 Social reasons and respi[INVESTIGATOR_108999]s general 
condition ; 
 Treatment on an emergency outpatient basis that does not result in hospi[INVESTIGATOR_656317].  
ANY SERIOUS ADVERSE EVENT MUST BE REPORTED IMMEDIATELY (WITHIN 
24 HOURS) BY [CONTACT_656368] .  ENTER THE SUBJECTS AVAILABLE INFORMATION INTO THE  eCRF 
WITHIN [ADDRESS_883653]s subsequent medical course following a n SAE  must be submitted 
to Covance Patient Safety  until the event has subsided or, in case of permanent impairment, it 
stabilizes , and the overall clinical outcome has been ascertained.  
SAE R EPORTING EMAIL:   SAEIntake@covance .com  
Medical Monitor:  
Norberto Soto, MD  Telephone:  ([PHONE_13587]  
Covance Physician /Medical Monitor  Email:  [EMAIL_12503]  
Sponsor Representative:  
Barbara Powers, MSN, Ph.D.  Telephone:  M: ([PHONE_13588]  
VP, Clinical Operations  Email:  [EMAIL_12502]   
All SAEs will be reported to the IRB  periodically, at the end of the study , or per local institutional 
guidelines.   
10.6 Suspected Unexpected S erious  Adverse Reactions (S[LOCATION_003]Rs)  
Suspected, unexpected, serious advers e reactions ( S[LOCATION_003]Rs ) are SAEs that are both related to the 
study drug (Relationship = Related) and unexpected (not previously described in the investigators 
brochure).  All S[LOCATION_003]Rs will be reported in an expedited manner to the Sponsor or designee  and 
IRB by [CONTACT_656369]. Expectedness 
will be judged by [CONTACT_656370] . It is critical  that all SAEs are 
reported within the 24 -hour guideline so that the expectedness determination can be made. 
S[LOCATION_003]Rs require immediate attention and expedited reporting to relevant regulatory authorities.  
The Sponsor will ensure that all relevant informatio n about fatal  or life -threatening  S[LOCATION_003]R s are 
appropriately recorded and reported  to the concerned Regulatory Authority and to the concerned 
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 37 of 50 
PROTOCOL VERSION  1.0 DATE:  [ADDRESS_883654] 2020  
 
IRB(s)  within seven (7) calendar days of the date of first report to Covance Patient Safety / 
Sponsor . Follow -up inf ormation will be communicated to the relevant Regulatory Authorit y within 
an additional eight calendar days.  
All other S[LOCATION_003]Rs will be reported to the Regulatory Authority and to the IRB(s) concerned as 
soon as possible within a maximum of fifteen calendar days of first notification to Covance Patient 
Safety / Sponsor.  
The Sponsor or designee will also inform all Investigators studying  the investigational medicinal 
product about S[LOCATION_003]Rs  and ensure that all IRBs have been notified . 
For reported deaths of a subject, the Investigator shall supply the Sponsor and the IRB(s) with 
requested additional information on an expedited basis .   
10.[ADDRESS_883655]s partner during the study period wil l be 
documented in the subjects source documents and reported to Covance Patient Safety (by [CONTACT_656371] [EMAIL_6533])  and to the IRB by [CONTACT_144300] [ADDRESS_883656]s partner will begin at the first dose of study drug and will continue through [ADDRESS_883657]s partner has consented to this. Monitoring 
of the baby [CONTACT_656372] [ADDRESS_883658]s partner has 
consented to this.  
Pregnancy itself is not an AE; it should be reported for tracking purposes. The Investigator or 
designee will discontinue the pregnant subject from the treatment aspects of the study, continue to 
follow her per protocol for safety outcomes only, and advise  her to seek prenatal care and 
counseling from her primary care provider. Data on fetal outcome and breast -feeding will be 
collected for regulatory reporting and drug safety evaluation , if the subject has consented to this . 
If the pregnancy is due to a sub jects failure to comply with the contraceptive requirements of this 
protocol, this should be documented as a protocol deviation.  
Complications of pregnancy or congenital abnormalities in the newborn child will be reported 
appropriately as (S)AEs.  
The si te clinical staff will request the pregnant subject to notify the site of the outcome of the 
pregnancy (i.e., birth, loss, or termination). To help ensure this, the site clinical staff will follow 
the subject until the end of pregnancy, with the subjects consent. This request and the subjects 
response will be documented in the subjects source document.  
10.[ADDRESS_883659] a dose 
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 38 of 50 
PROTOCOL VERSION  1.0 DATE:  [ADDRESS_883660] to hematologic toxicit y. In addition to 
enhancing safety by [CONTACT_20683] a relatively brief 5 -day exposure and a low brequinar dose, all 
subjects in the clinical trial will be under the care of highly qualified medical personnel. Clinically 
significant out -of-range lab oratory  results will be reported as adverse events.  
In addition to real time assessments by [CONTACT_314107], t he Covance  Medical Monitor 
will assess the available hematology data on a periodic  basis to identify any pathologic trends or 
safety issues. Any ap parent increase in the expected rate or severity of hematologic safety events 
will be discussed with the Princip al Investigators  and the Sponsor. In addition, the Data Monitoring 
Committee (DMC) will assess available hematology data on a periodic  basis to independently 
assess any pathologic trends or safety issues.  If the rate or severity of hematologic toxicities 
appears to be above the expected rate or the severity appears worse than that expected, the trial 
enrollment will be suspended and no further sub jects will be treated while a comprehensive data 
review is conducted. Depending on the outcome of the safety review the study may be stopped , 
the design adjusted , or the study may continue as designed . Individual and Study stoppi[INVESTIGATOR_656318] 8.4. 
Safety laboratory results are to be initially assessed in real time by [CONTACT_656373] n. Any study drug -related clinically significant out -of-range laboratories or study 
drug-related adverse events will be followed as needed until resolution or stable.  
The in-clinic  assessments and telemedicine /phone call visits will specifically ask about possible 
hematologic toxicity including any evidence of  the list below. Subjects will be provided with a list 
of the following events in lay terms and will be instructed to call the research team if any of these 
events occur.  
 Ecchymosis /purpura/petechiae  
 Epi[INVESTIGATOR_3940]  
 Hemoptysis  
 Hematuria  
 Gingival bleeding  
 Prolonged bleeding time from needle sticks, abrasions or lacerations  
 Hematemesis  
 Rectal bleeding  
 Blood in stool  
 Any other unusual bleeding noted by [CONTACT_656374].  
10.9 Data Monitoring Committee  
A Data Monitoring Committee  (DM C) will be established to provide independent oversight to this 
trial. The primary responsibility of the DMC  will be to review the progress and conduct of the trial 
in order to maintain scientific rigor and to ensure the wellbeing of subjects participating in the 
trial. The specific responsibilities of the DMC  will be detailed in a separate DMC  charter. The 
DMC  will include at a minimum at least one statistician and two clinicians who will perform 
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 39 of 50 
PROTOCOL VERSION  1.0 DATE:  [ADDRESS_883661] 40 subjects complete the Day 8 visit. 
 
 
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 40 of 50 
PROTOCOL VERSION  1.0 DATE:  [ADDRESS_883662] 2020  
 
11 STATISTICAL CONSIDERATIONS  
A separate, detailed statistical analysis plan (SAP) will be finalized prior to locking the database. 
All analyses will be descriptive in nature and presented by [CONTACT_19313].   
Summaries for quantitative variables will include the mean, median, quartiles, standa rd error, 
minimum, and maximum. For qualitative variables, the summaries will include the number and 
percentage of subjects for each outcome, and 95% confidence interval (CI) , when appropriate. Any 
statistical testing will be considered exploratory and des criptive. All computations will be 
performed using SAS (Version 9.4 or higher).  
Subject disposition, subject demographics and baseline characteristics will be summarized. 
Subject data listings will also be provided. The following sections will briefly sum marize of the 
planned statistical analyses and analysis sets for the primary and secondary endpoints.  
11.[ADDRESS_883663]-randomization adverse events  will be tabulated by [CONTACT_656375], and by [CONTACT_78621]. All laboratory results  and 
study assessments  will be summarized using appropriate descriptive statistics.  
11.3 Efficacy Analyses  
Efficacy will primarily be assessed via viral load  changes . 
11.4 Sample Size Considerations  
Formal sample size calculations are not applicable for this proof -of-concept study. The s ample 
size of approximately  100 subjects planned to be entered in this trial  is expected to be adequate to 
provide safety and efficacy information to advise future study design . 
11.5 Randomization  
A randomization scheme will be provided by [CONTACT_656376]  + brequinar  or SOC +  placebo  in a 1: 1 
ratio.  
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 41 of 50 
PROTOCOL VERSION  1.0 DATE:  [ADDRESS_883664] 2020  
 
11.6 Pooling of Study Centers  
Not applicable to this small, early phase study.  
11.7 Interim Analysis  
No interim analysis is planned for this trial.  
 
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 42 of 50 
PROTOCOL VERSION  1.0 DATE:  [ADDRESS_883665] 2020  
 
12 INVESTIGATOR RESPONSIBILITIES  
12.1 Investigators Performance  
The Investigator will ensure that all those concerned with conducting the trial are : 
 provided with copi[INVESTIGATOR_656319];  
 trained regarding the conduct of the study and the training has been documented.  
The Investigator will sign the Investigators Statement and Agreement  found in Section 15.[ADDRESS_883666] that his/her identity will be protected and confidentiality 
will be maintained during all audits and inspections of the trial site and documentation. A unique 
number will be assigned to each subject at the start of the trial and this, with the subjects initials, 
will be used to identify the subject . In some cases, a further step may be taken to assign fake 
initials to the subject, per individual site requirements. The subjects  number will be the site 
number followed by [CONTACT_656377], on all trial correspondence and in the trial database. The 
Investigator will keep a list of identification codes or initials used for  each subject  along with the 
unique number assigned.  
All information provided to  the Investigator relevant to the investigational product ( IP), as well as 
information obtained during the course of the trial will be regarded as confidential. The 
Investigator and members of his/her research team agree not to disclose or publish such 
information in any way to any third -party without prior written permission from the Sponsor which 
will not be unreasonably withheld, except as required by [CONTACT_2371], or as permitted by [CONTACT_656378], Section  12.7. 
The Investigator will take all measures to ensure subjects  confidentiality will be maintained at all 
times.  
12.[ADDRESS_883667] access to the subjects ' medical or clinic records is necessary. The In vestigator will 
ensure that certain information is contained in the medical or clinic written or electronic records 
of the subject  and that the entries are signed and dated, as follows:  
 sufficient data to allow verification of the entry criteria in terms o f past and present medical 
and medication histories;  
 a note on the day the subject entered the trial describing the trial number, the IP being 
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 43 of 50 
PROTOCOL VERSION  1.0 DATE:  [ADDRESS_883668]  and a statement that consent was obtained;  
 a note of each su bsequent trial visit including any concerns about AEs and their resolution;  
 notes of all concomitant medication taken by [CONTACT_19578] , including start and stop dates;  
 a note of when the subject  terminated from the trial, the reason for termination and the subject s 
general condition at termination;  
 a copy of the signed informed consent form should be kept in the medical records of each 
subject during the clinical phase of the study. A signed copy should also be filed in the 
investigator file.  
12.[ADDRESS_883669] the research staff 
with a ny queries. All queries and discrepancies relating to the data collection are to be resolved at 
the completion of the trial . Remote data capture is encouraged whenever possible.  
12.5 Case Report Forms, Investigators Site File and Record Retention  
The Sponsor m ay provide the CRFs in paper, electronic (eCRF), or other media. The forms will 
be reviewed against source documentation at each monitoring visit. All CRFs and supporting 
source documentation must be completed and available to the Sponsor in a timely manne r. 
Changes or corrections due to data clarification and resolutions will be tracked by [CONTACT_656379].  
Prior to review of the case report forms by [CONTACT_1034]s representative, they should be reviewed 
for completeness and accuracy by [CONTACT_29517] a member of the research team.  
The Investigator must maintain an Investigator Site File which include s, but is not limited to, the 
IB, the protocol plus any amendments, all correspondence with the IRB including the approval for 
the trial to proceed, Regulatory Authority approval/ notification (if applicable) including a sample 
of an approved informed consent, IP accountability, Source D ocuments, investigator and staff 
curricula vitae ( CVs, ) trial documentation, and all trial correspondence. The original signed 
informed consent forms and the final report will be kept in the Investigator Site File.  
The Investigator will archive all essenti al documents. The medical files of trial subjects shall be 
retained in accordance with national legislation and in accordance with the maximum period of 
time permitted by [CONTACT_5035][INVESTIGATOR_307], institution or private practice. The Investigator has a responsibility 
to retain essential documents for as long as is required by [CONTACT_656380]. It is the responsibility of the Sponsor to inform the Investigator as to when these 
documents no longer need to be retained. Investigators will b e asked to contact [CONTACT_656381]:  CCB -CRISIS -02      Page 44 of 50 
PROTOCOL VERSION  1.0 DATE:  [ADDRESS_883670] 30 days before its submission for any meeting or 
journal. In addition, if deemed necessary by [CONTACT_656382] t filing, the Investigator agrees to a further delay of 60 days before any presentation 
or publication is submitted. The Sponsor reserves the right to include the report of this trial in any 
regulatory documentation or submission or in any informational ma terials prepared for the medical 
profession.  
Authorship determination will be at the discretion of the Sponsor and will include evaluation of 
the following criteria: Investigator must participate in the review of and content of the protocol; 
review and com ment on the study results; participate in the writing, reviewing and commenting of 
the manuscript; and approve the final manuscript for submission.  
 
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 45 of 50 
PROTOCOL VERSION  1.0 DATE:  [ADDRESS_883671] 2020  
 
13 SPONSOR RESPONSIBILITIES  
13.1 General  
The Sponsor agrees to adhere to the ICH Note for Guidance on GCP  (CPMP/ICH /135/95, Jan.97)  
and US FDA Regulations. It is the Sponsor's responsibility to obtain appropriate regulatory 
approval to perform the trial (if applicable). The Sponsor should notify promptly all concerned 
investigator(s), IRB(s) and the Regulatory Authorit y of findings that could adversely affect the 
health of the patients/ subjects, impact on the conduct of the trial or alter the Regulatory 
Authoritys authorization  to continue the trial. If it is necessary to change or deviate from the 
protocol to elimina te an immediate hazard to the subjects the Sponsor will notify the relevant 
regulatory authority and relevant IRB of the new events, the measures taken and the plan for further 
action as soon as possible.  This will be by [CONTACT_656383] a written 
report.   
On completion of the trial, the Sponsor will inform the regulatory authority that the trial has ended.  
If the study is terminated for any reason the Sponsor will provide a written statement to the relevant 
regulatory authorit y and the IRB with the reasons for termination of the trial. This will be 
conducted within [ADDRESS_883672] (EHR) or conduct remote monitoring visits at regular 
intervals during the trial for monitoring purposes and to assist the research staf f with any queries. 
CRFs and source documentation will be available for review during monitoring visits to the trial 
site. The function of this monitoring is to ensure compliance with the protocol, adherence to 
regulatory and GCP  obligations, proper mainte nance of records including IP accountability 
records, correct administration of IP including storage conditions and accurate reporting of AEs. 
On-site visits are not required for any monitoring visits for this study.    
Once the data from the case report fo rms have been entered onto the database, they will be 
reviewed , and the data verified against the subjects source data. Any discrepancies will be tracked 
by [CONTACT_656384].  
13.4  Audit  
The Sponsor has an obligation to au dit a proportion of studies.  A department other than the clinical 
department will undertake this obligation.  Therefore , the Sponsor, an independent auditor or a 
regulatory authority may audit the trial site and trial documentation. These audits may take p lace 
while the trial is being conducted or up to several years later.   
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 46 of 50 
PROTOCOL VERSION  1.0 DATE:  [ADDRESS_883673] s name, and subject s 
confidentiality will be maintained at all times.  
13.[ADDRESS_883674] of a separate agreement between the Investigator /Institution  and Sponsor.  
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 47 of 50 
PROTOCOL VERSION  1.0 DATE:  [ADDRESS_883675] 2020  
 
14 REFERENCES   
1. Sykes DB, Kfoury  YS, Mercier FE, et al. Inhibition of dihydroorotate dehydrogenase 
overcomes differentiation blockade in acute myeloid leukemia. Cell 2016; 167(1): 171 -
186. 
2. Zhou  F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality 
of adult inpatients with COVID -19 in Wuhan, China: a retrospective cohort study. 
Published online March 9, 2020. https://doi.org/10.1016/S0140 -6736(20)[ZIP_CODE] -3 
3. Phelan  A, Katz R, and Gostin L. The nov el coronavirus originating in Wuhan, China. 
Challenges for global health governance. Jama. 2020;323(8):709 -710.   
4. Handel A, Mille J, Yang G, Fung I. If containment is not possible, how do we minimize 
mortality for COVID -19 and other emerging disease outbre aks. March 13, 2020. 
https://doi.org/10.1101/2020.03.13.20034892 . 
5. Brequinar Investigators Brochure  
6. Chen S, Ding S, Yin Y, Xu L, Li P, Peppelenbosch MP, et al. Suppression of pyrimidine 
biosynthes is by [CONTACT_656385]. 
Antiviral Res. 2019 Jul;167:35 44.  
7. Mei-Jiao G, Shi -Fang L, Yan -Yan C, Jun -Jun S, Yue -Feng S, Ting -Ting R, et al. 
Antiviral effects of selected IMPDH and DHODH inhibitors against foot an d mouth 
disease virus. Biomed Pharmacother. [ADDRESS_883676];118:109305.  
8. Wang QY, Bushell S, Qing M, Xu HY, Bonavia A, Nunes S, et al. Inhibition of Dengue 
Virus through Suppression of Host Pyrimidine Biosynthesis. 2011 Jun 9;85(13):6548 56.  
9. Luthra P, Naidoo J, Pi[INVESTIGATOR_656320], De S, Khadka S, Anantpadma M, et al. Inhibiting 
pyrimidine biosynthesis impairs Ebola virus replication through depletion of nucleoside 
pools and activation of innate immune responses. Antiviral Res. [ADDRESS_883677];158:288 302.  
10. Andersen PI, Krpi[INVESTIGATOR_28947] K, Ianevski A, Shtaida N, Jo E, Yang J, et al. Novel Antiviral 
Activities of Obatoclax, Emetine, Niclosamide, Brequinar, and Homoharringtonine. 
Viruses. [ADDRESS_883678] 18;11(10).  
11. Xiong  R, Zhang L , Li S, Sun Y , Ding M , Wang, Y , et al. Novel and potent inhibitors 
targeting DHODH, a rate -limiting enzyme in de novo pyrimidine biosynthesis, are broad -
spectrum antiviral against RNA viruses including newly emerged coronavirus SARS -
CoV -2. 
12. Sah R, Rodriguez -Morales AJ, Jha R, Chu DKW, Gu H, Peiris M, et al. Comp lete Genome 
Sequence of a 2019 Novel Coronavirus (SARS -CoV -2) Strain Isolated in Nepal. Microbiol 
Resour Announc. 2020 Mar 12;9(11).  
13. Liu Q, Gupta A, Okesli -Armlovich A, Qiao W, Fischer C, Smith M, et al. Enhancing the 
Antiviral Efficacy of RNA -Dependent RN A Polymerase Inhibition by [CONTACT_656386]. bioRxiv. 2020 Jan 1;2020.03.24.992230.  
14. Study DUP 785 -001 Clinical Study Report (on file with Clear Creek)  
15. Study DUP 785 -003 Clinical Study Report (on file with Clear Creek)  
16. Study DUP 785 -005 Clinical Study Report (on file with Clear Creek)  
17. Study DUP 785 -022 Clinical Study Report (on file with Clear Creek)  
18. Study DUP 785 -031 Clinical Study Report (on file with Clear Creek)  
19. Study DUP 785 -034 Clinical Study Report (on file with Cle ar Creek)  
20. FDA Guidance COVID -19: Developi[INVESTIGATOR_656321] ( https://www.fda.gov/media/137926/download ) 
 
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 48 of 50 
PROTOCOL VERSION  1.0 DATE:  [ADDRESS_883679] 2020  
 
15 APPENDICES  
15.1 Appendix  A:  CCB -CRISIS -02 Schedule of Events  
CCB -CRISIS -02  
Schedule of Events  
 
Procedures  Screen  D1 D2, 3  
( 8 
hr) D4 
( 8 
hrs) D5 
( 8 
hrs) D8 
( 1 
day)  D12 
( 1 
day)  D15 
( 1 
day) D22 
(1 
day) Final Visit   
D29 
( 2 days)  
Informed Consent (note Date and 
Time)  X          
AE/Concomitant Medications 
(dose, route, duration or 
ongoing)  X X  X  X X X X X 
Medical history (relevant within 
one year or ongoing)/ History of 
current illness (date of symptom 
onset or change in baseline co -
morbidity thought to be due to 
COVID -19 infection)  X          
Demographics (subject reported 
height and weight, date of birth, 
gender, race, ethnicity)  X          
Check for Physical Exam 
abnormalities (subject self -
reported)  X          
Pregnancy Test (WOCBP)  X 
(serum)          X 
(urine)  
Hematology/Chemistrya X X     X  X   
Vital Signsb X X  X  X X X X X 
Symptom Assessmentc X X  X  X X X X X 
Viral load  sampled X X   X  X X X X X 
Hospi[INVESTIGATOR_656304]       X  X X X 
WHO Ordinal Scale Assessment   X    X  X X X 
Randomize subject and dispense 
Study Medication   X         
Study drug administratione  X X X X      
Drug Accountability       X     
aDo not repeat if within 48h of Day 1 visit.  Send to Covance Central Laboratory Services (CCLS) for analysis.  
bVital signs include heart rate, respi[INVESTIGATOR_697], body temperature, pO2.  
cSymptom Assessment will be using a checklist  provided to the subject with  symptoms such as sore throat, cough, GI 
symptoms (vom iting, diarrhea), anosmia , dysgeusia, other (specify), etc.  
dSample Day [ADDRESS_883680] using an Oragene collection system or similar. These samples are to be sent to CCLS for analysis.  The 
viral load sample may also be used to perform viral cultures (sample can be spl it, no additional sample required).  
eSubject will self -administer study drug once daily Days 1  [ADDRESS_883681] doses in a medication diary.  
Note that any visits/visit activities may be conducted via telephone, telemedicine , or digital media other than serum  
pregnancy test and chemistry/hematology sample collection. These labs may be collected at the clinical site or another 
designated out -patient facility/laboratory or collected via home visit.  Arrangements for shippi[INVESTIGATOR_656322].   
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 49 of 50 
PROTOCOL VERSION  1.0 DATE:  [ADDRESS_883682] 2020  
 
15.2 Appendix  B: Investigators Statement and Agreement  
STUDY NUMBER:    CCB -CRISIS -02 
The CRISIS2 Study: A phase 2, randomized , double blind, placebo -controlled, multi -center study 
assessing the safety and anti -coronavirus response of suppression of host nucleotide synthesis in 
out-patient adults with SARS -CoV -2.  
INVESTIGATORS STATEMENT AND AGREEMENT  
I (the Investigator ) have read this protocol and hereby [CONTACT_656387].  It is further agreed that the details of this trial and all information provided to 
me by [CONTACT_656388], Inc.  (the Sponsor ) will be held in the strictest confidence and will not be 
revealed for any reason without written authorization from Clear Creek Bio, Inc. except  to those 
who are to participate in the conduct of the trial.  
I agree that all data, the case report forms , and all materials provided for the conduct of the trial 
are the property of Clear Creek Bio, Inc.  unless specified otherwise in writing. It is under stood that 
Clear Creek Bio, Inc. will utilize the information derived from this trial in various ways, such as 
for submission to government regulatory agencies, required internal reports , and presentations 
without violating patient/ subject confidentiality  in any way.  
I further agree that Clear Creek Bio, Inc.  or its representatives will be permitted access , in 
accordance with current Good Clinical Practice Guidelines , to all data generated by [CONTACT_656389].  
PRINCIPAL INVESTIGATOR  
[INVESTIGATOR_67476]: ____________________________________  
 
Signature: ________________________________ ____________  Date: __________________  
 
  
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 50 of 50 
PROTOCOL VERSION  1.0 DATE:  [ADDRESS_883683] 2020  
 
15.3 Appendix C: WHO Ordinal Scale  
 
WHO clinical progression scale  
 

PROTOCOL NUMBER:  CCB -CRISIS -02      Page 1 of 51 
PROTOCOL VERSION  2.0 DATE:  15 SEPT 2020  
 
Clear Creek Bio, Inc.  
CONFIDENTIAL  STUDY PROTOCOL  
The CRISIS 2 Study: A phase 2, randomized , double blind, placebo -controlled, multi -center 
study  assessing the safety and anti -coronavirus response of suppression of host nucleot ide 
synthe sis in out-patient adults with SARS -CoV -2  
 
Study No: CCB -CRISIS -02 
Version: 2.0 
 Version Date:  15 September 2020   
 
Sponsor:  
Clear Creek Bio, Inc.  
[ADDRESS_883684], 4th Floor,  
Cambridge MA [ZIP_CODE]  
 
Sponsor Telephone: ([PHONE_13583]  
Sponsor Facsimile: ([PHONE_13584]  
 
IND Number: 149291  
 
 
 
 
This confidential document is the property of Clear Creek Bio, Inc .  No unpublished information contained herein may 
be disclosed without the prior written approval of Clear Creek Bio, Inc. This trial will be conducted in accordance with 
the ICH Note for Guidance on Good Clinical Practice (CPMP/ICH/135/95, Jan.97), the De claration of Helsinki (1964, 
1975, 1983, 1989, 1996, 2000 (Note for Clarification 2002 & 2004) and 2008), FDA Regulations and locally applicable 
regulations.   
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 2 of 51 
PROTOCOL VERSION  2.0 DATE:  15 SEPT 2020  
 
Clear Creek Bio, Inc.  
CONFIDENTIAL  TABLE OF CONTENTS  
2 SYNOPSIS  ................................ ................................ ................................ ............................  9 
3 INTRODUCTION  ................................ ................................ ................................ ..............  16 
3.1 Coronavirus -19 (COVID -19) ................................ ................................ .....................  [ADDRESS_883685] Nucleotide Synthesis  ................................ ................................ .........................  16 
3.3 Dihydroorotate dehydrogenase (DHODH)  ................................ ................................  16 
3.4 Brequinar  ................................ ................................ ................................ ....................  17 
3.5 Rationale for the Planned Trial  ................................ ................................ ..................  17 
3.5.1  Brequinar Dose Selection  ................................ ................................ .............................  18 
3.5.2  Risk/Benefit of Brequinar  ................................ ................................ ............................  18 
3.6 Risks Associated with Participation in the Clinical Study  ................................ .........  19 
3.7 Possible Interactions with Concomitant Medical Treatments  ................................ .... 19 
3.7.1  CYP Interactions  ................................ ................................ ................................ ..........  19 
3.8 Steps to be Taken to Control or Mitigate Risks  ................................ .........................  19 
4 TRIAL OBJECTIVES  ................................ ................................ ................................ ........  20 
4.1 Primar y Objective  ................................ ................................ ................................ ...... 20 
4.2 Secondary Objectives  ................................ ................................ ................................ . 20 
4.3 EXPLORATORY OBJECTIVES  ................................ ................................ ..............  20 
5 TRIA L DESIGN  ................................ ................................ ................................ .................  21 
6 TRIAL ENDPOINTS ................................ ................................ ................................ ..........  22 
6.1 Primary Endpoint  ................................ ................................ ................................ ....... 22 
6.2 Secondar y Endpoints  ................................ ................................ ................................ .. 22 
6.3 Exploratory Endpoints ................................ ................................ ................................  22 
7 TRIAL POPULATION  ................................ ................................ ................................ ....... 23 
7.1 Number of Subjects  ................................ ................................ ................................ .... 23 
7.2 Inclusion criteria  ................................ ................................ ................................ .........  23 
7.3 Exclusion Criteria  ................................ ................................ ................................ ....... 23 
8 STUDY TR EATMENTS  ................................ ................................ ................................ .... 25 
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 3 of 51 
PROTOCOL VERSION  2.0 DATE:  15 SEPT 2020  
 
Clear Creek Bio, Inc.  
CONFIDENTIAL  8.1 Description of Study Medications  ................................ ................................ ..............  25 
8.1.1  Brequinar  ................................ ................................ ................................ ......................  25 
8.2 Treatment Admi nistration  ................................ ................................ ..........................  25 
8.2.1  Safety/Tolerability  ................................ ................................ ................................ ........  25 
8.3 Study Discontinuation  ................................ ................................ ................................  26 
8.4 Stoppi[INVESTIGATOR_2121]  ................................ ................................ ................................ ........  26 
8.4.1  Individual Stoppi[INVESTIGATOR_2121]  ................................ ................................ .........................  26 
8.4.2  Study -Level Stoppi[INVESTIGATOR_2121] ................................ ................................ ......................  26 
8.5 Concomitant Medication/Treatment  ................................ ................................ ..........  26 
8.6 Treatment Compliance  ................................ ................................ ...............................  26 
8.7 Storage, Stability, Labeling and Packaging  ................................ ...............................  27 
8.7.1  Storage and Stability  ................................ ................................ ................................ .... 27 
8.7.2  Labeling and Packaging  ................................ ................................ ...............................  27 
8.7.3  Blinding and Randomization  ................................ ................................ ........................  27 
8.7.4  Unblinding/Expectedness  ................................ ................................ .............................  [ADDRESS_883686]  ................................ ................................ ................................ ............  31 
9.5.1  Unscheduled Visits  ................................ ................................ ................................ ....... 31 
9.6 Compliance with Study Procedures  ................................ ................................ ...........  32 
9.7 Early Withdrawal from the Study  ................................ ................................ ..............  32 
9.8 Early Termination of the Study  ................................ ................................ ..................  32 
9.9 Non-Childbearing Potential ................................ ................................ ........................  33 
10 ADVERSE EVENT REPORTING ................................ ................................ .....................  34 
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 4 of 51 
PROTOCOL VERSION  2.0 DATE:  15 SEPT 2020  
 
Clear Creek Bio, Inc.  
CONFIDENTIAL  10.1  Follow Up of Grade 3 or 4 Toxicities  ................................ ................................ ........  35 
10.2  Infection Follow Up  ................................ ................................ ................................ ... 35 
10.3  Classification of Causality  ................................ ................................ .........................  35 
10.4  Classification of Severity  ................................ ................................ ...........................  36 
10.5  Serious Adverse Event (SAE) Reporting  ................................ ................................ ... 36 
10.6  Suspected Unexpected Serious Adverse Reactions (S[LOCATION_003]Rs)  ................................ . [ADDRESS_883687] e Size Considerations  ................................ ................................ .......................  41 
11.5  Randomization  ................................ ................................ ................................ ...........  41 
11.6  Pooling of Study Centers ................................ ................................ ............................  42 
11.7  Interim Analysis  ................................ ................................ ................................ .........  42 
12 INVESTIGATOR RESPONSIBILITIES  ................................ ................................ ...........  43 
12.1  Investigators Performance  ................................ ................................ ........................  43 
12.2 Confidentiality  ................................ ................................ ................................ ............  43 
12.3  Source Documentation  ................................ ................................ ...............................  43 
12.4  Data Collection  ................................ ................................ ................................ ...........  44 
12.5  Case Re port Forms, Investigators Site File and Record Retention  ...........................  44 
12.6  Non-Protocol Research  ................................ ................................ ..............................  45 
12.7  Publication  ................................ ................................ ................................ ..................  45 
13 SPONSOR RESPONSIBILITIES  ................................ ................................ ......................  46 
13.1  General  ................................ ................................ ................................ .......................  46 
13.2  Indemnity  ................................ ................................ ................................ ...................  46 
13.3  Data Monitoring  ................................ ................................ ................................ .........  46 
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 5 of 51 
PROTOCOL VERSION  2.0 DATE:  15 SEPT 2020  
 
Clear Creek Bio, Inc.  
CONFIDENTIAL  13.4  Audit  ................................ ................................ ................................ ...........................  46 
13.5  Confidentiality  ................................ ................................ ................................ ............  47 
13.6  Finance  ................................ ................................ ................................ .......................  47 
14 REFERENCES  ................................ ................................ ................................ ...................  48 
15 APPENDICES  ................................ ................................ ................................ ....................  49 
15.1  Appendix A:  CCB -CRISIS -02 Schedule of Events  ................................ ..................  49 
15.2  Appendix B: Investigators Statement and Agreement  ................................ ..............  50 
15.3  Appendix C: WHO Ordinal Scale  ................................ ................................ ..............  51 
 
 
  
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 6 of 51 
PROTOCOL VERSION  2.0 DATE:  [ADDRESS_883688] OF FIGURES   
Figure 3 -1. DHODH is a mitochondrial enzyme that catalyzes the 4th step of pyrimidine synthesis; it 
is completely essential for the generation of UMP . ................................ ...................  16 
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 7 of 51 
PROTOCOL VERSION  2.0 DATE:  [ADDRESS_883689]  
ESR Erythrocyte Sedimentation Rate  
EUA  Emergency Use Authorization  
FDA  [LOCATION_002] Food and Drug Administration  
GCP  Good Clinical Practice  
HIV Human immunodeficiency virus  
IB Investigator Brochure  
ICF Informed consent form  
ICH International Council on Harmonization  
ICU Intensive care unit  
IMP Inosine -5 phosphate  
IP Investigational product  
IRB Institutional Review Board  
LDH  Lactate dehydrogenase  
MedDRA  Medical Dictionary for Regulatory Activities  
NCI National Cancer Institute  
NEWS2  National Early Warning System (NEWS) [ADDRESS_883690] of Care  
S[LOCATION_003]R  Suspected unexpected serious adverse reaction  
SpO 2 Peripheral capi[INVESTIGATOR_656323]:  CCB -CRISIS -02      Page 8 of 51 
PROTOCOL VERSION  2.0 DATE:  15 SEPT 2020  
 
Clear Creek Bio, Inc.  
CONFIDENTIAL  Abbreviation  Definition  
UMP  Uridine 5-monophosphatase  
US [LOCATION_002]  
XMP  Xanthosine -5 phosphate  
WHO  World Health Organization  
WOCBP  Women of childbearing potential  
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 9 of 51 
PROTOCOL VERSION  2.0 DATE:  15 SEPT 2020  
 
Clear Creek Bio, Inc.  
CONFIDENTIAL  2 SYNOPSIS  
CCB -CRISIS -02 SYNOPSIS  
IND 149291  
Title  The CRISIS2 Study: A phase 2, randomized, double blind, placebo -controlled, 
multi -center study assessing the safety and anti -coronavirus response of 
suppression of host nucleotide synthesis in out-patient adults with SARS -CoV -[ADDRESS_883691] SARS -CoV -2 is likely 
due to DHODH inhibitio n and shows  nanomolar potency and a high selectivity 
index in inhibiting viral replica tion in  in vitro  studies.    
The CRISIS2 trial will study out-patients ( non-hospi[INVESTIGATOR_9643] ) who have  a 
positive SARS -CoV -[ADDRESS_883692] of care (SOC)  + 5 days of brequinar or SOC + [ADDRESS_883693] and 
Dosage  Subjects will be randomized in a 1:[ADDRESS_883694] of care (SOC) + 5 days 
of brequinar  100 mg or SOC + [ADDRESS_883695] will be supplied as either b requinar 100 mg oral capsules  
or placebo capsules . The subjects are to self -administer one capsule on  Study Days 
1  5.  
Treatment assignment will be randomized, double -blind.   
Primary 
Objective s  To demonstrate a change from baseline in quantitative SARS -CoV -2 viral load 
for brequinar -treated subjects compared to placebo -treated subjects through 
Day 29. 
Secondary 
Objectives  Through Day 29:  
 To characterize  the safety and tolerability of brequinar i n out-patient COVID -
19 subjects  as measured by [CONTACT_656340] 3 and 4 AEs and SAEs ; 
 To demonstrate a shorter duration of viral shedding in subjects treated with 
brequinar compared to  subjects who received placebo ;  
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 10 of 51 
PROTOCOL VERSION  2.0 DATE:  15 SEPT 2020  
 
Clear Creek Bio, Inc.  
CONFIDENTIAL   To reduce the percentage of subject s requiring hospi[INVESTIGATOR_656300] -
patient for > 24 hours  for brequinar subjects compared to  subjects who received 
placebo ; 
 To reduce all-cause mortality through Day 29  for brequinar subjects compared 
to subjects who received placebo.  
Exploratory 
Objective s Through Day 29:  
 To determine time to viral clearance (two consecutive negative tests) ;  
 To determine time to resolution of new onset COVID -19-related clinical 
symptoms and pre -existing non-COVID -19 symptoms returned to baseline ; 
 To determine time to clinical improvement  as measured by a favorable shift in 
the WHO Ordinal Scale score measured for the subset of subject s with baseline 
WHO Ordinal Scale of [ADDRESS_883696] a Screening Visit followed as soon as possible with Study Day 
1. Study procedures are presented in detail in the Schedule of Events . Study visits 
(virtual or in person) will take place at Screening  and on Study Days  1, 8, 15, 22, 
and 29. The visits that include bloodwork must be conducted at the study site or 
arrangements made for sample collection at the subjects home or other appropriate 
location. Other visits /visit activities for that visit  may be conducted remotely using 
telemedicine  or other remote technique . Subjects are to self -collect a viral load 
sample , obtain their respi[INVESTIGATOR_697], heart rate, body temperature and SpO2, and 
complete a symptom assessment on Days 1, 4, 8, 12, 15, 22, and [ADDRESS_883697] at Screening and on study Days 1, 8, 15, 22, and 29. 
Telemedicine visits will be conducted by [CONTACT_656390] 4 and 12.  
Sample Siz e: Approximately 100 subjects will be randomized to 5 days of either SOC  + 
brequinar 100 mg or SOC + placebo in a 1:1 ratio (approximately 50 subjects 
assigned to brequinar 100 mg and 50 subjects to placebo ).  
Number of Sites:  Approximately 15 
Study Period:  An enrollment period of 3 months is expected.  
Inclusion 
Criteria:  
 1. Willing and able to provide informed consent for the trial, written, 
electronic, verbal , or other method deemed acceptable by [CONTACT_656342].  
2. 18 years of age or older.  
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 11 of 51 
PROTOCOL VERSION  2.0 DATE:  15 SEPT 2020  
 
Clear Creek Bio, Inc.  
CONFIDENTIAL  3. Laboratory -confirmed SARS -CoV -2 infection as determined by [CONTACT_656343] (RT -PCR) or other FDA -approved commercial 
or public health assay  within [ADDRESS_883698] dose. 
4. Out-patient  (never hospi[INVESTIGATOR_656324] -patient for COVID -19 or was 
evaluated/treated for COVID -19 only in the Emergency Room with a stay 
of < 24 hours).  
5. The effects of brequinar on the developi[INVESTIGATOR_19241] . For 
this reason, women of child -bearing pote ntial and men must agree to use 
adequate contraception (hormonal or barrier method of birth control; 
abstinence) prior to study entry and for the duration of study participation. 
Should a woman become pregnant or suspect she is pregnant while she or 
her pa rtner is participating in this study, she should inform her treating 
physician immediately. Men and women treated or enrolled on this protocol 
must also agree to use adequate contraception for the duration of study 
participation, and for [ADDRESS_883699] one COVID -19 symptom including but not limited to 
fever, cough, sore throat, malaise, headache, muscle pain, gastrointestinal 
symptoms, shortness of breath , dyspnea , anosmia , dysgeusia, or other 
symptom commonly associated with COVID -19.  
8. Able to swallow capsules.  
Exclusion 
Criteria:  1. Any physical examination findings and/or history of any illness that, in the 
opi[INVESTIGATOR_103160], might confound the results of the study 
or pose an additional risk to the patient  
2. Nursing women or women of childbearing potential (WOCBP) with a 
positive pregnancy test  
3. Treatment with another DHODH inhibitor  (e.g., leflunomide , 
teriflunomide ) or other agents known to cause bone marrow suppression 
leading to thrombocytopenia  
4. Platelets 150,000 cell/mm3 
5. Hemoglobin < 10 gm/dL  
6. Absolute neutrophil count < 1500 cells/mm3 
7. Renal dysfunction, i.e., creatinine clearance < 30 mL/min  
8. AST and/or ALT > [ADDRESS_883700], or total bilirubin > ULN . Gilberts Syndrome 
is allowed.  
9. Bleeding disorders or blood loss requiring transfusion  in the six weeks 
preceding enrollment  
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 12 of 51 
PROTOCOL VERSION  2.0 DATE:  [ADDRESS_883701] dose. 
11. Chronic  hepatitis B  infection , active hepatitis C infection, active liver  
disease and/or cirrhosis  per subject report.  
12. Heart failure, current uncontrolled cardiovascular disease, including 
unstable angina, uncontrolled arrhythmias, major adverse cardiac event 
within 6 months (e.g. stroke, myocardial infarction, hospi[INVESTIGATOR_656302], or revascularization procedure).   
Treatment  All subjects will receive standard of care (SOC)  including symptomatic care. 
Subjects will be randomly assigned to SOC + brequinar 100 mg daily x 5 or SOC 
+ placebo daily x 5. Study encounters will be conducted remotely whenever 
possible.  
DMC A Data Monitoring Committee  (DM C) will meet periodically to review the safety 
and scientific conduct of the study. At a minimum, the DMC  is to review adverse 
events and safety laboratory assessments after the first [ADDRESS_883702] 40 subjects complet e Day 8.  
Procedures  Study procedures are outlined in the Schedule of Events.  
Study completion or the reason for study discontinuation will be recorded in the 
source document and the eCRF.  
Safety/  
Tolerability  Safety/Tolerability  
Adverse events will be collected from the time of first dose  through Day 29. After 
Day 29, collect/re cord only Serious Adverse Events (SAEs) or those judged by [CONTACT_656363]. Treatment -emergent  
adverse events will be those with an onset after the date and time of first treatment . 
Subjects who develop Gra de 3 or 4 toxicities or SAEs are to be re -evaluated every 
2 days, as feasible, until the toxicity returns to Grade  2 severity.  
Stoppi[INVESTIGATOR_656303]:  
 Participants who develop a Grade 3 toxicity that is assessed by [CONTACT_656345].  
 Participants who develop a Grade 4 toxicity, regardless of relatedness to 
study drug, are to be permanently discontinued from study treatment.  
Study -Level  Stoppi[INVESTIGATOR_2121]:  
Study enrollment is to be paused  if any of the below criteria are met:  
 If  [ADDRESS_883703] s develop the same  related Grade 4 (life -threatening) adverse 
event or laboratory abnormality;  
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 13 of 51 
PROTOCOL VERSION  2.0 DATE:  15 SEPT 2020  
 
Clear Creek Bio, Inc.  
CONFIDENTIAL   If  5 subjects develop the same  related Grade 3 or 4 adverse event or 
laboratory abnormality ; 
 If  10 subjects develop any related Grade 3 or 4 adverse event or 
laboratory abnormality .  
Following assessment by [CONTACT_1578] (DMC), the DMC will 
determine whether to stop the study, amend the protocol, or continue the study per 
protocol.  
Statistical 
Analysis  A separate, detailed statistical analysis plan (SAP) will be finalized prior to locking 
the database. All analyses of safety and efficacy for this study will be descriptive 
in nature and presented by [CONTACT_19313]. Subject demographics and baseline 
characteristics will be summarized. Subject data listings  will also be provided.  
Summaries for quantitative variables will include the mean, median, quartiles, 
standard error, minimum, and maximum. For qualitative variables, the summaries 
will include the number and percentage of subjects for each outcome, and the 95% 
CI, when appropriate.  Any statistical testing will be considered exploratory and 
descriptive. All computations will be performed using SAS (Version 9.4 or 
higher). Safety and tolerability will be assessed in terms of AEs, SAEs, and safety 
laborat ory data.  
Adverse event data will be descriptively evaluated. All AEs will be reported in data 
listings. The incidence of treatment -emergent  adverse events, defined as TEAEs 
occurring after first dose  will be tabulated by [CONTACT_656391] (MedDRA) preferred term and system organ class, and by [CONTACT_656392]. All laboratory results and other clinical measures 
will be summarized using appropriate descriptive statistics.  
 
  
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 14 of 51 
PROTOCOL VERSION  2.0 DATE:  [ADDRESS_883704] dose time  
 
Procedures  Screen  
(days  
-14 to -1) D1 D2, 3  
( 8 
hrs) D4 
( 8 
hrs) D5 
( 8 
hrs) D8 
( 1 
day)  D12 
( 1 
day)  D15 
( 1 
day) D22 
(1 
day) Final 
Visit   
D29 
( 2 days)  
Informed Consent (note Date and Time)  X          
AE/Concomitant Medications (dose, route, duration 
or ongoing)  X X  X  X X X X X 
Medical history (relevant within one year or 
ongoing)/ History of current illness (date of 
symptom onset or change in baseline co -morbidity 
thought to be due to COVID -19 infection)  X          
Demographics (subject reported height and weight, 
date of birth, gender, race, ethnicity)  X          
Check for Physical Exam abnormalities (subject 
self-reported)  X          
Pregnancy Test (WOCBP)  X 
(serum)          X 
(urine)  
Hematology/Chemistrya X X     X  X   
Vital Signsb X X  X  X X X X X 
Symptom Assessmentc X X  X  X X X X X 
SARS -CoV -2 RT -PCR/ Viral load  sampled X X   X  X X X X X 
Hospi[INVESTIGATOR_656304]       X  X X X 
WHO Ordinal Scale Assessment   X    X  X X X 
Confirm Eligibility   X         
Randomize subject and dispense Study Medication   X         
Study drug administratione  X X X X      
Drug Accountability       X     
aDo not repeat if within 48h of Day 1 visit.  Send to Covance Central Laboratory Services (CCLS) for analysis.  
bVital signs include heart rate, respi[INVESTIGATOR_697], body temperature, SpO2.  Subject will be provided with a thermometer and 
pulse oximeter with heart rate monitoring capability. Training will be provided during the first visit by [CONTACT_656393]. Vital signs parameters will be observed and recorded by [CONTACT_656394] a visit by [CONTACT_656395].  
cSymptom Assessment will use a checklist  provided to the subject with  symptoms such as sore throat, cough, GI symptoms 
(vom iting, diarrhea), anosmia, dysgeusia, other (specify), etc.  Severity Mild, Moderate, or Severe will be collected.  
dRT-PCR at Screening may be performed by [CONTACT_656396] a positive SARS -CoV -
[ADDRESS_883705] using 
an Oragene collection system or similar. The home health nurse will train the subject and observe sample collection 
on Day 1. These samples are to be sent to CCLS for analysis.  The viral load sample may also be used to perf orm viral 
cultures (sample can be split  by [CONTACT_2237] , no additional sample required).  
eSubject will self -administer study drug once daily Days 1  [ADDRESS_883706] doses in a medication diary.  Note that any 
visits/visit activities may be conducted  via telephone, telemedicine , or digital media other than serum pregnancy test and 
chemistry/hematology sample collection. These labs may be collected at the clinical site or another designated out -patient 
facility/laboratory or collected via home visit.  Arrangements for shippi[INVESTIGATOR_656325].  
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 15 of 51 
PROTOCOL VERSION  2.0 DATE:  [ADDRESS_883707]  
Name:  [CONTACT_656462], MSN, Ph.D.  
Title:  Clinical Operations  
Address:  Clear Creek Bio, Inc.  
[ADDRESS_883708], 4th Floor,  
Cambridge, MA [ZIP_CODE]  
Telephone No.:  [PHONE_13585]  
Fax No.:  [PHONE_13586]  
E-mail:  [EMAIL_12502]   
 
MEDICAL MONITOR  
Name:  [CONTACT_656463], MD  
Title:  Senior Medical Director  
Telephone No.:  (609) 212 -7892  
E-mail:  [EMAIL_12503]  
 
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 16 of 51 
PROTOCOL VERSION  2.0 DATE:  15 SEPT 2020  
 
Clear Creek Bio, Inc.  
CONFIDENTIAL  3 INTRODUCTION  
3.1 Coronavirus -19 (COVID -19) 
Beginning in December  2019, Chinese scientists isolated a novel coronavirus, severe acute respi[INVESTIGATOR_11520] 2 (SARS -CoV -2) from patients with virus -infected pneumonia which was later 
designated as coronavirus disease 2019 (COVID -19) by [CONTACT_88442] (WHO) ( Zhou 
et al., 2020  [2]; Phelan et al., 2020  [3]).  
Approximately 14% of those affected with this virus will develop severe disease requir ing 
hospi[INVESTIGATOR_656306]; 5% will require admission to the intensive care unit ( Handel et 
al., 2020  [4]). Severe cases may be complicat ed by [CONTACT_171958][INVESTIGATOR_656307] (ARDS), sepsis 
and septic shock, and multi -organ failure, including acute kidney injury and cardiac injury. Risk 
factors for death include older age and co -morbid disease such as hypertension and diabetes ( Zhou, et 
al., 2020  [2]). This means that most  patients will be treated as out -patients. Reducing viral load in this 
environment is critically important for both the subjects themselves by [CONTACT_656397][INVESTIGATOR_059], but also to reduce the transmission of the disease to 
others in the patients households and their communities.  
3.1.[ADDRESS_883709] RNA building blocks, and without these building blocks they are unable 
to replicate.  The SARS -CoV -2 is a single -stranded (positive sense) RNA virus with a genome that is 
29,811 nucleotides long, quite a lot larg er than other RNA -based viruses (e.g. the hepatitis C genome 
comprises only 9600 nucleotides). The nucleotide composition is broken down as: 29.9% adenosines, 
18.4% cytosines, 19.6% guanines, and 32.1% uridines  (Sah et al., 
2020  [12]). 
3.[ADDRESS_883710] de novo  pyrimidine synthesis generates uridine monophosphate 
(UMP) as the building block for all pyrimidine ribonucleotides and 
deoxyribo nucleotides  (Figure 3 -1). There exists no salvage pathway 
for the synthesis of UMP, the fundamental building block  of 
pyrimidines . Inhibition of enzymatic steps upstream of UMP  (Figure 
3-1) leads to a rapid  and profound  depletion of intracellular 
pyrimidines.   
3.3  Dihydroorotate dehydrogenase (DHODH)  
The enzyme dihydroorotate dehydrogenase ( DHODH ) catalyzes the 
4th step of de novo  pyrimidine synthesis  and inhibition of DHODH 
completely halts all pyrimidine production. As sh own in  Figure 3 -1, 
DHODH  is located on the inner mitochondrial membrane and 
transfers electrons between DHO and complex III of the electron - 
Figure 3-1. DHODH is a 
mitochondrial enzyme that 
catalyzes the 4th step of pyrimidine 
synthesis; it is completely essential 
for the generation of UMP.    

PROTOCOL NUMBER:  CCB -CRISIS -02      Page 17 of 51 
PROTOCOL VERSION  2.0 DATE:  15 SEPT 2020  
 
Clear Creek Bio, Inc.  
CONFIDENTIAL  transport chain via the reduction of its ubiquinone (coenzyme Q10) cofactor.  
DHODH is a clear therapeutic target fo r the inhibition of host pyrimidine synthesis. The chemical 
inhibition of DHODH in vitro  or in vivo  leads to the rapid depletion of UMP and subsequent depletion 
of downstream products thymine and cytosine.  This forces a cell to rely on the salvage of extracellular 
pyrimidine nucleotides and this extracellular salvage is not capable of maintaining the ce lls normal 
nucleotide pool  (Sykes et al., 2016) [ 1]).    
3.[ADDRESS_883711] -targeting antiviral. 
It is an orally available and potent inhibitor of dihydroorotate dehydrogenase (DHODH) , the enzyme 
that catalyzes the fourth step in pyrimidine synthesis, namely the conversion of dihydroorotate (DHO) 
to orotate.  DHODH inhibitors, including brequinar, inhibit de novo  pyrimidine synthesis thereby 
[CONTACT_331577] a depletion of a cells pool of uridine, cytidine and thymidine ribonucleotides and 
deoxyribonucleotides.  
The anti viral activity of brequinar has been demonstr ated in studies  of rotavirus replication in human 
intestinal Caco -2 cell s as well as in human primary intestinal organoids  (Chen et al., 2019  [6]). 
Treatment with teriflunomide , another DH ODHi,  has been effective in vitro  and in vivo  in a murine 
model of foot and mouth disease virus (Mei-Jian et al., 2019  [7]). DHODH inhibition (DHODHi) also 
inhibited the growth of dengue virus in vitro  (Wang et al., 2011  [8]). DHOD Hi also showed antiviral 
effects against RNA viruses including influenza A, Zika, Ebola and coronavirus SARS -CoV -2 (Xiong 
et al., 2020  [11]). Brequinar has also been shown to inhibit the replication of Ebola virus , vesicular 
stomatitis virus and Zika virus in vitro (Luthra et al., 2018  [9]). Brequinar inhibits the replication of 
human immunodeficiency virus ( HIV) in vitro  (Andersen et al., 2019  [10]). When considering 
brequinar as an antiviral for treatment of SARS -CoV-2, oral brequinar is highly bioavailable (>95%) 
and has good penetration of lung tissue  with an average tissue:blood ratio of 0.5 following a single 
dose of brequinar in the rat . It is therefore expected to achieve a similar period of DHODH inhibition 
in lung tissue  (Brequinar IB  [5]). 
3.5  Rationale for the Planned Trial  
DHODH inhibition has been extensively studied as a potential therapeutic target in the treatment of 
RNA -based viruses. The inhibition of DHODH is effective in inhibiting viral replication in pre -clinical 
models involving many RNA -based viruses with nanomolar potency and a high selectivity index (see 
the Brequinar IB [5], Section 5 ). In these pre -clinical models, the benefit of DHODH inhibition can 
be reversed by [CONTACT_656398], confirming that the on -target effect of 
host pyrimidine depletion is key to the anti -viral activity.  
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 18 of 51 
PROTOCOL VERSION  2.0 DATE:  [ADDRESS_883712] of care (SOC) with 5 days of brequinar (DHODH 
inhibition) compared to SOC with [ADDRESS_883713] pyrimidine nucleotides, thereby [CONTACT_656399]. A recent 
publication demonstrated that inhibitors of DHODH could potentiate the activity of inhibitors of RNA -
dependent RNA polymerase (RdRp) in the treatment of dengue virus, another single -stranded RNA 
virus  similar to SARS -CoV -2 (Liu et al., 2020 [13]). This inhibition of viral replication may restore 
the balance in favor of the host immune system for the clearance of SARS -CoV -2. 
Marketed DHODHi medications are available, includ ing leflunomide or teriflunomide, however these 
are very weak inhibitors of DHODH with cellular potency ~[ADDRESS_883714] that 5 days of daily doses of 100 mg  p.o. will be safe and well tolerated. A dose of 
brequinar 100 mg achieves plasma concentrations of approxi mately 1 uM (0.4 ug/ml)  that should result 
in sufficient suppression of nucleotide synthesis . When given over 5  days, these plasma concentrations 
are achieved on a daily basis without accumulation, also assuring the safety of this regimen  (see 
Brequinar IB  [5]).  
3.5.2    Risk/Benefit of Brequinar  
As presented in the Brequinar IB  [5], an extensive safety and pharma cokinetic database exists with 
more than 1,000 patients treated with brequinar. Cancer patients (N = 806) have been exposed to this 
compound for treatment of a variety of solid tumors  at various  treatment regimens, doses, and routes  
including a single dose, once weekly, twice weekly, single dose every [ADDRESS_883715]  
also been utilized for patients with  psoriasis and organ transpla nt. The maximum intravenous dose 
given was 2,250 mg/m2 every 3 weeks, and the maximum oral dose was 100 mg/m2 daily for 21 days. 
There has been limited testing of DHODHi to date in the clinic for infection with SARS -CoV -2. 
DHODHi therapy at relatively high  doses in the context of trials for patients with cancer has the 
expected safety side-effects of mucositis and bone marrow suppression.  Importantly, h owever, the 
prior clinical experience in 39 subjects who received daily brequinar for 5 consecutive days a t or lower 
than 100 mg/day show no cases of mucositis and only 1 (2.6%) epi[INVESTIGATOR_656308]. 
Based on these data the [ADDRESS_883716] de novo pyrimidine synthesis  for this period  thus 
decreasing viral load.  Inhibition of DHODH is expected to reduce the ability of the virus to replicate 
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 19 of 51 
PROTOCOL VERSION  2.0 DATE:  [ADDRESS_883717] been the primary dose -limiting toxic ities. In addition, skin rash, nausea/vomiting, fatigue, and 
leukopenia have been dose -limiting in trials utilizing other schedules of brequinar administration. 
However , these effects were self -limiting, transient, required treatment in few cases,  and reso lved 
following discontinuation of dosing . These adverse effects have been associated  with higher doses of 
brequinar given via the intravenous route and for longer durations than the 100 mg dose and 5 -day 
regimen proposed for this study .  
In addition to studying a higher risk population  with symptomatic COVID -19, a comprehensive safety 
monitoring plan will be utilized in this study to assess the ongoing safety and well -being of participants 
(see Section 10.8).  
3.[ADDRESS_883718] been no apparent hepat otoxic  effects in 
the clinical studies. Brequinar itself does not appear to be a substrate for metabolism by [CONTACT_9058] 
P450 enzymes when tested under a variety of conditio ns. (See Brequinar IB [5]; nonclinical d ata on 
file with Clear Creek).   
3.8 Steps to be Taken to Control or Mitigate Risks  
All subjects will be treated  by [CONTACT_656400] .  
 
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 20 of 51 
PROTOCOL VERSION  2.0 DATE:  15 SEPT 2020  
 
Clear Creek Bio, Inc.  
CONFIDENTIAL  4 TRIAL OBJECTIVES  
4.1 Primary Objective  
To demonstrate a change from baseline in quantitative SARS -CoV -2 viral load for brequinar -treated 
subjects compared to placebo -treated subjects through Day  29. 
4.2 Secondary Objectives  
The secondary objectives of this study are:  
Through Day 29:  
 To characterize  the safety and tolerability of brequinar in  out-patient  COVID -19 subjects  as 
measured by [CONTACT_656340] 3 and 4 AEs and SAEs ; 
 To demonstrate a shorter duration of viral shedding in subjects treated with brequinar compared 
to subjects who received placebo ;  
 To reduce the percentage of subjects  requiring hospi[INVESTIGATOR_656309]  >24 hours  for 
brequinar subjects compared to  subjects who received placebo ; 
 To reduce all -cause mortality  through Day 29  for brequinar subjects compared to  subjects who 
received placebo . 
4.3 EXPLORATORY OBJECTIVES  
Through Day 29:  
 To determine time to viral clearance (two consecutive negative tests) ;  
 To determine time to resolution of new onset COVID -19-related clinical symptoms and pre -
existing  non-COVID -19 symptoms returned to baseline ; 
 To determine time to clinical improvement  as measured by a favorable shift in the WHO Ordinal 
Scale score for the subset of subjects with baseline WHO Ordinal Scale of 2  for brequinar subjects 
compared to  subjects who received placebo . 
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 21 of 51 
PROTOCOL VERSION  2.0 DATE:  [ADDRESS_883719] of care per (SOC) institutional 
guidelines for treatment of patients with COVID -[ADDRESS_883720] a Screening Visit followed as soon as possible with Study Day 1. Study procedures 
are presented in detail in the Schedule of Events (Appendix 15.1). Study visits (virtual or in person) 
will take place at Screening and on Study Days 1, 8, 15, 22, and 29. The visits that include bloodwork 
must be conducted at the study site or arrangements made for sample collection at the subjects home 
or other appropriate location. Other visits/visit activities for that visit may be conducted remotely using 
telemedicine  or other remote technique . Subjects are to self -collect a viral load sample, obtain their 
respi [INVESTIGATOR_697], heart rate, body temperature and SpO2, and complete a symptom assessment checklist 
on Days 1, 4, 8, 12, 15, 22, and 29.    
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 22 of 51 
PROTOCOL VERSION  2.0 DATE:  15 SEPT 2020  
 
Clear Creek Bio, Inc.  
CONFIDENTIAL  6 TRIAL ENDPOINTS  
6.1 Primary Endpoint  
Quantitative SARS -CoV -2 viral load  through Day  29. 
6.2 Secondary Endpoints  
The secondary endpoints  of this study are:  
Through Day 29:  
 Rates of AEs and SAEs including laboratory assessments ; 
 Duration of viral shedding ;  
 Percentage of subjects requiring admission as an inpatient for  >24 hours . 
 All-cause mortality.  
6.3 Exploratory Endpoints  
Through Day 29:  
 Time to viral clearance (two consecutive negative tests) ;  
 Time to resolution of new onset COVID -19-related clinical symptoms and pre -existing non-
COVID -19 symptoms returned to baseline ; 
 Time to clinical improvement  measured by a favorable shift in WHO Ordinal Scale score for the 
subset of subjects with baseline WHO Ordinal Scale of 2 . 
 
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 23 of 51 
PROTOCOL VERSION  2.0 DATE:  [ADDRESS_883721] of care plus placebo in a 1:1 ratio ( approximately 
[ADDRESS_883722] of care  plus placebo ).  
7.2 Inclusion criteria  
1. Willing and able to provide informed consent for the trial, written, electronic, verbal or other 
method deemed acceptable by [CONTACT_656353].  
2. 18 years of age or older.  
3. Laboratory -confirmed SARS -CoV -2 infection as determined by [CONTACT_656401] e chain 
reaction (RT -PCR) or other FDA -approved commercial or public health assay  within [ADDRESS_883723] dose . 
4. Out-patient ( never hospi[INVESTIGATOR_656326] -patient for COVID -19 or was evaluated/treated for 
COVID -19 only in the Emergency Room with a stay of < 24 hours) . 
5. The effects of brequinar on the developi[INVESTIGATOR_19241] . For this reason, women 
of child -bearing potential and men must agree to use adequate contraception (hormonal or 
barrier method of birth control; abstinence) prior to study entry  and for the duration of study 
participation. Should a woman become pregnant or suspect she is pregnant while she or her 
partner is participating in this study, she should inform her treating physician immediately. 
Men and women treated or enrolled on this  protocol must also agree to use adequate 
contraception for the duration of study participation, and for [ADDRESS_883724] one COVID -19 symptom including but not limited to fever, cough, sore throat, 
malaise, headache, muscle pain, gastrointestinal  symptoms, sho rtness of breath, dyspnea, 
anosmia , dysgeusia, or other symptom commonly associated with COVID -19. 
8. Able to swallow capsules.  
7.3 Exclusion Criteria  
1. Any physical examination findings and/or history of any illness that, in the opi[INVESTIGATOR_656327], might confound the results of the study or pose an additional risk to the patient  
2. Nursing women or women of childbearing potential (WOCBP) with a positive pregnancy test  
3. Treatment with another DHODH inhibitor (e.g., leflunomide, teriflunomide ) or other agents 
known to cause bone marrow suppression leading to thrombocytopenia  
4. Platelets 150,000 cell/mm3 
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 24 of 51 
PROTOCOL VERSION  2.0 DATE:  15 SEPT 2020  
 
Clear Creek Bio, Inc.  
CONFIDENTIAL  5. Hemoglobin < 10 gm/dL  
6. Absolute neutrophil count < 1500 cells/mm3 
7. Renal dysfunction, i.e., creatinine clearance < 30 mL/min  
8. AST and/or ALT > [ADDRESS_883725], or total bilirubin > ULN . Gilberts Syndrome is allowed.  
9. Bleeding disorders or blood loss requiring transfusion in the six weeks preceding enrollment  
10. Ongoing  gastrointestinal ulcer, or gastrointestinal bleeding  within [ADDRESS_883726] dose. 
11. Chronic  hepatitis B  infection , active hepatitis  C infection, active liver disease and/or cirrhosis  
per subject report.  
12. Heart failure, current uncontrolled cardiovascular disease, including unstable angina, 
uncontrolled arrhythmias, major adverse  cardiac event within 6 months (e.g. stroke, 
myocardial infarction, hospi[INVESTIGATOR_144651], or revascularization procedure).  
 
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 25 of 51 
PROTOCOL VERSION  2.0 DATE:  [ADDRESS_883727] of care (SOC) for COV ID-19 infection. 
Subjects will be randomly assigned in a 1: [ADDRESS_883728] of care 
plus placebo . 
8.2.1 Safety/Tolerability  
Safety/tolerability is assessed for each subject at each study visit . The NIH Division of AIDS (DAIDS) 
Table for Grading the Severity of Adult and Pediatric Adverse Events, Corrected Version 2.1 (July 2017)  
will be utilized for AE reporting. All appropriate treatment areas should have access to a copy of the 
criteria .  
Adverse events (AEs) commonly observed in patients treated with brequinar are provided in the 
Investigators Brochure  (IB) and include thromb ocytopenia, nausea, anemia, diarrhea, vomiting, 
leukopenia, stomatitis, rash, granulocytopenia, fatigue,  and infection . In a study of 209 cancer subjects 
treated once -weekly  (DuP 785 -012, see Brequinar IB  [5]), the deaths of three patients were attributed 
to study drug toxicity (two to hemorrhage , one following acute renal failure). Severe toxicities grades 
(Grades 3 to 4) which typi[INVESTIGATOR_656328] 
(anemia , thrombocytopenia, leukopenia , granulocytopenia ), digestive  system toxicity (nausea, 
vomiting, stomatitis , others  including gastric hemorrhage) and mucositis.  
In three oncology studi es with five consecutive days of intravenous (IV) brequinar dosing in 168 
subjects (Study 785 -001 [14], 785-003 [15], and 785-005 [16]) there were no toxic deaths . For 
subjects from these three studies who were treated with a daily dose of 100 mg or below  (as will be 
dosed in CCB -CRISIS -02), AEs through 21 days showed that 2 of 39 subjects (5.1%) had a severe 
(Grades 3 or 4) AE related to study drug ([ADDRESS_883729] each with hyperbilirubinemia and 
hyperglycemia), and no subjects discontinued from the study due to a study drug -related AE. The 
few study drug related AEs through [ADDRESS_883730] each with 
thrombocytopenia and diarrhea. When only studies with oral dosing were considered at this dose 
level  (Studies 785 -022 [17], 785 -031 [18] , and  785-034 [19]), the study drug related AEs through 
21 days (each observed in on e subject only) included diarrhea, headache, nausea, pruritus, 
abdominal pain, anorexia, chest pain, dry mouth, fatigue, keratosis, stomatitis, and vomiting. See 
brequinar IB [5]. 
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 26 of 51 
PROTOCOL VERSION  2.0 DATE:  [ADDRESS_883731] Study Day 29 (or longer if needed to follow up study 
drug-related adverse events).  Participants may discontinue  from the study by [CONTACT_656402] 9.7. 
8.4 Stoppi[INVESTIGATOR_2121]  
8.4.1 Individual Stoppi[INVESTIGATOR_2121]  
 Participants who develop a Grade 3 toxicity that is assessed by [CONTACT_656403] a re to be permanently discontinued from study treatment.  
 Participants who develop a Grade 4 toxicity, regardless of relatedness to study drug, are to  be 
permanently discontinued from study treatment.  
 Subjects who develop Grade 3 or 4 toxicities are to be fo llowed by [INVESTIGATOR_1312] -evaluation every 2 days, 
as feasible, until the toxicity returns to  Grade 2 severity.  
8.4.2 Study -Level Stoppi[INVESTIGATOR_656312] : 
 If  [ADDRESS_883732] s develop the same  related Grade 4 (life -threatening) adverse event or laboratory 
abnormality ; 
 If  5 subjects develop the same  related Grade 3 or 4 adverse event or laboratory abnormality ; 
 If  10 subjects develop any related Grade 3 or 4 adverse event or laboratory abnormality .  
Following assessment by [CONTACT_1578] (DMC, see Section 10.9), the DMC will 
determine whether to stop the study, amend the protocol, or continue the study per protocol.  
8.5 Concomitant Medication/Treatment  
Record t he name, dose, start/stop  date, indication for use , route, and whether ongoing or stopped for 
medications/treatments taken within two weeks prior to study entry  as well as any medications taken 
during the study  are to be recorded . Prohibited medications are identified in Section 8.8.  
8.[ADDRESS_883733]s medication diary and study records as 
appropriate.  
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 27 of 51 
PROTOCOL VERSION  2.0 DATE:  [ADDRESS_883734] of care plus  placebo . The brequinar and placebo capsules will be 
provided to each participating institution  in pre -numbered bottles intended for individual subjects to 
be dispensed by [CONTACT_8236]s pharmacist  or designated person . Randomization assignments will be 
provided by [CONTACT_656404] . The pharmacist/designate d 
person will dispense the next number in sequence to the next patient who qualifies for the study at an 
individual site.  
8.7.4 Unblinding/ Expectedness  
Contact [CONTACT_656405] (AE) . Each site will be provided with a sealed envelope containing individual 
sealed envelopes for subject numbers assigned to that site. Each individual subject number sealed 
envelope will have the treatment (brequinar or placebo) randomly assi gned to that subject number. Do 
not open the outer envelope or the individual sealed envelope unless it has been agreed with the 
Medical Monitor and the Sponsor that unblinding is necessary for that particular AE. Unblinding must 
be documented in the study  records. Envelope seals are to be checked to ensure they remain intact 
during drug accountability monitoring.  
If after a discussion with the Medical Monitor, the investigator or treating clinician believes the AE 
leading to unblinding to be related to the  study drug, no further doses of drug should be administered  
to that subject .  
Expectedness will be determined by [CONTACT_656406] -[ADDRESS_883735] . Adequate drug is to be dispensed for the number of subjects expected 
to be treated at each institution.   
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 28 of 51 
PROTOCOL VERSION  2.0 DATE:  [ADDRESS_883736]/ staff member  responsible for drug accountability is to document t he date and time  of 
dispensing  and for what subject the study drug was intended (i.e., record subject initials and birth date 
or other unique identifier). A pharmacy manual will be provided by [CONTACT_1034].   
At the end of the study any unused study drug  will be returned to the Sponsor for destruction or may 
be destroyed locally; disposition of study drug  will be documented .   
The Sponsor will be permitted access to the trial supplies at any time within usual business hours and 
with appropriate notice during or after completion of the study to perform drug accountability 
reconciliation.  Records may be electronic or paper and may be accessed remotel y for monitoring/drug 
accountability purposes.  
Each subject will be provided with one bottle with five brequinar or five placebo capsules for the five 
days of dosing.  
8.8 Prohibited Medications  
Treatment is prohibited with another DHODH inhibitor (e.g., leflunomide and teriflunomide ). 
Treatment is prohibited with agents known to cause bone marrow suppression leading to 
thrombocytopenia.  
8.[ADDRESS_883737] of care is 
expected to chang e as additional information, such as that from randomized controlled trials, emerges, 
and the Sponsor and the treating clinicians will need to address anticipated off -label use of any other 
drugs, devices, or interventions that might be used to manage COVI D-19 (e.g. anticoagulants).  
The Sponsor and treating clinicians are to consider changes in SOC over time, for example, 
overlappi[INVESTIGATOR_656313] a SOC treatment expected to be widely used is to be 
considered. The availability of new standard  of care treatment may change over time and vary from 
one clinical trial site to another. The Sponsor will discuss these issues with FDA should the need arise.  
 
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 29 of 51 
PROTOCOL VERSION  2.0 DATE:  [ADDRESS_883738] OF THE TRIAL  
9.1 Ethical and Regulatory Considerations  
The trial will be performed in accordance with the Declaration of Helsinki (1964)  as revised in Tokyo 
(1975), Venice (1983), Hong Kong (1989), South Africa (1996), Scotland (2000, Note of Clarification 
2002 & 2004) and Seoul 2008 (Appendix A), and Fortaleza (Brazil) (2013),  and with the International 
Council on Harmonization ( ICH) Tripartite Guideline on Good Clinical Practice (CPMP/ICH/135/95, 
Jan.97) and [LOCATION_002] ( US) FDA Regulations.  
9.[ADDRESS_883739] be obtained in accordance with US Code of Federal Regulations (21 CFR Part 50) ,  the 
FDA Guidance on Conduct of Cl inical Trials of Medical Products during the COVID -19 Public Health 
Emergency (March 2020, Updated April 16, 2020)  [20], as well as local and national regulations. 
Information should be given in both oral and written form whenever possible and deemed app ropriate 
by [CONTACT_4707] ( IRB). Subjects  and their relatives, if necessary, must be given 
ample opportunity to inquire about d etails of the study.  
The Investigator  or qualified designated person  will verbally inform subjects as to the nature, expected 
duration and purpose of the trial, the administration of the Investigational Product ( IP), and the hazards 
involved, as well as th e potential benefits that may come from treatment with this IP. The trial 
procedures will be explained in lay language and any questions will be answered.  The subjects will be 
given an IRB-approved consent form. The subjects will be given appropriate time to consider their 
participation in the trial and have any questions answered prior to signing the consent form. If a subject 
agrees to participate, he/she will sign and date an informed consent form and be provided with a copy 
of the signed consent. All su bjects who sign a n informed consent form are to be recorded on the 
applicable screening log . If the subject is unable to consent for any reason, a designated family member 
or healthcare power of attorney or other person may consent per institutional policy .  
The subject will be informed that his/her  medical records will be subject to review by [CONTACT_1034], 
Sponsors representatives , and possibly by a representative of the FDA  and other relevant regulatory 
authorities. Subjects will be informed that they are free to refuse participation in this clinical 
investigation, and if they should participate, it will be made clear to them that they may withdraw from 
the trial at any time  without prejudicing further  medical  care they may require . The subject will receive 
a copy of the consent form as well as an information sheet about the trial.  
Informed consent must be obtained from every subject  prior to any study -specific procedures . 
Standard procedures carried out prior to completing  the informed consent process but within the time 
constraints of the protocol may be used for baseline evaluation; they need not be repeated. 
Documentation of c onsent will be subject to review by [CONTACT_13099] r; if in writing, a copy will be given 
to the subject  and a copy will be filed with the subjects medical notes.  Verbal consents will be 
documented by [CONTACT_656360].  
Note that informed consent procedures have been affe cted by [CONTACT_4113] -19, and the study staff may use 
any consent method that has been approved by [CONTACT_1201] (e.g., phone consent, verbal consent with 
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 30 of 51 
PROTOCOL VERSION  2.0 DATE:  15 SEPT 2020  
 
Clear Creek Bio, Inc.  
CONFIDENTIAL  witness, e -consent, etc.)  of the local institution . In-person consent, w ritten consent signatures and 
providing har d copi[INVESTIGATOR_656329].  
The study should be discussed with the potential participant only after an initial review of his/her 
clinical status and appropriateness for participation ha ve been evaluated to determine if he/she  meets 
the subject selection criteria.  
A sample subject  information sheet and consent form are available from Clear Creek .  The final 
version at each institution may differ  depending on institutional requirement s and standard format s. 
This protocol will not be amended for site specific changes  as such changes are to be made to the sites 
consent when required . 
9.[ADDRESS_883740]  
It is the responsibility of the Inves tigator to submit the protocol, consent form a nd information sheet 
to the IRB . An IB will be available for review by [CONTACT_1201]. The protocol and informed consent form  
(ICF) must be approved by [CONTACT_656407] . The templa te consent 
form may be revised in accordance with site -specific requirements with Sponsor review and approval.  
A copy of the IRB written approval must be provided  to the Sponsor and investigator before the trial 
may start  at that institution . Written appro val from the IRB is also required for substantial protocol 
amendments prior to their implementation.    
A substantial amendment may arise from changes to the protocol or from new information relating to 
the scientific documents in support of the trial.  Amendments are substantial  when they are likely to 
have an impact on:  
 the safety or physical or mental i ntegrity of the subjects ; 
 the scientific value of the trial;  
 the conduct or management of the trial; or  
 the quality or safety of any IP used in the trial.  
If it is necessary to change or deviate from the protocol to eliminate an immediate hazard to the 
subjects, the Investigator will notify the Sponsor and the IRB of the new events and the measures taken 
as soon as possible.   
The Investigator will report promptly to the Sponsor and IRB any new information that may adversely 
affect the safety of the subject s or the conduct of the trial. On completion of the trial, the Investigator 
will inform the applicable IRB as per local IRB requirements that the trial has ended. If the study is 
terminated for any reason , the investigator will return all clinical supplies  and study -related equipment 
supplied by [CONTACT_656362].  
9.[ADDRESS_883741] the saliva sample for viral load testing  and perform 
other study activities such as body temperature, heart rate, respi[INVESTIGATOR_697], SpO2,  and symptom 
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 31 of 51 
PROTOCOL VERSION  2.0 DATE:  [ADDRESS_883742] of study assessments and timings.   
Blood chemistry tests include blood urea nitrogen (BUN), creatinine, alkaline phosphatase (AL K), 
alanine amino transferase (ALT), aspartate amino transferase (AST), total bilirubin, total protein, 
albumin, glucose, serum electrolytes (sodium, potassium, chloride, carbon dioxide/bicarbonate, and 
calcium ), lactate dehydrogenase (LDH) . 
Hematology test s include hemoglobin, hematocrit, complete blood count with full differential , and 
platelet count.  
Viral load sampling  is to be carried out on Days [ADDRESS_883743] a documented positive result to be 
eligible fo r the study.  
Hospi[INVESTIGATOR_656330] -patient with admission > 24 hours.    
As much of the study as possible will be conducted via telemedicine remote from the site (e.g. , consent , 
medical history, concomitant medications may be collected remotely) . Subjects will be visited at home 
(or place of residence) by a home health nurse at Screening  and on study Days 1, 8, 15, 22, and 29. 
On study Days [ADDRESS_883744]  
The study visits are to be conducted as shown in the Schedule of Events, Appendix 15.1. 
Study completion or the reason for study discontinuation will be recorded in the source document and 
the eCRF.  
9.5.1 Unscheduled Visits  
Unscheduled visits and tests  are permi tted as needed  to assess AEs /SAEs  throughout the study. 
Unscheduled visits and tests  are also permitted as needed to assess  AEs/  SAE s with onset within two 
(2) weeks after the final study  visit providing the AE is considered related to study drug  
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 32 of 51 
PROTOCOL VERSION  2.0 DATE:  [ADDRESS_883745]s study participation  after discussion 
with the other party if  it is believe d it would be unsafe for the subject to continue in the study .   
Subjects must discontinue study medication  if any of the following events occur:  
 Significant protocol violation or non -compliance, either on the part of the subject or the 
investigator or other site personnel;  
 Decision of the Investigator or Sponsor that removal is in the subject's best interest;  
 Severe unrelated medical illness or complication;  
 Safety reasons/ significant adverse event;  
 Subject request (withdrawal of consent);  
 Sponsor decision.  
Collect/co nduct  all scheduled evaluations  even for subjects who discontinue stu dy medication  prior to 
completing the treatment  period  unless consent is withdrawn . 
9.8 Early Termination of the Study  
If the Sponsor or an Investigator believes it would be unsafe to continue the study, or for any reason 
at the Sponsors request, the study may be terminated at that site or the entire study terminated after 
discussion with the other part ies. 
The Sponsor will provide a written statement to the IRB and the relevant regulatory authority with the 
reasons for termination of the study. This will be c onducted within 15 days of the decision to terminate 
the study.  
If the study is terminated, a close out monitoring visit will be performed and applicable procedures 
will be carried out to close the trial site(s).  
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 33 of 51 
PROTOCOL VERSION  2.0 DATE:  [ADDRESS_883746] had a hysterectomy or tubal ligation. A woman is also presumed to be infertile due to natural 
causes if she has been amenorrheic for greater than 12 months and has an FSH greater than 40 IU/L.  
In the absence of such  documentation, a negative serum pregnancy test is required for inclusion into 
the study.  
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 34 of 51 
PROTOCOL VERSION  2.0 DATE:  [ADDRESS_883747] a causal relationship with this treatment. An 
AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), 
symptom, or disease temporally associated with the use of the medicinal product, whether or not 
considered related to the medicinal product.  
Events that occur prior to  first dose  will be entered as medical history; events  that occur after first dose  
will be ente red as adverse events (AEs)  on the AE form.  
Subjects will be questioned and observed for evidence of AEs, whether or not judged by [CONTACT_656363] . All AEs will be documented in the 
subject's medical record and CRF. For any pre -existing condition or abnormal laboratory finding that 
changes in severity after dosing, this change should be recorded as an AE. New abnormal laboratory 
findings that are clinically significant are considered AEs. 
Adverse events  will be collected  from the time of first dose  through  Day 29. After Day 29, 
collect/record only Serious Adverse Events (SAEs) which are  assessed  by [CONTACT_656364].  AE details are to be documented including start and 
stop date and times, whether continuous or intermittent, severity, any intervention utilized to correct 
the event  (e.g., medication, surgery , or other therapy) , outcome and the relationship to the study drug.   
AEs identified in the protocol as critical to the evaluation of safety mus t be reported to the Sponsor by 
[CONTACT_656365].  
AEs determined by [CONTACT_656408] c onsidered stable or for at least [ADDRESS_883748] results occurring after study enrollment constitute AEs only if they 
induce clinical signs or symptoms, are considered clinically significant , are Grades 3 or 4, or require 
therapy.  
If a death occurs during the SAE reporting period, the cause of death such as pneumonia, ARDS, or 
respi[INVESTIGATOR_1399], is considered as the AE and the death is considered its outcome. Death should be 
considered an o utcome, not an event. The event or condition leading to death should be recorded and 
reported as a single medical concept on the AE eCRF. Generally, only one such event should be 
reported. Fatal will be recorded as the outcome of this respective event; d eath due to an outcome of 
an AE will not be recorded as separate event. If the primary cause of death is disease progression, the 
cause of death should be clearly identified as COVID -19. 
In cases of surgical or diagnostic procedures, the condition leading to the procedure is considered as 
the AE instead of the procedure itself. Each AE will be coded by [CONTACT_656409] a preferred term using a thesaurus based on the Medical Dictionary for Regulatory Activities 
(MedDRA) . For example, rec ord appendicitis, not appendectomy.  
The following g uidelines will be followed for the recording and reporting of adverse and serious 
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 35 of 51 
PROTOCOL VERSION  2.0 DATE:  [ADDRESS_883749] dose  are to be recorded in the eCRF using the AE form.  
3. Serious adverse events will be reported to the local IRB according to institutional policy.  
The NIH Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse 
Events, Corrected Version 2.1 (July 2017) 
(https://rsc.niaid.nih.gov/sites/def ault/files/daidsgradingcorrectedv21.pdf ) will be used for adverse 
event reporting.    
10.1 Follow Up of Grade 3 or 4 Toxicities  
Grade 3 or 4 toxicities are to be followed by [INVESTIGATOR_1312] -evaluation every 2 days, as feasible, until the toxicity 
returns to Grade  2 severit y. 
10.2 Infection Follow Up  
Any new infection that occurs on study regardless of infecting agent (i.e., viral or non -viral) should be 
captured. Additionally, the site of infection and source of culture (BAL, tracheal aspi[INVESTIGATOR_337], sputum, 
blood, urine, etc.) should  also be recorded.  
10.3 Classification of Causality  
Attribution is the relationship between an adverse event or serious adverse event  
and the study treatment. Attribution will be assigned as follows:  
 Definite  The AE is clearly related to the study treatment.  
 Probable  The AE is likely related to the study treatment  
 Possible  The AE may be related to the study treatment.  
 Unlikely - The AE is doubtfully related to the study treatment.  
 Unrelated - The AE is clearly NOT related to the study treatment  
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 36 of 51 
PROTOCOL VERSION  2.0 DATE:  15 SEPT 2020  
 
Clear Creek Bio, Inc.  
CONFIDENTIAL  Guidance for assessing causality:  
The Investigator will need to determine whether an AE is considered related to ( caused by) the 
study drug rather than some underlying condition , for example, COVID -19.   
For the purposes of this study, drug related sh all mean Definite, Probable and Possible 
relationship to drug as determined by [CONTACT_737] . 
10.4 Classification of Severity  
The NIH Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse 
Events, Corrected Version 2.1 (July 2017)  will be utilized for AE reporting. All appropriate treatment 
areas should have access to a copy of the criteria.  
AEs that are expected are subject to expedited reporting only if the adverse event varies in nature, 
intensity or frequ ency from the expected toxicity information that is provided in the Investigator 
Brochure . 
10.5 Serious Adverse Event (SAE) Reporting  
The regulatory definition of a n SAE  is any untoward medical occurrence or effect that at any dose  
fulfills one or more of these  criteria : 
 results in death ; 
 is life threatening (at the time of the event) ; 
 requires in -patient hospi[INVESTIGATOR_1081] ; 
 results in persistent or significant disability / incapacity  
 is a congenital anomaly / birth defect ; 
 or is an  event considered medically serious by [CONTACT_737].  
 
Disability  is defined as a substantial disruption of a persons ability to conduct normal life functions.  
A life -threatening adverse event  is one that places the patient /subject , in the view of the Investigator, 
at immediate risk of death from the event as it occurred.  It does not include an event that, had it 
occurred in a more severe form, might have caused death.   
An unexpected adverse event  is any adverse drug event, the nature or severity of which is not 
consistent with the applicable product information (e.g. IB for an unauthorized  investigational product 
or summary of product characteristics for an authorized  product).  
Enter only one event as the reason for the SAE on the SAE form.  Other non -serious events which did 
not directly result in the SAE should be detailed in the description section on the SAE form and listed 
separately as AEs if necessary.  For fatal SAEs, report the cause of death as an SAE with a fatal 
outcome rathe r than reporting death as the SAE term.  
Note that hospi[INVESTIGATOR_286742]:  
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 37 of 51 
PROTOCOL VERSION  2.0 DATE:  15 SEPT 2020  
 
Clear Creek Bio, Inc.  
CONFIDENTIAL   Routine treatment or monitoring of COVID -19 infection , not associated with any 
deterioration in condition ;  
 Elective or pre -planne d treatment for a pre -existing condition that is unrelated to the 
indication under study and has not worsened since signing the informed consent ;  
 Social reasons and respi[INVESTIGATOR_108999]s general 
condition ; 
 Treatment on an emergency outpatient basis that does not result in hospi[INVESTIGATOR_656331].  
ANY SERIOUS ADVERSE EVENT MUST BE REPORTED IMMEDIATELY (WITHIN 24 
HOURS) BY [CONTACT_656410] E SAE REPORTING EMAIL  USING THE FORM PROVIDED .  
ENTER THE SUBJECTS AVAILABLE INFORMATION INTO THE  eCRF WITHIN [ADDRESS_883750]s subsequent medical course following a n SAE  must be submitted to 
Covance Patient Safety  until the event  has subsided or, in case of permanent impairment, it stabilizes , 
and the overall clinical outcome has been ascertained.  
SAE R EPORTING EMAIL:   SAEIntake@covance .com  
Medical Monitor:  
Norberto Soto, MD  Telephone:  ([PHONE_13587]  
Covance Physician /Medical Monitor  Email:  [EMAIL_12503]  
Sponsor Representative:  
Barbara Powers, MSN, Ph.D.  Telephone:  M: ([PHONE_13588]  
VP, Clinical Operations  Email:  [EMAIL_12502]   
All SAEs will be reported to the IRB  periodically, at the end of the study , or per local institutional 
guidelines.   
10.6 Suspected Unexpected S erious  Adverse Reactions (S[LOCATION_003]Rs)  
Suspected, unexpected, serious adverse reactions ( S[LOCATION_003]Rs ) are SAEs that are both related to the study 
drug (Relationship = Related) and unexpected (not previously described in the investigators 
brochure).  All S[LOCATION_003]Rs will be reported in an expedited manner to the Sponsor or designee  and IRB 
by [CONTACT_656369]. Expectedness will be 
judged by [CONTACT_656370] . It is critical  that all SAEs are reported within 
the 24 -hour guideline so that the expectedness determi nation can be made. S[LOCATION_003]Rs require immediate 
attention and expedited reporting to relevant regulatory authorities.  
The Sponsor will ensure that all relevant information about fatal  or life -threatening  S[LOCATION_003]R s are 
appropriately recorded and reported  to the c oncerned Regulatory Authority and to the concerned 
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 38 of 51 
PROTOCOL VERSION  2.0 DATE:  15 SEPT 2020  
 
Clear Creek Bio, Inc.  
CONFIDENTIAL  IRB(s)  within seven (7) calendar days of the date of first report to Covance Patient Safety / Sponsor . 
Follow -up information will be communicated to the relevant Regulatory Authorit y within an 
additional e ight calendar days.  
All other S[LOCATION_003]Rs will be reported to the Regulatory Authority and to the IRB(s) concerned as soon 
as possible within a maximum of fifteen calendar days of first notification to Covance Patient Safety 
/ Sponsor.  
The Sponsor or designee will also inform all Investigators studying  the investigational medicinal 
product about S[LOCATION_003]Rs  and ensure that all IRBs have been notified . 
For reported deaths of a subject, the Investigator shall supply the Sponsor and the IRB(s) with 
requested additional information on an expedited basis .   
10.[ADDRESS_883751]s partner during the study period will be 
documented in the subjects source documents and reported to Covance Patient Safety (by [CONTACT_20143] 
[EMAIL_6533])  and to the IRB by [CONTACT_656411] [ADDRESS_883752]s 
partner will begin at the first dose of study drug and will continue through [ADDRESS_883753]s partner has consented to this. Monitoring of the baby [CONTACT_656412] [ADDRESS_883754]s partner has con sented to this.  
Pregnancy itself is not an AE; it should be reported for tracking purposes. The Investigator or designee 
will discontinue the pregnant subject from the treatment aspects of the study, continue to follow her 
per protocol for safety outcomes  only, and advise her to seek prenatal care and counseling from her 
primary care provider. Data on fetal outcome and breast -feeding will be collected for regulatory 
reporting and drug safety evaluation , if the subject has consented to this . 
If the pregnanc y is due to a subjects failure to comply with the contraceptive requirements of this 
protocol, this should be documented as a protocol deviation.  
Complications of pregnancy or congenital abnormalities in the newborn child will be reported 
appropriately a s (S)AEs.  
The site clinical staff will request the pregnant subject to notify the site of the outcome of the 
pregnancy (i.e., birth, loss, or termination). To help ensure this, the site clinical staff will follow the 
subject until the end of pregnancy, wi th the subjects consent. This request and the subjects response 
will be documented in the subjects source document.  
10.[ADDRESS_883755] to he matologic toxicity. In addition to enhancing safety by 
[CONTACT_459704]:  CCB -CRISIS -02      Page 39 of 51 
PROTOCOL VERSION  2.0 DATE:  15 SEPT 2020  
 
Clear Creek Bio, Inc.  
CONFIDENTIAL  selecting a relatively brief 5 -day exposure and a low brequinar dose, all subjects in the clinical trial 
will be under the care of highly qualified medical personnel. Clinically significant out -of-range 
laboratory  results will be reported as adverse events.  
In addition to real time assessments by [CONTACT_314107], t he Covance  Medical Monitor will 
assess the available hematology data on a periodic  basis to identify any pathologic trends or safe ty 
issues. Any apparent increase in the expected rate or severity of hematologic safety events will be 
discussed with the Princip al Investigators  and the Sponsor. In addition, the Data Monitoring 
Committee (DMC) will assess available hematology data on a periodic  basis to independently assess 
any pathologic trends or safety issues.  If the rate or severity of hematologic toxicities appears to be 
above the expected rate or the severity appears worse than that expect ed, the trial enrollment will be 
suspended and no further subjects will be treated while a comprehensive data review is conducted. 
Depending on the outcome of the safety review the study may be stopped , the design adjusted , or the 
study may continue as des igned . Individual and Study stoppi[INVESTIGATOR_656332] 8.4. 
Safety laboratory results are to be initially assessed in real time by [CONTACT_656413]. Any study drug -related clinically significant out -of-range laboratories or study 
drug-related adverse events will be followed as needed until resolution or stable.  
The in-clinic  assessments and telemedicine /phone call visits will  specifically ask about possible 
hematologic toxicity including any evidence of  the list below. Subjects will be provided with a list of 
the following events in lay terms and will be instructed to call the research team if any of these events 
occur.  
 Ecchym osis/purpura/petechiae  
 Epi[INVESTIGATOR_3940]  
 Hemoptysis  
 Hematuria  
 Gingival bleeding  
 Prolonged bleeding time from needle sticks, abrasions or lacerations  
 Hematemesis  
 Rectal bleeding  
 Blood in stool  
 Any other unusual bleeding noted by [CONTACT_656414] e symptoms considered clinically significant will be recorded as an adverse event and must 
be followed until resol ved or stable.  
10.9 Data Monitoring Committee  
A Data Monitoring Committee  (DM C) will be established to provide independent oversight to this 
trial. The primary responsibility of the DMC  will be to review the progress and conduct of the trial in 
order to maintain scientific rigor and to ensure the wellbeing of subjects participating in the trial. The 
specific responsibilities of the DMC  will be detailed in a separate DMC  charter. The DMC  will include 
at a minimum at least one statistician and two clinicians who will perform periodic data review to 
assess whether there are clinically significant differences between treatment arms that could affect 
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 40 of 51 
PROTOCOL VERSION  2.0 DATE:  [ADDRESS_883756] 40 subjects complete the Day 8 visit. 
 
 
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 41 of 51 
PROTOCOL VERSION  2.0 DATE:  15 SEPT 2020  
 
Clear Creek Bio, Inc.  
CONFIDENTIAL  11 STATISTICAL CONSIDERATIONS  
A separate, detailed statistical analysis plan (SAP) will be finalized prior to locking the database. All 
analyses will be descriptive in nature and presented by [CONTACT_19313].   
Summaries for quantitative variables will include the mean, median, quartiles, standa rd error, 
minimum, and maximum. For qualitative variables, the summaries will include the number and 
percentage of subjects for each outcome, and 95% confidence interval (CI) , when appropriate. Any 
statistical testing will be considered exploratory and des criptive. All computations will be performed 
using SAS (Version 9.4 or higher).  
Subject disposition, subject demographics and baseline characteristics will be summarized. Subject 
data listings will also be provided. The following sections will briefly sum marize of the planned 
statistical analyses and analysis sets for the primary and secondary endpoints.  
11.[ADDRESS_883757] dose (treatment -emergent) adverse events  will be tabulated by [CONTACT_167546], and by [CONTACT_78621]. All 
laboratory results  and study assessments  will be summarized using appropriate descriptive statistics.  
11.3 Efficacy Analyses  
Efficacy wi ll primarily be assessed via viral load  changes . 
11.4 Sample Size Considerations  
Formal sample size calculations are not applicable for this proof -of-concept study. The sample size of 
approximately  100 subjects planned to be entered in this trial  is expected to  be adequate to provide 
safety and efficacy information to advise future study design . 
11.5 Randomization  
A randomization scheme will be provided by [CONTACT_656415]  + brequinar  or SOC +  placebo  in a 1: 1 
ratio.  
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 42 of 51 
PROTOCOL VERSION  2.0 DATE:  15 SEPT 2020  
 
Clear Creek Bio, Inc.  
CONFIDENTIAL  11.6 Pooling of Study Centers  
Not applicable to this small, early phase study.  
11.7 Interim Analysis  
No interim analysis is planned for this trial.  
 
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 43 of 51 
PROTOCOL VERSION  2.0 DATE:  15 SEPT 2020  
 
Clear Creek Bio, Inc.  
CONFIDENTIAL  12 INVESTIGATOR RESPONSIBILITIES  
12.1 Investigators Performance  
The Investigator will ensure that all those concerned with conducting the trial are : 
 provided with copi[INVESTIGATOR_656319];  
 trained regarding the conduct of the study and the training has been documente d. 
The Investigator will sign the Investigators Statement and Agreement  found in Section 15.[ADDRESS_883758] that his/her identity will be protected and confidentiality will 
be maintained during all audits and inspections of the trial site and documentation. A unique number 
will be assigned to each subject  at the start of the trial and this, with the subjects initials, will be used 
to identify the subject. In some cases, a further step may be taken to assign fake initials to the subject, 
per individual site requirements. The subjects  number will be the site number followed by [CONTACT_656416], on all trial correspondence and in the trial database. The Investigator will keep a list of 
identification code s or initials used for  each subject  along with the unique number assigned.  
All information provided to the Investigator relevant to the investigational product ( IP), as well as 
information obtained during the course of the trial will be regarded as confide ntial. The Investigator 
and members of his/her research team agree not to disclose or publish such information in any way to 
any third -party without prior written permission from the Sponsor which will not be unreasonably 
withheld, except as required by [INVESTIGATOR_23057] w, or as permitted by [CONTACT_656417], 
Section  12.7. 
The Investigator will take all measures to ensure subjects  confidentiality will be maintained at all 
times.  
12.[ADDRESS_883759] 
access to the subjects ' medical or clinic records is necessary. The Invest igator will ensure that certain 
information is contained in the medical or clinic written or electronic records of the subject  and that 
the entries are signed and dated, as follows:  
 sufficient data to allow verification of the entry criteria in terms of pa st and present medical and 
medication histories;  
 a note on the day the subject entered the trial describing the trial number, the IP being evaluated, 
the trial number assigned to that subject  and a statement that consent was obtained;  
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 44 of 51 
PROTOCOL VERSION  2.0 DATE:  15 SEPT 2020  
 
Clear Creek Bio, Inc.  
CONFIDENTIAL   a note of each subseq uent trial visit including any concerns about AEs and their resolution;  
 notes of all concomitant medication taken by [CONTACT_19578] , including start and stop dates;  
 a note of when the subject  terminated from the trial, the reason for termination and the subje cts 
general condition at termination;  
 a copy of the signed informed consent form should be kept in the medical records of each subject 
during the clinical phase of the study. A signed copy should also be filed in the investigator file.  
12.[ADDRESS_883760] the research staff with 
any q ueries. All queries and discrepancies relating to the data collection are to be resolved at the 
completion of the trial . Remote data capture is encouraged whenever possible.  
12.5 Case Report Forms, Investigators Site File and Record Retention  
The Sponsor may p rovide the CRFs in paper, electronic (eCRF), or other media. The forms will be 
reviewed against source documentation at each monitoring visit. All CRFs and supporting source 
documentation must be completed and available to the Sponsor in a timely manner. C hanges or 
corrections due to data clarification and resolutions will be tracked by [CONTACT_656418].  
Prior to review of the case report forms by [CONTACT_1034]s representative, they should be reviewed for 
completeness and accuracy by [CONTACT_29517] a member of the research team.  
The Investigator must maintain an Investigator Site File which include s, but is not limited to, the IB, 
the protocol plus any amendments, all correspondence with the IRB including the approval for the 
trial to proceed, Regulatory Authority approval/ notification (if applicable) including a sample of an 
approved informed consent, IP accountability, Source D ocuments, investigator and staff curricula 
vitae ( CVs, ) trial documentation, and all trial correspondence. The original signed informed consent 
forms and the final report will be kept in the Investigator Site File.  
The Investigator will archive all essenti al documents. The medical files of trial subjects shall be 
retained in accordance with national legislation and in accordance with the maximum period of time 
permitted by [CONTACT_5035][INVESTIGATOR_307], institution or private practice. The Investigator has a responsibility to retain 
essential documents for as long as is required by [CONTACT_656419]. It 
is the responsibility of the Sponsor to inform the Investigator as to when these documents no longer 
need to be retained. Investigators will b e asked to contact [CONTACT_656420]. Any transfer of ownership of the data or of documents will be docu mented in 
writing. The new owner will assume responsibility for data retention and archiving.  
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 45 of 51 
PROTOCOL VERSION  2.0 DATE:  [ADDRESS_883761] 30 days before its submission for any meeting or journal. In addition, if 
deemed necessary by [CONTACT_656421] t filing, the 
Investigator agrees to a further delay of 60 days before any presentation or publication is submitted. 
The Sponsor reserves the right to include the report of this trial in any regulatory documentation or 
submission or in any informational ma terials prepared for the medical profession.  
Authorship determination will be at the discretion of the Sponsor and will include evaluation of the 
following criteria: Investigator must participate in the review of and content of the protocol; review 
and com ment on the study results; participate in the writing, reviewing and commenting of the 
manuscript; and approve the final manuscript for submission.  
 
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 46 of 51 
PROTOCOL VERSION  2.0 DATE:  15 SEPT 2020  
 
Clear Creek Bio, Inc.  
CONFIDENTIAL  13 SPONSOR RESPONSIBILITIES  
13.1 General  
The Sponsor agrees to adhere to the ICH Note for Guidance on GCP  (CPMP/ICH /135/95, Jan.97)  and 
US FDA Regulations. It is the Sponsor's responsibility to obtain appropriate regulatory approval to 
perform the trial (if applicable). The Sponsor should notify promptly all concerned investigator(s), 
IRB(s) and the Regulatory Authorit y of findings that could adversely affect the health of the patients/ 
subjects, impact on the conduct of the trial or alter the Regulatory Authoritys authorization  to continue 
the trial. If it is necessary to change or deviate from the protocol to elimina te an immediate hazard to 
the subjects the Sponsor will notify the relevant regulatory authority and relevant IRB of the new 
events, the measures taken and the plan for further action as soon as possible.  This will be by [CONTACT_656422] a written report.   
On completion of the trial, the Sponsor will inform the regulatory authority that the trial has ended.  If 
the study is terminated for any reason the Sponsor will provide a written statement to the relevant 
regulatory authorit y and the IRB with the reasons for termination of the trial. This will be conducted 
within [ADDRESS_883762] (EHR) or conduct remote monitoring visits at regular intervals 
during the trial for monitoring purposes and to assist the research staf f with any queries. CRFs and 
source documentation will be available for review during monitoring visits to the trial site. The 
function of this monitoring is to ensure compliance with the protocol, adherence to regulatory and 
GCP  obligations, proper mainte nance of records including IP accountability records, correct 
administration of IP including storage conditions and accurate reporting of AEs. On-site visits are not 
required for any monitoring visits for this study.    
Once the data from the case report fo rms have been entered onto the database, they will be reviewed , 
and the data verified against the subjects source data. Any discrepancies will be tracked by [CONTACT_656423].  
13.4  Audit  
The Sponsor has an obligation to au dit a proportion of studies.  A department other than the clinical 
department will undertake this obligation.  Therefore , the Sponsor, an independent auditor or a 
regulatory authority may audit the trial site and trial documentation. These audits may take p lace while 
the trial is being conducted or up to several years later.   
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 47 of 51 
PROTOCOL VERSION  2.0 DATE:  [ADDRESS_883763] s name, and subject s 
confidentiality will be maintained at all times.  
13.[ADDRESS_883764] of a separate agreement between the Investigator /Institution  and Sponsor.  
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 48 of 51 
PROTOCOL VERSION  2.0 DATE:  15 SEPT 2020  
 
Clear Creek Bio, Inc.  
CONFIDENTIAL  14 REFERENCES   
1. Sykes DB, Kfoury  YS, Mercier FE, et al. Inhibition of dihydroorotate dehydrogenase 
overcomes differentiation blockade in acute myeloid leukemia. Cell 2016; 167(1): 171 -186. 
2. Zhou  F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality 
of adult inpatients with COVID -19 in Wuhan, China: a retrospective cohort study. Published 
online March 9, 2020. https://doi.org/10.1016/S0140 -6736(20)[ZIP_CODE] -3 
3. Phelan  A, Katz R, and Gostin L. The nov el coronavirus originating in Wuhan, China. 
Challenges for global health governance. Jama. 2020;323(8):709 -710.   
4. Handel A, Mille J, Yang G, Fung I. If containment is not possible, how do we minimize 
mortality for COVID -19 and other emerging disease outbre aks. March 13, 2020. 
https://doi.org/10.1101/2020.03.13.20034892 . 
5. Brequinar Investigators Brochure  
6. Chen S, Ding S, Yin Y, Xu L, Li P, Peppelenbosch MP, et al. Suppression of pyrimidine 
biosynthes is by [CONTACT_656385]. Antiviral 
Res. 2019 Jul;167:35 44.  
7. Mei-Jiao G, Shi -Fang L, Yan -Yan C, Jun -Jun S, Yue -Feng S, Ting -Ting R, et al. Antiviral 
effects of selected IMPDH and DHODH inhibitors against foot an d mouth disease virus. 
Biomed Pharmacother. [ADDRESS_883765];118:109305.  
8. Wang QY, Bushell S, Qing M, Xu HY, Bonavia A, Nunes S, et al. Inhibition of Dengue 
Virus through Suppression of Host Pyrimidine Biosynthesis. 2011 Jun 9;85(13):6548 56.  
9. Luthra P, Naidoo J, Pi[INVESTIGATOR_656320], De S, Khadka S, Anantpadma M, et al. Inhibiting 
pyrimidine biosynthesis impairs Ebola virus replication through depletion of nucleoside 
pools and activation of innate immune responses. Antiviral Res. [ADDRESS_883766];158:288 302.  
10. Andersen PI, Krpi[INVESTIGATOR_28947] K, Ianevski A, Shtaida N, Jo E, Yang J, et al. Novel Antiviral Activities 
of Obatoclax, Emetine, Niclosamide, Brequinar, and Homoharringtonine. Viruses. [ADDRESS_883767] 
18;11(10).  
11. Xiong  R, Zhang L , Li S, Sun Y , Ding M , Wang, Y , et al. Novel and potent inhibitors 
targeting DHODH, a rate -limiting enzyme in de novo pyrimidine biosynthesis, are broad -
spectrum antiviral against RNA viruses including newly emerged coronavirus SARS -CoV -2. 
12. Sah R, Rodriguez -Morales AJ, Jha R, Chu DKW, Gu H, Peiris M, et al. Comp lete Genome 
Sequence of a 2019 Novel Coronavirus (SARS -CoV -2) Strain Isolated in Nepal. Microbiol 
Resour Announc. 2020 Mar 12;9(11).  
13. Liu Q, Gupta A, Okesli -Armlovich A, Qiao W, Fischer C, Smith M, et al. Enhancing the 
Antiviral Efficacy of RNA -Dependent RN A Polymerase Inhibition by [CONTACT_656386]. bioRxiv. 2020 Jan 1;2020.03.24.992230.  
14. Study DUP 785 -001 Clinical Study Report (on file with Clear Creek)  
15. Study DUP 785 -003 Clinical Study Report (on file with Clear Creek)  
16. Study DUP 785 -005 Clinical Study Report (on file with Clear Creek)  
17. Study DUP 785 -022 Clinical Study Report (on file with Clear Creek)  
18. Study DUP 785 -031 Clinical Study Report (on file with Clear Creek)  
19. Study DUP 785 -034 Clinical Study Report (on file with Cle ar Creek)  
20. FDA Guidance COVID -19: Developi[INVESTIGATOR_656333] ( https://www.fda.gov/media/137926/download ) 
 
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 49 of 51 
PROTOCOL VERSION  2.0 DATE:  15 SEPT 2020  
 
Clear Creek Bio, Inc.  
CONFIDENTIAL  15 APPENDICES  
15.1 Appendix  A:  CCB -CRISIS -[ADDRESS_883768] dose time  
Procedures  Screen  
(days  
-14 to -1) D1 D2, 3  
( 8 
hrs) D4 
( 8 
hrs) D5 
( 8 
hrs) D8 
( 1 
day)  D12 
( 1 
day)  D15 
( 1 
day) D22 
(1 
day) Final 
Visit   
D29 
( 2 days)  
Informed Consent (note Date and Time)  X          
AE/Concomitant Medications (dose, route, duration 
or ongoing)  X X  X  X X X X X 
Medical history (relevant within one year or 
ongoing)/ History of current illness (date of 
symptom onset or change in baseline co -morbidity 
thought to be due to COVID -19 infection)  X          
Demographics (subject reported height and weight, 
date of birth, gender, race, ethnicity)  X          
Check for Physical Exam abnormalities (subject 
self-reported)  X          
Pregnancy Test (WOCBP)  X 
(serum)          X 
(urine)  
Hematology/Chemistrya X X     X  X   
Vital Signsb X X  X  X X X X X 
Symptom Assessmentc X X  X  X X X X X 
SARS -CoV -2 RT-PCR/ Viral load  sampled X X   X  X X X X X 
Hospi[INVESTIGATOR_656304]       X  X X X 
WHO Ordinal Scale Assessment   X    X  X X X 
Confirm Eligibility   X         
Randomize subject and dispense Study Medication   X         
Study drug administratione  X X X X      
Drug Accountability       X     
aDo not repeat if within 48h of Day 1 visit.  Send to Covance Central Laboratory Services (CCLS) for analysis.  
bVital signs include heart rate, respi[INVESTIGATOR_697], body temperature, and S pO2. Subject will be provided with a thermometer 
and pulse oximeter  with heart rate  monitoring capability . Training will be provided during the first visit by [CONTACT_656393]. Vital signs parameters will be observed and recorded by [CONTACT_656424] a visit by [CONTACT_656395].  
cSymptom Assessment will use a checklist  provided to the subject with  symptoms such as sore throat, cough, GI symptoms 
(vom iting, diarrhea), anosmia, dysgeusia, other (specify), etc.  Severity Mild, Moderate, or Severe will be collected.  
d RT-PCR at Screening may be p erformed by [CONTACT_656425] a positive SARS -CoV -
[ADDRESS_883769] using an 
Oragene collection system or similar. The home health nurse will train the subject and observe sample collectio n on Day 
1. These samples are to be sent to CCLS for analysis.  The viral load sample may also be used to perform viral cultures 
(sample can be split  by [CONTACT_2237] , no additional sample required).  
eSubject  will self -administer study drug once daily Days 1  [ADDRESS_883770] doses in a medication diary.  
Note that any visits/visit activities may be conducted via telephone, telemedicine , or digital media other than serum 
pregnancy test and chemistry/hematology sam ple collection. These labs may be collected at the clinical site or another 
designated out -patient facility/laboratory or collected via home visit.  Arrangements for shippi[INVESTIGATOR_656334].   
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 50 of 51 
PROTOCOL VERSION  2.0 DATE:  15 SEPT 2020  
 
Clear Creek Bio, Inc.  
CONFIDENTIAL  15.2 Appendix  B: Investigators Sta tement and Agreement  
STUDY NUMBER:    CCB -CRISIS -02 
The CRISIS2 Study: A phase 2, randomized , double blind, placebo -controlled, multi -center study 
assessing the safety and anti -coronavirus response of suppression of host nucleotide synthesis in out -
patient adults with SARS -CoV -2.  
INVESTIGATORS STATEMENT AND AGREEMENT  
I (the Investigator ) have read this protocol and hereby [CONTACT_656426].  It is further agreed that the details of this trial and all informatio n provided to me by 
[CONTACT_656388], Inc.  (the Sponsor ) will be held in the strictest confidence and will not be revealed for 
any reason without written authorization from Clear Creek Bio, Inc. except to those who are to 
participate in the conduct of the trial.  
I agree that all data, the case report forms , and all materials provided for the conduct of the trial are 
the property of Clear Creek Bio, Inc.  unless specified otherwise in writing. It is understood that Clear 
Creek Bio, Inc. will utilize the i nformation derived from this trial in various ways, such as for 
submission to government regulatory agencies, required internal reports , and presentations without 
violating patient/ subject confidentiality in any way.  
I further agree that Clear Creek Bio, Inc. or its representatives will be permitted access , in accordance 
with current Good Clinical Practice Guidelines , to all data generated by [CONTACT_656427].  
PRINCIPAL INVESTIGATOR  
[CONTACT_257808]: ____________________________________  
 
Signature: ________________________________ ____________  Date: __________________  
 
  
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 51 of 51 
PROTOCOL VERSION  2.0 DATE:  15 SEPT 2020  
 
Clear Creek Bio, Inc.  
CONFIDENTIAL  15.3 Appendix C: WHO Ordinal Scale  
 
Patient State  Descriptor  Score  
Uninfected  Uninfected; no viral RNA detected  0 
Ambulatory mild disease  Asymptomatic; viral RNA detected  1 
Symptomatic; independent  2 
Symptomatic; assistance needed  3 
Hospi[INVESTIGATOR_057]: moderate disease  Hospi[INVESTIGATOR_057]; no oxygen therapy*  4 
Hospi[INVESTIGATOR_057]; oxygen by [CONTACT_88543]  5 
Hospi[INVESTIGATOR_057]: severe disease  Hospi[INVESTIGATOR_057]; oxygen by [CONTACT_656428]  6 
Intubation and mechanical ventilation, pO 2/FiO 2 150 or SpO 2/FiO 2  200  7 
Mechanical ventilation pO 2/FiO 2 <150 (SpO 2/FiO 2 < 200) or vasopressors  8 
Mechanical ventilation pO 2/FiO 2 <150 and vasopressors, dialysis, or ECMO  9 
Dead  Dead  10 
 
WHO clinical progression scale  
 
PROTOCOL NUMBER:  CCB -CRISIS -02  Page 1 of 51 
PROTOCOL VERSION  3.0 DATE:  23 SEPT 2020  
Clear Creek Bio, Inc. 
CONFIDENTIAL  STUDY PROTOCOL  
The CRISIS 2 Study: A phase 2, randomized , double blind, placebo -controlled, multi -center 
study  assessing the safety and anti -coronavirus response of suppression of host nucleot ide 
synthe sis in out-patient adults with SARS -CoV -2  
Study No: CCB -CRISIS -02 
Version: 3.0 
Version Date:  23 September 2020  
Sponsor:  
Clear Creek Bio, Inc.  
[ADDRESS_883771], 4th Floor,  
Cambridge MA [ZIP_CODE]  
Sponsor Telephone: ([PHONE_13583]  
Sponsor Facsimile: ([PHONE_13584]  
IND Number: 149291  
This confidential document is the property of Clear Creek Bio, Inc .  No unpublished information contained herein may 
be disclosed without the prior written approval of Clear Creek Bio, Inc. This trial will be conducted in accordance with 
the ICH Note for Guidance on Good Clinical Practice (CPMP/ICH/135/95, Jan.97), the De claration of Helsinki (1964, 
1975, 1983, 1989, 1996, 2000 (Note for Clarification 2002 & 2004) and 2008), FDA Regulations and locally applicable 
regulations.  
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 2 of 51 
PROTOCOL VERSION  3.0 DATE:  23 SEPT 2020  
 
Clear Creek Bio, Inc. 
CONFIDENTIAL  TABLE OF CONTENTS  
2 SYNOPSIS  ................................ ................................ ................................ ............................  9 
3 INTRODUCTION  ................................ ................................ ................................ ..............  16 
3.1 Coronavirus -19 (COVID -19) ................................ ................................ .....................  [ADDRESS_883772] Nucleotide Synthesis  ................................ ................................ .........................  16 
3.3 Dihydroorotate dehydrogenase (DHODH)  ................................ ................................  16 
3.4 Brequinar  ................................ ................................ ................................ ....................  17 
3.5 Rationale for the Planned Trial  ................................ ................................ ..................  17 
3.5.1  Brequinar Dose Selection  ................................ ................................ .............................  18 
3.5.2  Risk/Benefit of Brequinar  ................................ ................................ ............................  18 
3.6 Risks Associated with Participation in the Clinical Study  ................................ .........  19 
3.7 Possible Interactions with Concomitant Medical Treatments  ................................ .... 19 
3.7.1  CYP Interactions  ................................ ................................ ................................ ..........  19 
3.8 Steps to be Taken to Control or Mitigate Risks  ................................ .........................  19 
4 TRIAL OBJECTIVES  ................................ ................................ ................................ ........  20 
4.1 Primar y Objective  ................................ ................................ ................................ ...... 20 
4.2 Secondary Objectives  ................................ ................................ ................................ . 20 
4.3 EXPLORATORY OBJECTIVES  ................................ ................................ ..............  20 
5 TRIA L DESIGN  ................................ ................................ ................................ .................  21 
6 TRIAL ENDPOINTS ................................ ................................ ................................ ..........  22 
6.1 Primary Endpoint  ................................ ................................ ................................ ....... 22 
6.2 Secondar y Endpoints  ................................ ................................ ................................ .. 22 
6.3 Exploratory Endpoints ................................ ................................ ................................  22 
7 TRIAL POPULATION  ................................ ................................ ................................ ....... 23 
7.1 Number of Subjects  ................................ ................................ ................................ .... 23 
7.2 Inclusion criteria  ................................ ................................ ................................ .........  23 
7.3 Exclusion Criteria  ................................ ................................ ................................ ....... 23 
8 STUDY TR EATMENTS  ................................ ................................ ................................ .... 25 
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 3 of 51 
PROTOCOL VERSION  3.0 DATE:  23 SEPT 2020  
 
Clear Creek Bio, Inc. 
CONFIDENTIAL  8.1 Description of Study Medications  ................................ ................................ ..............  25 
8.1.1  Brequinar  ................................ ................................ ................................ ......................  25 
8.2 Treatment Admi nistration  ................................ ................................ ..........................  25 
8.2.1  Safety/Tolerability  ................................ ................................ ................................ ........  25 
8.3 Study Discontinuation  ................................ ................................ ................................  26 
8.4 Stoppi[INVESTIGATOR_2121]  ................................ ................................ ................................ ........  26 
8.4.1  Individual Stoppi[INVESTIGATOR_2121]  ................................ ................................ .........................  26 
8.4.2  Study -Level Stoppi[INVESTIGATOR_2121] ................................ ................................ ......................  26 
8.5 Concomitant Medication/Treatment  ................................ ................................ ..........  26 
8.6 Treatment Compliance  ................................ ................................ ...............................  26 
8.7 Storage, Stability, Labeling and Packaging  ................................ ...............................  27 
8.7.1  Storage and Stability  ................................ ................................ ................................ .... 27 
8.7.2  Labeling and Packaging  ................................ ................................ ...............................  27 
8.7.3  Blinding and Randomization  ................................ ................................ ........................  27 
8.7.4  Unblinding/Expectedness  ................................ ................................ .............................  [ADDRESS_883773]  ................................ ................................ ................................ ............  31 
9.5.1  Unscheduled Visits  ................................ ................................ ................................ ....... 32 
9.6 Compliance with Study Procedures  ................................ ................................ ...........  32 
9.7 Early Withdrawal from the Study  ................................ ................................ ..............  32 
9.8 Early Termination of the Study  ................................ ................................ ..................  32 
9.9 Non-Childbearing Potential ................................ ................................ ........................  33 
10 ADVERSE EVENT REPORTING ................................ ................................ .....................  34 
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 4 of 51 
PROTOCOL VERSION  3.0 DATE:  23 SEPT 2020  
 
Clear Creek Bio, Inc. 
CONFIDENTIAL  10.1  Follow Up of Grade 3 or 4 Toxicities  ................................ ................................ ........  35 
10.2  Infection Follow Up  ................................ ................................ ................................ ... 35 
10.3  Classification of Causality  ................................ ................................ .........................  35 
10.4  Classification of Severity  ................................ ................................ ...........................  36 
10.5  Serious Adverse Event (SAE) Reporting  ................................ ................................ ... 36 
10.6  Suspected Unexpected Serious Adverse Reactions (S[LOCATION_003]Rs)  ................................ . [ADDRESS_883774] e Size Considerations  ................................ ................................ .......................  41 
11.5  Randomization  ................................ ................................ ................................ ...........  41 
11.6  Pooling of Study Centers ................................ ................................ ............................  42 
11.7  Interim Analysis  ................................ ................................ ................................ .........  42 
12 INVESTIGATOR RESPONSIBILITIES  ................................ ................................ ...........  43 
12.1  Investigators Performance  ................................ ................................ ........................  43 
12.2 Confidentiality  ................................ ................................ ................................ ............  43 
12.3  Source Documentation  ................................ ................................ ...............................  43 
12.4  Data Collection  ................................ ................................ ................................ ...........  44 
12.5  Case Re port Forms, Investigators Site File and Record Retention  ...........................  44 
12.6  Non-Protocol Research  ................................ ................................ ..............................  45 
12.7  Publication  ................................ ................................ ................................ ..................  45 
13 SPONSOR RESPONSIBILITIES  ................................ ................................ ......................  46 
13.1  General  ................................ ................................ ................................ .......................  46 
13.2  Indemnity  ................................ ................................ ................................ ...................  46 
13.3  Data Monitoring  ................................ ................................ ................................ .........  46 
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 5 of 51 
PROTOCOL VERSION  3.0 DATE:  23 SEPT 2020  
 
Clear Creek Bio, Inc. 
CONFIDENTIAL  13.4  Audit  ................................ ................................ ................................ ...........................  46 
13.5  Confidentiality  ................................ ................................ ................................ ............  47 
13.6  Finance  ................................ ................................ ................................ .......................  47 
14 REFERENCES  ................................ ................................ ................................ ...................  48 
15 APPENDICES  ................................ ................................ ................................ ....................  49 
15.1  Appendix A:  CCB -CRISIS -02 Schedule of Events  ................................ ..................  49 
15.2  Appendix B: Investigators Statement and Agreement  ................................ ..............  50 
15.3  Appendix C: WHO Ordinal Scale  ................................ ................................ ..............  51 
 
 
  
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 6 of 51 
PROTOCOL VERSION  3.0 DATE:  [ADDRESS_883775] OF FIGURES  
Figure 3 -1.  DHODH is a mitochondrial enzyme that catalyzes the 4th step of pyrimidine synthesis; 
it is completely essential for the generation of UMP.  ................................ .................  16 
  
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 7 of 51 
PROTOCOL VERSION  3.0 DATE:  [ADDRESS_883776]  
ESR Erythrocyte Sedimentation Rate  
EUA  Emergency Use Authorization  
FDA  [LOCATION_002] Food and Drug Administration  
GCP  Good Clinical Practice  
HIV Human immunodeficiency virus  
IB Investigator Brochure  
ICF Informed consent form  
ICH International Council on Harmonization  
ICU Intensive care unit  
IMP Inosine -5 phosphate  
IP Investigational product  
IRB Institutional Review Board  
LDH  Lactate dehydrogenase  
MedDRA  Medical Dictionary for Regulatory Activities  
NCI National Cancer Institute  
NEWS2  National Early Warning System (NEWS) [ADDRESS_883777] of Care  
S[LOCATION_003]R  Suspected unexpected serious adverse reaction  
SpO 2 Peripheral capi[INVESTIGATOR_656323]:  CCB -CRISIS -02      Page 8 of 51 
PROTOCOL VERSION  3.0 DATE:  23 SEPT 2020  
 
Clear Creek Bio, Inc. 
CONFIDENTIAL  Abbreviation  Definition  
UMP  Uridine 5 -monophosphatase  
US [LOCATION_002]  
XMP  Xanthosine -5 phosphate  
WHO  World Health Organization  
WOCBP  Women of childbearing potential  
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 9 of 51 
PROTOCOL VERSION  3.0 DATE:  23 SEPT 2020  
 
Clear Creek Bio, Inc. 
CONFIDENTIAL  2 SYNOPSIS  
CCB -CRISIS -02 SYNOPSIS  
IND 149291  
Title  The CRISIS2 Study: A phase 2, randomized, double blind, placebo -controlled, 
multi -center study assessing the safety and anti -coronavirus response of 
suppression of host nucleotide synthesis in out-patient adults with SARS -CoV -[ADDRESS_883778] SARS -CoV -2 is likely 
due to DHODH inhibitio n and shows  nanomolar potency and a high selectivity 
index in inhibiting viral replica tion in  in vitro  studies.    
The CRISIS2 trial will study out-patients ( non-hospi[INVESTIGATOR_9643] ) who have  a 
positive SARS -CoV -[ADDRESS_883779] of care (SOC)  + 5 days of brequinar or SOC + [ADDRESS_883780] and 
Dosage  Subjects will be randomized in a 1:[ADDRESS_883781] of care (SOC) + 5 days 
of brequinar  100 mg or SOC + [ADDRESS_883782] will be supplied as either b requinar 100 mg oral capsules  
or placebo capsules . The subjects are to self -administer one capsule on  Study Days 
1  5.  
Treatment assignment will be randomized, double -blind.   
Primary 
Objective s  To demonstrate a change from baseline in quantitative SARS -CoV -2 viral load 
for brequinar -treated subjects compared to placebo -treated subjects through 
Day 29. 
Secondary 
Objectives  Through Day 29:  
 To characterize  the safety and tolerability of brequinar i n out-patient COVID -
19 subjects  as measured by [CONTACT_656340] 3 and 4 AEs and SAEs ; 
 To demonstrate a shorter duration of viral shedding in subjects treated with 
brequinar compared to  subjects who received placebo ;  
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 10 of 51 
PROTOCOL VERSION  3.0 DATE:  23 SEPT 2020  
 
Clear Creek Bio, Inc. 
CONFIDENTIAL   To reduce the percentage of subject s requiring hospi[INVESTIGATOR_656300] -
patient for > 24 hours  for brequinar subjects compared to  subjects who received 
placebo ; 
 To reduce all-cause mortality through Day 29  for brequinar subjects compared 
to subjects who received placebo.  
Exploratory 
Objective s Through Day 29:  
 To determine time to viral clearance (two consecutive negative tests) ;  
 To determine time to resolution of new onset COVID -19-related clinical 
symptoms and pre -existing non-COVID -19 symptoms returned to baseline ; 
 To determine time to clinical improvement  as measured by a favorable shift in 
the WHO Ordinal Scale score measured for the subset of subject s with baseline 
WHO Ordinal Scale of [ADDRESS_883783] a Screening Visit followed as soon as possible with Study Day 
1. Study procedures are presented in detail in the Schedule of Events . Study visits 
(virtual or in person) will take place at Screening  and on Study Days  [ADDRESS_883784]s home or other 
appropriate location. Other visits /visit activities for that visit  may be conducted 
remotely using telephone, telemedicine  or other remote technique . Subjects are to 
self-collect a viral load sample , obtain their respi[INVESTIGATOR_697], heart rate, body 
temperature and SpO2, and complete a symptom assessment  with the site via 
telemedicine  on Days 1, 4, 8, 12, 15, 22, and [ADDRESS_883785] at 
Screening and on study Days 1, 8, 15, and 29. Telemedicine only visits will be 
conducted by [CONTACT_656390] 4 , 12, and 22 . 
Sample Size:  Approximately 100 subjects will be randomized to 5 days of either SOC  + 
brequinar 100 mg or SOC + placebo in a 1:1 ratio (approximately 50 subjects 
assigned to brequinar 100 mg and 50 subjects to placebo ).  
Number of Sites:  Approximately 15 
Study Period:  An enrollment period of 3 months is expected.  
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 11 of 51 
PROTOCOL VERSION  3.0 DATE:  23 SEPT 2020  
 
Clear Creek Bio, Inc. 
CONFIDENTIAL  Inclusion 
Criteria:  
 1. Willing and able to provide informed consent for the trial, written, 
electronic, verbal , or other method deemed acceptable by [CONTACT_656342].  
2. 18 years of age or older.  
3. Laboratory -confirmed SARS -CoV -2 infection as determined by [CONTACT_656343] (RT -PCR) or other FDA -approved commercial 
or public health assay  within [ADDRESS_883786] dose. 
4. Out-patient (never hospi[INVESTIGATOR_656324] -patient for COVID -19 or was 
evaluated/treated for COVID -19 only in the Emergency Room with a stay 
of < 24 hours).  
5. The effects of brequinar on the developi[INVESTIGATOR_656335] . For 
this reason, women of child -bearing potential and men must agree to use 
adequate contraception (hormonal or barrier method of birth control; 
abstinence) prior to study entry and for the duration of study participation. 
Should a woma n become pregnant or suspect she is pregnant while she or 
her partner is participating in this study, she should inform her treating 
physician immediately. Men and women treated or enrolled on this protocol 
must also agree to use adequate contraception for  the duration of study 
participation, and for [ADDRESS_883787] one COVID -19 symptom including but not limited to 
fever, cough, sore throat, malaise, headache, muscle pain, gastrointestinal 
symptoms, shortness of breath , dyspnea , anosmia , dysgeusia, or other 
symptom commonly associated with COVID -19.  
8. Able to swallow capsules.  
Exclusion 
Criteria:  1. Any physical examination findings and/or history of any illness that, in the 
opi[INVESTIGATOR_103160], might confound the results of th e study 
or pose an additional risk to the patient  
2. Nursing women or women of childbearing potential (WOCBP) with a 
positive pregnancy test  
3. Treatment with another DHODH inhibitor  (e.g., leflunomide , 
teriflunomide ) or other agents known to cause bone marrow suppression 
leading to thrombocytopenia  
4. Platelets 150,000 cell/mm3 
5. Hemoglobin < 10 gm/dL  
6. Absolute neutrophil count < 1500 cells/mm3 
7. Renal dysfunction, i.e., creatinine clearance < 30 mL/min  
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 12 of 51 
PROTOCOL VERSION  3.0 DATE:  [ADDRESS_883788] and/or ALT > [ADDRESS_883789], or total bilirubin > ULN . Gilbe rts Syndrome 
is allowed.  
9. Bleeding disorders or blood loss requiring transfusion  in the six weeks 
preceding enrollment  
10. Ongoing  gastrointestinal ulcer, or gastrointestinal bleeding  within [ADDRESS_883790] dose. 
11. Chronic  hepatitis B  infection , active hepatiti s C infection, active liver 
disease and/or cirrhosis  per subject report.  
12. Heart failure, current uncontrolled cardiovascular disease, including 
unstable angina, uncontrolled arrhythmias, major adverse cardiac event 
within 6 months (e.g. stroke, myocardial i nfarction, hospi[INVESTIGATOR_656302], or revascularization procedure).   
Treatment  All subjects will receive standard of care (SOC)  including symptomatic care. 
Subjects will be randomly assigned to SOC + brequinar 100 mg daily x 5 or SOC 
+ placebo daily x 5. Study encounters will be conducted remotely whenever 
possible.  
DMC A Data Monitoring Committee  (DM C) will meet periodically to review the safety 
and scientific conduct of the study. At a minimum, the DMC  is to review adverse 
events and safety laboratory assessments after the first [ADDRESS_883791] 40 subjects complet e Day 8.  
Procedures  Study procedures are outlined in the Schedule of Events.  
Study completion or the reason for study discontinuation will be recorded in the 
source document and the eCRF.  
Safety/  
Tolerability  Safety/Tolerability  
Adverse events will be collected from the time of first dose  through Day 29. After 
Day 29, collect/re cord only Serious Adverse Events (SAEs) or those judged by [CONTACT_656363]. Treatment -emergent  
adverse events will be those with an onset after the date and time of first treatment . 
Subjects who develop Gra de 3 or 4 toxicities or SAEs are to be re -evaluated every 
2 days, as feasible, until the toxicity returns to Grade  [ADDRESS_883792] any signs or symptoms of muco sitis or thrombocytopenia, e.g.:  
 Ecchymosis/purpura/petechiae  
 Epi[INVESTIGATOR_3940]  
 Hemoptysis  
 Hematuria  
 Gingival bleeding  
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 13 of 51 
PROTOCOL VERSION  3.0 DATE:  23 SEPT 2020  
 
Clear Creek Bio, Inc. 
CONFIDENTIAL   Prolonged bleeding time from needle sticks, abrasions or lacerations  
 Hematemesis  
 Rectal bleeding  
 Blood in stool  
 Any other unusual bleeding noted by [CONTACT_656429][INVESTIGATOR_656303]:  
 Participants who develop a Grade 3 toxicity that is assessed by [CONTACT_656345].  
 Participants who develop a Grade 4 toxicity, regardless of relatedness to 
study drug, are to be permanently discontinued from study treatment.  
Study -Level Stoppi[INVESTIGATOR_2121]:  
Study enrollment is to be paused  if any of the below criteria are met:  
 If  [ADDRESS_883793] s develop the same  related Grade 4 (life -threatening) adverse 
event or laboratory abnormality;  
 If  5 subjects develop the same  related Grade 3 or 4 adverse event or 
laboratory abnormality ; 
 If  10 subjects develop any related Grade 3 or 4 adverse event or 
laboratory abnormality .  
All adverse events will be reviewed by [CONTACT_656430]. Following 
assessment by [CONTACT_1578] (DMC), the DMC will determine 
whether to stop the study, amend the protocol, or continue the study per protocol.   
Statistical 
Analysis  A separate, detailed statistical analysis plan (SAP) will be finalized prior to locking 
the database. All analyses of safety and efficacy for this study will be descriptive 
in nature and presented by [CONTACT_19313]. Subject demographics and baseline 
characteristics  will be summarized. Subject data listings will also be provided.  
Summaries for quantitative variables will include the mean, median, quartiles, 
standard error, minimum, and maximum. For qualitative variables, the summaries 
will include the number and per centage of subjects for each outcome, and the 95% 
CI, when appropriate.  Any statistical testing will be considered exploratory and 
descriptive. All computations will be performed using SAS (Version 9.4 or 
higher). Safety and tolerability will be assessed  in terms of AEs, SAEs, and safety 
laboratory data.  
Adverse event data will be descriptively evaluated. All AEs will be reported in data 
listings. The incidence of treatment -emergent  adverse events, defined as TEAEs 
occurring after first dose  will be tabulated by [CONTACT_12513]  (MedDRA) preferred term and system organ class, and by [CONTACT_656392]. All laboratory results and other clinical measures 
will be summarized using appropriate descriptive statistics.  
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 14 of 51 
PROTOCOL VERSION  3.0 DATE:  [ADDRESS_883794] dose time  
Procedures  Screen  
(days  
-14 to -1) 
HH+TMf D1 
HH
+ 
TM D2, 3  
( 8 
hrs) 
TCf D4 
( 8 
hrs) 
TM D5,6, 
7 
( 8 
hrs) 
TC D8 
( 1 
day)  
HH+
TM D12 
( 1 
day)  
TM D15 
( 1 
day)  
HH+
TM D22 
(1 
day)  
TM Final 
Visit   
D29 
( 2 days)  
HH+TM  
Informed Consent (note Date and Time)  X          
AE/Concomitant Medications (dose, route, duration 
or ongoing)  X X X X X X X X X X 
Medical history (relevant within one year or 
ongoing)/ History of current illness (date of 
symptom onset or change in baseline co -morbidity 
thought to be due to COVID -19 infection)  X          
Demographics (subject reported height and weight, 
date of birth, gender, race, ethnicity)  X          
Check for Physical Exam abnormalities (subject 
self-reported)  X          
Pregnancy Test (WOCBP)  X 
(serum)          X 
(urine)  
Hematology/Chemistrya X X     X  X   
Vital Signsb X X  X  X X X X X 
Symptom Assessmentc X X  X  X X X X X 
SARS -CoV -2 RT -PCR/V iral load  sampled X X   X  X X X X X 
Hospi[INVESTIGATOR_656304]       X  X X X 
WHO Ordinal Scale Assessment   X    X  X X X 
Confirm Eligibility   X         
Randomize subject and dispense Study Medication   X         
Study drug administratione  X X X X 
D5 
only      
Drug Accountability       X     
aDo not repeat if within 48h of Day 1 visit.  Send to Covance Central Laboratory Services (CCLS) for analysis.  
bVital signs include heart rate, respi[INVESTIGATOR_697], body temperature, SpO2.  Subject will be provided with a thermometer and pulse 
oximeter with heart rate monitoring capability. Training will be provided during the first visit by [CONTACT_535758]. Vi tal signs 
parameters will be observed and recorded by [CONTACT_656424] a visit by [CONTACT_535758].  
cSymptom Assessment will use a checklist  provided to the subject with  symptoms such as sore throat, cough, GI symptoms (vom iting, 
diarrhea), an osmia, dysgeusia, other (specify), etc.  Severity None,  Mild, M oderate, or Severe will be collected.  
dRT-PCR at Screening may be performed by [CONTACT_656425] a positive SARS -CoV -[ADDRESS_883795] using an Omnigene  collection system or 
similar. The home health nurse will train the subject and observe sample collection on Day 1. These samples are to be sent to CCLS 
for analysis.  The viral load sample may also be used to perform viral cultures (sample can be split  by [CONTACT_2237] , no 
additional sample required).  
eSubject will self -administer study drug once daily Days 1  [ADDRESS_883796] doses in a medication diary. Note that any visits/visit activities 
may be conducted via telephone, telemedicine , or digital media other than serum pregnancy test and chemistry/hematology sample 
collection. These labs may be collected at the clinical site or another designated out -patient facility/laboratory or collected via home 
visit.  Arrangements for shippi[INVESTIGATOR_656336] . 
fHH = Home Health in -person visit; TC = Telephone Call with site  and subject ; TM = Telemedicine with site  and subject.  
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 15 of 51 
PROTOCOL VERSION  3.0 DATE:  [ADDRESS_883797]  
Name:  [CONTACT_656462], MSN, Ph.D.  
Title:  Clinical Operations  
Address:  Clear Creek Bio, Inc.  
[ADDRESS_883798], 4th Floor,  
Cambridge, MA [ZIP_CODE]  
Telephone No.:  [PHONE_13585]  
Fax No.:  [PHONE_13586]  
E-mail:  [EMAIL_12502]   
 
MEDICAL MONITOR  
Name:  [CONTACT_656463], MD  
Title:  Senior Medical Director  
Telephone No.:  (609) 212 -7892  
E-mail:  [EMAIL_12503]  
 
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 16 of 51 
PROTOCOL VERSION  3.0 DATE:  23 SEPT 2020  
 
Clear Creek Bio, Inc. 
CONFIDENTIAL  3 INTRODUCTION  
3.1 Coronavirus -19 (COVID -19) 
Beginning in December  2019, Chinese scientists isolated a novel coronavirus, severe acute respi[INVESTIGATOR_11520] 2 (SARS -CoV -2) from patients with virus -infected pneumonia which was later 
designated as coronavirus disease 2019 (COVID -19) by [CONTACT_88442] (WHO) ( Zhou 
et al., 2020  [2]; Phelan et al., 2020  [3]).  
Approximately 14% of those affected with this virus will develop severe disease requiring 
hospi[INVESTIGATOR_656306]; 5% will require admission to the intensive care unit ( Handel et 
al., 2020  [4]). Severe cases ma y be complicated by [CONTACT_171958][INVESTIGATOR_656307] (ARDS), sepsis 
and septic shock, and multi -organ failure, including acute kidney injury and cardiac injury. Risk 
factors for death include older age and co -morbid disease such as hypertension and diabe tes (Zhou, et 
al., 2020  [2]). This means that most  patients will be treated as out -patients. Reducing viral load in this 
environment is critically important for both the subjects themselves by [CONTACT_656397][INVESTIGATOR_059], but also to reduce the transmission of th e disease to 
others in the patients households and their communities.  
3.1.[ADDRESS_883799] RNA building blocks, and without these building blocks they are unable 
to replicate.  The SARS -CoV -2 is a single -strand ed (positive sense) RNA virus with a genome that is 
29,811 nucleotides long, quite a lot larger than other RNA -based viruses (e.g. the hepatitis C genome 
comprises only 9600 nucleotides). The nucleotide composition is broken down as: 29.9% adenosines, 
18.4% cytosines, 19.6% guanines, and 32.1% uridines  (Sah et al., 
2020  [12]). 
3.[ADDRESS_883800] de novo  pyrimidine synthesis generates uridin e monophosphate 
(UMP) as the building block for all pyrimidine ribonucleotides and 
deoxyribonucleotides  (Figure 3 -1). There exists no salvage pathway 
for the synthesis of UMP, the fundamental building block  of 
pyrimidines . Inhibition of enzymatic steps upstream of UMP  (Figure 
3-1) leads to a rapid  and profound  depletion of intracellular 
pyrimidines.   
3.3  Dihydroorotate dehydrogenase (DHODH)  
The enzyme dihydroorotate dehydrogenase ( DHODH ) catalyzes the 
4th step of de novo  pyrimid ine synthesis  and inhibition of DHODH 
completely halts all pyrimidine production. As shown in  Figure 3 -1, 
DHODH  is located on the inner mitochondrial membrane and 
transfers electrons between DHO and complex III of the electron - 
Figure 3-1. DHODH is a 
mitochondrial enzy me that 
catalyzes the 4th step of pyrimidine 
synthesis; it is completely essential 
for the generation of UMP.    

PROTOCOL NUMBER:  CCB -CRISIS -02      Page 17 of 51 
PROTOCOL VERSION  3.0 DATE:  23 SEPT 2020  
 
Clear Creek Bio, Inc. 
CONFIDENTIAL  transport chain via the reduc tion of its ubiquinone (coenzyme Q10) cofactor.  
DHODH is a clear therapeutic target for the inhibition of host pyrimidine synthesis. The chemical 
inhibition of DHODH in vitro  or in vivo  leads to the rapid depletion of UMP and subsequent depletion 
of downs tream products thymine and cytosine.  This forces a cell to rely on the salvage of extracellular 
pyrimidine nucleotides and this extracellular salvage is not capable of maintaining the cells normal 
nucleotide pool  (Sykes et al., 2016) [ 1]).    
3.[ADDRESS_883801] -targeting antiviral. 
It is an orally available and pot ent inhibitor of dihydroorotate dehydrogenase (DHODH) , the enzyme 
that catalyzes the fourth step in pyrimidine synthesis, namely the conversion of dihydroorotate (DHO) 
to orotate.  DHODH inhibitors, including brequinar, inhibit de novo  pyrimidine synthesis thereby 
[CONTACT_331577] a depletion of a cells pool of uridine, cytidine and thymidine ribonucleotides and 
deoxyribonucleotides.  
The anti viral activity of brequinar has been demonstrated  in studies  of rotavirus replication in human 
intes tinal Caco -2 cell s as well as in human primary intestinal organoids  (Chen et al., 2019  [6]). 
Treatment with teriflunomide , another DHODHi,  has been effective in vitro  and in vivo  in a mur ine 
model of foot and mouth disease virus (Mei-Jian et al., 2019  [7]). DHODH inhibition (DHODHi) also 
inhibited the growth of dengue virus in vitro  (Wang et al., 2011  [8]). DHODHi also showed antiviral 
effects against RNA viruses including influ enza A, Zika, Ebola and coronavirus SARS -CoV -2 (Xiong 
et al., 2020  [11]). Brequinar has also been shown to inhibit the replication of Ebola virus , vesicular 
stomatitis virus and Zika virus in vitro (Luthra et al., 2018  [9]). Brequinar inhibits the replication of 
human immunodeficiency virus ( HIV) in vitro  (Andersen et al., 2019  [10]). When considering 
brequinar as an antiviral for treatment of SARS -CoV -2, oral brequinar is highly bioavailable (>95%) 
and has good penetration of lung tissue  with an average tissue:blood ratio of 0.5 following a single 
dose of brequinar in the rat . It is therefore expected to achieve a similar period of DHODH inhibition 
in lung tissue  (Brequinar IB  [5]). 
3.5  Rationale for the Planned Trial  
DHODH inhibition has been extensively studied as a potential therapeutic target in the treatment of 
RNA -based viruses. The inhibition of DHODH is effective in inhibiting viral replication in pre -clinical 
models involving many RNA -based viruses with nanomolar potency and a high selectivity index (see 
the Brequinar IB [5], Section 5 ). In these pre -clinical models, the benefit of DHODH inhibition can 
be reversed by [CONTACT_656398], confirming that the on -target effect of 
host pyrimidine depletion is key to the anti -viral activity.  
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 18 of 51 
PROTOCOL VERSION  3.0 DATE:  [ADDRESS_883802] of care (SOC) with 5 days of brequinar (DHODH 
inhibition) compared to SOC with [ADDRESS_883803] pyrimidine nucleotides, thereby [CONTACT_656399]. A recent 
publication demonstrated that inhibitors of DHODH could potentiate the activity of inhibitors of RNA -
dependent RNA polymerase (RdRp) in the treatment of dengue virus, another single -stranded RNA 
virus  similar to SARS -CoV -2 (Liu et al., 2020 [13]). This inhibition of viral replication may restore 
the balance in favor of the host immune system for the clearance of SARS -CoV -2. 
Marketed DHODHi medications are available, includ ing leflunomide or teriflunomide, however these 
are very weak inhibitors of DHODH with cellular potency ~[ADDRESS_883804] that 5 days of daily doses of 100 mg  p.o. will be safe and well tolerated. A dose of 
brequinar 100 mg achieves plasma concentrations of approximately 1 uM (0.4 ug/ml)  that should result 
in sufficient suppres sion of nucleotide synthesis . When given over 5  days, these plasma concentrations 
are achieved on a daily basis without accumulation, also assuring the safety of this regimen  (see 
Brequinar IB  [5]).  
3.5.2    Risk/Benefit of Brequinar  
As presented in the Brequinar IB  [5], an extensive safety and pharmacokinetic database exists with 
more than 1,000 patients treated with brequinar. Cancer patients (N = 806) have been exposed to this 
compound for treatment of a variety of solid tumors  at various  treatment regimens, doses, and routes  
including a single dose, once weekly, twice weekly, single dose every [ADDRESS_883805]  
also been utilized for patients with  psoriasis and organ transplant. The maximum intravenous dose 
given was 2,250 mg/m2 every 3 weeks, and the maximum oral dose was 100 mg/m2 daily for 21 days. 
There has been limited testing of DHODHi to date in the clinic for infection with SARS -CoV -2. 
DHODHi therapy at relatively high doses in the context of trials for patients with cancer has the 
expected safety side-effects of mucositis and bone marrow suppression.  Importantly, h owever, the 
prior clinical experience in 39 subjects who received daily brequinar for 5 consecutive days at or lower 
than 100 mg/day show no cases of mucositis and only 1 (2.6%) epi[INVESTIGATOR_656308]. 
Based on these data the [ADDRESS_883806] de novo pyrimidine synthesis  for this period  thus 
decreasing viral load.  Inhibition of DHODH is expected to reduce the ability of the virus to replicate 
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 19 of 51 
PROTOCOL VERSION  3.0 DATE:  [ADDRESS_883807] been the primary dose -limiting toxicities. In addition, skin rash, nausea/vomiting, fatigue, and 
leukopenia have been dose -limiting in trials utilizing other sch edules of brequinar administration. 
However , these effects were self -limiting, transient, required treatment in few cases,  and resolved 
following discontinuation of dosing . These adverse effects have been associated  with higher doses of 
brequinar given via the intravenous route and for longer durations than the 100 mg dose and 5 -day 
regimen proposed for this study .  
In addition to studying a higher risk population  with symptomatic COVID -19, a comprehensive safety 
monitoring plan will be utilized in this stu dy to assess the ongoing safety and well -being of participants 
(see Section 10.8).  
3.[ADDRESS_883808] been no apparent hepat otoxic  effects in 
the clinical studies. Brequinar itself does not appear to be a substrate for metabolism by [CONTACT_9058] 
P450 enzymes when tested under a variety of conditions . (See Brequinar IB [5]; nonclinical d ata on 
file with Clear Creek).   
3.8 Steps to be Taken to Control or Mitigate Risks  
All subjects will be treated  by [CONTACT_656350] d clinicians  familiar with the treatment of viral 
infections and their complications .  
 
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 20 of 51 
PROTOCOL VERSION  3.0 DATE:  23 SEPT 2020  
 
Clear Creek Bio, Inc. 
CONFIDENTIAL  4 TRIAL OBJECTIVES  
4.1 Primary Objective  
To demonstrate a change from baseline in quantitative SARS -CoV -2 viral load for brequinar -treated 
subjects compared to placebo -treated subjects through Day  29. 
4.2 Secondary Objectives  
The secondary objectives of this study are:  
Through Day 29:  
 To characterize  the safety and tolerability of brequinar in  out-patient  COVID -19 subjects  as 
measured by [CONTACT_656340] 3 and 4 AEs and SAEs ; 
 To demonstrate a shorter duration of viral shedding in subjects treated with brequinar compared 
to subjects who received placebo ;  
 To reduce the percentage of subjects  requiring hospi[INVESTIGATOR_656309]  >24 hours  for 
brequinar subjects compared to  subjects who received placebo ; 
 To reduce all -cause mortality  through Day 29  for brequinar subjects compared to  subjec ts who 
received placebo . 
4.3 EXPLORATORY OBJECTIVES  
Through Day 29:  
 To determine time to viral clearance (two consecutive negative tests) ;  
 To determine time to resolution of new onset COVID -19-related clinical symptoms and pre -
existing  non-COVID -19 symptoms r eturned to baseline ; 
 To determine time to clinical improvement  as measured by a favorable shift in the WHO Ordinal 
Scale score for the subset of subjects with baseline WHO Ordinal Scale of 2  for brequinar subjects 
compared to  subjects who received placebo . 
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 21 of 51 
PROTOCOL VERSION  3.0 DATE:  [ADDRESS_883809] of care per (SOC) institutional 
guidelines for treatme nt of patients with COVID -[ADDRESS_883810] a Screening Visit followed as soon as possible with Study Day 1. Study procedures 
are presented in detail in the Schedule of Events (Appendix 15.1). Study visits (virtual or in person) 
will take place at Screening and on Study Days [ADDRESS_883811]s home or other appropriate location. Other visits/visit activities for that visit may be conducted 
remotely using telephone, telemedicine  or other remote technique . Subjects are to self -collect a viral 
load sample, obtain their respi[INVESTIGATOR_697], heart rate, body temperat ure and SpO2, and complete a 
symptom assessment checklist with the site via telemedicine on Days 1, 4, 8, 12, 15, 22, and 29.  The 
site will also have a telephone  call with  the subject on Study Days 2, 3, 5, 6, and 7 for changes in 
concomitant medications and assessment of adverse events, especially those that may indicate 
thrombocytopenia (see Section 10.8) and mucositis . A home health nurse will visit the subject at 
Screening and on study Days 1, 8, 15, and 29. Telemedicine only visits will be conducted by [CONTACT_656431] 4, 12, and 22.  
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 22 of 51 
PROTOCOL VERSION  3.0 DATE:  23 SEPT 2020  
 
Clear Creek Bio, Inc. 
CONFIDENTIAL  6 TRIAL ENDPOINTS  
6.1 Primary Endpoint  
Quantitative SARS -CoV -2 viral load  through Da y 29. 
6.2 Secondary Endpoints  
The secondary endpoints  of this study are:  
Through Day 29:  
 Rates of AEs and SAEs including laboratory assessments ; 
 Duration of viral shedding ;  
 Percentage of subjects requiring admission as an inpatient for  >24 hours . 
 All-cause mortality.  
6.3 Exploratory Endpoints  
Through Day 29:  
 Time to viral clearance (two consecutive negative tests) ;  
 Time to resolution of new onset COVID -19-related clinical symptoms and pre -existing non-
COVID -19 symptoms returned to baseline ; 
 Time to cl inical improvement  measured by a favorable shift in WHO Ordinal Scale score for the 
subset of subjects with baseline WHO Ordinal Scale of 2 . 
 
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 23 of 51 
PROTOCOL VERSION  3.0 DATE:  [ADDRESS_883812] of care plus placebo in a 1:1 ratio ( approximately 
[ADDRESS_883813] of care  plus placebo ).  
7.2 Inclusion criteria  
1. Willing and able to provide informed consent for the trial, written, electronic, verbal or other 
meth od deemed acceptable by [CONTACT_656353].  
2. 18 years of age or older.  
3. Laboratory -confirmed SARS -CoV -2 infection as determined by [CONTACT_656432] (RT -PCR) or other FDA -approved commercial or public health assay  within [ADDRESS_883814] dose . 
4. Out-patient ( never hospi[INVESTIGATOR_656326] -patient for COVID -19 or was evaluated/treated for 
COVID -19 only in the Emergency Room with a stay of < 24 hours) . 
5. The effects of brequinar on the developi[INVESTIGATOR_19241] . For this reason, women 
of child -bearing potential and men must agree to use adequate contraception (hormonal or 
barrier method of birth control; abstinence) prior to study entry and for the duration of study 
participation. Should a woman become pregnant or suspect she is pregnant while she or her 
partner is participating in this study, she should inform her treating physician immediately. 
Men and women treated or enrolled on this protocol must also agree to use adequate 
contraception for the duration of study partic ipation, and for [ADDRESS_883815] one COVID -19 symptom including but not limited to fever, cough, sore throat, 
malaise, headache, muscle pain, gastrointestinal  symptoms, shortness of breath, dyspnea, 
anosmia , dysgeusia, or other symptom commonly associated with COVID -19. 
8. Able to swallow capsules.  
7.3 Exclusion Criteria  
1. Any physical examination findings and/or history of any illness that, in the opi[INVESTIGATOR_656327], might confound the results of the study or pose an additional risk to the patient  
2. Nursing women or women of childbearing potential (WOCBP) with a positive pregnancy test  
3. Treatment with another DHODH inhibitor (e.g., leflunomide, teriflunomide) or other agents 
known to cause bone marrow suppression leading to thrombocytopenia  
4. Platelets 15 0,000 cell/mm3 
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 24 of 51 
PROTOCOL VERSION  3.0 DATE:  23 SEPT 2020  
 
Clear Creek Bio, Inc. 
CONFIDENTIAL  5. Hemoglobin < 10 gm/dL  
6. Absolute neutrophil count < 1500 cells/mm3 
7. Renal dysfunction, i.e., creatinine clearance < 30 mL/min  
8. AST and/or ALT > [ADDRESS_883816], or total bilirubin > ULN . Gilberts Syndrome is allowed.  
9. Bleeding disorders or blood loss r equiring transfusion in the six weeks preceding enrollment  
10. Ongoing  gastrointestinal ulcer, or gastrointestinal bleeding  within [ADDRESS_883817] dose. 
11. Chronic  hepatitis B  infection , active hepatitis  C infection, active liver disease and/or cirrhosis  
per sub ject report.  
12. Heart failure, current uncontrolled cardiovascular disease, including unstable angina, 
uncontrolled arrhythmias, major adverse cardiac event within 6 months (e.g. stroke, 
myocardial infarction, hospi[INVESTIGATOR_144651], or revascul arization procedure).  
 
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 25 of 51 
PROTOCOL VERSION  3.0 DATE:  [ADDRESS_883818] of care (SOC) for COV ID-19 infection. 
Subjects will be randomly assigned in a 1: [ADDRESS_883819] of care 
plus placebo . 
8.2.1 Safety/Tolerability  
Safety/tolerability is assessed for each s ubject at each study visit . The NIH Division of AIDS (DAIDS) 
Table for Grading the Severity of Adult and Pediatric Adverse Events, Corrected Version 2.1 (July 2017)  
will be utilized for AE reporting. All appropriate treatment areas should have access to a copy of the 
criteria .  
Adverse events (AEs) commonly observed in patients treated with brequinar are provided in the 
Investigators Brochure  (IB) and include thrombocytopenia, nausea, anemia, diarrhea, vomiting, 
leukopenia, stomatitis, rash, granulocytopen ia, fatigue,  and infection . In a study of 209 cancer subjects 
treated once -weekly  (DuP 785 -012, see Brequinar IB  [5]), the deaths of three patients were attributed 
to study drug toxicity (two to hemorrhage , one following acute renal failure). Severe toxicities grades 
(Grades 3 to 4) which typi[INVESTIGATOR_656328] 
(anemia , thrombocytopenia, leukopenia , granulocytopenia ), digestive  system toxicity (nausea, 
vomiting, stomatitis , others  including gastric hemorrhage) and mucositis.  
In three oncology studies with five consecutive days of intravenous (IV) brequinar dosing in 168 
subjects (Study 785 -001 [14], 785-003 [15], and 785-005 [16]) there were no toxic deaths . For 
subjects from these three studies who were treated with a daily dose of 100 mg or below  (as will be 
dosed in CCB -CRISIS -02), AEs through 21 days showed that 2 of 39 subj ects (5.1%) had a severe 
(Grades 3 or 4) AE related to study drug ([ADDRESS_883820] each with hyperbilirubinemia and 
hyperglycemia), and no subjects discontinued from the study due to a study drug -related AE. The 
few study drug related AEs through [ADDRESS_883821] each with 
thrombocytopenia and diarrhea. When only studies with oral dosing were considered at this dose 
level (Studies 7 85-022 [17], 785 -031 [18] , and  785-034 [19]), the study drug related AEs through 
21 days (each observed in one subject only) included diarrhea, headache, nausea, pruritus, 
abdominal pain, ano rexia, chest pain, dry mouth, fatigue, keratosis, stomatitis, and vomiting. See 
brequinar IB [5]. 
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 26 of 51 
PROTOCOL VERSION  3.0 DATE:  [ADDRESS_883822] Study Day 29 (or longer if needed to follow up study 
drug-related adverse events).  Participants may discontinue  from the study by [CONTACT_656402] 9.7. 
8.4 Stoppi[INVESTIGATOR_2121]  
8.4.1 Individual Stoppi[INVESTIGATOR_2121]  
 Participants who develop a Grade 3 toxicity that is assessed by [CONTACT_656433].  
 Participants who develop a Grade 4 toxicity, regardless of relatedness to study drug, are to  be 
permanently discontinued from study treatment.  
 Subjects who develop Grade 3 or 4 toxicities are to be followed by [INVESTIGATOR_1312] -evaluation every 2 days, 
as feasible, until the toxicity returns to  Grade 2 severity.  
8.4.2 Study -Level Stoppi[INVESTIGATOR_656312] : 
 If  3 subjects develop the same  related Grade 4 (life -threatening) adverse event or laboratory 
abnormality ; 
 If  5 subjects develop the same  related Grade 3 or 4 adverse event or laboratory abnormality ; 
 If  10 subjects develop any related Grade 3 or 4 adverse event or laboratory abnormality .  
Following assessment by [CONTACT_1578] (DMC, see Section 10.9), the DMC will 
determine whether to stop the study, amend the protocol, or continue the study per protocol.  
8.5 Concomitant Medication/Treatment  
Record t he name, dose, start/stop  date, indication for use , route, and whether ongoing or stopped for 
medications/treatments taken within two weeks prior to study entry  as well as any medications taken 
during the study  are to be recorded . Prohibited medications are identified in Section 8.8.  
8.[ADDRESS_883823]s medication diary and study records as 
appropriate.  
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 27 of 51 
PROTOCOL VERSION  3.0 DATE:  [ADDRESS_883824] of care plus  placebo . The brequinar and placebo capsules will be 
provided to each participating institution  in pre -numbered bottles intended for individual subjects to 
be dispensed by [CONTACT_8236]s pharmacist  or designated person . Randomization assignments will be 
provided by [CONTACT_656404] . The pharmacist/designate d 
person will dispense the next number in sequence to the next patient who qualifies for the study at an 
individual site.  
8.7.4 Unblinding/ Expectedness  
Contact [CONTACT_656405] (AE) . Each site will be provided with a sealed envelope containing individual 
sealed envelopes for subject numbers assigned to that site. Each individual subject number sealed 
envelope will have the treatment (brequinar or placebo) randomly assi gned to that subject number. Do 
not open the outer envelope or the individual sealed envelope unless it has been agreed with the 
Medical Monitor and the Sponsor that unblinding is necessary for that particular AE. Unblinding must 
be documented in the study  records. Envelope seals are to be checked to ensure they remain intact 
during drug accountability monitoring.  
If after a discussion with the Medical Monitor, the investigator or treating clinician believes the AE 
leading to unblinding to be related to the  study drug, no further doses of drug should be administered  
to that subject .  
Expectedness will be determined by [CONTACT_656406] -[ADDRESS_883825] . Adequate drug is to be dispensed for the number of subjects expected 
to be treated at each institution.   
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 28 of 51 
PROTOCOL VERSION  3.0 DATE:  [ADDRESS_883826]/ staff member  responsible for drug accountability is to document t he date and time  of 
dispensing  and for what subject the study drug was intended (i.e., record subject initials and birth date 
or other unique identifier). A pharmacy manual will be provided by [CONTACT_1034].   
At the end of the study any unused study drug  will be returned to the Sponsor for destruction or may 
be destroyed locally; disposition of study drug  will be documented .   
The Sponsor will be permitted access to the trial supplies at any time within usual business hours and 
with appropriate notice during or after completion of the study to perform drug accountability 
reconciliation.  Records may be electronic or paper and may be accessed remotel y for monitoring/drug 
accountability purposes.  
Each subject will be provided with one bottle with five brequinar or five placebo capsules for the five 
days of dosing.  
8.8 Prohibited Medications  
Treatment is prohibited with another DHODH inhibitor (e.g., leflunomide and teriflunomide ). 
Treatment is prohibited with agents known to cause bone marrow suppression leading to 
thrombocytopenia.  
8.[ADDRESS_883827] of care is 
expected to chang e as additional information, such as that from randomized controlled trials, emerges, 
and the Sponsor and the treating clinicians will need to address anticipated off -label use of any other 
drugs, devices, or interventions that might be used to manage COVI D-19 (e.g. anticoagulants).  
The Sponsor and treating clinicians are to consider changes in SOC over time, for example, 
overlappi[INVESTIGATOR_656313] a SOC treatment expected to be widely used is to be 
considered. The availability of new standard  of care treatment may change over time and vary from 
one clinical trial site to another. The Sponsor will discuss these issues with FDA should the need arise.  
 
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 29 of 51 
PROTOCOL VERSION  3.0 DATE:  [ADDRESS_883828] OF THE TRIAL  
9.1 Ethical and Regulatory Considerations  
The trial will be performed in accordance with the Declaration of Helsinki (1964)  as revised in Tokyo 
(1975), Venice (1983), Hong Kong (1989), South Africa (1996), Scotland (2000, Note of Clarification 
2002 & 2004) and Seoul 2008 (Appendix A), and Fortaleza (Brazil) (2013),  and with the International 
Council on Harmonization ( ICH) Tripartite Guideline on Good Clinical Practice (CPMP/ICH/135/95, 
Jan.97) and [LOCATION_002] ( US) FDA Regulations.  
9.[ADDRESS_883829] be obtained in accordance with US Code of Federal Regulations (21 CFR Part 50) ,  the 
FDA Guidance on Conduct of Cl inical Trials of Medical Products during the COVID -19 Public Health 
Emergency (March 2020, Updated April 16, 2020)  [20], as well as local and national regulations. 
Information should be given in both oral and written form whenever possible and deemed app ropriate 
by [CONTACT_4707] ( IRB). Subjects  and their relatives, if necessary, must be given 
ample opportunity to inquire about d etails of the study.  
The Investigator  or qualified designated person  will verbally inform subjects as to the nature, expected 
duration and purpose of the trial, the administration of the Investigational Product ( IP), and the hazards 
involved, as well as th e potential benefits that may come from treatment with this IP. The trial 
procedures will be explained in lay language and any questions will be answered.  The subjects will be 
given an IRB-approved consent form. The subjects will be given appropriate time to consider their 
participation in the trial and have any questions answered prior to signing the consent form. If a subject 
agrees to participate, he/she will sign and date an informed consent form and be provided with a copy 
of the signed consent. All su bjects who sign a n informed consent form are to be recorded on the 
applicable screening log . If the subject is unable to consent for any reason, a designated family member 
or healthcare power of attorney or other person may consent per institutional policy .  
The subject will be informed that his/her  medical records will be subject to review by [CONTACT_1034], 
Sponsors representatives , and possibly by a representative of the FDA  and other relevant regulatory 
authorities. Subjects will be informed that they are free to refuse participation in this clinical 
investigation, and if they should participate, it will be made clear to them that they may withdraw from 
the trial at any time  without prejudicing further  medical  care they may require . The subject will receive 
a copy of the consent form as well as an information sheet about the trial.  
Informed consent must be obtained from every subject  prior to any study -specific procedures . 
Standard procedures carried out prior to completing  the informed consent process but within the time 
constraints of the protocol may be used for baseline evaluation; they need not be repeated. 
Documentation of c onsent will be subject to review by [CONTACT_13099] r; if in writing, a copy will be given 
to the subject  and a copy will be filed with the subjects medical notes.  Verbal consents will be 
documented by [CONTACT_656360].  
Note that informed consent procedures have been affe cted by [CONTACT_4113] -19, and the study staff may use 
any consent method that has been approved by [CONTACT_1201] (e.g., phone consent, verbal consent with 
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 30 of 51 
PROTOCOL VERSION  3.0 DATE:  23 SEPT 2020  
 
Clear Creek Bio, Inc. 
CONFIDENTIAL  witness, e -consent, etc.)  of the local institution . In-person consent, w ritten consent signatures and 
providing har d copi[INVESTIGATOR_656329].  
The study should be discussed with the potential participant only after an initial review of his/her 
clinical status and appropriateness for participation ha ve been evaluated to determine if he/she  meets 
the subject selection criteria.  
A sample subject  information sheet and consent form are available from Clear Creek .  The final 
version at each institution may differ  depending on institutional requirement s and standard format s. 
This protocol will not be amended for site specific changes  as such changes are to be made to the sites 
consent when required . 
9.[ADDRESS_883830]  
It is the responsibility of the Investigator to submit the protocol, consent form a nd information sheet 
to the IRB . An IB will be available for review by [CONTACT_1201]. The protocol and informed consent form  
(ICF) must be approved by [CONTACT_656434] e first  subject . The template consent 
form may be revised in accordance with site -specific requirements with Sponsor review and approval.  
A copy of the IRB written approval must be provided  to the Sponsor and investigator before the trial 
may start  at that  institution . Written approval from the IRB is also required for substantial protocol 
amendments prior to their implementation.    
A substantial amendment may arise from changes to the protocol or from new information relating to 
the scientific documents i n support of the trial.  Amendments are substantial  when they are likely to 
have an impact on:  
 the safety or physical or mental integrity of the subjects ; 
 the scientific value of the trial;  
 the conduct or management of the trial; or  
 the quality or safety  of any IP used in the trial.  
If it is necessary to change or deviate from the protocol to eliminate an immediate hazard to the 
subjects, the Investigator will notify the Sponsor and the IRB of the new events and the measures taken 
as soon as possible.   
The Investigator will report promptly to the Sponsor and IRB any new information that may adversely 
affect the safety of the subjects or the conduct of the trial. On completion of the trial, the Investigator 
will inform the applicable IRB as per local IRB r equirements that the trial has ended. If the study is 
terminated for any reason , the investigator will return all clinical supplies and study -related equipment 
supplied by [CONTACT_656362].  
9.[ADDRESS_883831] the saliva sample for viral load testing  and perform 
other study activities such as body temperature, heart rate, respi[INVESTIGATOR_697], SpO2,  and symptom 
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 31 of 51 
PROTOCOL VERSION  3.0 DATE:  [ADDRESS_883832] of study assessments and timings.   
Blood chemistry tests include blood urea nitrogen (BUN), creatinine, alkaline phosphatase (AL K), 
alanine amino transferase (ALT), aspartate amino transferase (AST), total bilirubin, total protein, 
albumin, glucose, serum electrolytes (sodium, potassium, chloride, carbon dioxide/bicarbonate, and 
calcium ), lactate dehydrogenase (LDH) . 
Hematology tests include hemoglobin, hematocrit, complete blood count with full differential , and 
platelet count.  
Viral load sampling  is to be carried out on Days [ADDRESS_883833] a 
documented positive result to be eligible for the study.  
Safety laboratory results (chemistry and hematology) are to be reviewed by [CONTACT_656435] 48 hours of receipt of results.  
Hospi[INVESTIGATOR_656330] -patient with admission > 24 hours.    
As much of the study as possible will be conducted via telemedicine remote from the site (e.g., co nsent , 
medical history, concomitant medications may be collected remotely) . Subjects will be visited at home 
(or place of residence) by a home health nurse at Screening  and on study Days 1, 8, 15, and 29. On 
study Days [ADDRESS_883834]  
The study visits are to be conducted as shown in the Schedule of Events, Appendix 15.1. 
Study completion or the reason for study discontinuation will be recorded in the source document and 
the eCRF.  
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 32 of 51 
PROTOCOL VERSION  3.0 DATE:  23 SEPT 2020  
 
Clear Creek Bio, Inc. 
CONFIDENTIAL  9.5.1 Unscheduled Visits  
Unscheduled visits and tests  are permitted as needed  to assess AEs /SAEs  throughout the study. 
Unscheduled visits and tests  are also permitted as needed to assess  AEs/  SAE s with onset within two 
(2) weeks after the final study  visit providing the AE is considered related to study drug  
9.[ADDRESS_883835]s st udy participation  after discussion 
with the other party if  it is believe d it would be unsafe for the subject to continue in the study .   
Subjects must discontinue study medication  if any of the following events occur:  
 Significant protocol violation or non -compliance, either on the part of the subject or the 
investigator or other site personnel;  
 Decision of the Investigator or Sponsor that removal is in the subject's best interest;  
 Severe unrelated medical illness or complication;  
 Safety reasons/ significant  adverse event;  
 Subject request (withdrawal of consent);  
 Sponsor decision.  
Collect/co nduct  all scheduled evaluations  even for subjects who discontinue study medication  prior to 
completing the treatment  period  unless consent is withdrawn . 
9.8 Early Termination of the Study  
If the Sponsor or an Investigator believes it would be unsafe to continue the study, or for any reason 
at the Sponsors request, the study may be terminated at that site or the entire study terminated after 
discussion with the other part ies. 
The Sponsor will provide a written statement to the IRB and the relevant regulatory authority with the 
reasons for termination of the study. This will be conducted within 15 days of the decision to terminate 
the study.  
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 33 of 51 
PROTOCOL VERSION  3.0 DATE:  23 SEPT 2020  
 
Clear Creek Bio, Inc. 
CONFIDENTIAL  If the study is terminated, a close out monitoring visit will be performed and applicable procedures 
will be carried out to close the trial site(s).  
9.[ADDRESS_883836] had a hysterectomy or tubal ligation. A woman is also presumed to be infertile due to natural 
causes if she has been amenorrheic for greater than 12 months and has an FSH greater than 40 IU/L.  
In the absence of such documentation, a nega tive serum pregnancy test is required for inclusion into 
the study.  
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 34 of 51 
PROTOCOL VERSION  3.0 DATE:  [ADDRESS_883837] a causal relationship with this treatment. An 
AE can therefore be any unfavorable and unintended  sign (including an abnormal laboratory finding), 
symptom, or disease temporally associated with the use of the medicinal product, whether or not 
considered related to the medicinal product.  
Events that occur prior to  first dose  will be entered as medical  history; events  that occur after first dose  
will be ente red as adverse events (AEs)  on the AE form.  
Subjects will be questioned and observed for evidence of AEs, whether or not judged by [CONTACT_656363] . All AEs will be documented in the 
subject's medical record and CRF. For any pre -existing condition or abnormal laboratory finding that 
changes in severity after dosing, this change should be recorded as an AE. New abnormal laboratory 
findings that are clinically significant are considered AEs. Investigators and site staff are to elicit from 
the subject and note any signs or symptoms of mucositis and thrombocytopenia (see Section 10.8). 
Adverse events  will be collected  from the time of first dose  through  Day 29. After Day 29, 
collect/record only Serious Adverse Events (SAEs) which are  assessed  by [CONTACT_656364].  AE details are to be documented including start and 
stop date and times, wh ether continuous or intermittent, severity, any intervention utilized to correct 
the event  (e.g., medication, surgery , or other therapy) , outcome and the relationship to the study drug.   
AEs identified in the protocol as critical to the evaluation of safe ty must be reported to the Sponsor by 
[CONTACT_656365].  
AEs determined by [CONTACT_656436] [ADDRESS_883838] results occurring after study enrollment constitute AEs only if they 
induce clinical signs or symptoms, are considered clinically signi ficant, are Grades 3 or 4, or require 
therapy.  
If a death occurs during the SAE reporting period, the cause of death such as pneumonia, ARDS, or 
respi[INVESTIGATOR_1399], is considered as the AE and the death is considered its outcome. Death should be 
considered an outcome, not an event. The event or condition leading to death should be recorded and 
reported as a single medical concept on the AE eCRF. Generally, only one su ch event should be 
reported. Fatal will be recorded as the outcome of this respective event; death due to an outcome of 
an AE will not be recorded as separate event. If the primary cause of death is disease progression, the 
cause of death should be clear ly identified as COVID -19. 
In cases of surgical or diagnostic procedures, the condition leading to the procedure is considered as 
the AE instead of the procedure itself. Each AE will be coded by [CONTACT_656409] a preferred term using a thesaurus based on the Medical Dictionary for Regulatory Activities 
(MedDRA) . For example, record appendicitis, not appendectomy.  
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 35 of 51 
PROTOCOL VERSION  3.0 DATE:  [ADDRESS_883839] dose  are to be recorded in the eCRF using the AE form.  
3. Serious adverse events will be reported to the local IRB accordin g to institutional policy.  
The NIH Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse 
Events, Corrected Version 2.1 (July 2017) 
(https://rsc.niaid.nih.gov/sites/default/files/daidsgradingcorrectedv21.pdf ) will be used for adverse 
event reporting.    
10.1 Follow Up of Grade 3 or 4 Toxicities  
Grade 3 or 4 toxicities are to be followed by [INVESTIGATOR_1312] -evaluation every 2 days, as feasible, until the toxicity 
returns to Grade  2 severity.  
10.2 Infection Follow Up  
Any new infection that occurs on study regardless of infecting agent (i.e., viral or non -viral) sho uld be 
captured. Additionally, the site of infection and source of culture (BAL, tracheal aspi[INVESTIGATOR_337], sputum, 
blood, urine, etc.) should also be recorded.  
10.3 Classification of Causality  
Attribution is the relationship between an adverse event or serious adverse  event  
and the study treatment. Attribution will be assigned as follows:  
 Definite  The AE is clearly related to the study treatment.  
 Probable  The AE is likely related to the study treatment  
 Possible  The AE may be related to the study treatment.  
 Unlike ly - The AE is doubtfully related to the study treatment.  
 Unrelated - The AE is clearly NOT related to the study treatment  
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 36 of 51 
PROTOCOL VERSION  3.0 DATE:  23 SEPT 2020  
 
Clear Creek Bio, Inc. 
CONFIDENTIAL  Guidance for assessing causality:  
The Investigator will need to determine whether an AE is considered related to ( caused by) the 
study drug rather than some underlying condition , for example, COVID -19.   
For the purposes of this study, drug related shall mean Definite, Probable and Possible 
relationship to drug as determined by  [CONTACT_737] . 
10.4 Classification of Severity  
The NIH Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse 
Events, Corrected Version 2.1 (July 2017)  will be utilized for AE reporting. All appropriate treatment 
areas should  have access to a copy of the criteria.  
AEs that are expected are subject to expedited reporting only if the adverse event varies in nature, 
intensity or frequency from the expected toxicity information that is provided in the Investigator 
Brochure . 
10.5 Serious Adverse Event (SAE) Reporting  
The regulatory definition of a n SAE  is any untoward medical occurrence or effect that at any dose  
fulfills one or more of these criteria : 
 results in death ; 
 is life threatening (at the time of the event) ; 
 requires in -patient hospi[INVESTIGATOR_1081] ; 
 results in persistent or significant disability / incapacity  
 is a congenital anomaly / birth defect ; 
 or is an  event considered medically serious by [CONTACT_737].  
 
Disability  is defined as a substantial disruption of a persons ability to conduct normal life functions.  
A life -threatening adverse event  is one that places the patient /subject , in the view of the Investigator, 
at immediate risk of death from the event as it occurred.  It does  not include an event that, had it 
occurred in a more severe form, might have caused death.   
An unexpected adverse event  is any adverse drug event, the nature or severity of which is not 
consistent with the applicable product information (e.g. IB for an unauthorized  investigational product 
or summary of product characteristics for an authorized  product).  
Enter only one event as the reason for the SAE on the SAE form.  Other non -serious events which did 
not directly result in the SAE should be detailed in t he description section on the SAE form and listed 
separately as AEs if necessary.  For fatal SAEs, report the cause of death as an SAE with a fatal 
outcome rather than reporting death as the SAE term.  
Note that hospi[INVESTIGATOR_656337]:  
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 37 of 51 
PROTOCOL VERSION  3.0 DATE:  23 SEPT 2020  
 
Clear Creek Bio, Inc. 
CONFIDENTIAL   Routine treatment or monitoring of COVID -19 infection , not associated with any 
deterioration in condition ;  
 Elective or pre -planned treatment for a pre -existing condition that is unrelated to the 
indication under study and has not worsened since signing the informed consent ;  
 Social reasons and respi[INVESTIGATOR_108999]s general 
condition ; 
 Treatment on an emergency outpatient basis that does not result in hospi[INVESTIGATOR_656338].  
ANY SERIOUS ADVERSE EVENT MUST BE REPORTED IMMEDIATELY (WITHIN 24 
HOURS) BY [CONTACT_656437] .  
ENTER THE SUBJECTS AVAILABLE INFORMATION INTO TH E eCRF WITHIN [ADDRESS_883840]s subsequent medical course following a n SAE  must be submitted to 
Covance Patient Safety  until the event has subsided or, in case of permanent impairment, it stabilizes , 
and the overall clinical outcome has been ascertained.  
SAE R EPORTING EMAIL:   SAEIntake@covance .com  
Medical Monitor:  
Norberto Soto, MD  Telephone:  ([PHONE_13587]  
Covance Physician /Medical Monitor  Email:  [EMAIL_12503]  
Sponsor Representative:  
Barbara Powers, MSN, Ph.D.  Telephone:  M: ([PHONE_13588]  
VP, Clinical Operations  Email:  [EMAIL_12502]   
All SAEs will be reported to the IRB  periodically, at the end of the study , or per local institutional 
guidelines.   
10.6 Suspected Unexpected S erious  Adverse Reactions (S[LOCATION_003]Rs)  
Suspected, unexpected, serious adverse reactions ( S[LOCATION_003]Rs ) are SAEs that are both related to the study 
drug (Relationship = Related) and unexpected (not previo usly described in the investigators 
brochure).  All S[LOCATION_003]Rs will be reported in an expedited manner to the Sponsor or designee  and IRB 
by [CONTACT_656369]. Expectedness will be 
judged by [CONTACT_656438] . It is critical  that all SAEs are reported within 
the 24 -hour guideline so that the expectedness determination can be made. S[LOCATION_003]Rs require immediate 
attention and expedited reporting to relevant regulatory authorities.  
The Sponsor will ensure that all relevant information about fatal  or life -threatening  S[LOCATION_003]R s are 
appropriately recorded and reported  to the concerned Regulatory Authority and to the concerned 
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 38 of 51 
PROTOCOL VERSION  3.0 DATE:  23 SEPT 2020  
 
Clear Creek Bio, Inc. 
CONFIDENTIAL  IRB(s)  within seven (7) calendar days of the date of first report to Covance Patient Safety / Sponsor . 
Follow -up information will be communicated to the relevant Regulatory Authorit y within an 
additional eight calendar days.  
All other S[LOCATION_003]Rs will be reported to t he Regulatory Authority and to the IRB(s) concerned as soon 
as possible within a maximum of fifteen calendar days of first notification to Covance Patient Safety 
/ Sponsor.  
The Sponsor or designee will also inform all Investigators studying  the investigati onal medicinal 
product about S[LOCATION_003]Rs  and ensure that all IRBs have been notified . 
For reported deaths of a subject, the Investigator shall supply the Sponsor and the IRB(s) with 
requested additional information on an expedited basis .   
10.[ADDRESS_883841]s partner during the study period will be 
documented in the subjects source documents and reported to Covance Patient Safety (by [CONTACT_20143] 
[EMAIL_6533])  and to the IRB by [CONTACT_144300]  [ADDRESS_883842]s 
partner will begin at the first dose of study drug and will continue through [ADDRESS_883843]s partner has consented to this. Monitoring of the baby [CONTACT_656412] [ADDRESS_883844]s partner has consented to  this.  
Pregnancy itself is not an AE; it should be reported for tracking purposes. The Investigator or designee 
will discontinue the pregnant subject from the treatment aspects of the study, continue to follow her 
per protocol for safety outcomes only, an d advise her to seek prenatal care and counseling from her 
primary care provider. Data on fetal outcome and breast -feeding will be collected for regulatory 
reporting and drug safety evaluation , if the subject has consented to this . 
If the pregnancy is due to a subjects failure to comply with the contraceptive requirements of this 
protocol, this should be documented as a protocol deviation.  
Complications of pregnancy or congenital abnormalities in the newborn child will be reported 
appropriately as (S)AEs.   
The site clinical staff will request the pregnant subject to notify the site of the outcome of the 
pregnancy (i.e., birth, loss, or termination). To help ensure this, the site clinical staff will follow the 
subject until the end of pregnancy, with the su bjects consent. This request and the subjects response 
will be documented in the subjects source document.  
10.[ADDRESS_883845] to  hematologic toxicity. In addition to enhancing safety by 
[CONTACT_459704]:  CCB -CRISIS -02      Page 39 of 51 
PROTOCOL VERSION  3.0 DATE:  23 SEPT 2020  
 
Clear Creek Bio, Inc. 
CONFIDENTIAL  selecting a relatively brief 5 -day exposure and a low brequinar dose, all subjects in the clinical trial 
will be under the care of highly qualified medical personnel. Clinically significant out -of-range 
laboratory  results will be reported as adverse events.  
In addition to real time assessments by [CONTACT_314107], t he Covance  Medical Monitor will 
assess the available hematology data on a periodic  basis to identify any pathologic trends or s afety 
issues. Any apparent increase in the expected rate or severity of hematologic safety events will be 
discussed with the Princip al Investigators  and the Sponsor. In addition, the Data Monitoring 
Committee (DMC) will assess available hematology data on a periodic  basis to independently assess 
any pathologic trends or safety issues.  If the rate or severity of hematologic toxicities appears to be 
above the expected rate or the severity appears worse than that expected, the trial enrollment will be 
suspende d and no further subjects will be treated while a comprehensive data review is conducted. 
Depending on the outcome of the safety review the study may be stopped , the design adjusted , or the 
study may continue as designed . Individual and Study stoppi[INVESTIGATOR_1877] s are provided in Section 8.4. 
Safety laboratory results are to be initially assessed in real time by [CONTACT_656439]. Any study drug-related clinically significant out -of-range laboratories or study 
drug-related adverse events will be followed as needed until resolution or stable.  
The in-clinic  assessments and telemedicine /phone call visits will specifically ask about possible 
hema tologic toxicity including any evidence of  the list below. Subjects will be provided with a list of 
the following events in lay terms and will be instructed to call the research team if any of these events 
occur.  
 Ecchymosis /purpura/petechiae  
 Epi[INVESTIGATOR_3940]  
 Hemoptysis  
 Hematuria  
 Gingival bleeding  
 Prolonged bleeding time from needle sticks, abrasions or lacerations  
 Hematemesis  
 Rectal bleeding  
 Blood in stool  
 Any other unusual bleeding noted by [CONTACT_656440].  
10.9 Data Monitoring Committee  
A Data Monitoring Committee  (DM C) will be established to provide independent oversight to this 
trial. The  primary responsibility of the DMC  will be to review the progress and conduct of the trial in 
order to maintain scientific rigor and to ensure the wellbeing of subjects participating in the trial. The 
specific responsibilities of the DMC  will be detailed i n a separate DMC  charter. The DMC  will include 
at a minimum at least one statistician and two clinicians who will perform periodic data review to 
assess whether there are clinically significant differences between treatment arms that could affect 
participa nt safety.  All adverse events will be reviewed by [CONTACT_656430]. Following 
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 40 of 51 
PROTOCOL VERSION  3.0 DATE:  [ADDRESS_883846] 40 subjects complete the Day 8 visit. 
 
 
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 41 of 51 
PROTOCOL VERSION  3.0 DATE:  23 SEPT 2020  
 
Clear Creek Bio, Inc. 
CONFIDENTIAL  11 STATISTICAL CONSIDERATIONS  
A separate, det ailed statistical analysis plan (SAP) will be finalized prior to locking the database. All 
analyses will be descriptive in nature and presented by [CONTACT_19313].   
Summaries for quantitative variables will include the mean, median, quartiles, standard error, 
minim um, and maximum. For qualitative variables, the summaries will include the number and 
percentage of subjects for each outcome, and 95% confidence interval (CI) , when appropriate. Any 
statistical testing will be considered exploratory and descriptive. All c omputations will be performed 
using SAS (Version 9.4 or higher).  
Subject disposition, subject demographics and baseline characteristics will be summarized. Subject 
data listings will also be provided. The following sections will briefly summarize of the p lanned 
statistical analyses and analysis sets for the primary and secondary endpoints.  
11.[ADDRESS_883847] dose (treatment -emergent) adverse events  will be tabulated by [CONTACT_167546], and by [CONTACT_656441]. All 
laboratory results  and study assessments  will be summarized using appropriate descriptive statistics.  
11.3 Efficacy Analyses  
Efficacy will primarily be assessed via viral load  changes . 
11.4 Sample Size Considerations  
Formal sample size calculations are not applicable for this proof -of-concept study. The sample size of 
approximately  100 subjects planned to be entered in this trial  is expected to be adequate to provide 
safety and efficacy information to advise future stu dy design . 
11.5 Randomization  
A randomization scheme will be provided by [CONTACT_656415]  + brequinar  or SOC +  placebo  in a 1: 1 
ratio.  
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 42 of 51 
PROTOCOL VERSION  3.0 DATE:  23 SEPT 2020  
 
Clear Creek Bio, Inc. 
CONFIDENTIAL  11.6 Pooling of Study Centers  
Not applica ble to this small, early phase study.  
11.7 Interim Analysis  
No interim analysis is planned for this trial.  
 
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 43 of 51 
PROTOCOL VERSION  3.0 DATE:  23 SEPT 2020  
 
Clear Creek Bio, Inc. 
CONFIDENTIAL  12 INVESTIGATOR RESPONSIBILITIES  
12.1 Investigators Performance  
The Investigator will ensure that all those concerned with conducting the trial are : 
 provided wi th copi[INVESTIGATOR_656319];  
 trained regarding the conduct of the study and the training has been documented.  
The Investigator will sign the Investigators Statement and Agreement  found in Section 15.[ADDRESS_883848] that his/her identity will be protected an d confidentiality will 
be maintained during all audits and inspections of the trial site and documentation. A unique number 
will be assigned to each subject at the start of the trial and this, with the subjects initials, will be used 
to identify the subje ct. In some cases, a further step may be taken to assign fake initials to the subject, 
per individual site requirements. The subjects  number will be the site number followed by [CONTACT_656442], on all trial correspondence and in the trial database. The Investigator will keep a list of 
identification codes or initials used for  each subject  along with the unique number assigned.  
All information provided to the Investigator relevant to the investigational product ( IP), as well as 
information obtained during the course of  the trial will be regarded as confidential. The Investigator 
and members of his/her research team agree not to disclose or publish such information in any way to 
any third -party without prior written permission from the Sponsor which will not be unreasona bly 
withheld, except as required by [CONTACT_2371], or as permitted by [CONTACT_656417], 
Section  12.7. 
The Investigator will take all measures to ens ure subjects  confidentiality will be maintained at all 
times.  
12.[ADDRESS_883849] 
access to the subjects ' medical or clinic records is necessary. The Investigator will ensure that certain 
information is contained in the medical or clinic written or electronic records of the subject  and that 
the entries are signed and dated, as follows:  
 sufficient data to allow verification of the entry criteria in terms of past and present medical and 
medication histories;  
 a note on the day the subject entered the trial describing the trial number, the IP being evaluated, 
the trial number assigned to that subject  and a statement that consent was obtained;  
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 44 of 51 
PROTOCOL VERSION  3.0 DATE:  23 SEPT 2020  
 
Clear Creek Bio, Inc. 
CONFIDENTIAL   a note of each subsequent trial visit including any concerns about AEs and their resolution;  
 notes of all concomitant medication take n by [CONTACT_19578] , including start and stop dates;  
 a note of when the subject  terminated from the trial, the reason for termination and the subject s 
general condition at termination;  
 a copy of the signed informed consent form should be kept in the medical records of each subject 
during the clinical phase of the study. A signed copy should also be filed in the investigator file.  
12.[ADDRESS_883850] the research staff with 
any queries. All queries and discrepancies relating to the data collection are to be resolved at the 
completi on of the trial . Remote data capture is encouraged whenever possible.  
12.5 Case Report Forms, Investigators Site File and Record Retention  
The Sponsor may provide the CRFs in paper, electronic (eCRF), or other media. The forms will be 
reviewed against source d ocumentation at each monitoring visit. All CRFs and supporting source 
documentation must be completed and available to the Sponsor in a timely manner. Changes or 
corrections due to data clarification and resolutions will be tracked by [CONTACT_656443].  
Prior to review of the case report forms by [CONTACT_1034]s representative, they should be reviewed for 
completeness and accuracy by [CONTACT_29517] a member of the research team.  
The Investigator must maintain an Investigator Sit e File which include s, but is not limited to, the IB, 
the protocol plus any amendments, all correspondence with the IRB including the approval for the 
trial to proceed, Regulatory Authority approval/ notification (if applicable) including a sample of an 
approved informed consent, IP accountability, Source Documents, investigator and staff curricula 
vitae ( CVs, ) trial documentation, and all trial correspondence. The original signed informed consent 
forms and the final report will be kept in the Investigator Site File.  
The Investigator will archive all essential documents. The medical files of trial subjects shall be 
retained in accordance with national legislation and in accordance with the maximum period of time 
permitted by [CONTACT_5035][INVESTIGATOR_307], institution or priv ate practice. The Investigator has a responsibility to retain 
essential documents for as long as is required by [CONTACT_656419]. It 
is the responsibility of the Sponsor to inform the Investigator as to when these documents  no longer 
need to be retained. Investigators will be asked to contact [CONTACT_656420]. Any transfer o f ownership of the data or of documents will be documented in 
writing. The new owner will assume responsibility for data retention and archiving.  
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 45 of 51 
PROTOCOL VERSION  3.0 DATE:  [ADDRESS_883851] 30 days before its submission for any meeting or journal. In addition, if 
deemed necessary by [CONTACT_656444], the 
Investigator agrees to a further delay of 60 days before any presentation or publication is submitted. 
The Sponsor reserves the right to include the report of this trial in any regulatory do cumentation or 
submission or in any informational materials prepared for the medical profession.  
Authorship determination will be at the discretion of the Sponsor and will include evaluation of the 
following criteria: Investigator must participate in the r eview of and content of the protocol; review 
and comment on the study results; participate in the writing, reviewing and commenting of the 
manuscript; and approve the final manuscript for submission.  
 
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 46 of 51 
PROTOCOL VERSION  3.0 DATE:  23 SEPT 2020  
 
Clear Creek Bio, Inc. 
CONFIDENTIAL  13 SPONSOR RESPONSIBILITIES  
13.1 General  
The Sponsor agrees to adhere to the ICH Note for Guidance on GCP  (CPMP/ICH/135/95, Jan.97)  and 
US FDA Regulations. It is the Sponsor's responsibility to obtain appropriate regulatory approval to 
perform the trial (if applicable). The Sponsor should notify promptly all concerned investigator(s), 
IRB(s) and the Regulatory Authority of findings that could adversely affect the health of the patients/ 
subjects, impact on the conduct of the trial or alter the Regulatory Authoritys authorization  to continue 
the trial. If it is necessary to change or deviate from the protocol to eliminate an immediate hazard to 
the subjects the Sponsor will notify the relevant regulatory authority and relevant IRB of the new 
events, the measures taken and the plan for further actio n as soon as possible.  This will be by [CONTACT_656445] a written report.   
On completion of the trial, the Sponsor will inform the regulatory authority that the trial has ended.  If 
the study is terminated for any reason the Sp onsor will provide a written statement to the relevant 
regulatory authority and the IRB with the reasons for termination of the trial. This will be conducted 
within [ADDRESS_883852] (EHR) or conduct remote monitoring visits at regular intervals 
during the trial for monitoring purposes and to assist the research staff with any queries. CRFs and 
source documentation will be available for review during monitoring visits to the trial site. The 
function of this monitoring is to en sure compliance with the protocol, adherence to regulatory and 
GCP  obligations, proper maintenance of records including IP accountability records, correct 
administration of IP including storage conditions and accurate reporting of AEs. On-site visits are n ot 
required for any monitoring visits for this study.    
Once the data from the case report forms have been entered onto the database, they will be reviewed , 
and the data verified against the subjects source data. Any discrepancies will be tracked by [CONTACT_656446].  
13.[ADDRESS_883853] while 
the trial is being conducted or up to several years later.   
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 47 of 51 
PROTOCOL VERSION  3.0 DATE:  [ADDRESS_883854] s name,  and subject s 
confidentiality will be maintained at all times.  
13.[ADDRESS_883855] of a separate agreement between the Investigator /Institution  and Sponsor.  
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 48 of 51 
PROTOCOL VERSION  3.0 DATE:  23 SEPT 2020  
 
Clear Creek Bio, Inc. 
CONFIDENTIAL  14 REFERENCES   
1. Sykes DB, Kfoury YS, Mercier FE, et al. Inhibition of dihydroorotate deh ydrogenase 
overcomes differentiation blockade in acute myeloid leukemia. Cell 2016; 167(1): 171 -186. 
2. Zhou  F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality 
of adult inpatients with COVID -19 in Wuhan, China: a retrosp ective cohort study. Published 
online March 9, 2020. https://doi.org/10.1016/S0140 -6736(20)[ZIP_CODE] -3 
3. Phelan  A, Katz R, and Gostin L. The novel coronavirus originating in Wuhan, China. 
Challenges f or global health governance. Jama. 2020;323(8):709 -710.   
4. Handel A, Mille J, Yang G, Fung I. If containment is not possible, how do we minimize 
mortality for COVID -19 and other emerging disease outbreaks.  March 13, 2020. 
https://doi.org/10.1101/2020.03.13.20034892 . 
5. Brequinar Investigators Brochure  
6. Chen S, Ding S, Yin Y, Xu L, Li P, Peppelenbosch MP, et al. Suppression of pyrimidine 
biosynthesis by [CONTACT_656447] e nzyme robustly inhibits rotavirus replication. Antiviral 
Res. 2019 Jul;167:35 44.  
7. Mei-Jiao G, Shi -Fang L, Yan -Yan C, Jun -Jun S, Yue -Feng S, Ting -Ting R, et al. Antiviral 
effects of selected IMPDH and DHODH inhibitors against foot and mouth disease virus. 
Biomed Pharmacother. [ADDRESS_883856];118:109305.  
8. Wang QY, Bushell S, Qing M, Xu HY, Bonavia  A, Nunes S, et al. Inhibition of Dengue 
Virus through Suppression of Host Pyrimidine Biosynthesis. 2011 Jun 9;85(13):6548 56.  
9. Luthra P, Naidoo J, Pi[INVESTIGATOR_656320], De S, Khadka S, Anantpadma M, et al. Inhibiting 
pyrimidine biosynthesis impairs Ebola virus rep lication through depletion of nucleoside 
pools and activation of innate immune responses. Antiviral Res. [ADDRESS_883857];158:288 302.  
10. Andersen PI, Krpi[INVESTIGATOR_28947] K, Ianevski A, Shtaida N, Jo E, Yang J, et al. Novel Antiviral Activities 
of Obatoclax, Emetine, Niclosamide , Brequinar, and Homoharringtonine. Viruses. [ADDRESS_883858] 
18;11(10).  
11. Xiong  R, Zhang L , Li S, Sun Y , Ding M , Wang, Y , et al. Novel and potent inhibitors 
targeting DHODH, a rate -limiting enzyme in de novo pyrimidine biosynthesis, are broad -
spectrum antiviral ag ainst RNA viruses including newly emerged coronavirus SARS -CoV -2. 
12. Sah R, Rodriguez -Morales AJ, Jha R, Chu DKW, Gu H, Peiris M, et al. Complete Genome 
Sequence of a 2019 Novel Coronavirus (SARS -CoV -2) Strain Isolated in Nepal. Microbiol 
Resour Announc. 2020  Mar 12;9(11).  
13. Liu Q, Gupta A, Okesli -Armlovich A, Qiao W, Fischer C, Smith M, et al. Enhancing the 
Antiviral Efficacy of RNA -Dependent RNA Polymerase Inhibition by [CONTACT_656386]. bioRxiv. 2020 Jan 1;2020.03.24.992230 . 
14. Study DUP 785 -001 Clinical Study Report (on file with Clear Creek)  
15. Study DUP 785 -003 Clinical Study Report (on file with Clear Creek)  
16. Study DUP 785 -005 Clinical Study Report (on file with Clear Creek)  
17. Study DUP 785 -022 Clinical Study Report (on file with  Clear Creek)  
18. Study DUP 785 -031 Clinical Study Report (on file with Clear Creek)  
19. Study DUP 785 -034 Clinical Study Report (on file with Clear Creek)  
20. FDA Guidance COVID -19: Developi[INVESTIGATOR_656333] ( https://www.fda.gov/media/137926/download ) 
 
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 49 of 51 
PROTOCOL VERSION  3.0 DATE:  23 SEPT 2020  
 
Clear Creek Bio, Inc. 
CONFIDENTIAL  15 APPENDICES  
15.1 Appendix  A:  CCB -CRISIS -[ADDRESS_883859] dose time  
 
Procedures  Screen  
(days  
-14 to -1) 
HH+TMf D1 
HH+
TM D2, 3  
( 8 
hrs) 
TCf D4 
( 8 
hrs) 
TM D5,6,
7 
( 8 
hrs) 
TC D8 
( 1 
day)  
HH+
TM D12 
( 1 
day)  
TM D15 
( 1 
day)  
HH+
TM D22 
(1 
day)  
TM Final 
Visit   
D29 
( 2 days)  
HH+TM  
Informed Consent (note Date and Time)  X          
AE/Concomitant Medications (dose, route, duration 
or ongoing)  X X X X X X X X X X 
Medical history (relevant within one year or 
ongoing)/ History of current illness (date of 
symptom onset or change in baseline co -morbidity 
thought to be due to COVID -19 infection)  X          
Demographics (subject reported height and weight, 
date of birth, gender, race, ethnicity)  X          
Check for Physical Exam abnormalities (subject 
self-reported)  X          
Pregnancy Test (WOCBP)  X 
(serum)          X 
(urine)  
Hematology/Chemistrya X X     X  X   
Vital Signsb X X  X  X X X X X 
Symptom Assessmentc X X  X  X X X X X 
SARS -CoV -2 RT-PCR/ Viral load  sampled X X   X  X X X X X 
Hospi[INVESTIGATOR_656304]       X  X X X 
WHO Ordinal Scale Assessment   X    X  X X X 
Confirm Eligibility   X         
Randomize subject and dispense Study Medication   X         
Study drug administratione  X X X X 
D5 
Only       
Drug Accountability       X     
aDo not repeat if within 48h of Day 1 visit.  Send to Covance Central Laboratory Services (CCLS) for analysis.  
bVital signs include heart rate, respi[INVESTIGATOR_697], body temperature, and S pO2. Subject will be provided with a thermometer and pulse 
oximeter with heart rate monitoring capability. Training will be provided during the first visit by [CONTACT_535758]. Vital signs 
parameters will be observed and recorded by [CONTACT_656394] a visit by [CONTACT_535758].  
cSymptom Assessment will use a checklist  provided to the subj ect with  symptoms such as sore throat, cough, GI symptoms (vom iting, 
diarrhea), an osmia, dysgeusia, other (specify), etc.  Severity None, Mild, Moderate, or Severe will be collected.  
d RT-PCR at Screening may be performed by [CONTACT_656448] p rovide documentation of a positive SARS -CoV -[ADDRESS_883860] using an O mnigene collection system or 
similar. The home health nurse will train the subject and observe sample collection on Day 1. These samples are to be sent to CCLS 
for analysis.  The viral load sample may also be used to perform  viral cultures (sample can be split  by [CONTACT_2237] , no 
additional sample required).  
eSubject  will self -administer study drug once daily Days 1  [ADDRESS_883861] doses in a medication diary.  Note that any visits/visit activities 
may be conducted via telephone, telemedicine , or digital media other than serum pregnancy test and chemistry/hematology sam ple 
collection. These labs may be collected at the clinical site or another designated out -patient facility/laboratory or collected via home 
visit.  Arrangements for shippi[INVESTIGATOR_656336].  
fHH = Home Health in -person visit; TC = Telephone Call with site  and subject ; TM = Telemedicine with site  and subject.  
 
  
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 50 of 51 
PROTOCOL VERSION  3.0 DATE:  23 SEPT 2020  
 
Clear Creek Bio, Inc. 
CONFIDENTIAL  15.2 Appendix  B: Investigators Statement and Agreement  
STUDY NUMBER:    CCB -CRISIS -02 
The CRISIS2 Study: A phase 2, randomized , double blind,  placebo -controlled, multi -center study 
assessing the safety and anti -coronavirus response of suppression of host nucleotide synthesis in out -
patient adults with SARS -CoV -2.  
INVESTIGATORS STATEMENT AND AGREEMENT  
I (the Investigator ) have read this protoc ol and hereby [CONTACT_656426].  It is further agreed that the details of this trial and all information provided to me by 
[CONTACT_656388], Inc.  (the Sponsor ) will be held in the strictest confidence and will not be revealed for 
any reason without written authorization from Clear Creek Bio, Inc. except to those who are to 
participate in the conduct of the trial.  
I agree that all data, the case report forms , and all materials provided for the conduct of the tria l are 
the property of Clear Creek Bio, Inc.  unless specified otherwise in writing. It is understood that Clear 
Creek Bio, Inc. will utilize the information derived from this trial in various ways, such as for 
submission to government regulatory agencies, r equired internal reports , and presentations without 
violating patient/ subject confidentiality in any way.  
I further agree that Clear Creek Bio, Inc.  or its representatives will be permitted access , in accordance 
with current Good Clinical Practice Guidelines , to all data generated by [CONTACT_656427].  
PRINCIPAL INVESTIGATOR  
[INVESTIGATOR_67476]: ____________________________________  
 
Signature: ________________________________ ____________  Date: __________________  
 
  
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 51 of 51 
PROTOCOL VERSION  3.0 DATE:  23 SEPT 2020  
 
Clear Creek Bio, Inc. 
CONFIDENTIAL  15.3 Appendix C: WHO Ordinal Scale  
 
Patient State  Descriptor  Score  
Uninfected  Uninfected; no viral RNA detected  0 
Ambulatory mild disease  Asymptomatic; viral RNA detected  1 
Symptomatic; independent  2 
Symptomatic; assistance needed  3 
Hospi[INVESTIGATOR_057]: moderate disease  Hospi[INVESTIGATOR_057]; no oxygen therapy*  4 
Hospi[INVESTIGATOR_057]; oxygen by [CONTACT_88543]  5 
Hospi[INVESTIGATOR_057]: severe disease  Hospi[INVESTIGATOR_057]; oxygen by [CONTACT_656428]  6 
Intubation and mechanical ventilation, pO 2/FiO 2 150 or SpO 2/FiO 2  200  7 
Mechanical ventilation pO 2/FiO 2 <150 (SpO 2/FiO 2 < 200) or vasopressors  8 
Mechanical ventilation pO 2/FiO 2 <150 and vasopressors, dialysis, or ECMO  9 
Dead  Dead  10 
 
WHO clinical progression scale  
 
PROTOCOL NUMBER:  CCB -CRISIS -02  Page 1 of 52 
PROTOCOL VERSION  4.0 DATE:  [ADDRESS_883862] 2020  
Clear Creek Bio, Inc. 
CONFIDENTIAL  STUDY PROTOCOL  
The CRISIS 2 Study: A phase 2, randomized , double blind, placebo -controlled, multi -center 
study  assessing the safety and anti -coronavirus response of suppression of host nucleot ide 
synthe sis in out-patient adults with SARS -CoV -2  
Study No: CCB -CRISIS -02 
Version: 4.0 
Version Date:  01 October  2020  
Sponsor:  
Clear Creek Bio, Inc.  
[ADDRESS_883863], 4th Floor,  
Cambridge MA [ZIP_CODE]  
Sponsor Telephone: ([PHONE_13583]  
Sponsor Facsimile: ([PHONE_13584]  
IND Number: 149291  
This confidential document is the property of Clear Creek Bio, Inc .  No unpublished information contained herein may 
be disclosed without the prior written approval of Clear Creek Bio, Inc. This trial will be conducted in accordance with 
the ICH Note for Guidance on Good Clinical Practice (CPMP/ICH/135/95, Jan.97), the De claration of Helsinki (1964, 
1975, 1983, 1989, 1996, 2000 (Note for Clarification 2002 & 2004) and 2008), FDA Regulations and locally applicable 
regulations.  
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 2 of 52 
PROTOCOL VERSION  4.0 DATE:  [ADDRESS_883864] 2020  
 
Clear Creek Bio, Inc. 
CONFIDENTIAL  TABLE OF CONTENTS  
2 SYNOPSIS  ................................ ................................ ................................ ............................  9 
3 INTRODUCTION  ................................ ................................ ................................ ..............  16 
3.1 Coronavirus -19 (COVID -19) ................................ ................................ .....................  [ADDRESS_883865] Nucleotide Synthesis  ................................ ................................ .........................  16 
3.3 Dihydroorotate dehydrogenase (DHODH)  ................................ ................................  17 
3.4 Brequinar  ................................ ................................ ................................ ....................  17 
3.5 Rationale for the Planned Trial  ................................ ................................ ..................  18 
3.5.1  Brequinar Dose Selection  ................................ ................................ .............................  19 
3.5.2  Risk/Benefit of Brequinar  ................................ ................................ ............................  19 
3.6 Risks Associated with Participation in the Clinical Study  ................................ .........  19 
3.7 Possible Interactions with Concomitant Medical Treatments  ................................ .... 20 
3.7.1  CYP Interactions  ................................ ................................ ................................ ..........  20 
3.8 Steps to be Taken to Control or Mitigate Risks  ................................ .........................  20 
4 TRIAL OBJECTIVES  ................................ ................................ ................................ ........  21 
4.1 Primar y Objective  ................................ ................................ ................................ ...... 21 
4.2 Secondary Objectives  ................................ ................................ ................................ . 21 
4.3 EXPLORATORY OBJECTIVES  ................................ ................................ ..............  21 
5 TRIA L DESIGN  ................................ ................................ ................................ .................  22 
6 TRIAL ENDPOINTS ................................ ................................ ................................ ..........  23 
6.1 Primary Endpoint  ................................ ................................ ................................ ....... 23 
6.2 Secondar y Endpoints  ................................ ................................ ................................ .. 23 
6.3 Exploratory Endpoints ................................ ................................ ................................  23 
7 TRIAL POPULATION  ................................ ................................ ................................ ....... 24 
7.1 Number of Subjects  ................................ ................................ ................................ .... 24 
7.2 Inclusion criteria  ................................ ................................ ................................ .........  24 
7.3 Exclusion Criteria  ................................ ................................ ................................ ....... 24 
8 STUDY TR EATMENTS  ................................ ................................ ................................ .... 26 
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 3 of 52 
PROTOCOL VERSION  4.0 DATE:  [ADDRESS_883866] 2020  
 
Clear Creek Bio, Inc. 
CONFIDENTIAL  8.1 Description of Study Medications  ................................ ................................ ..............  26 
8.1.1  Brequinar  ................................ ................................ ................................ ......................  26 
8.2 Treatment Admi nistration  ................................ ................................ ..........................  26 
8.2.1  Safety/Tolerability  ................................ ................................ ................................ ........  26 
8.3 Study Discontinuation  ................................ ................................ ................................  27 
8.4 Stoppi[INVESTIGATOR_2121]  ................................ ................................ ................................ ........  27 
8.4.1  Individual Stoppi[INVESTIGATOR_2121]  ................................ ................................ .........................  27 
8.4.2  Study -Level Stoppi[INVESTIGATOR_2121] ................................ ................................ ......................  27 
8.5 Concomitant Medication/Treatment  ................................ ................................ ..........  27 
8.6 Treatment Compliance  ................................ ................................ ...............................  27 
8.7 Storage, Stability, Labeling and Packaging  ................................ ...............................  28 
8.7.1  Storage and Stability  ................................ ................................ ................................ .... 28 
8.7.2  Labeling and Packaging  ................................ ................................ ...............................  28 
8.7.3  Blinding and Randomization  ................................ ................................ ........................  28 
8.7.4  Unblinding/Expectedness  ................................ ................................ .............................  [ADDRESS_883867]  ................................ ................................ ................................ ............  32 
9.5.1  Unscheduled Visits  ................................ ................................ ................................ ....... 33 
9.6 Compliance with Study Procedures  ................................ ................................ ...........  33 
9.7 Early Withdrawal from the Study  ................................ ................................ ..............  33 
9.8 Early Termination of the Study  ................................ ................................ ..................  33 
9.9 Non-Childbearing Potential ................................ ................................ ........................  34 
10 ADVERSE EVENT REPORTING ................................ ................................ .....................  35 
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 4 of 52 
PROTOCOL VERSION  4.0 DATE:  [ADDRESS_883868] 2020  
 
Clear Creek Bio, Inc. 
CONFIDENTIAL  10.1  Follow Up of Grade 3 or 4 Toxicities  ................................ ................................ ........  36 
10.2  Infection Follow Up  ................................ ................................ ................................ ... 36 
10.3  Classification of Causality  ................................ ................................ .........................  36 
10.4  Classification of Severity  ................................ ................................ ...........................  37 
10.5  Serious Adverse Event (SAE) Reporting  ................................ ................................ ... 37 
10.6  Suspected Unexpected Serious Adverse Reactions (S[LOCATION_003]Rs)  ................................ . [ADDRESS_883869] e Size Considerations  ................................ ................................ .......................  42 
11.5  Randomization  ................................ ................................ ................................ ...........  42 
11.6  Pooling of Study Centers ................................ ................................ ............................  43 
11.7  Interim Analysis  ................................ ................................ ................................ .........  43 
12 INVESTIGATOR RESPONSIBILITIES  ................................ ................................ ...........  44 
12.1  Investigators Performance  ................................ ................................ ........................  44 
12.2 Confidentiality  ................................ ................................ ................................ ............  44 
12.3  Source Documentation  ................................ ................................ ...............................  44 
12.4  Data Collection  ................................ ................................ ................................ ...........  45 
12.5  Case Re port Forms, Investigators Site File and Record Retention  ...........................  45 
12.6  Non-Protocol Research  ................................ ................................ ..............................  46 
12.7  Publication  ................................ ................................ ................................ ..................  46 
13 SPONSOR RESPONSIBILITIES  ................................ ................................ ......................  47 
13.1  General  ................................ ................................ ................................ .......................  47 
13.2  Indemnity  ................................ ................................ ................................ ...................  47 
13.3  Data Monitoring  ................................ ................................ ................................ .........  47 
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 5 of 52 
PROTOCOL VERSION  4.0 DATE:  [ADDRESS_883870] 2020  
 
Clear Creek Bio, Inc. 
CONFIDENTIAL  13.4  Audit  ................................ ................................ ................................ ...........................  47 
13.5  Confidentiality  ................................ ................................ ................................ ............  48 
13.6  Finance  ................................ ................................ ................................ .......................  48 
14 REFERENCES  ................................ ................................ ................................ ...................  49 
15 APPENDICES  ................................ ................................ ................................ ....................  50 
15.1  Appendix A:  CCB -CRISIS -02 Schedule of Events  ................................ ..................  50 
15.2  Appendix B: Investigators Statement and Agreement  ................................ ..............  51 
15.3  Appendix C: WHO Ordinal Scale  ................................ ................................ ..............  52 
 
 
  
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 6 of 52 
PROTOCOL VERSION  4.0 DATE:  [ADDRESS_883871] OF FIGURES  
Figure 3 -1. DHODH is a mitochondrial enzyme that catalyzes the 4th step of pyrimidine synthesis; 
it is completely essential for the generation of UMP.  ................................ .................  17 
 
 
  
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 7 of 52 
PROTOCOL VERSION  4.0 DATE:  [ADDRESS_883872]  
ESR Erythrocyte Sedimentation Rate  
EUA  Emergency Use Authorization  
FDA  [LOCATION_002] Food and Drug Administration  
GCP  Good Clinical Practice  
HIV Human immunodeficiency virus  
IB Investigator Brochure  
ICF Informed consent form  
ICH International Council on Harmonization  
ICU Intensive care unit  
IMP Inosine -5 phosphate  
IP Investigational product  
IRB Institutional Review Board  
LDH  Lactate dehydrogenase  
MedDRA  Medical Dictionary for Regulatory Activities  
NCI National Cancer Institute  
NEWS2  National Early Warning System (NEWS) [ADDRESS_883873] of Care  
S[LOCATION_003]R  Suspected unexpected serious adverse reaction  
SpO 2 Peripheral capi[INVESTIGATOR_656323]:  CCB -CRISIS -02      Page 8 of 52 
PROTOCOL VERSION  4.0 DATE:  [ADDRESS_883874] 2020  
 
Clear Creek Bio, Inc. 
CONFIDENTIAL  Abbreviation  Definition  
UMP  Uridine 5-monophosphatase  
US [LOCATION_002]  
XMP  Xanthosine -5 phosphate  
WHO  World Health Organization  
WOCBP  Women of childbearing potential  
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 9 of 52 
PROTOCOL VERSION  4.0 DATE:  [ADDRESS_883875] 2020  
 
Clear Creek Bio, Inc. 
CONFIDENTIAL  2 SYNOPSIS  
CCB -CRISIS -02 SYNOPSIS  
IND 149291  
Title  The CRISIS2 Study: A phase 2, randomized, double blind, placebo -controlled, 
multi -center study assessing the safety and anti -coronavirus response of 
suppression of host nucleotide synthesis in out-patient adults with SARS -CoV -[ADDRESS_883876] SARS -CoV -2 is likely 
due to DHODH inhibitio n and shows  nanomolar potency and a high selectivity 
index in inhibiting viral replica tion in  in vitro  studies.    
The CRISIS2 trial will study out-patients ( non-hospi[INVESTIGATOR_9643] ) who have  a 
positive SARS -CoV -[ADDRESS_883877] of care (SOC)  + 5 days of brequinar or SOC + [ADDRESS_883878] and 
Dosage  Subjects will be randomized in a 1:[ADDRESS_883879] of care (SOC) + 5 days 
of brequinar  100 mg or SOC + [ADDRESS_883880] will be supplied as either b requinar 100 mg oral capsules  
or placebo capsules . The subjects are to self -administer one capsule on  Study Days 
1  5.  
Treatment assignment will be randomized, double -blind.   
Primary 
Objective s  To demonstrate a change from baseline in quantitative SARS -CoV -2 viral load 
for brequinar -treated subjects compared to placebo -treated subjects through 
Day 29. 
Secondary 
Objectives  Through Day 29:  
 To characterize  the safety and tolerability of brequinar i n out-patient COVID -
19 subjects  as measured by [CONTACT_656340] 3 and 4 AEs and SAEs ; 
 To demonstrate a shorter duration of viral shedding in subjects treated with 
brequinar compared to  subjects who received placebo ;  
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 10 of 52 
PROTOCOL VERSION  4.0 DATE:  [ADDRESS_883881] 2020  
 
Clear Creek Bio, Inc. 
CONFIDENTIAL   To reduce the percentage of subject s requiring hospi[INVESTIGATOR_656300] -
patient for > 24 hours  for brequinar subjects compared to  subjects who received 
placebo ; 
 To reduce all-cause mortality through Day 29  for brequinar subjects compared 
to subjects who received placebo.  
Exploratory 
Objective s Through Day 29:  
 To determine time to viral clearance (two consecutive negative tests) ;  
 To determine time to resolution of new onset COVID -19-related clinical 
symptoms and pre -existing non-COVID -19 symptoms returned to baseline ; 
 To determine time to clinical improvement  as measured by a favorable shift in 
the WHO Ordinal Scale score measured for the subset of subject s with baseline 
WHO Ordinal Scale of [ADDRESS_883882] a Screening Visit followed as soon as possible with Study Day 
1. Study procedures are presented in detail in the Schedule of Events . Study visits 
(virtual or in person) will take place at Screening  and on Study Days  [ADDRESS_883883]s home or other 
appropriate location. Other visits /visit activities for that visit  may be conducted 
remotely using telephone, telemedicine  or other remote technique . Subjects are to 
self-collect a viral load sample , obtain their respi[INVESTIGATOR_697], heart rate, body 
temperature and SpO2, and complete a symptom assessment  with the site via 
telemedicine  on Days 1, 4, 8, 12, 15, 22, and [ADDRESS_883884] at 
Screening and on study Days 1, 8, 15, and 29. Telemedicine only visits will be 
conducted by [CONTACT_656390] 4 , 12, and 22 . 
Sample Size:  Approximately 100 subjects will be randomized to 5 days of either SOC  + 
brequinar 100 mg or SOC + placebo in a 1:1 ratio (approximately 50 subjects 
assigned to brequinar 100 mg and 50 subjects to placebo ).  
Number of Sites:  Approximately 15 
Study Period:  An enrollment period of 3 months is expected.  
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 11 of 52 
PROTOCOL VERSION  4.0 DATE:  [ADDRESS_883885] 2020  
 
Clear Creek Bio, Inc. 
CONFIDENTIAL  Inclusion 
Criteria:  
 1. Willing and able to provide informed consent for the trial, written, 
electronic, verbal , or other method deemed acceptable by [CONTACT_656342].  
2. 18 years of age or older.  
3. Laboratory -confirmed SARS -CoV -2 infection as determined by [CONTACT_656343] (RT -PCR) or other FDA -approved commercial 
or public health assay  within [ADDRESS_883886] dose. 
4. Out-patient (never hospi[INVESTIGATOR_656324] -patient for COVID -19 or was 
evaluated/treated for COVID -19 only in the Emergency Room with a stay 
of < 24 hours).  
5. The effects of brequinar on the developi[INVESTIGATOR_656335] . For 
this reason, women of child -bearing potential and men must agree to use 
adequate contraception (hormonal or barrier method of birth control; 
abstinence) prior to study entry and for the duration of study participation. 
Should a woma n become pregnant or suspect she is pregnant while she or 
her partner is participating in this study, she should inform her treating 
physician immediately. Men and women treated or enrolled on this protocol 
must also agree to use adequate contraception for  the duration of study 
participation, and for [ADDRESS_883887] one COVID -19 symptom including but not limited to 
fever, cough, sore throat, malaise, headache, muscle pain, gastrointestinal 
symptoms, shortness of breath , dyspnea , anosmia , dysgeusia, or other 
symptom commonly associated with COVID -19.  
8. Able to swallow capsules.  
Exclusion 
Criteria:  1. Any physical examination findings and/or history of any illness that, in the 
opi[INVESTIGATOR_103160], might confound the results of th e study 
or pose an additional risk to the patient  
2. Nursing women or women of childbearing potential (WOCBP) with a 
positive pregnancy test  
3. Treatment with another DHODH inhibitor  (e.g., leflunomide , 
teriflunomide ) or other agents known to cause bone marrow suppression 
leading to thrombocytopenia  
4. Platelets 150,000 cell/mm3 
5. Hemoglobin < 10 gm/dL  
6. Absolute neutrophil count < 1500 cells/mm3 
7. Renal dysfunction, i.e., creatinine clearance < 30 mL/min  
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 12 of 52 
PROTOCOL VERSION  4.0 DATE:  [ADDRESS_883888] and/or ALT > [ADDRESS_883889], or total bilirubin > ULN . Gilbe rts Syndrome 
is allowed.  
9. Bleeding disorders or blood loss requiring transfusion  in the six weeks 
preceding enrollment  
10. Ongoing  gastrointestinal ulcer, or gastrointestinal bleeding  within [ADDRESS_883890] dose. 
11. Chronic  hepatitis B  infection , active hepatiti s C infection, active liver 
disease and/or cirrhosis  per subject report.  
12. Heart failure, current uncontrolled cardiovascular disease, including 
unstable angina, uncontrolled arrhythmias, major adverse cardiac event 
within 6 months (e.g. stroke, myocardial i nfarction, hospi[INVESTIGATOR_656302], or revascularization procedure).   
Treatment  All subjects will receive standard of care (SOC)  including symptomatic care. 
Subjects will be randomly assigned to SOC + brequinar 100 mg daily x 5 or SOC 
+ placebo daily x 5. Study encounters will be conducted remotely whenever 
possible.  
DMC A Data Monitoring Committee  (DM C) will meet periodically to review the safety 
and scientific conduct of the study. At a minimum, the DMC  is to review adverse 
events and safety laboratory assessments after the first [ADDRESS_883891] 40 subjects complet e Day 8.  
Procedures  Study procedures are outlined in the Schedule of Events.  
Study completion or the reason for study discontinuation will be recorded in the 
source document and the eCRF.  
Safety/  
Tolerability  Safety/Tolerability  
Adverse events will be collected from the time of first dose  through Day 29. After 
Day 29, collect/re cord only Serious Adverse Events (SAEs) or those judged by [CONTACT_656363]. Treatment -emergent  
adverse events will be those with an onset after the date and time of first treatment . 
Subjects who develop Gra de 3 or 4 toxicities or SAEs are to be re -evaluated every 
2 days, as feasible, until the toxicity returns to Grade  [ADDRESS_883892] any signs or symptoms of muco sitis or thrombocytopenia, e.g.:  
 Ecchymosis/purpura/petechiae  
 Epi[INVESTIGATOR_3940]  
 Hemoptysis  
 Hematuria  
 Gingival bleeding  
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 13 of 52 
PROTOCOL VERSION  4.0 DATE:  [ADDRESS_883893] 2020  
 
Clear Creek Bio, Inc. 
CONFIDENTIAL   Prolonged bleeding time from needle sticks, abrasions or lacerations  
 Hematemesis  
 Rectal bleeding  
 Blood in stool  
 Any other unusual bleeding noted by [CONTACT_656429][INVESTIGATOR_656303]:  
 Participants who develop a Grade 3 toxicity that is assessed by [CONTACT_656345].  
 Participants who develop a Grade 4 toxicity, regardless of relatedness to 
study drug, are to be permanently discontinued from study treatment.  
Study -Level Stoppi[INVESTIGATOR_2121]:  
Study enrollment is to be paused  if any of the below criteria are met:  
 If  [ADDRESS_883894] s develop the same  related Grade 4 (life -threatening) adverse 
event or laboratory abnormality;  
 If  5 subjects develop the same  related Grade 3 or 4 adverse event or 
laboratory abnormality ; 
 If  10 subjects develop any related Grade 3 or 4 adverse event or 
laboratory abnormality .  
All adverse events will be reviewed by [CONTACT_656430]. Following 
assessment by [CONTACT_1578] (DMC), the DMC will determine 
whether to stop the study, amend the protocol, or continue the study per protocol.   
Statistical 
Analysis  A separate, detailed statistical analysis plan (SAP) will be finalized prior to locking 
the database. All analyses of safety and efficacy for this study will be descriptive 
in nature and presented by [CONTACT_19313]. Subject demographics and baseline 
characteristics  will be summarized. Subject data listings will also be provided.  
Summaries for quantitative variables will include the mean, median, quartiles, 
standard error, minimum, and maximum. For qualitative variables, the summaries 
will include the number and per centage of subjects for each outcome, and the 95% 
CI, when appropriate.  Any statistical testing will be considered exploratory and 
descriptive. All computations will be performed using SAS (Version 9.4 or 
higher). Safety and tolerability will be assessed  in terms of AEs, SAEs, and safety 
laboratory data.  
Adverse event data will be descriptively evaluated. All AEs will be reported in data 
listings. The incidence of treatment -emergent  adverse events, defined as TEAEs 
occurring after first dose  will be tabulated by [CONTACT_12513]  (MedDRA) preferred term and system organ class, and by [CONTACT_656392]. All laboratory results and other clinical measures 
will be summarized using appropriate descriptive statistics.  
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 14 of 52 
PROTOCOL VERSION  4.0 DATE:  [ADDRESS_883895] dose time  
Procedures  Screen  
(days  
-14 to -1) 
HH+TMf D1 
HH
+ 
TM D2, 3  
( 8 
hrs) 
TCf D4 
( 8 
hrs) 
TM D5,6, 
7 
( 8 
hrs) 
TC D8 
( 1 
day)  
HH+
TM D12 
( 1 
day)  
TM D15 
( 1 
day)  
HH+
TM D22 
(1 
day)  
TM Final 
Visit   
D29 
( 2 days)  
HH+TM  
Informed Consent (note Date and Time)  X          
AE/Concomitant Medications (dose, route, duration 
or ongoing)  X X X X X X X X X X 
Medical history (relevant within one year or 
ongoing)/ History of current illness (date of 
symptom onset or change in baseline co -morbidity 
thought to be due to COVID -19 infection)  X          
Demographics (subject reported height and weight, 
date of birth, gender, race, ethnicity)  X          
Check for Physical Exam abnormalities (subject 
self-reported)  X          
Pregnancy Test (WOCBP)  X 
(serum)          X 
(urine)  
Hematology/Chemistrya X X     X  X   
Vital Signsb X X  X  X X X X X 
Symptom Assessmentc X X  X  X X X X X 
SARS -CoV -2 RT -PCR/V iral load  sampled X X   X  X X X X X 
Hospi[INVESTIGATOR_656304]       X  X X X 
WHO Ordinal Scale Assessment   X    X  X X X 
Confirm Eligibility   X         
Randomize subject and dispense Study Medication   X         
Study drug administratione  X X X X 
D5 
only      
Drug Accountability       X     
aDo not repeat if within 48h of Day 1 visit.  Send to Covance Central Laboratory Services (CCLS) for analysis.  
bVital signs include heart rate, respi[INVESTIGATOR_697], body temperature, SpO2.  Subject will be provided with a thermometer and pulse 
oximeter with heart rate monitoring capability. Training will be provided during the first visit by [CONTACT_535758]. Vi tal signs 
parameters will be observed and recorded by [CONTACT_656424] a visit by [CONTACT_535758].  
cSymptom Assessment will use a checklist  provided to the subject with  symptoms such as sore throat, cough, GI symptoms (vom iting, 
diarrhea), an osmia, dysgeusia, other (specify), etc.  Severity None,  Mild, M oderate, or Severe will be collected.  
dRT-PCR at Screening may be performed by [CONTACT_656425] a positive SARS -CoV -[ADDRESS_883896] using an Omnigene  collection system or 
similar. The home health nurse will train the subject and observe sample collection on Day 1. These samples are to be sent to CCLS 
for analysis.  The viral load sample may also be used to perform viral cultures (sample can be split  by [CONTACT_2237] , no 
additional sample required).  
eSubject will self -administer study drug once daily Days 1  [ADDRESS_883897] doses in a medication diary. Note that any visits/visit activities 
may be conducted via telephone, telemedicine , or digital media other than serum pregnancy test and chemistry/hematology sample 
collection. These labs may be collected at the clinical site or another designated out -patient facility/laboratory or collected via home 
visit.  Arrangements for shippi[INVESTIGATOR_656336] . 
fHH = Home Health in -person visit; TC = Telephone Call with site  and subject ; TM = Telemedicine with site  and subject.  
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 15 of 52 
PROTOCOL VERSION  4.0 DATE:  [ADDRESS_883898]  
Name:  [CONTACT_656462], MSN, Ph.D.  
Title:  Clinical Operations  
Address:  Clear Creek Bio, Inc.  
[ADDRESS_883899], 4th Floor,  
Cambridge, MA [ZIP_CODE]  
Telephone No.:  [PHONE_13585]  
Fax No.:  [PHONE_13586]  
E-mail:  [EMAIL_12502]   
 
MEDICAL MONITOR  
Name:  [CONTACT_656463], MD  
Title:  Senior Medical Director  
Telephone No.:  (609) 212 -7892  
E-mail:  [EMAIL_12503]  
 
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 16 of 52 
PROTOCOL VERSION  4.0 DATE:  [ADDRESS_883900] 2020  
 
Clear Creek Bio, Inc. 
CONFIDENTIAL  3 INTRODUCTION  
3.1 Coronavirus -19 (COVID -19) 
Beginning in December  2019, Chinese scientists isolated a novel coronavirus, severe acute respi[INVESTIGATOR_11520] 2 (SARS -CoV -2) from patients with virus -infected pneumonia which was later 
designated as coronavirus disease 2019 (COVID -19) by [CONTACT_88442] (WHO) ( Zhou 
et al., 2020  [2]; Phelan et al., 2020  [3]).  
Approximately 14% of those affected with this virus will develop severe disease requiring 
hospi[INVESTIGATOR_656306]; 5% will require admission to the intensive care unit ( Handel et 
al., 2020  [4]). Severe cases ma y be complicated by [CONTACT_171958][INVESTIGATOR_656307] (ARDS), sepsis 
and septic shock, and multi -organ failure, including acute kidney injury and cardiac injury. Risk 
factors for death include older age and co -morbid disease such as hypertension and diabe tes (Zhou, et 
al., 2020  [2]). This means that most  patients will be treated as out -patients. Reducing viral load in this 
environment is critically important for both the subjects themselves by [CONTACT_656397][INVESTIGATOR_059], but also to reduce the transmission of th e disease to 
others in the patients households and their communities.  
3.1.[ADDRESS_883901] RNA building blocks, and without these building blocks they are unable 
to replicate.  The SARS -CoV -2 is a single -stranded (positive sense) RNA virus with a genome that is 
29,811 nucleotides lon g, quite a lot larger than other RNA -based viruses (e.g. the hepatitis C genome 
comprises only 9600 nucleotides). The nucleotide composition is broken down as: 29.9% adenosines, 
18.4% cytosines, 19.6% guanines, and 32.1% uridines  (Sah et al., 2020  [12]). 
3.[ADDRESS_883902] de novo  pyrimidine synthesis generates uridine monophosphate (UMP) as the building block for 
all pyrimidine ribonucleotides and deoxyribonucleotides  (Error! Reference source not found. ). 
There exists  no salvage pathway for the synthesis of UMP, the fundamental building block  of 
pyrimidines . Inhibition of enzymatic steps upstream of UMP  (Figure 3 -1) leads to a rapid  and profound  
depletion of intracellular pyrimidines.   
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 17 of 52 
PROTOCOL VERSION  4.0 DATE:  [ADDRESS_883903] 2020  
 
Clear Creek Bio, Inc. 
CONFIDENTIAL   
Figure 3-1. DHODH is a mitochondrial enzyme that catalyzes the 4th step of pyrimidine 
synthesis; it is completely essential for the generation of UMP.   
3.3  Dihydroorotate dehydrogenase (DHODH)  
The enzyme dihydroorotate dehydrogenase ( DHO DH) catalyzes the 4th step of de novo  pyrimidine 
synthesis  and inhibition of DHODH completely halts all pyrimidine production. As shown in  Figure 
3-1, DHODH  is located on the inner mitochondrial membrane and transfers electrons between DHO 
and complex III of the electron -transport chain via the reduction of its ubiquinone (coenzyme Q10) 
cofactor.  
DHODH is a clear therapeutic target for the inhibition of host pyrimidine synthesis. The chemical 
inhibition of DHODH in vitro  or in vivo  leads to the rapid deple tion of UMP and subsequent depletion 
of downstream products thymine and cytosine.  This forces a cell to rely on the salvage of extracellular 
pyrimidine nucleotides and this extracellular salvage is not capable of maintaining the cells normal 
nucleotide po ol (Sykes et al., 2016) [ 1]).    
3.[ADDRESS_883904] -targeting antiviral. 
It is an orally available and potent inhibitor of dihydroorotate dehydrogenase (DHODH) , the enzyme 

PROTOCOL NUMBER:  CCB -CRISIS -02      Page 18 of 52 
PROTOCOL VERSION  4.0 DATE:  [ADDRESS_883905] 2020  
 
Clear Creek Bio, Inc. 
CONFIDENTIAL  that catalyzes the fourth step in pyrimidine synthesis, namely the conversion of dihydroorotate (DHO) 
to orotate.  DHODH inhibitors, including brequinar, inhibit de novo  pyrimidine synthesis thereby 
[CONTACT_331577] a depletion of a cells pool of uridine, cytidine and thymidine ribonucleotides and 
deoxyribonucleotides.  
The anti viral activity of brequinar has been demonstrated  in studies  of rotavirus replication in human 
intes tinal Caco -2 cell s as well as in human primary intestinal organoids  (Chen et al., 2019  [6]). 
Treatment with teriflunomide , another DHODHi,  has been effective in vitro  and in vivo  in a mur ine 
model of foot and mouth disease virus (Mei-Jian et al., 2019  [7]). DHODH inhibition (DHODHi) also 
inhibited the growth of dengue virus in vitro  (Wang et al., 2011  [8]). DHODHi also showed antiviral 
effects against RNA viruses including influ enza A, Zika, Ebola and coronavirus SARS -CoV -2 (Xiong 
et al., 2020  [11]). Brequinar has also been shown to inhibit the replication of Ebola virus , vesicular 
stomatitis virus and Zika virus in vitro (Luthra et al., 2018  [9]). Brequinar inhibits the replication of 
human immunodeficiency virus ( HIV) in vitro  (Andersen et al., 2019  [10]). When considering 
brequinar as an antiviral for treatment of SARS -CoV -2, oral brequinar is highly bioavailable (>95%) 
and has good penetration of lung tissue  with an average tissue:blood ratio of 0.5 following a single 
dose of brequinar in the rat . It is therefore expected to achieve a similar period of DHODH inhibition 
in lung tissue  (Brequinar IB  [5]). 
3.5  Rationale for the Planned Trial  
DHODH inhibition has been extensively studied as a potential therapeutic target in the treatment of 
RNA -based viruses. The inhibition of DHODH is effective in inhibiting viral replication in pre -clinical 
models involving many RNA -based viruses with nanomolar potency and a high selectivity index (see 
the Brequinar IB [5], Section 5 ). In these pre -clinical models, the benefit of DHODH inhibition can 
be reversed by [CONTACT_656398], confirming that the on -target effect of 
host pyrimidine depletion is key to the anti -viral activity.  
The CCB -CRISIS -[ADDRESS_883906] of care (SOC) with 5 days of brequinar (DHODH 
inhibition) compared to SOC with [ADDRESS_883907] pyrimidine nucleotides, thereby [CONTACT_656399]. A recent 
publication demonstrated that inhibitors of DHODH could potentiate the activity of inhibitors of RNA -
dependent RNA polymerase (RdRp) in the treatment of dengue virus, another single -stranded RNA 
virus  similar to SARS -CoV -2 (Liu et al., 2020 [13]). This inhibition of viral replication may restore 
the balance in favor of the host immune system for the clearance of SARS -CoV -2. 
Marketed DHODHi medications are available, includ ing leflunomide or teriflunomide, however these 
are very weak inhibitors of DHODH with cellular potency ~[ADDRESS_883908] the abil ity to acutely lower the pool of 
intracellular pyrimidines to the degree that is required  for decreasing the viral load associated with 
SARS -CoV -2 infection , making brequinar the better choice for acute SARS -CoV -2 infection .  
The CRISIS2 study is a proof -of-concept study  in patients with SARS -Cov-2 infection and will serve 
as a basis for future studies to determine the safety and effectiveness of brequinar in COVID -19. 
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 19 of 52 
PROTOCOL VERSION  4.0 DATE:  [ADDRESS_883909] that 5 days of daily doses of 100 mg  p.o. will be safe and well tolerated. A dose of 
brequinar 100 mg achieves plasma concentrations of approximately 1 uM (0.4 ug/ml)  that should result 
in sufficient suppression of nucleotide synthesis . When given over 5  days, these plasma concentrations 
are achieved on a daily basis without accumulation, also assuring the safety of this regimen  (see 
Brequinar IB  [5]).  
3.5.2    Risk/Benefit of Brequinar  
As presented in the Brequinar IB  [5], an extensive safety and pharmacokinetic database exists with 
more than 1,000 patients treated with brequinar. Cancer patients (N = 806) have been exposed to this 
compound for treatment of a variety of solid tumors  at various  treatment regimens, doses, and routes  
including a single dose, once weekly, twice weekly, single dose every [ADDRESS_883910]  
also been utilized for patients with  psoriasis and organ transplant. The maximum intravenous dose 
given was 2,250 mg/m2 every 3 weeks, and the maximum oral dose was 100 mg/m2 daily for 21 days. 
There has been limited testing of DHODHi to date in the clinic for infection with SARS -CoV -2. 
DHODHi therapy at relatively high doses in the context of trials for patients with cancer has the 
expected safety side-effects of mucositis and bone marrow suppression.  Importantly, h owever, the 
prior clinical experience in 39 subjects who received daily brequinar for 5 consecutive days at or lower 
than 100 mg/day show no cases of mucositis and only 1 (2.6%) epi[INVESTIGATOR_656308]. 
Based on these data the [ADDRESS_883911] been the primary dose -limiting toxicities. In addition, skin rash, nausea/vomiting, fatigue, and 
leukopenia have been dose -limiting in trials utilizing other sch edules of brequinar administration. 
However , these effects were self -limiting, transient, required treatment in few cases,  and resolved 
following discontinuation of dosing . These adverse effects have been associated  with higher doses of 
brequinar given via the intravenous route and for longer durations than the 100 mg dose and 5 -day 
regimen proposed for this study .  
In addition to studying a higher risk population  with symptomatic COVID -19, a comprehensive safety 
monitoring plan will be utilized in this stu dy to assess the ongoing safety and well -being of participants 
(see Section 10.8).  
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 20 of 52 
PROTOCOL VERSION  4.0 DATE:  [ADDRESS_883912] been no apparent hepat otoxic  effects in 
the clinical studies. Brequinar itself does not appear to be a substrate for metabolism by [CONTACT_9058] 
P450 enzymes when tested under a variety of conditions . (See Brequinar IB [5]; nonclinical d ata on 
file with Clear Creek).   
3.8 Steps to be Taken to Control or Mitigate Risks  
All subjects will be treated  by [CONTACT_656350] d clinicians  familiar with the treatment of viral 
infections and their complications .  
 
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 21 of 52 
PROTOCOL VERSION  4.0 DATE:  [ADDRESS_883913] 2020  
 
Clear Creek Bio, Inc. 
CONFIDENTIAL  4 TRIAL OBJECTIVES  
4.1 Primary Objective  
To demonstrate a change from baseline in quantitative SARS -CoV -2 viral load for brequinar -treated 
subjects compared to placebo -treated subjects through Day  29. 
4.2 Secondary Objectives  
The secondary objectives of this study are:  
Through Day 29:  
 To characterize  the safety and tolerability of brequinar in  out-patient  COVID -19 subjects  as 
measured by [CONTACT_656340] 3 and 4 AEs and SAEs ; 
 To demonstrate a shorter duration of viral shedding in subjects treated with brequinar compared 
to subjects who received placebo ;  
 To reduce the percentage of subjects  requiring hospi[INVESTIGATOR_656309]  >24 hours  for 
brequinar subjects compared to  subjects who received placebo ; 
 To reduce all -cause mortality  through Day 29  for brequinar subjects compared to  subjects who 
received placebo . 
4.3 EXPLORATORY OBJECTIVES  
Through Day 29:  
 To determi ne time to viral clearance (two consecutive negative tests) ;  
 To determine time to resolution of new onset COVID -19-related clinical symptoms and pre -
existing  non-COVID -19 symptoms returned to baseline ; 
 To determine time to clinical improvement  as measured by a favorable shift in the WHO Ordinal 
Scale score for the subset of subjects with baseline WHO Ordinal Scale of 2  for brequinar subjects 
compared to  subjects who received placebo . 
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 22 of 52 
PROTOCOL VERSION  4.0 DATE:  [ADDRESS_883914] of care per (SOC) institutional 
guidelines for treatment of patients with COVID -[ADDRESS_883915] a Screening Visit followed as soon as possible with Study Day 1. Study procedures 
are presented in detail in the Schedule of Events (Appendix 15.1). Study visits (virtual or in person) 
will take place at Screening and on Study Days [ADDRESS_883916]s home or other appropriate location. Other visits/visit activities for that visit may be conducted 
remotely using telephone, telemedicine  or other remote technique . Subjects are to self -collect a viral 
load sample, ob tain their respi[INVESTIGATOR_697], heart rate, body temperature and SpO2, and complete a 
symptom assessment checklist with the site via telemedicine on Days 1, 4, 8, 12, 15, 22, and 29.  The 
site will also have a telephone  call with  the subject on Study Days 2, 3 , 5, 6, and 7 for changes in 
concomitant medications and assessment of adverse events, especially those that may indicate 
thrombocytopenia (see Section 10.8) and mucositis . A home health nurse will visit the subject at 
Screening and on study Days 1, 8, 15, and 29. Telemedicine only visits will be conducted by [CONTACT_656431] 4, 12, and 22.  
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 23 of 52 
PROTOCOL VERSION  4.0 DATE:  [ADDRESS_883917] 2020  
 
Clear Creek Bio, Inc. 
CONFIDENTIAL  6 TRIAL ENDPOINTS  
6.1 Primary Endpoint  
Quantitative SARS -CoV -2 viral load  through Day  29. 
6.2 Secondary Endpoints  
The secondary endpoints  of this study are:  
Through Day 29:  
 Rates of AEs and SAEs including laboratory assessments ; 
 Duration of viral shedding ;  
 Percentage of subjects requiring admission as an inpatient for  >24 hours . 
 All-cause mortality.  
6.3 Exploratory Endpoints  
Through Day 29:  
 Time to viral clearance (two consecutive negative tests) ;  
 Time to resolution of new onset COVID -19-related clinical symptoms and pre -existing non-
COVID -19 symptoms returned to baseline ; 
 Time to clinical improvement  measured by a favorable shift in WHO Ordinal Scale score for the 
subset of subjects with baseline WHO Ordinal Scale of 2 . 
 
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 24 of 52 
PROTOCOL VERSION  4.0 DATE:  [ADDRESS_883918] of care plus placebo in a 1:1 ratio ( approximately 
[ADDRESS_883919] of care  plus placebo ).  
7.2 Inclusion criteria  
1. Willing and able to provide informed consent for the trial, written, electronic, verbal or other 
meth od deemed acceptable by [CONTACT_656353].  
2. 18 years of age or older.  
3. Laboratory -confirmed SARS -CoV -2 infection as determined by [CONTACT_656432] (RT -PCR) or other FDA -approved commercial or public health assay  within [ADDRESS_883920] dose . 
4. Out-patient ( never hospi[INVESTIGATOR_656326] -patient for COVID -19 or was evaluated/treated for 
COVID -19 only in the Emergency Room with a stay of < 24 hours) . 
5. The effects of brequinar on the developi[INVESTIGATOR_19241] . For this reason, women  
of child -bearing potential and men must agree to use adequate contraception (hormonal or 
barrier method of birth control; abstinence) prior to study entry and for the duration of study 
participation. Should a woman become pregnant or suspect she is pregna nt while she or her 
partner is participating in this study, she should inform her treating physician immediately. 
Men and women treated or enrolled on this protocol must also agree to use adequate 
contraception for the duration of study participation, and for [ADDRESS_883921] one COVID -19 symptom including but not limited to fever, cough, sore throat, 
malaise, headache, muscle pain, gastrointestinal  symptoms, shortness of breath, dyspnea, 
anosmia , dysgeusia, or other symptom commonly associated with COVID -19. 
8. Able to swallow capsules.  
7.3 Exclusion Criteria  
1. Any physical examination findings and/or history of any illness that, in the opi[INVESTIGATOR_656327], might confound the results of the study or pose an additional risk to the patient  
2. Nursing women o r women of childbearing potential (WOCBP) with a positive pregnancy test  
3. Treatment with another DHODH inhibitor (e.g., leflunomide, teriflunomide) or other agents 
known to cause bone marrow suppression leading to thrombocytopenia  
4. Platelets 150,000 cell/mm3 
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 25 of 52 
PROTOCOL VERSION  4.0 DATE:  [ADDRESS_883922] 2020  
 
Clear Creek Bio, Inc. 
CONFIDENTIAL  5. Hemoglobin < 10 gm/dL  
6. Absolute neutrophil count < 1500 cells/mm3 
7. Renal dysfunction, i.e., creatinine clearance < 30 mL/min  
8. AST and/or ALT > [ADDRESS_883923], or total bilirubin > ULN . Gilberts Syndrome is allowed.  
9. Bleeding disorders or blood loss requiring tran sfusion in the six weeks preceding enrollment  
10. Ongoing  gastrointestinal ulcer, or gastrointestinal bleeding  within [ADDRESS_883924] dose. 
11. Chronic  hepatitis B  infection , active hepatitis  C infection, active liver disease and/or cirrhosis  
per subject report.  
12. Heart failure, current uncontrolled cardiovascular disease, including unstable angina, 
uncontrolled arrhythmias, major adverse cardiac event within 6 months (e.g. stroke, 
myocardial infarction, hospi[INVESTIGATOR_144651], or revascularization pro cedure).  
 
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 26 of 52 
PROTOCOL VERSION  4.0 DATE:  [ADDRESS_883925] of care (SOC) for COV ID-19 infection. 
Subjects will be randomly assigned in a 1: [ADDRESS_883926] of care 
plus placebo . 
8.2.1 Safety/Tolerability  
Safety/tolerability is assessed for each s ubject at each study visit . The NIH Division of AIDS (DAIDS) 
Table for Grading the Severity of Adult and Pediatric Adverse Events, Corrected Version 2.1 (July 2017)  
will be utilized for AE reporting. All appropriate treatment areas should have access to a copy of the 
criteria .  
Adverse events (AEs) commonly observed in patients treated with brequinar are provided in the 
Investigators Brochure  (IB) and include thrombocytopenia, nausea, anemia, diarrhea, vomiting, 
leukopenia, stomatitis, rash, granulocytopen ia, fatigue,  and infection . In a study of 209 cancer subjects 
treated once -weekly  (DuP 785 -012, see Brequinar IB  [5]), the deaths of three patients were attributed 
to study drug toxicity (two to hemorrhage , one following acute renal failure). Severe toxicities grades 
(Grades 3 to 4) which typi[INVESTIGATOR_656328] 
(anemia , thrombocytopenia, leukopenia , granulocytopenia ), digestive  system toxicity (nausea, 
vomiting, stomatitis , others  including gastric hemorrhage) and mucositis.  
In three oncology studies with five consecutive days of intravenous (IV) brequinar dosing in 168 
subjects (Study 785 -001 [14], 785-003 [15], and 785-005 [16]) there were no toxic deaths . For 
subjects from these three studies who were treated with a daily dose of 100 mg or below  (as will be 
dosed in CCB -CRISIS -02), AEs through 21 days showed that 2 of 39 subj ects (5.1%) had a severe 
(Grades 3 or 4) AE related to study drug ([ADDRESS_883927] each with hyperbilirubinemia and 
hyperglycemia), and no subjects discontinued from the study due to a study drug -related AE. The 
few study drug related AEs through [ADDRESS_883928] each with 
thrombocytopenia and diarrhea. When only studies with oral dosing were considered at this dose 
level (Studies 7 85-022 [17], 785 -031 [18] , and  785-034 [19]), the study drug related AEs through 
21 days (each observed in one subject only) included diarrhea, headache, nausea, pruritus, 
abdominal pain, ano rexia, chest pain, dry mouth, fatigue, keratosis, stomatitis, and vomiting. See 
brequinar IB [5]. 
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 27 of 52 
PROTOCOL VERSION  4.0 DATE:  [ADDRESS_883929] Study Day 29 (or longer if needed to follow up study 
drug-related adverse events).  Participants may discontinue  from the study by [CONTACT_656402] 9.7. 
8.4 Stoppi[INVESTIGATOR_2121]  
8.4.1 Individual Stoppi[INVESTIGATOR_2121]  
 Participants who develop a Grade 3 toxicity that is assessed by [CONTACT_656433].  
 Participants who develop a Grade 4 toxicity, regardless of relatedness to study drug, are to  be 
permanently discontinued from study treatment.  
 Subjects who develop Grade 3 or 4 toxicities are to be followed by [INVESTIGATOR_1312] -evaluation every 2 days, 
as feasible, until the toxicity returns to  Grade 2 severity.  
8.4.2 Study -Level Stoppi[INVESTIGATOR_656312] : 
 If  3 subjects develop the same  related Grade 4 (life -threatening) adverse event or laboratory 
abnormality ; 
 If  5 subjects develop the same  related Grade 3 or 4 adverse event or laboratory abnormality ; 
 If  10 subjects develop any related Grade 3 or 4 adverse event or laboratory abnormality .  
Following assessment by [CONTACT_1578] (DMC, see Section 10.9), the DMC will 
determine whether to stop the study, amend the protocol, or continue the study per protocol.  
8.5 Concomitant Medication/Treatment  
Record t he name, dose, start/stop  date, indication for use , route, and whether ongoing or stopped for 
medications/treatments taken within two weeks prior to study entry  as well as any medications taken 
during the study  are to be recorded . Prohibited medications are identified in Section 8.8.  
8.[ADDRESS_883930]s medication diary and study records as 
appropriate.  
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 28 of 52 
PROTOCOL VERSION  4.0 DATE:  [ADDRESS_883931] of care plus  placebo . The brequinar and placebo capsules will be 
provided to each participating institution  in pre -numbered bottles intended for individual subjects to 
be dispensed by [CONTACT_8236]s pharmacist  or designated person . Randomization assignments will be 
provided by [CONTACT_656404] . The pharmacist/designate d 
person will dispense the next number in sequence to the next patient who qualifies for the study at an 
individual site.  
8.7.4 Unblinding/ Expectedness  
Contact [CONTACT_656405] (AE) . Each site will be provided with a sealed envelope containing individual 
sealed envelopes for subject numbers assigned to that site. Each individual subject number sealed 
envelope will have the treatment (brequinar or placebo) randomly assi gned to that subject number. Do 
not open the outer envelope or the individual sealed envelope unless it has been agreed with the 
Medical Monitor and the Sponsor that unblinding is necessary for that particular AE. Unblinding must 
be documented in the study  records. Envelope seals are to be checked to ensure they remain intact 
during drug accountability monitoring.  
If after a discussion with the Medical Monitor, the investigator or treating clinician believes the AE 
leading to unblinding to be related to the  study drug, no further doses of drug should be administered  
to that subject .  
Expectedness will be determined by [CONTACT_656406] -[ADDRESS_883932] . Adequate drug is to be dispensed for the number of subjects expected 
to be treated at each institution.   
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 29 of 52 
PROTOCOL VERSION  4.0 DATE:  [ADDRESS_883933]/ staff member  responsible for drug accountability is to document t he date and time  of 
dispensing  and for what subject the study drug was intended (i.e., record subject initials and birth date 
or other unique identifier). A pharmacy manual will be provided by [CONTACT_1034].   
At the end of the study any unused study drug  will be returned to the Sponsor for destruction or may 
be destroyed locally; disposition of study drug  will be documented .   
The Sponsor will be permitted access to the trial supplies at any time within usual business hours and 
with appropriate notice during or after completion of the study to perform drug accountability 
reconciliation.  Records may be electronic or paper and may be accessed remotel y for monitoring/drug 
accountability purposes.  
Each subject will be provided with one bottle with five brequinar or five placebo capsules for the five 
days of dosing.  
8.8 Prohibited Medications  
Treatment is prohibited with another DHODH inhibitor (e.g., leflunomide and teriflunomide ). 
Treatment is prohibited with agents known to cause bone marrow suppression leading to 
thrombocytopenia.  
8.[ADDRESS_883934] of care is 
expected to chang e as additional information, such as that from randomized controlled trials, emerges, 
and the Sponsor and the treating clinicians will need to address anticipated off -label use of any other 
drugs, devices, or interventions that might be used to manage COVI D-19 (e.g. anticoagulants).  
The Sponsor and treating clinicians are to consider changes in SOC over time, for example, 
overlappi[INVESTIGATOR_656313] a SOC treatment expected to be widely used is to be 
considered. The availability of new standard  of care treatment may change over time and vary from 
one clinical trial site to another. The Sponsor will discuss these issues with FDA should the need arise.  
 
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 30 of 52 
PROTOCOL VERSION  4.0 DATE:  [ADDRESS_883935] OF THE TRIAL  
9.1 Ethical and Regulatory Considerations  
The trial will be performed in accordance with the Declaration of Helsinki (1964)  as revised in Tokyo 
(1975), Venice (1983), Hong Kong (1989), South Africa (1996), Scotland (2000, Note of Clarification 
2002 & 2004) and Seoul 2008 (Appendix A), and Fortaleza (Brazil) (2013),  and with the International 
Council on Harmonization ( ICH) Tripartite Guideline on Good Clinical Practice (CPMP/ICH/135/95, 
Jan.97) and [LOCATION_002] ( US) FDA Regulations.  
9.[ADDRESS_883936] be obtained in accordance with US Code of Federal Regulations (21 CFR Part 50) ,  the 
FDA Guidance on Conduct of Cl inical Trials of Medical Products during the COVID -19 Public Health 
Emergency (March 2020, Updated April 16, 2020)  [20], as well as local and national regulations. 
Information should be given in both oral and written form whenever possible and deemed app ropriate 
by [CONTACT_4707] ( IRB). Subjects  and their relatives, if necessary, must be given 
ample opportunity to inquire about d etails of the study.  
The Investigator  or qualified designated person  will verbally inform subjects as to the nature, expected 
duration and purpose of the trial, the administration of the Investigational Product ( IP), and the hazards 
involved, as well as th e potential benefits that may come from treatment with this IP. The trial 
procedures will be explained in lay language and any questions will be answered.  The subjects will be 
given an IRB-approved consent form. The subjects will be given appropriate time to consider their 
participation in the trial and have any questions answered prior to signing the consent form. If a subject 
agrees to participate, he/she will sign and date an informed consent form and be provided with a copy 
of the signed consent. All su bjects who sign a n informed consent form are to be recorded on the 
applicable screening log . If the subject is unable to consent for any reason, a designated family member 
or healthcare power of attorney or other person may consent per institutional policy .  
The subject will be informed that his/her  medical records will be subject to review by [CONTACT_1034], 
Sponsors representatives , and possibly by a representative of the FDA  and other relevant regulatory 
authorities. Subjects will be informed that they are free to refuse participation in this clinical 
investigation, and if they should participate, it will be made clear to them that they may withdraw from 
the trial at any time  without prejudicing further  medical  care they may require . The subject will receive 
a copy of the consent form as well as an information sheet about the trial.  
Informed consent must be obtained from every subject  prior to any study -specific procedures . 
Standard procedures carried out prior to completing  the informed consent process but within the time 
constraints of the protocol may be used for baseline evaluation; they need not be repeated. 
Documentation of c onsent will be subject to review by [CONTACT_13099] r; if in writing, a copy will be given 
to the subject  and a copy will be filed with the subjects medical notes.  Verbal consents will be 
documented by [CONTACT_656360].  
Note that informed consent procedures have been affe cted by [CONTACT_4113] -19, and the study staff may use 
any consent method that has been approved by [CONTACT_1201] (e.g., phone consent, verbal consent with 
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 31 of 52 
PROTOCOL VERSION  4.0 DATE:  [ADDRESS_883937] 2020  
 
Clear Creek Bio, Inc. 
CONFIDENTIAL  witness, e -consent, etc.)  of the local institution . In-person consent, w ritten consent signatures and 
providing har d copi[INVESTIGATOR_656329].  
The study should be discussed with the potential participant only after an initial review of his/her 
clinical status and appropriateness for participation ha ve been evaluated to determine if he/she  meets 
the subject selection criteria.  
A sample subject  information sheet and consent form are available from Clear Creek .  The final 
version at each institution may differ  depending on institutional requirement s and standard format s. 
This protocol will not be amended for site specific changes  as such changes are to be made to the sites 
consent when required . 
9.[ADDRESS_883938]  
It is the responsibility of the Investigator to submit the protocol, consent form a nd information sheet 
to the IRB . An IB will be available for review by [CONTACT_1201]. The protocol and informed consent form  
(ICF) must be approved by [CONTACT_656434] e first  subject . The template consent 
form may be revised in accordance with site -specific requirements with Sponsor review and approval.  
A copy of the IRB written approval must be provided  to the Sponsor and investigator before the trial 
may start  at that  institution . Written approval from the IRB is also required for substantial protocol 
amendments prior to their implementation.    
A substantial amendment may arise from changes to the protocol or from new information relating to 
the scientific documents i n support of the trial.  Amendments are substantial  when they are likely to 
have an impact on:  
 the safety or physical or mental integrity of the subjects ; 
 the scientific value of the trial;  
 the conduct or management of the trial; or  
 the quality or safety  of any IP used in the trial.  
If it is necessary to change or deviate from the protocol to eliminate an immediate hazard to the 
subjects, the Investigator will notify the Sponsor and the IRB of the new events and the measures taken 
as soon as possible.   
The Investigator will report promptly to the Sponsor and IRB any new information that may adversely 
affect the safety of the subjects or the conduct of the trial. On completion of the trial, the Investigator 
will inform the applicable IRB as per local IRB r equirements that the trial has ended. If the study is 
terminated for any reason , the investigator will return all clinical supplies and study -related equipment 
supplied by [CONTACT_656362].  
9.[ADDRESS_883939] the saliva sample for viral load testing  and perform 
other study activities such as body temperature, heart rate, respi[INVESTIGATOR_697], SpO2,  and symptom 
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 32 of 52 
PROTOCOL VERSION  4.0 DATE:  [ADDRESS_883940] of study assessments and timings.   
Blood chemistry tests include blood urea nitrogen (BUN), creatinine, alkaline phosphatase (AL K), 
alanine amino transferase (ALT), aspartate amino transferase (AST), total bilirubin, total protein, 
albumin, glucose, serum electrolytes (sodium, potassium, chloride, carbon dioxide/bicarbonate, 
calci um, lactate dehydrogenase (LDH) , and C -reactive protein (CRP) . Chemistry samples may be 
banked for future analyses.  
Hematology tests include hemoglobin, hematocrit, complete blood count with full differential , and 
platelet count.  
Viral load sampling  is to be carried out on Days [ADDRESS_883941] a 
documented positive result to be eligible for the study.  
Safety laboratory results (chemistry and hematology) are to be reviewed by [CONTACT_656435] 48 hours of receipt of results.  
Hospi[INVESTIGATOR_656330] -patient with admission > 24 hours.    
As much of the study as po ssible will be conducted via telemedicine remote from the site (e.g., consent , 
medical history, concomitant medications may be collected remotely) . Subjects will be visited at home 
(or place of residence) by a home health nurse at Screening  and on study Da ys 1, 8, 15, and 29. On 
study Days [ADDRESS_883942]  
The study visits are to be conducted as shown in the Schedule of Events, Appendi x 15.1. 
Study completion or the reason for study discontinuation will be recorded in the source document and 
the eCRF.  
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 33 of 52 
PROTOCOL VERSION  4.0 DATE:  [ADDRESS_883943] 2020  
 
Clear Creek Bio, Inc. 
CONFIDENTIAL  9.5.1 Unscheduled Visits  
Unscheduled visits and tests  are permitted as needed  to assess AEs /SAEs  throughout the study. 
Unscheduled visits and tests  are also permitted as needed to assess  AEs/  SAE s with onset within two 
(2) weeks after the final study  visit providing the AE is considered related to study drug  
9.[ADDRESS_883944]s study participation  after discussion 
with the other pa rty if  it is believe d it would be unsafe for the subject to continue in the study .   
Subjects must discontinue study medication  if any of the following events occur:  
 Significant protocol violation or non -compliance, either on the part of the subject or the  
investigator or other site personnel;  
 Decision of the Investigator or Sponsor that removal is in the subject's best interest;  
 Severe unrelated medical illness or complication;  
 Safety reasons/ significant adverse event;  
 Subject request (withdrawal of conse nt); 
 Sponsor decision.  
Collect/co nduct  all scheduled evaluations  even for subjects who discontinue study medication  prior to 
completing the treatment  period  unless consent is withdrawn . 
9.8 Early Termination of the Study  
If the Sponsor or an Investigator believes it would be unsafe to continue the study, or for any reason 
at the Sponsors request, the study may be terminated at that site or the entire study terminated after 
discussion with the other part ies. 
The Sponsor will provide a written  statement to the IRB and the relevant regulatory authority with the 
reasons for termination of the study. This will be conducted within 15 days of the decision to terminate 
the study.  
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 34 of 52 
PROTOCOL VERSION  4.0 DATE:  [ADDRESS_883945] 2020  
 
Clear Creek Bio, Inc. 
CONFIDENTIAL  If the study is terminated, a close out monitoring visit will be perfo rmed and applicable procedures 
will be carried out to close the trial site(s).  
9.[ADDRESS_883946] had a hysterectomy or tubal ligation. A woman is also presumed to be infertile due to natural 
causes  if she has been amenorrheic for greater than 12 months and has an FSH greater than 40 IU/L.  
In the absence of such documentation, a negative serum pregnancy test is required for inclusion into 
the study.  
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 35 of 52 
PROTOCOL VERSION  4.0 DATE:  [ADDRESS_883947] a causal relationship with this treatment. An 
AE can therefore be any unfavorable and unintended  sign (including an abnormal laboratory finding), 
symptom, or disease temporally associated with the use of the medicinal product, whether or not 
considered related to the medicinal product.  
Events that occur prior to  first dose  will be entered as medical  history; events  that occur after first dose  
will be ente red as adverse events (AEs)  on the AE form.  
Subjects will be questioned and observed for evidence of AEs, whether or not judged by [CONTACT_656363] . All AEs will be documented in the 
subject's medical record and CRF. For any pre -existing condition or abnormal laboratory finding that 
changes in severity after dosing, this chang e should be recorded as an AE. New abnormal laboratory 
findings that are clinically significant are considered AEs. Investigators and site staff are to elicit from 
the subject and note any signs or symptoms of mucositis and thrombocytopenia (see Section 10.8). 
Adverse events  will be collected  from the time of first dose  through  Day 29. After Day 29, 
collect/record only Serious Adverse Events (SAEs) which are  assessed  by [CONTACT_656449] 14 days of study completion 
(Day 29 or earlier if discontinue prior to Day 29) .  AE details are to be documented including start and 
stop date and times, whether continuous or intermittent, severity, any intervention utilized to correct 
the event  (e.g., medication, surgery , or other therapy) , outcome and the relationship to the study drug.   
AEs identified in the protocol as critical to the evaluation of safety mus t be reported to the Sponsor by 
[CONTACT_656365].  
AEs determined by [CONTACT_656408] c onsidered stable or for at least [ADDRESS_883948] results occurring after study enrollment constitute AEs only if they 
induce clinical signs or symptoms, are considered clinically significant, are Grades 3 or 4, or require 
therapy.  
If a death occurs during the SAE report ing period, the cause of death such as pneumonia, ARDS, or 
respi[INVESTIGATOR_1399], is considered as the AE and the death is considered its outcome. Death should be 
considered an outcome, not an event. The event or condition leading to death should be recorded  and 
reported as a single medical concept on the AE eCRF. Generally, only one such event should be 
reported. Fatal will be recorded as the outcome of this respective event; death due to an outcome of 
an AE will not be recorded as separate event. If the p rimary cause of death is disease progression, the 
cause of death should be clearly identified as COVID -19. 
In cases of surgical or diagnostic procedures, the condition leading to the procedure is considered as 
the AE instead of the procedure itself. Each AE will be coded by [CONTACT_656409] a preferred term using a thesaurus based on the Medical Dictionary for Regulatory Activities 
(MedDRA) . For example, record appendicitis, not appendectomy.  
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 36 of 52 
PROTOCOL VERSION  4.0 DATE:  [ADDRESS_883949] dose  are to be recorded in the eCRF using the AE form.  
3. Serious adverse events will be reported to the local IRB according to institutional policy.  
The NIH Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse 
Events, Corrected Version 2.1 (July 2017) 
(https://rsc.niaid.nih.gov/sites/default/files/daidsgradingcorrectedv21.pdf ) will be used for adverse 
event reporting.    
10.1 Follow Up of Grade 3 or 4 Toxicities  
Grade 3 or  4 toxicities are to be followed by [INVESTIGATOR_1312] -evaluation every 2 days, as feasible, until the toxicity 
returns to Grade  2 severity.  
10.2 Infection Follow Up  
Any new infection that occurs on study regardless of infecting agent (i.e., viral or non -viral) should be 
captured. Additionally, the site of infection and source of culture (BAL, tracheal aspi[INVESTIGATOR_337], sputum, 
blood, urine, etc.) should also be recorded.  
10.3 Classification of Causality  
Attribution is the relationship between an adverse event or serious adverse event  
and the study treatment. Attribution will be assigned as follows:  
 Definite  The AE is clearly related to the study treatment.  
 Probable  The AE is likely related to the study treatment  
 Possible  The AE may be related to the study treatment.  
 Unlikely - The A E is doubtfully related to the study treatment.  
 Unrelated - The AE is clearly NOT related to the study treatment  
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 37 of 52 
PROTOCOL VERSION  4.0 DATE:  [ADDRESS_883950] 2020  
 
Clear Creek Bio, Inc. 
CONFIDENTIAL  Guidance for assessing causality:  
The Investigator will need to determine whether an AE is considered related to ( caused by) the 
study drug rather than some underlying condition , for example, COVID -19.   
For the purposes of this study, drug related shall mean Definite, Probable and Possible 
relationship to drug as determined by  [CONTACT_737] . 
10.4 Classification of Severity  
The NIH Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse 
Events, Corrected Version 2.1 (July 2017)  will be utilized for AE reporting. All appropriate treatment 
areas should have access to a copy of the criteria.  
AEs that are expected are subject to expedited reporting only if the adverse event varies in nature, 
intensity or frequency from the expected toxicity information that is provided in the Investigator 
Brochure . 
10.5 Serious Adverse Event (SAE) Reporting  
The regulatory definition of a n SAE  is any untoward medical occurrence or effect that at any dose  
fulfills one or more of these criteria : 
 results in d eath; 
 is life threatening (at the time of the event) ; 
 requires in -patient hospi[INVESTIGATOR_1081] ; 
 results in persistent or significant disability / incapacity  
 is a congenital anomaly / birth defect ; 
 or is an  event consi dered medically serious by [CONTACT_737].  
 
Disability  is defined as a substantial disruption of a persons ability to conduct normal life functions.  
A life -threatening adverse event  is one that places the patient /subject , in the view of the Investigator , 
at immediate risk of death from the event as it occurred.  It does not include an event that, had it 
occurred in a more severe form, might have caused death.   
An unexpected adverse event  is any adverse drug event, the nature or severity of which is not 
consistent with the applicable product information (e.g. IB for an unauthorized  investigational product 
or summary of product characteristics for an authorized  product).  
Enter only one event as the reason for the SAE on the SAE form.  Other non -serious eve nts which did 
not directly result in the SAE should be detailed in the description section on the SAE form and listed 
separately as AEs if necessary.  For fatal SAEs, report the cause of death as an SAE with a fatal 
outcome rather than reporting death as th e SAE term.  
Note that hospi[INVESTIGATOR_286742]:  
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 38 of 52 
PROTOCOL VERSION  4.0 DATE:  [ADDRESS_883951] 2020  
 
Clear Creek Bio, Inc. 
CONFIDENTIAL   Routine treatment or monitoring of COVID -19 infection , not associated with any 
deterioration in condition ;  
 Elective or pre -planned treatment for a pre-existing condition that is unrelated to the 
indication under study and has not worsened since signing the informed consent ;  
 Social reasons and respi[INVESTIGATOR_108999]s general 
condition ; 
 Treatment on an emergen cy outpatient basis that does not result in hospi[INVESTIGATOR_656331].  
ANY SERIOUS ADVERSE EVENT MUST BE REPORTED IMMEDIATELY (WITHIN 24 
HOURS) BY [CONTACT_656437] .  
ENTER THE SUBJECTS AVAILABLE INFORMATION INTO THE  eCRF WITHIN [ADDRESS_883952]s subsequent medical course following a n SAE  must be submitted to 
Covance Patient Safety  until the event has subsided or, in case of permanent impairment, it stabilizes , 
and the overall clinical outcome has been ascertained.  
SAE R EPORTING EMAIL:   SAEIntake@covance .com  
Medical Monitor:  
Norberto Soto, MD  Telephone:  ([PHONE_13587]  
Covance Phys ician /Medical Monitor  Email:  [EMAIL_12503]  
Sponsor Representative:  
Barbara Powers, MSN, Ph.D.  Telephone:  M: ([PHONE_13588]  
VP, Clinical Operations  Email:  [EMAIL_12502]   
All SAEs will be reported to the IRB  periodically, at the end of the study , or per local institutional 
guidelines.   
10.6 Suspected Unexpected S erious  Adverse Reactions (S[LOCATION_003]Rs)  
Suspected, unexpected, serious adverse reactions ( S[LOCATION_003]Rs ) are SAEs that are both related to the study 
drug (Relationship = Related) and unexpected (not previously described in the investigators 
brochure).  All S[LOCATION_003]Rs will be reported in an expedited manner to the Sponsor or designee  and IRB 
by [CONTACT_656369]. Expectedness will be 
judged by [CONTACT_656370] . It is critical  that all SAEs are reported within 
the 24 -hour guideline so that the expectedness determi nation can be made. S[LOCATION_003]Rs require immediate 
attention and expedited reporting to relevant regulatory authorities.  
The Sponsor will ensure that all relevant information about fatal  or life -threatening  S[LOCATION_003]R s are 
appropriately recorded and reported  to the concerned Regulatory Authority and to the concerned 
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 39 of 52 
PROTOCOL VERSION  4.0 DATE:  [ADDRESS_883953] 2020  
 
Clear Creek Bio, Inc. 
CONFIDENTIAL  IRB(s)  within seven (7) calendar days of the date of first report to Covance Patient Safety / Sponsor . 
Follow -up information will be communicated to the relevant Regulatory Authorit y within an 
additional eight calendar days.  
All other S[LOCATION_003]Rs will be reported to the Regulatory Authority and to the IRB(s) concerned as soon 
as possible within a maximum of fifteen calendar days of first notification to Covance Patient Safety 
/ Sponsor.  
The Sponsor or designee will also inform all Investigators studying  the investigational medicinal 
product about S[LOCATION_003]Rs  and ensure that all IRBs have been notified . 
For reported deaths of a subject, the Investigator shall supply the Sponsor and the IRB(s) with 
requested additional information on an expedited basis .   
10.[ADDRESS_883954]s partner during the study period will be 
documented in the subjects source documents and reported to Covance Patient Safety (by [CONTACT_656450] [EMAIL_12504])  and to the IRB by [CONTACT_144300] [ADDRESS_883955]s 
partner will begin at the first dose of study drug and will conti nue through [ADDRESS_883956]s partner has consented to this. Monitoring of the baby [CONTACT_656412] [ADDRESS_883957]s partner has consented to this.  
Pregnancy itself is not an AE; it should be reported for tracking purposes. The Investigator or designee 
will discontinue the pregnant subject from the treatment aspects of the stud y, continue to follow her 
per protocol for safety outcomes only, and advise her to seek prenatal care and counseling from her 
primary care provider. Data on fetal outcome and breast -feeding will be collected for regulatory 
reporting and drug safety evaluat ion, if the subject has consented to this . 
If the pregnancy is due to a subjects failure to comply with the contraceptive requirements of this 
protocol, this should be documented as a protocol deviation.  
Complications of pregnancy or congenital abnormali ties in the newborn child will be reported 
appropriately as (S)AEs.  
The site clinical staff will request the pregnant subject to notify the site of the outcome of the 
pregnancy (i.e., birth, loss, or termination). To help ensure this, the site clinical st aff will follow the 
subject until the end of pregnancy, with the subjects consent. This request and the subjects response 
will be documented in the subjects source document.  
10.[ADDRESS_883958] to hematologic toxicity. In addition to enhancing safety by 
[CONTACT_459704]:  CCB -CRISIS -02      Page 40 of 52 
PROTOCOL VERSION  4.0 DATE:  [ADDRESS_883959] 2020  
 
Clear Creek Bio, Inc. 
CONFIDENTIAL  selecting a relatively brief 5 -day exposure and a low brequinar dose, all subjects in the clinical trial 
will be under the care of highly  qualified medical personnel. Clinically significant out -of-range 
laboratory  results will be reported as adverse events.  
In addition to real time assessments by [CONTACT_314107], t he Covance  Medical Monitor will 
assess the available hematology da ta on a periodic  basis to identify any pathologic trends or safety 
issues. Any apparent increase in the expected rate or severity of hematologic safety events will be 
discussed with the Princip al Investigators  and the Sponsor. In addition, the Data Monitor ing 
Committee (DMC) will assess available hematology data on a periodic  basis to independently assess 
any pathologic trends or safety issues.  If the rate or severity of hematologic toxicities appears to be 
above the expected rate or the severity appears wo rse than that expected, the trial enrollment will be 
suspended and no further subjects will be treated while a comprehensive data review is conducted. 
Depending on the outcome of the safety review the study may be stopped , the design adjusted , or the 
study  may continue as designed . Individual and Study stoppi[INVESTIGATOR_656332] 8.4. 
Safety laboratory results are to be initially assessed in real time by [CONTACT_656439]. Any study drug -related clinically significant out -of-range laboratories or study 
drug-related adverse events will be followed as needed until resolution or stable.  
The in-clinic  assessments a nd telemedicine /phone call visits will specifically ask about possible 
hematologic toxicity including any evidence of  the list below. Subjects will be provided with a list of 
the following events in lay terms and will be instructed to call the research tea m if any of these events 
occur.  
 Ecchymosis /purpura/petechiae  
 Epi[INVESTIGATOR_3940]  
 Hemoptysis  
 Hematuria  
 Gingival bleeding  
 Prolonged bleeding time from needle sticks, abrasions or lacerations  
 Hematemesis  
 Rectal bleeding  
 Blood in stool  
 Any other unusual bleeding noted by [CONTACT_656451].  
10.9 Data Monitoring Committee  
A Data Monitoring Committee  (DM C) will be established to  provide independent oversight to this 
trial. The primary responsibility of the DMC  will be to review the progress and conduct of the trial in 
order to maintain scientific rigor and to ensure the wellbeing of subjects participating in the trial. The 
specif ic responsibilities of the DMC  will be detailed in a separate DMC  charter. The DMC  will include 
at a minimum at least one statistician and two clinicians who will perform periodic data review to 
assess whether there are clinically significant differences b etween treatment arms that could affect 
participant safety.  All adverse events will be reviewed by [CONTACT_656430]. Following 
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 41 of 52 
PROTOCOL VERSION  4.0 DATE:  [ADDRESS_883960] 40 subjects complete the Day 8 visit. 
 
 
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 42 of 52 
PROTOCOL VERSION  4.0 DATE:  [ADDRESS_883961] 2020  
 
Clear Creek Bio, Inc. 
CONFIDENTIAL  11 STATIS TICAL CONSIDERATIONS  
A separate, detailed statistical analysis plan (SAP) will be finalized prior to locking the database. All 
analyses will be descriptive in nature and presented by [CONTACT_19313].   
Summaries for quantitative variables will include the mean, medi an, quartiles, standard error, 
minimum, and maximum. For qualitative variables, the summaries will include the number and 
percentage of subjects for each outcome, and 95% confidence interval (CI) , when appropriate. Any 
statistical testing will be considere d exploratory and descriptive. All computations will be performed 
using SAS (Version 9.4 or higher).  
Subject disposition, subject demographics and baseline characteristics will be summarized. Subject 
data listings will also be provided. The following sect ions will briefly summarize of the planned 
statistical analyses and analysis sets for the primary and secondary endpoints.  
11.[ADDRESS_883962] dose (treatment -emergent) adverse events  will be tabulated by [CONTACT_167546], and by [CONTACT_656441]. All 
laboratory results  and study assessments  will be summarized using appropriate descriptive statistics.  
11.3 Efficacy Analyses  
Efficacy will primarily be assessed via viral load  changes . 
11.4 Sample Size Considerations  
Formal sample size calculations are not applicable for this proof -of-concept study. The sample size of 
approximately  100 subjects planned to be entered in this trial  is expected to be adequate to provide 
safety and efficacy information to advise future stu dy design . 
11.5 Randomization  
A randomization scheme will be provided by [CONTACT_656415]  + brequinar  or SOC +  placebo  in a 1: 1 
ratio.  
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 43 of 52 
PROTOCOL VERSION  4.0 DATE:  [ADDRESS_883963] 2020  
 
Clear Creek Bio, Inc. 
CONFIDENTIAL  11.6 Pooling of Study Centers  
Not applica ble to this small, early phase study.  
11.7 Interim Analysis  
No interim analysis is planned for this trial.  
 
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 44 of 52 
PROTOCOL VERSION  4.0 DATE:  [ADDRESS_883964] 2020  
 
Clear Creek Bio, Inc. 
CONFIDENTIAL  12 INVESTIGATOR RESPONSIBILITIES  
12.1 Investigators Performance  
The Investigator will ensure that all those concerned with conducting the trial are : 
 provided wi th copi[INVESTIGATOR_656319];  
 trained regarding the conduct of the study and the training has been documented.  
The Investigator will sign the Investigators Statement and Agreement  found in Section 15.[ADDRESS_883965] that his/her identity will be protected an d confidentiality will 
be maintained during all audits and inspections of the trial site and documentation. A unique number 
will be assigned to each subject at the start of the trial and this, with the subjects initials, will be used 
to identify the subje ct. In some cases, a further step may be taken to assign fake initials to the subject, 
per individual site requirements. The subjects  number will be the site number followed by [CONTACT_656442], on all trial correspondence and in the trial database. The Investigator will keep a list of 
identification codes or initials used for  each subject  along with the unique number assigned.  
All information provided to the Investigator relevant to the investigational product ( IP), as well as 
information obtained during the course of the trial will be regarded as confidential. The Investigator 
and members of his/her research team agree not to disclose or publish such information in any way to 
any third -party without prior written p ermission from the Sponsor which will not be unreasonably 
withheld, except as required by [CONTACT_2371], or as permitted by [CONTACT_656417], 
Section  12.7. 
The Investigator will take all measures to ensure subjects  confidentiality will be maintained at all 
times.  
12.[ADDRESS_883966] 
access to the subjects ' medical or clinic records is necessary. The Investigator will ensure that certain 
information is contained i n the medical or clinic written or electronic records of the subject  and that 
the entries are signed and dated, as follows:  
 sufficient data to allow verification of the entry criteria in terms of past and present medical and 
medication histories;  
 a note on  the day the subject entered the trial describing the trial number, the IP being evaluated, 
the trial number assigned to that subject  and a statement that consent was obtained;  
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 45 of 52 
PROTOCOL VERSION  4.0 DATE:  [ADDRESS_883967] 2020  
 
Clear Creek Bio, Inc. 
CONFIDENTIAL   a note of each subsequent trial visit including any concerns about AEs and thei r resolution;  
 notes of all concomitant medication taken by [CONTACT_19578] , including start and stop dates;  
 a note of when the subject  terminated from the trial, the reason for termination and the subject s 
general condition at termination;  
 a copy of the signed informed consent form should be kept in the medical records of each subject 
during the clinical phase of the study. A signed copy should also be filed in the investigator file.  
12.[ADDRESS_883968] the research staff with 
any queries. All queries and discrepancies relating to the  data collection are to be resolved at the 
completion of the trial . Remote data capture is encouraged whenever possible.  
12.5 Case Report Forms, Investigators Site File and Record Retention  
The Sponsor may provide the CRFs in paper, electronic (eCRF), or other  media. The forms will be 
reviewed against source documentation at each monitoring visit. All CRFs and supporting source 
documentation must be completed and available to the Sponsor in a timely manner. Changes or 
corrections due to data clarification and r esolutions will be tracked by [CONTACT_656418].  
Prior to review of the case report forms by [CONTACT_1034]s representative, they should be reviewed for 
completeness and accuracy by [CONTACT_29517] a member of the research team.  
The Investigator must maintain an Investigator Site File which include s, but is not limited to, the IB, 
the protocol plus any amendments, all correspondence with the IRB including the approval for the 
trial to proceed, Regulatory Authority approval/ notif ication (if applicable) including a sample of an 
approved informed consent, IP accountability, Source Documents, investigator and staff curricula 
vitae ( CVs, ) trial documentation, and all trial correspondence. The original signed informed consent 
forms and  the final report will be kept in the Investigator Site File.  
The Investigator will archive all essential documents. The medical files of trial subjects shall be 
retained in accordance with national legislation and in accordance with the maximum period of time 
permitted by [CONTACT_5035][INVESTIGATOR_307], institution or private practice. The Investigator has a responsibility to retain 
essential documents for as long as is required by [CONTACT_656419]. It 
is the responsibility of the Sponsor to  inform the Investigator as to when these documents no longer 
need to be retained. Investigators will be asked to contact [CONTACT_656420]. Any transfer of ownership of the data or of documents will be documented in 
writing. The new owner will assume responsibility for data retention and archiving.  
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 46 of 52 
PROTOCOL VERSION  4.0 DATE:  [ADDRESS_883969] 30 days before its submission for any meeting or journal. I n addition, if 
deemed necessary by [CONTACT_656444], the 
Investigator agrees to a further delay of 60 days before any presentation or publication is submitted. 
The Sponsor reserves the right to in clude the report of this trial in any regulatory documentation or 
submission or in any informational materials prepared for the medical profession.  
Authorship determination will be at the discretion of the Sponsor and will include evaluation of the 
followi ng criteria: Investigator must participate in the review of and content of the protocol; review 
and comment on the study results; participate in the writing, reviewing and commenting of the 
manuscript; and approve the final manuscript for submission.  
 
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 47 of 52 
PROTOCOL VERSION  4.0 DATE:  [ADDRESS_883970] 2020  
 
Clear Creek Bio, Inc. 
CONFIDENTIAL  13 SPONSOR RESPONSIBILITIES  
13.1 General  
The Sponsor agrees to adhere to the ICH Note for Guidance on GCP  (CPMP/ICH/135/95, Jan.97)  and 
US FDA Regulations. It is the Sponsor's responsibility to obtain appropriate regulatory approval to 
perform the trial (if applic able). The Sponsor should notify promptly all concerned investigator(s), 
IRB(s) and the Regulatory Authority of findings that could adversely affect the health of the patients/ 
subjects, impact on the conduct of the trial or alter the Regulatory Authority s authorization  to continue 
the trial. If it is necessary to change or deviate from the protocol to eliminate an immediate hazard to 
the subjects the Sponsor will notify the relevant regulatory authority and relevant IRB of the new 
events, the measures tak en and the plan for further action as soon as possible.  This will be by [CONTACT_656445] a written report.   
On completion of the trial, the Sponsor will inform the regulatory authority that the trial has ended.  If 
the study is  terminated for any reason the Sponsor will provide a written statement to the relevant 
regulatory authority and the IRB with the reasons for termination of the trial. This will be conducted 
within [ADDRESS_883971] (EHR) or conduct remote moni toring visits at regular intervals 
during the trial for monitoring purposes and to assist the research staff with any queries. CRFs and 
source documentation will be available for review during monitoring visits to the trial site. The 
function of this monitoring is to en sure compliance with the protocol, adherence to regulatory and 
GCP  obligations, proper maintenance of records including IP accountability records, correct 
administration of IP including storage conditions and accurate reporting of AEs. On-site visits are n ot 
required for any monitoring visits for this study.    
Once the data from the case report forms have been entered onto the database, they will be reviewed , 
and the data verified against the subjects source data. Any discrepancies will be tracked by [CONTACT_656446].  
13.[ADDRESS_883972] while 
the trial is being conducted or up to several years later.   
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 48 of 52 
PROTOCOL VERSION  4.0 DATE:  [ADDRESS_883973] s name,  and subject s 
confidentiality will be maintained at all times.  
13.[ADDRESS_883974] of a separate agreement between the Investigator /Institution  and Sponsor.  
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 49 of 52 
PROTOCOL VERSION  4.0 DATE:  [ADDRESS_883975] 2020  
 
Clear Creek Bio, Inc. 
CONFIDENTIAL  14 REFERENCES   
1. Sykes DB, Kfoury YS, Mercier FE, et al. Inhibition of dihydroorotate deh ydrogenase 
overcomes differentiation blockade in acute myeloid leukemia. Cell 2016; 167(1): 171 -186. 
2. Zhou  F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality 
of adult inpatients with COVID -19 in Wuhan, China: a retrosp ective cohort study. Published 
online March 9, 2020. https://doi.org/10.1016/S0140 -6736(20)[ZIP_CODE] -3 
3. Phelan  A, Katz R, and Gostin L. The novel coronavirus originating in Wuhan, China. 
Challenges f or global health governance. Jama. 2020;323(8):709 -710.   
4. Handel A, Mille J, Yang G, Fung I. If containment is not possible, how do we minimize 
mortality for COVID -19 and other emerging disease outbreaks.  March 13, 2020. 
https://doi.org/10.1101/2020.03.13.20034892 . 
5. Brequinar Investigators Brochure  
6. Chen S, Ding S, Yin Y, Xu L, Li P, Peppelenbosch MP, et al. Suppression of pyrimidine 
biosynthesis by [CONTACT_656447] e nzyme robustly inhibits rotavirus replication. Antiviral 
Res. 2019 Jul;167:35 44.  
7. Mei-Jiao G, Shi -Fang L, Yan -Yan C, Jun -Jun S, Yue -Feng S, Ting -Ting R, et al. Antiviral 
effects of selected IMPDH and DHODH inhibitors against foot and mouth disease virus. 
Biomed Pharmacother. [ADDRESS_883976];118:109305.  
8. Wang QY, Bushell S, Qing M, Xu HY, Bonavia  A, Nunes S, et al. Inhibition of Dengue 
Virus through Suppression of Host Pyrimidine Biosynthesis. 2011 Jun 9;85(13):6548 56.  
9. Luthra P, Naidoo J, Pi[INVESTIGATOR_656320], De S, Khadka S, Anantpadma M, et al. Inhibiting 
pyrimidine biosynthesis impairs Ebola virus rep lication through depletion of nucleoside 
pools and activation of innate immune responses. Antiviral Res. [ADDRESS_883977];158:288 302.  
10. Andersen PI, Krpi[INVESTIGATOR_28947] K, Ianevski A, Shtaida N, Jo E, Yang J, et al. Novel Antiviral Activities 
of Obatoclax, Emetine, Niclosamide , Brequinar, and Homoharringtonine. Viruses. [ADDRESS_883978] 
18;11(10).  
11. Xiong  R, Zhang L , Li S, Sun Y , Ding M , Wang, Y , et al. Novel and potent inhibitors 
targeting DHODH, a rate -limiting enzyme in de novo pyrimidine biosynthesis, are broad -
spectrum antiviral ag ainst RNA viruses including newly emerged coronavirus SARS -CoV -2. 
12. Sah R, Rodriguez -Morales AJ, Jha R, Chu DKW, Gu H, Peiris M, et al. Complete Genome 
Sequence of a 2019 Novel Coronavirus (SARS -CoV -2) Strain Isolated in Nepal. Microbiol 
Resour Announc. 2020  Mar 12;9(11).  
13. Liu Q, Gupta A, Okesli -Armlovich A, Qiao W, Fischer C, Smith M, et al. Enhancing the 
Antiviral Efficacy of RNA -Dependent RNA Polymerase Inhibition by [CONTACT_656386]. bioRxiv. 2020 Jan 1;2020.03.24.992230 . 
14. Study DUP 785 -001 Clinical Study Report (on file with Clear Creek)  
15. Study DUP 785 -003 Clinical Study Report (on file with Clear Creek)  
16. Study DUP 785 -005 Clinical Study Report (on file with Clear Creek)  
17. Study DUP 785 -022 Clinical Study Report (on file with  Clear Creek)  
18. Study DUP 785 -031 Clinical Study Report (on file with Clear Creek)  
19. Study DUP 785 -034 Clinical Study Report (on file with Clear Creek)  
20. FDA Guidance COVID -19: Developi[INVESTIGATOR_656333] ( https://www.fda.gov/media/137926/download ) 
 
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 50 of 52 
PROTOCOL VERSION  4.0 DATE:  [ADDRESS_883979] 2020  
 
Clear Creek Bio, Inc. 
CONFIDENTIAL  15 APPENDICES  
15.1 Appendix  A:  CCB -CRISIS -[ADDRESS_883980] dose time  
 
Procedures  Screen  
(days  
-14 to -1) 
HH+TMf D1 
HH+
TM D2, 3  
( 8 
hrs) 
TCf D4 
( 8 
hrs) 
TM D5,6,
7 
( 8 
hrs) 
TC D8 
( 1 
day)  
HH+
TM D12 
( 1 
day)  
TM D15 
( 1 
day)  
HH+
TM D22 
(1 
day)  
TM Final 
Visit   
D29 
( 2 days)  
HH+TM  
Informed Consent (note Date and Time)  X          
AE/Concomitant Medications (dose, route, duration 
or ongoing)  X X X X X X X X X X 
Medical history (relevant within one year or 
ongoing)/ History of current illness (date of 
symptom onset or change in baseline co -morbidity 
thought to be due to COVID -19 infection)  X          
Demographics (subject reported height and weight, 
date of birth, gender, race, ethnicity)  X          
Check for Physical Exam abnormalities (subject 
self-reported)  X          
Pregnancy Test (WOCBP)  X 
(serum)          X 
(urine)  
Hematology/Chemistrya X X     X  X   
Vital Signsb X X  X  X X X X X 
Symptom Assessmentc X X  X  X X X X X 
SARS -CoV -2 RT-PCR/ Viral load  sampled X X   X  X X X X X 
Hospi[INVESTIGATOR_656304]       X  X X X 
WHO Ordinal Scale Assessment   X    X  X X X 
Confirm Eligibility   X         
Randomize subject and dispense Study Medication   X         
Study drug administratione  X X X X 
D5 
Only       
Drug Accountability       X     
aDo not repeat if within 48h of Day 1 visit.  Send to Covance Central Laboratory Services (CCLS) for analysis.  
bVital signs include heart rate, respi[INVESTIGATOR_697], body temperature, and S pO2. Subject will be provided with a thermometer and pulse 
oximeter with heart rate monitoring capability. Training will be provided during the first visit by [CONTACT_535758]. Vi tal signs 
parameters will be observed and recorded by [CONTACT_656424] a visit by [CONTACT_535758].  
cSymptom Assessment will use a checklist  provided to the subject with  symptoms such as sore throat, cough, GI symptoms (vom iting, 
diarrhea), an osmia, dysgeusia, other (specify), etc.  Severity None, Mild, M oderate, or Severe will be collected.  
d RT-PCR at Screening may be performed by [CONTACT_656425] a positive SARS -CoV -[ADDRESS_883981] using an O mnigene collection system or 
similar. The home health nurse will train the subject and observe sample collectio n on Day 1. These samples are to be sent to CCLS 
for analysis.  The viral load sample may also be used to perform viral cultures (sample can be split  by [CONTACT_2237] , no 
additional sample required).  
eSubject  will self -administer study drug once daily Days 1  [ADDRESS_883982] doses in a medication diary.  Note that any visits/visit activities 
may be conducted via telephone, telemedicine , or digital media other than serum pregnancy test and chemistry/hematology sam ple 
collection. These labs may be collected at the clinical site or another designated out -patient facility/laboratory or collected via home 
visit.  Arrangements for shippi[INVESTIGATOR_656336].  
fHH = Home Health in -person visit; TC = Telephone Call with site  and subject ; TM = Telemedicine with site  and subject.  
 
  
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 51 of 52 
PROTOCOL VERSION  4.0 DATE:  [ADDRESS_883983] 2020  
 
Clear Creek Bio, Inc. 
CONFIDENTIAL  15.2 Appendix  B: Investigators Statement and Agreement  
STUDY NUMBER:    CCB -CRISIS -02 
The CRISIS2 Study: A phase 2, randomized , double blind,  placebo -controlled, multi -center study 
assessing the safety and anti -coronavirus response of suppression of host nucleotide synthesis in out -
patient adults with SARS -CoV -2.  
INVESTIGATORS STATEMENT AND AGREEMENT  
I (the Investigator ) have read this protoc ol and hereby [CONTACT_656426].  It is further agreed that the details of this trial and all information provided to me by 
[CONTACT_656388], Inc.  (the Sponsor ) will be held in the strictest confidence and will not be revealed for 
any reason without written authorization from Clear Creek Bio, Inc. except to those who are to 
participate in the conduct of the trial.  
I agree that all data, the case report forms , and all materials provided for the conduct of the tria l are 
the property of Clear Creek Bio, Inc.  unless specified otherwise in writing. It is understood that Clear 
Creek Bio, Inc. will utilize the information derived from this trial in various ways, such as for 
submission to government regulatory agencies, r equired internal reports , and presentations without 
violating patient/ subject confidentiality in any way.  
I further agree that Clear Creek Bio, Inc.  or its representatives will be permitted access , in accordance 
with current Good Clinical Practice Guidelines , to all data generated by [CONTACT_656427].  
PRINCIPAL INVESTIGATOR  
[INVESTIGATOR_67476]: ____________________________________  
 
Signature: ________________________________ ____________  Date: __________________  
 
  
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 52 of 52 
PROTOCOL VERSION  4.0 DATE:  [ADDRESS_883984] 2020  
 
Clear Creek Bio, Inc. 
CONFIDENTIAL  15.3 Appendix C: WHO Ordinal Scale  
 
Patient State  Descriptor  Score  
Uninfected  Uninfected; no viral RNA detected  0 
Ambulatory mild disease  Asymptomatic; viral RNA detected  1 
Symptomatic; independent  2 
Symptomatic; assistance needed  3 
Hospi[INVESTIGATOR_057]: moderate disease  Hospi[INVESTIGATOR_057]; no oxygen therapy*  4 
Hospi[INVESTIGATOR_057]; oxygen by [CONTACT_88543]  5 
Hospi[INVESTIGATOR_057]: severe disease  Hospi[INVESTIGATOR_057]; oxygen by [CONTACT_656428]  6 
Intubation and mechanical ventilation, pO 2/FiO 2 150 or SpO 2/FiO 2  200  7 
Mechanical ventilation pO 2/FiO 2 <150 (SpO 2/FiO 2 < 200) or vasopressors  8 
Mechanical ventilation pO 2/FiO 2 <150 and vasopressors, dialysis, or ECMO  9 
Dead  Dead  10 
 
WHO clinical progression scale  
 
PROTOCOL NUMBER:  CCB -CRISIS -02  Page 1 of 53 
PROTOCOL VERSION  5.0 DATE:  19 NOV 2020  
Clear Creek Bio, Inc.  
CONFIDENTIAL  STUDY PROTOCOL  
The CRISIS 2 Study: A phase 2, randomized , double blind, placebo -controlled, multi -center 
study  assessing the safety and anti -coronavirus response of suppression of host nucleot ide 
synthe sis in out-patient adults with SARS -CoV -2  
Study No: CCB -CRISIS -02 
Version: 5.0 
Version Date:  19 November 2020  
Sponsor:  
Clear Creek Bio, Inc.  
[ADDRESS_883985], 4th Floor,  
Cambridge MA [ZIP_CODE]  
Sponsor Telephone: ([PHONE_13583]  
Sponsor Facsimile: ([PHONE_13584]  
IND Number: 149291  
This confidential document is the property of Clear Creek Bio, Inc .  No unpublished information contained herein may 
be disclosed without the prior written approval of Clear Creek Bio, Inc. This trial will be conducted in accordance with 
the ICH Note for Guidance on Good Clinical Practice (CPMP/ICH/135/95, Jan.97), the De claration of Helsinki (1964, 
1975, 1983, 1989, 1996, 2000 (Note for Clarification 2002 & 2004) and 2008), FDA Regulations and locally applicable 
regulations.  
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 2 of 53 
PROTOCOL VERSION  5.0 DATE:  19 NOV 2020  
 
Clear Creek Bio, Inc.  
CONFIDENTIAL  TABLE OF CONTENTS  
2 SYNOPSIS  ................................ ................................ ................................ ............................  9 
3 INTRODUCTION  ................................ ................................ ................................ ..............  17 
3.1 Coronavirus -19 (COVID -19) ................................ ................................ .....................  [ADDRESS_883986] Nucleotide Synthesis  ................................ ................................ .........................  17 
3.3 Dihydroorotate dehydrogenase (DHODH)  ................................ ................................  18 
3.4 Brequinar  ................................ ................................ ................................ ....................  18 
3.5 Rationale for the Planned Trial  ................................ ................................ ..................  19 
3.5.1  Brequinar Dose Selection  ................................ ................................ .............................  20 
3.5.2  Risk/Benefit of Brequinar  ................................ ................................ ............................  20 
3.6 Risks Associated with Participation in the Clinical Study  ................................ .........  20 
3.7 Possible Interactions with Concomitant Medical Treatments  ................................ .... 21 
3.7.1  CYP Interactions  ................................ ................................ ................................ ..........  21 
3.8 Steps to be Taken to Control or Mitigate Risks  ................................ .........................  21 
4 TRIAL OBJECTIVES  ................................ ................................ ................................ ........  22 
4.1 Primary Objective  ................................ ................................ ................................ ...... 22 
4.2 Secondary Objectives  ................................ ................................ ................................ . 22 
4.3 EXPLORATORY OBJECTIVES  ................................ ................................ ..............  22 
5 TRIA L DESIGN  ................................ ................................ ................................ .................  23 
6 TRIAL ENDPOINTS ................................ ................................ ................................ ..........  24 
6.1 Primary Endpoint  ................................ ................................ ................................ ....... 24 
6.2 Secondar y Endpoints  ................................ ................................ ................................ .. 24 
6.3 Exploratory Endpoints ................................ ................................ ................................  24 
7 TRIAL POPULATION  ................................ ................................ ................................ ....... 25 
7.1 Number of Subjects  ................................ ................................ ................................ .... 25 
7.2 Inclusion criteria  ................................ ................................ ................................ .........  25 
7.3 Exclusion Criteria  ................................ ................................ ................................ ....... 25 
8 STUDY TR EATMENTS  ................................ ................................ ................................ .... 27 
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 3 of 53 
PROTOCOL VERSION  5.0 DATE:  19 NOV 2020  
 
Clear Creek Bio, Inc.  
CONFIDENTIAL  8.1 Description of Study Medications  ................................ ................................ ..............  27 
8.1.1  Brequinar  ................................ ................................ ................................ ......................  27 
8.2 Treatment Admi nistration  ................................ ................................ ..........................  27 
8.2.1  Safety/Tolerability  ................................ ................................ ................................ ........  27 
8.3 Study Discontinuation  ................................ ................................ ................................  28 
8.4 Stoppi[INVESTIGATOR_2121]  ................................ ................................ ................................ ........  28 
8.4.1  Individual Stoppi[INVESTIGATOR_2121]  ................................ ................................ .........................  28 
8.4.2  Study -Level Stoppi[INVESTIGATOR_2121] ................................ ................................ ......................  28 
8.5 Concomitant Medication/Treatment  ................................ ................................ ..........  28 
8.6 Treatment Compliance  ................................ ................................ ...............................  28 
8.7 Storage, Stability, Labeling and Packaging  ................................ ...............................  29 
8.7.1  Storage and Stability  ................................ ................................ ................................ .... 29 
8.7.2  Labeling and Packaging  ................................ ................................ ...............................  29 
8.7.3  Blinding and Randomization  ................................ ................................ ........................  29 
8.7.4  Unblinding/Expectedness  ................................ ................................ .............................  [ADDRESS_883987]  ................................ ................................ ................................ ............  33 
9.5.1  Unscheduled Visits  ................................ ................................ ................................ ....... 34 
9.6 Compliance with Study Procedures  ................................ ................................ ...........  34 
9.7 Early Withdrawal from the Study  ................................ ................................ ..............  34 
9.8 Early Termination of the Study  ................................ ................................ ..................  34 
9.9 Non-Childbearing Potential ................................ ................................ ........................  35 
10 ADVERSE EVENT REPORTING ................................ ................................ .....................  36 
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 4 of 53 
PROTOCOL VERSION  5.0 DATE:  19 NOV 2020  
 
Clear Creek Bio, Inc.  
CONFIDENTIAL  10.1  Follow Up of Grade 3 or 4 Toxicities  ................................ ................................ ........  37 
10.2  Infection Follow Up  ................................ ................................ ................................ ... 37 
10.3  Classification of Causality  ................................ ................................ .........................  37 
10.4  Classification of Severity  ................................ ................................ ...........................  38 
10.5  Serious Adverse Event (SAE) Reporting  ................................ ................................ ... 38 
10.6  Suspected Unexpected Serious Adverse Reactions (S[LOCATION_003]Rs)  ................................ . 39 
10.7  Pregnancies ................................ ................................ ................................ .................  40 
10.8  Safety Monitoring for Hematologic Toxicities  ................................ ..........................  40 
10.9  Data Monitoring Committee  ................................ ................................ ......................  41 
10.9.1  DMC Safety Review Schedule  ................................ ................................ ...............  42 
11 STATISTICAL CONSIDERATIONS ................................ ................................ ................  43 
11.1  Study Populations for Analysis  ................................ ................................ ..................  43 
11.2  Safety Analyses  ................................ ................................ ................................ ..........  43 
11.3  Efficacy Analyses  ................................ ................................ ................................ ....... 43 
11.4  Sample Size Considerations  ................................ ................................ .......................  43 
11.5  Randomization  ................................ ................................ ................................ ...........  43 
11.6  Pooling of Study Centers ................................ ................................ ............................  44 
11.7  Interim Analysis  ................................ ................................ ................................ .........  44 
12 INVESTIGATOR RESPONSIBILITIES  ................................ ................................ ...........  45 
12.1  Investigators Performance  ................................ ................................ ........................  45 
12.2 Confidentiality  ................................ ................................ ................................ ............  45 
12.3  Source Documentation  ................................ ................................ ...............................  45 
12.4  Data Collection  ................................ ................................ ................................ ...........  46 
12.5  Case Report Forms, Investigators Site File and Record Retention  ...........................  46 
12.6  Non-Protocol Research  ................................ ................................ ..............................  47 
12.7  Publication  ................................ ................................ ................................ ..................  47 
13 SPONSOR RESPONSIBILITIES  ................................ ................................ ......................  48 
13.1  General  ................................ ................................ ................................ .......................  48 
13.2  Indemnity  ................................ ................................ ................................ ...................  48 
13.3  Data Monitoring  ................................ ................................ ................................ .........  48 
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 5 of 53 
PROTOCOL VERSION  5.0 DATE:  19 NOV 2020  
 
Clear Creek Bio, Inc.  
CONFIDENTIAL  13.4  Audit  ................................ ................................ ................................ ...........................  48 
13.5  Confidentiality  ................................ ................................ ................................ ............  49 
13.6  Finance  ................................ ................................ ................................ .......................  49 
14 REFERENCES  ................................ ................................ ................................ ...................  50 
15 APPENDICES  ................................ ................................ ................................ ....................  51 
15.1  Appendix A:  CCB -CRISIS -02 Schedule of Events  ................................ ..................  51 
15.2  Appendix B: Investigators Statement and Agreement  ................................ ..............  52 
15.3  Appendix C: WHO Ordinal Scale  ................................ ................................ ..............  53 
 
 
  
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 6 of 53 
PROTOCOL VERSION  5.0 DATE:  [ADDRESS_883988] OF FIGURES  
Figure 3 -1. DHODH is a mitochondrial enzyme that catalyzes the 4th step of pyrimidine synthesis; 
it is completely essential for the generation of UMP.  ................................ .................  18 
 
 
  
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 7 of 53 
PROTOCOL VERSION  5.0 DATE:  [ADDRESS_883989]  
ESR Erythrocyte Sedimentation Rate  
EUA  Emergency Use Authorization  
FDA  [LOCATION_002] Food and Drug Administration  
GCP  Good Clinical Practice  
HIV Human immunodeficiency virus  
IB Investigator Brochure  
ICF Informed consent form  
ICH International Council on Harmonization  
ICU Intensive care unit  
IMP Inosine -5 phosphate  
IP Investigational product  
IRB Institutional Review Board  
LDH  Lactate dehydrogenase  
MedDRA  Medical Dictionary for Regulatory Activities  
NCI National Cancer Institute  
NEWS2  National Early Warning System (NEWS) [ADDRESS_883990] of Care  
S[LOCATION_003]R  Suspected unexpected serious adverse reaction  
SpO 2 Peripheral capi[INVESTIGATOR_656323]:  CCB -CRISIS -02      Page 8 of 53 
PROTOCOL VERSION  5.0 DATE:  19 NOV 2020  
 
Clear Creek Bio, Inc.  
CONFIDENTIAL  Abbreviation  Definition  
UMP  Uridine 5-monophosphatase  
US [LOCATION_002]  
XMP  Xanthosine -5 phosphate  
WHO  World Health Organization  
WOCBP  Women of childbearing potential  
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 9 of 53 
PROTOCOL VERSION  5.0 DATE:  19 NOV 2020  
 
Clear Creek Bio, Inc.  
CONFIDENTIAL  2 SYNOPSIS  
CCB -CRISIS -02 SYNOPSIS  
IND 149291  
Title  The CRISIS2 Study: A phase 2, randomized, double blind, placebo -controlled, 
multi -center study assessing the safety and anti -coronavirus response of 
suppression of host nucleotide synthesis in out-patient adults with SARS -CoV -[ADDRESS_883991] SARS -CoV -2 is likely 
due to DHODH inhibitio n and shows  nanomolar potency and a high selectivity 
index in inhibiting viral replica tion in  in vitro  studies.    
The CRISIS2 trial will study out-patients ( non-hospi[INVESTIGATOR_9643] ) who have  a 
positive SARS -CoV -[ADDRESS_883992] of care (SOC)  + 5 days of brequinar or SOC + [ADDRESS_883993] and 
Dosage  Subjects will be randomized in a 1:[ADDRESS_883994] of care (SOC) + 5 days 
of brequinar  100 mg or SOC + [ADDRESS_883995] will be supplied as either b requinar 100 mg oral capsules  
or placebo capsules . The subjects are to self -administer one capsule on  Study Days 
1  5.  
Treatment assignment will be randomized, double -blind.   
Primary 
Objective s  To demonstrate a change from baseline in quantitative SARS -CoV -2 viral load 
for brequinar -treated subjects compared to placebo -treated subjects through 
Day 29. 
Secondary 
Objectives  Through Day 29:  
 To characterize  the safety and tolerability of brequinar i n out-patient COVID -
19 subjects  as measured by [CONTACT_656340] 3 and 4 AEs and SAEs ; 
 To demonstrate a shorter duration of viral shedding in subjects treated with 
brequinar compared to  subjects who received placebo ;  
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 10 of 53 
PROTOCOL VERSION  5.0 DATE:  19 NOV 2020  
 
Clear Creek Bio, Inc.  
CONFIDENTIAL   To reduce the percentage of subject s requiring hospi[INVESTIGATOR_656300] -
patient for > 24 hours  for brequinar subjects compared to  subjects who received 
placebo ; 
 To reduce all-cause mortality through Day 29  for brequinar subjects compared 
to subjects who received placebo.  
Exploratory 
Objective s Through Day 29:  
 To determine time to viral clearance (two consecutive negative tests) ;  
 To determine time to resolution of new onset COVID -19-related clinical 
symptoms and pre -existing non-COVID -19 symptoms returned to baseline ; 
 To determine time to clinical improvement  as measured by a favorable shift in 
the WHO Ordinal Scale score measured for the subset of subject s with baseline 
WHO Ordinal Scale of [ADDRESS_883996]  [ADDRESS_883997] symptom. Study procedures 
are presented in detail in the Schedule of Events . Study visits (virtual or in person) 
will take place at Screening and on Study Days  [ADDRESS_883998]s home or other appropriate location. Other 
visits /visit activities for that visit  may be conducted remotely usi ng telephone, 
telemedicine  or other remote technique . Subjects are to self -collect a viral load 
sample , obtain their respi[INVESTIGATOR_697], heart rate, body temperature and SpO2, and 
complete a symptom assessment  with the site via telemedicine  on Days 1, 4, 8, 12, 
15, 22, and [ADDRESS_883999] telemedicine 
or telephone components  if all study activities cannot be completed in person . 
Telemedicine only visits will be conduc ted by [CONTACT_656390] 4 , 12, and 
22. 
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 11 of 53 
PROTOCOL VERSION  5.0 DATE:  19 NOV 2020  
 
Clear Creek Bio, Inc.  
CONFIDENTIAL  Sample Size:  Approximately 100 subjects will be randomized to 5 days of either SOC  + 
brequinar 100 mg or SOC + placebo in a 1:1 ratio (approximately 50 subjects 
assigned to brequinar 100 mg and 50 subjects to placebo ).  
Number of Sites:  Approximately 15 
Study Period:  An enrollment period of 3 months is expected.  
Inclusion 
Criteria:  
 1. Willing and able to provide informed consent for the trial, written, 
electronic, verbal , or other method deemed ac ceptable by [CONTACT_656342].  
2. 18 years of age or older.  
3. Laboratory -confirmed SARS -CoV -2 infection as determined by [CONTACT_656343] (RT -PCR) or other FDA -approved commercial 
or public health assay.  
4. Out-patient (never hospi[INVESTIGATOR_18552] d as an in -patient for COVID -19 or was 
evaluated/treated for COVID -19 only in the Emergency Room with a stay 
of < 24 hours).  
5. The effects of brequinar on the developi[INVESTIGATOR_19241] . For 
this reason, women of child -bearing potential and men must agree to use 
adequate contraception (hormonal or barrier method of birth control; 
abstinence) prior to study entry and for the duration of study participation. 
Should a woman become pregnant or suspect she is pregnant while she or 
her partner is parti cipating in this study, she should inform her treating 
physician immediately. Men and women treated or enrolled on this protocol 
must also agree to use adequate contraception for the duration of study 
participation, and for [ADDRESS_884000] be [ADDRESS_884001] dose . 
8. Able to swallow capsules.  
Exclusion 
Criteria:  1. Any physical examination findings and/or history of any illness tha t, in the 
opi[INVESTIGATOR_103160], might confound the results of the study 
or pose an additional risk to the patient  
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 12 of 53 
PROTOCOL VERSION  5.0 DATE:  19 NOV 2020  
 
Clear Creek Bio, Inc.  
CONFIDENTIAL  2. Nursing women or women of childbearing potential (WOCBP) with a 
positive pregnancy test  
3. Treatment with another DHODH inhibitor  (e.g., leflunomide , 
teriflunomide ) or other agents known to cause bone marrow suppression 
leading to thrombocytopenia  
4. Platelets 150,000 cell/mm3 
5. Hemoglobin < 10 gm/dL  
6. Absolute neutrophil count < 1500 cells/mm3 
7. Renal dysfunction, i.e., creatinin e clearance < 30 mL/min  
8. AST or ALT > [ADDRESS_884002], or total bilirubin > ULN . Gilberts Syndrome is 
allowed.  
9. Bleeding disorders or blood loss requiring transfusion  in the six weeks 
preceding enrollment  
10. Ongoing  gastrointestinal ulcer, or gastrointestinal bleeding  within [ADDRESS_884003] dose. 
11. Chronic  hepatitis B  infection , active hepatitis C infection, active liver 
disease and/or cirrhosis  per subject report.  
12. Heart failure, current uncontrolled cardiovascular disease, including 
unstable angina, uncontrolled arrhythmias, major adverse cardiac event 
within 6 months (e.g. stroke, myocardial infarction, hospi[INVESTIGATOR_656302], or revascularization procedure).   
Treatment  All subjects will receive standard of care (SOC)  including symptomatic care. 
Subjects will be randomly assigned to SOC + brequinar 100 mg daily x 5 or SOC 
+ placebo daily x 5. Study encounters will be conducted remotely whenever 
possible.  
DMC A Data Monitoring Committee  (DM C) will meet periodically to review the safety 
and scientific conduct of the study. At a minimum, the DMC  is to review adverse 
events and safety laboratory assessments after the first [ADDRESS_884004] 40 subjects complete Day 8.  
Procedures  Study procedures are outlined in the Schedule of Events.  
Study completion or the reason for study discontinuation will be recorded in the 
source document and the eCRF.  
Safety/  
Tolerability  Safety/Tolerability  
Adverse events will be collected from the time of first dose  through Day 29. After 
Day 29, collect/re cord only Serious Adverse Events (SAEs) or those judged by [CONTACT_656452]:  CCB -CRISIS -02      Page 13 of 53 
PROTOCOL VERSION  5.0 DATE:  [ADDRESS_884005] treatment . 
Subjects who develop Gra de 3 or 4 toxicities or SAEs are to be re -evaluated every 
2 days, as feasible, until the toxicity returns to Grade  [ADDRESS_884006] any signs or symptoms of muco sitis or thrombocytopenia, e.g.:  
 Ecchymosis/purpura/petechiae  
 Epi[INVESTIGATOR_3940]  
 Hemoptysis  
 Hematuria  
 Gingival bleeding  
 Prolonged bleeding time from needle sticks, abrasions or lacerations  
 Hematemesis  
 Rectal bleeding  
 Blood in stool  
 Any other unusual bleeding noted by [CONTACT_656429][INVESTIGATOR_656303]:  
 Participants who develop a Grade 3 toxicity that is assessed by [CONTACT_656345].  
 Participants who develop a Grade 4 toxicity, regardless of relatedness to 
study drug, are to be permanently discontinued from study treatment.  
Study -Level Stoppi[INVESTIGATOR_2121]:  
Study enrollment is to be paused  if any of the below criteria are met:  
 If  [ADDRESS_884007] s develop the same  related Grade 4 (life -threatening) adverse 
event or laboratory abnormality;  
 If  5 subjects develop the same  related Grade 3 or 4 adverse event or 
laboratory abnormality ; 
 If  10 subjects develop any related Grade 3 or 4 adverse event or 
laboratory abnormality .  
All adverse events will be reviewed by [CONTACT_656430]. Following 
assessment by [CONTACT_1578] (DMC), the DMC will determine 
whether to stop the study, amend the pr otocol, or continue the study per protocol.   
Statistical 
Analysis  A separate, detailed statistical analysis plan (SAP) will be finalized prior to locking 
the database. All analyses of safety and efficacy for this study will be descriptive 
in nature and presented by [CONTACT_19313]. Subject demographics and baseline 
characteristics  will be summarized. Subject data listings will also be provided.  
Summaries for quantitative variables will include the mean, median, quartiles, 
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 14 of 53 
PROTOCOL VERSION  5.0 DATE:  [ADDRESS_884008] error, minimum, and maximum. For qualitative variables, the summaries 
will include the number and per centage of subjects for each outcome, and the 95% 
CI, when appropriate.  Any statistical testing will be considered exploratory and 
descriptive. All computations will be performed using SAS (Version 9.4 or 
higher). Safety and tolerability will be assessed  in terms of AEs, SAEs, and safety 
laboratory data.  
Adverse event data will be descriptively evaluated. All AEs will be reported in data 
listings. The incidence of treatment -emergent  adverse events, defined as TEAEs 
occurring after first dose  will be tabu lated by [CONTACT_12513] (MedDRA) preferred term and system organ class, and by [CONTACT_656392]. All laboratory results and other clinical measures 
will be summarized using appropriate descriptive s tatistics.  
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 15 of 53 
PROTOCOL VERSION  5.0 DATE:  [ADDRESS_884009] dose time  
Procedures  Screen  
(D -7 to  
-1) 
IPVf D1 
IPV D2, 3  
( 8 
hrs) 
TCf D4 
( 8 
hrs) 
TM D5, 6, 7 
( 8 hrs)  
TC D8 
( 8 hrs ) 
IPV+TM  D12 
( 1 
day)  
TM D15 
( 1 day)  
IPV+TM  D22 
(1 
day)  
TM Final 
Visit   
D29 
( 2 
days)  
IPV+TM  
Informed Consent (note Date and Time)  X          
AE/Concomitant Medications (dose, route, 
duration or ongoing)  X X X X X X X X X X 
Medical history (relevant within one year or 
ongoing)/ History of current illness (date of 
symptom onset or change in baseline co -morbidity 
thought to be due to COVID -19 infection)  X          
Demographics (subject reported height and weight, 
date of birth, gender, race, ethnicity)  X          
Check for Physical Exam abnormalities (subject 
self-reported)  X          
Pregnancy Test (WOCBP)  (serum at Screen and 
urine at D29)  X         X 
Hematology/Chemistrya X X     X  X   
Vital Signsb X X  X  X X X X X 
Symptom Assessmentc X X  X  X X X X X 
SARS -CoV -[ADDRESS_884010] X          
Viral load  sample  (Day 1 pre-dose)e  X  X  X X X X X 
Hospi[INVESTIGATOR_656304]       X  X X X 
WHO Ordinal Scale Assessment   X    X  X X X 
Confirm Eligibility   X         
Randomize subject and dispense Study Medication   X         
Study drug administration (Days 1  5 only)f  X X X X      
Drug Accountability       X     
aDo not repeat if within 48h of Day 1 visit.  Send to Covance Central Laboratory Services (CCLS) for analysis.  
bVital signs include heart rate, respi[INVESTIGATOR_697], body temperature, SpO2.  Subject will be provided with a thermometer and pulse oximeter 
with heart rate monitoring capability. Training will be provided during the first visit. Vital signs parameters will be obser ved and recorded 
by [CONTACT_656453]-person  visit (IPV) (at the study site or home visit by [CONTACT_535758] ). 
cSymptom Assessment will capture  symptoms such as sore throat, cough, GI symptoms (vom iting, diarrhea), an osmia, dysgeusia, other 
(specify), etc.  Severity None,  Mild, Moderate, or Severe wi ll be collected.  Symptom(s) onset date must be within [ADDRESS_884011] using an Omnigene  collection system or similar. The 
site staff or  home health nurse will train the subject and observe sample collection on Day 1. These samples are to be sent to CCLS for 
analysis.  The viral load sample may also be used to perform viral cultures (sample can be split  by [CONTACT_2237] , no additio nal 
sample required).  
fSubject will self -administer study drug once daily Days 1  [ADDRESS_884012] doses in a medication diary. Note that any visits/visit activities 
may be conducted via telephone, telemedicine , or digital media other than serum pregnancy tes t and chemistry/hematology sample 
collection. These labs may be collected at the clinical site or another designated out -patient facility/laboratory or collected via home visit.  
Arrangements for shippi[INVESTIGATOR_656336].  
fIPV= in-person visit  (subjects home or at clinical site , may also include TM or TC if all study visit activities cannot be completed by [CONTACT_656454]-person personnel ); TC = Telephone Call with site  and subject ; TM = Telemedicine with site  and subject.  
 
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 16 of 53 
PROTOCOL VERSION  5.0 DATE:  [ADDRESS_884013]  
Name:  [CONTACT_656462], MSN, Ph.D.  
Title:  Clinical Operations  
Address:  Clear Creek Bio, Inc.  
[ADDRESS_884014], 4th Floor,  
Cambridge, MA [ZIP_CODE]  
Telephone No.:  [PHONE_13585]  
Fax No.:  [PHONE_13586]  
E-mail:  [EMAIL_12502]   
 
MEDICAL MONITOR  
Name:  [CONTACT_656463], MD  
Title:  Senior Medical Director  
Telephone No.:  (609) 212 -7892  
E-mail:  [EMAIL_12503]  
 
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 17 of 53 
PROTOCOL VERSION  5.0 DATE:  19 NOV 2020  
 
Clear Creek Bio, Inc.  
CONFIDENTIAL  3 INTRODUCTION  
3.1 Coronavirus -19 (COVID -19) 
Beginning in December  2019, Chinese scientists isolated a novel coronavirus, severe acute respi[INVESTIGATOR_11520] 2 (SARS -CoV -2) from patients with virus -infected pneumonia which was later 
designated as coronavirus disease 2019 (COVID -19) by [CONTACT_88442] (WHO) ( Zhou 
et al., 2020  [2]; Phelan et al., 2020  [3]).  
Approximately 14% of those affected with this virus will develop severe disease requir ing 
hospi[INVESTIGATOR_656306]; 5% will require admission to the intensive care unit ( Handel et 
al., 2020  [4]). Severe cases may be complicated by [CONTACT_171958][INVESTIGATOR_656307] (ARDS), sepsis 
and septic shock, and multi -organ failure, including acute kidney injury and cardiac injury. Risk 
factor s for death include older age and co -morbid disease such as hypertension and diabetes ( Zhou, et 
al., 2020  [2]). This means that most  patients will be treated as out -patients. Reducing viral load in this 
environment is critically important for both the subjects themselves by [CONTACT_656397][INVESTIGATOR_059], but also to reduce the transmission of the disease to 
others in the patien ts households and their communities.  
3.1.[ADDRESS_884015] RNA building blocks, and without these building blocks they are unable 
to replicate.  The SARS -CoV -2 is a single -stranded (positive sense) RNA virus with a genome that is 
29,811 nucleotides long, quite a lot larger than other RNA -based viruses (e.g. the hepatitis C genome 
comprises only 9600 nucleotides). The nucleotide composition is broken down as: 29.9% adenosines, 
18.4% cytosines, 19.6% guanines, and 32.1% uridines  (Sah et al., 2020  [12]). 
3.[ADDRESS_884016] de novo  pyrimidine synthesis generates uridine monophosphate (UMP) as the building block for 
all pyrimidine rib onucleotides and deoxyribonucleotides  (Error! Reference source not found. ). 
There exists no salvage pathway for the synthesis of UMP, the fundamental building block  of 
pyrimidines . Inhibition of enzymatic steps upstream of UMP  (Figure 3 -1) leads to a rapid  and profound  
depletion of intracellular pyrimidines.   
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 18 of 53 
PROTOCOL VERSION  5.0 DATE:  19 NOV 2020  
 
Clear Creek Bio, Inc.  
CONFIDENTIAL   
Figure 3-1. DHODH is a mitochondrial enzyme that catalyzes the 4th step of py rimidine 
synthesis; it is completely essential for the generation of UMP.   
3.3  Dihydroorotate dehydrogenase (DHODH)  
The enzyme dihydroorotate dehydrogenase ( DHODH ) catalyzes the 4th step of de novo  pyrimidine 
synthesis  and inhibition of DHODH completely halts all pyrimidine production. As shown in  Figure 
3-1, DHODH  is located on the inner mitochondrial membrane and transfers electrons between DHO 
and complex III of the electron -transport chain via the reduction of its ubiqui none (coenzyme Q10) 
cofactor.  
DHODH is a clear therapeutic target for the inhibition of host pyrimidine synthesis. The chemical 
inhibition of DHODH in vitro  or in vivo  leads to the rapid depletion of UMP and subsequent depletion 
of downstream products thy mine and cytosine.  This forces a cell to rely on the salvage of extracellular 
pyrimidine nucleotides and this extracellular salvage is not capable of maintaining the cells normal 
nucleotide pool  (Sykes et al., 2016) [ 1]).    
3.[ADDRESS_884017] -targeting antiviral. 
It is an orally available and potent inhibitor of dihydroorotat e dehydrogenase (DHODH) , the enzyme 

PROTOCOL NUMBER:  CCB -CRISIS -02      Page 19 of 53 
PROTOCOL VERSION  5.0 DATE:  19 NOV 2020  
 
Clear Creek Bio, Inc.  
CONFIDENTIAL  that catalyzes the fourth step in pyrimidine synthesis, namely the conversion of dihydroorotate (DHO) 
to orotate.  DHODH inhibitors, including brequinar, inhibit de novo  pyrimidine synthesis thereby 
[CONTACT_331577] a depletion  of a cells pool of uridine, cytidine and thymidine ribonucleotides and 
deoxyribonucleotides.  
The anti viral activity of brequinar has been demonstrated  in studies  of rotavirus replication in human 
intestinal Caco -2 cell s as well as in human primary intes tinal organoids  (Chen et al., 2019  [6]). 
Treatment with teriflunomide , another DHODHi,  has been effective in vitro  and in vivo  in a murine 
model of foot and mouth disease virus (Mei-Jian et al., 2019  [7]). DHODH inhibition (DHODHi) also 
inhibited the growth of dengue virus in vitro  (Wang et al., 2011  [8]). DHODHi also showed antiviral 
effects against RNA viruses including influenza A, Zika, Ebola and coronavirus SARS -CoV -2 (Xiong 
et al., 2020  [11]). Brequinar has also been shown to inhibit the replication of Ebola virus , vesicular 
stomat itis virus and Zika virus in vitro (Luthra et al., 2018  [9]). Brequinar inhibits the replication of 
human immunodeficiency virus ( HIV) in vitro  (Andersen et al., 2019  [10]). When considering 
brequinar as an antiviral for treatment of SARS -CoV-2, oral brequinar is highly bioavailable (>95%) 
and has good penetration of lung tissue  with an average tissue:blood ratio of 0.5 following a single 
dose of brequinar in the rat . It is therefore expected to achieve a similar period of DHODH inhibition 
in lung tissue  (Brequinar IB  [5]). 
3.5  Rationale for the Planned Trial  
DHODH inhibition has been extensively studied as a potential therapeutic target in the treatment of 
RNA -based viruses. The inhibition of DHODH is effective in inhibiting viral replication in pre -clinical 
models involving many RNA -based viruses with nanomolar potency and a high selectivity index (see 
the Brequinar IB [5], Section 5 ). In these pre -clinical models, the benefit of DHODH inhibition can 
be reversed by [CONTACT_656398], confirming that the on -target effect of 
host pyrimidine depletion is key to the anti -viral activity.  
The CCB -CRISIS -[ADDRESS_884018] of care (SOC) with 5 days of brequinar (DHODH 
inhibition) compared to SOC with [ADDRESS_884019] pyrimidine nucleotides, thereby [CONTACT_656399]. A recent 
publication demonstrated that inhibitors of DHODH could potentiate the activity of inhibitors of RNA -
dependent RNA polymerase (RdRp) in the treatment of dengue virus, another single -stranded RNA 
virus  similar to SARS -CoV -2 (Liu et al., 2020 [13]). This inhibition of viral replication may restore 
the balance in favor of the host immune system for the clearance of SARS -CoV -2. 
Marketed DHODHi medications are available, includ ing lefluno mide or teriflunomide, however these 
are very weak inhibitors of DHODH with cellular potency ~[ADDRESS_884020] the ability to acutely lower the pool of 
intracellular pyrimidines to the degree that is required  for decreasing the viral load associated with 
SARS -CoV -2 infection , making brequinar the better choice for acute SARS -CoV -2 infection .  
The CRISIS2 study is a proof -of-concept study  in patients with SARS -Cov-2 infection and w ill serve 
as a basis for future studies to determine the safety and effectiveness of brequinar in COVID -19. 
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 20 of 53 
PROTOCOL VERSION  5.0 DATE:  [ADDRESS_884021] that 5 day s of daily doses of 100 mg  p.o. will be safe and well tolerated. A dose of 
brequinar 100 mg achieves plasma concentrations of approximately 1 uM (0.4 ug/ml)  that should result 
in sufficient suppression of nucleotide synthesis . When given over 5  days, these plasma concentrations 
are achieved on a daily basis without accumulation, also assuring the safety of this regimen  (see 
Brequinar IB  [5]).  
3.5.2    Risk/Benefit of Brequinar  
As presented in the Brequinar IB  [5], an extensive safety and pharmacokinetic database exists with 
more than 1,000 patients treated with brequinar. Cancer patients (N = 806) have been exposed to this 
compound for treatment of a variety of solid tumors  at various  treatment regimens, doses, and routes  
including a single dose, once weekly, twice weekly, single dose every [ADDRESS_884022]  
also been utilized for patients with  psoriasis and organ transplant. The maximum intravenous dose 
given was 2,250 mg/m2 every 3 weeks, and the maximum oral dose was 100 mg/m2 daily for 21 days. 
There has been limited testing of DHODHi to date in the clinic for infection with SARS -CoV -2. 
DHODHi therapy at relatively high doses in the context of trials for patients with cancer has the 
expected safety side-effects of mucositis and bone marrow suppre ssion.  Importantly, h owever, the 
prior clinical experience in 39 subjects who received daily brequinar for 5 consecutive days at or lower 
than 100 mg/day show no cases of mucositis and only 1 (2.6%) epi[INVESTIGATOR_656308]. 
Based on these data the  [ADDRESS_884023] been the primary dose -limiting toxicities. In addition, skin rash, nausea/vomiting, fatigue, and 
leukopenia have been dose -limiting in trials utilizing other schedules of brequinar administration. 
However , these effects were self -limiting, transient, required treatment in few cases,  and resolved 
following discontinuation of dosing . These adverse effects have been associated  with higher doses of 
brequinar given via the intravenous route and for longer durations than the 100 mg dose and 5 -day 
regimen proposed for this study .  
In addition to studying a higher risk population  with symptomatic COVID -19, a comprehensive safety 
monitor ing plan will be utilized in this study to assess the ongoing safety and well -being of participants 
(see Section 10.8).  
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 21 of 53 
PROTOCOL VERSION  5.0 DATE:  [ADDRESS_884024] been no apparent hepat otoxic effects in 
the clinical studies. Brequinar itself does not appear to be a substrate for metabolism by [CONTACT_9058] 
P450 enzymes when tested under a variety of conditions. ( See Brequinar IB [5]; nonclinical d ata on 
file with Clear Creek).   
3.8 Steps to be Taken to Control or Mitigate Risks  
All subjects will be treated  by [CONTACT_656350] d clinicians  familiar with the treatment of viral 
infections and their complication s.  
 
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 22 of 53 
PROTOCOL VERSION  5.0 DATE:  19 NOV 2020  
 
Clear Creek Bio, Inc.  
CONFIDENTIAL  4 TRIAL OBJECTIVES  
4.1 Primary Objective  
To demonstrate a change from baseline in quantitative SARS -CoV -2 viral load for brequinar -treated 
subjects compared to placebo -treated subjects through Day  29. 
4.2 Secondary Objectives  
The secondary objectives of this study are:  
Through Day 29:  
 To characterize  the safety and tolerability of brequinar in  out-patient  COVID -19 subjects  as 
measured by [CONTACT_656340] 3 and 4 AEs and SAEs ; 
 To demonstrate a shorter duration of viral shedding in subjects treated with  brequinar compared 
to subjects who received placebo ;  
 To reduce the percentage of subjects  requiring hospi[INVESTIGATOR_656309]  >24 hours  for 
brequinar subjects compared to  subjects who received placebo ; 
 To reduce all -cause mortality  through Day 29  for brequinar subjects compared to  subjects who 
received placebo . 
4.3 EXPLORATORY OBJECTIVES  
Through Day 29:  
 To determine time to viral clearance (two consecutive negative tests) ;  
 To determine time to resolution of new onset COVID -19-related clinical symptoms and pre -
existing  non-COVID -19 symptoms returned to baseline ; 
 To determine time to clinical improvement  as measured by a favorable shift in the WHO Ordinal 
Scale score for the subset of subjects with baseline WHO Ordinal S cale of 2  or 3 for brequinar 
subjects compared to  subjects who received placebo . 
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 23 of 53 
PROTOCOL VERSION  5.0 DATE:  [ADDRESS_884025] of care per (SOC) institutional 
guidelines for treatment of patients with COVID -[ADDRESS_884026] be [ADDRESS_884027] a Screening 
Visit followed as soon as possible with Study Day 1. Study procedures are presented in detai l in the 
Schedule of Events (Appendix 15.1). Study visits (virtual or in person) will take place at Screening 
and on Study Days [ADDRESS_884028]s home or other appropriate 
location. Other visits/visit activities for that visit may be conducted remotely using telephone, 
telemedicine  or other remote technique . Subjects are to self -collect a viral load sample . Subjects will 
obtain their own respi[INVESTIGATOR_697], heart rate, body temperature and SpO2 during telemedicine visits or 
study  staff will collect these parameters during an in -person visit at the clinic  or subjects home . The  
symptom assessment can be conducted with the study staff  via telemedicine or in the clinic on Days 
1, 4, 8, 12, 15, 22, and 29.  The site will also have a telephone  call with  the subject on Study Days 2, 
3, 5, 6, and 7 for changes in concomitant medications and assessment of adverse events, especially 
those that may indicate thrombocytopenia (see Section 10.8) and mucositis . An in-person visit will be 
conducted (at the clinic or  home visit ) at Screening and on study Days 1, 8, 15, and 29 ; in-person visits 
may be combined with telemedicine or telephone visits  if all requir ed study visit activities cannot be 
completed by [CONTACT_106269] -person personnel . Telemedicine only visits will be conducted by [CONTACT_656455] 4, 12, and 22.  
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 24 of 53 
PROTOCOL VERSION  5.0 DATE:  19 NOV 2020  
 
Clear Creek Bio, Inc.  
CONFIDENTIAL  6 TRIAL ENDPOINTS  
6.1 Primary Endpoint  
Quantitative SARS -CoV -2 viral load  through Day  29. 
6.2 Secondary Endpoints  
The secondary endpoints  of this study are:  
Through Day 29:  
 Rates of AEs and SAEs including laboratory assessments ; 
 Duration of viral shedding ;  
 Percentage of subjects requiring admission as an inpatient for  >24 hours . 
 All-cause mortalit y. 
6.3 Exploratory Endpoints  
Through Day 29:  
 Time to viral clearance (two consecutive negative tests) ;  
 Time to resolution of new onset COVID -19-related clinical symptoms and pre -existing non-
COVID -19 symptoms returned to baseline ; 
 Time to clinical improvement  measured by a favorable shift in WHO Ordinal Scale score for the 
subset of subjects with baseline WHO Ordinal Scale of 2 . 
 
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 25 of 53 
PROTOCOL VERSION  5.0 DATE:  [ADDRESS_884029] of care plus placebo in a 1:1 ratio ( approximately 
[ADDRESS_884030] of care  plus placebo ).  
7.2 Inclusion criteria  
1. Willing and able to provide informed consent for the trial, written, electronic, verbal or other 
method deemed acceptable by [CONTACT_656353].  
2. 18 years of age or older.  
3. Laboratory -confirmed SARS -CoV -2 infection as det ermined by [CONTACT_656432] (RT -PCR) or other FDA -approved commercial or public health assay.  
4. Out-patient ( never hospi[INVESTIGATOR_656326] -patient for COVID -19 or was evaluated/treated for 
COVID -19 only in the Emergency Room with a stay of <  24 hours) . 
5. The effects of brequinar on the developi[INVESTIGATOR_19241] . For this reason, women 
of child -bearing potential and men must agree to use adequate contraception (hormonal or 
barrier method of birth control; abstinence) prior to study entr y and for the duration of study 
participation. Should a woman become pregnant or suspect she is pregnant while she or her 
partner is participating in this study, she should inform her treating physician immediately. 
Men and women treated or enrolled on thi s protocol must also agree to use adequate 
contraception for the duration of study participation, and for [ADDRESS_884031] be [ADDRESS_884032] dose . 
8. Able to swallow capsules.  
7.3 Exclusion Criteria  
1. Any physical examination findings and/or history of any illness that, in the opi[INVESTIGATOR_656327], might confound the results of the study or pose an additional risk to the patient  
2. Nursing women or women of childbearing potential (WOCBP) with a positive pregnancy test  
3. Treatment with another DHODH inhibitor (e.g., leflunomide, teriflunomide) or other agents 
known to cause bone marrow suppression leading to thrombocytopenia  
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 26 of 53 
PROTOCOL VERSION  5.0 DATE:  19 NOV 2020  
 
Clear Creek Bio, Inc.  
CONFIDENTIAL  4. Platelets 150,000 cell/mm3 
5. Hemoglobi n < 10 gm/dL  
6. Absolute neutrophil count < 1500 cells/mm3 
7. Renal dysfunction, i.e., creatinine clearance < 30 mL/min  
8. AST or ALT > [ADDRESS_884033], or total bilirubin > ULN . Gilberts Syndrome is allowed.  
9. Bleeding disorders or blood loss requiring transfusion in the six weeks preceding enrollment  
10. Ongoing  gastrointestinal ulcer, or gastrointestinal bleeding  within [ADDRESS_884034] dose. 
11. Chronic  hepatitis B  infection , active hepatitis  C infection, active liver disease and/or cirrh osis 
per subject report.  
12. Heart failure, current uncontrolled cardiovascular disease, including unstable angina, 
uncontrolled arrhythmias, major adverse cardiac event within 6 months (e.g. stroke, 
myocardial infarction, hospi[INVESTIGATOR_144651],  or revascularization procedure).  
 
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 27 of 53 
PROTOCOL VERSION  5.0 DATE:  [ADDRESS_884035] of care (SOC) for COV ID-19 infection. 
Subjects will be randomly assigned in a 1: [ADDRESS_884036] of care 
plus placebo . 
8.2.1 Safety/Tolerability  
Safety/tolerability is assessed for each subject at each study visit . The NIH Division of AIDS (DAIDS) 
Table for Grading the Severity of Adult and Pediatric Adverse Events, Corrected Version 2.1 (July 2017)  
will be utilized for AE reporting. All appropriate treatment areas should have access to a copy of the 
criteria .  
Adverse event s (AEs) commonly observed in patients treated with brequinar are provided in the 
Investigators Brochure  (IB) and include thrombocytopenia, nausea, anemia, diarrhea, vomiting, 
leukopenia, stomatitis, rash, granulocytopenia, fatigue,  and infection . In a stu dy of 209 cancer subjects 
treated once -weekly  (DuP 785 -012, see Brequinar IB  [5]), the deaths of three patients were attributed 
to study drug toxicity (two to hemorrhage , one following acute renal failure). Severe toxicities grades 
(Grades 3 to 4) which typi[INVESTIGATOR_656328] 
(anemia , thrombocytopenia, leukopenia , granulocytopenia ), digestive  system toxicity (nausea, 
vomiting, stomatitis , others  including gastric hemorrhage) and mucositis.  
In three oncology studies with five consecutive days of intravenous (IV) brequinar dosing in 168 
subjects (Study 785 -001 [14], 785-003 [15], and 785-005 [16]) there were no toxic deaths . For 
subjects from these three studies who were treated with a daily dose of 100 mg or below  (as will be 
dosed in CCB -CRISIS -02), AEs through 21 days showed that 2 of 39 subj ects (5.1%) had a severe 
(Grades 3 or 4) AE related to study drug ([ADDRESS_884037] each with hyperbilirubinemia and 
hyperglycemia), and no subjects discontinued from the study due to a study drug -related AE. The 
few study drug related AEs through [ADDRESS_884038] each with 
thrombocytopenia and diarrhea. When only studies with oral dosing were considered at this dose 
level (Studies 7 85-022 [17], 785 -031 [18] , and  785-034 [19]), the study drug related AEs through 
21 days (each observed in one subject only) included diarrhea, headache, nausea, pruritus, 
abdominal pain, ano rexia, chest pain, dry mouth, fatigue, keratosis, stomatitis, and vomiting. See 
brequinar IB [5]. 
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 28 of 53 
PROTOCOL VERSION  5.0 DATE:  [ADDRESS_884039] Study Day 29 (or longer if needed to follow up study 
drug-related adverse events).  Participants may discontinue  from the study by [CONTACT_656402] 9.7. 
8.4 Stoppi[INVESTIGATOR_2121]  
8.4.1 Individual Stoppi[INVESTIGATOR_2121]  
 Participants who develop a Grade 3 toxicity that is assessed by [CONTACT_656433].  
 Participants who develop a Grade 4 toxicity, regardless of relatedness to study drug, are to  be 
permanently discontinued from study treatment.  
 Subjects who develop Grade 3 or 4 toxicities are to be followed by [INVESTIGATOR_1312] -evaluation every 2 days, 
as feasible, until the toxicity returns to  Grade 2 severity.  
8.4.2 Study -Level Stoppi[INVESTIGATOR_656312] : 
 If  3 subjects develop the same  related Grade 4 (life -threatening) adverse event or laboratory 
abnormality ; 
 If  5 subjects develop the same  related Grade 3 or 4 adverse event or laboratory abnormality ; 
 If  10 subjects develop any related Grade 3 or 4 adverse event or laboratory abnormality .  
Following assessment by [CONTACT_1578] (DMC, see Section 10.9), the DMC will 
determine whether to stop the s tudy, amend the protocol, or continue the study per protocol.  
8.5 Concomitant Medication/Treatment  
Record t he name, dose, start/stop  date, indication for use , route, and whether ongoing or stopped for 
medications/treatments taken within two weeks prior to stud y entry  as well as any medications taken 
during the study  are to be recorded . Prohibited medications are identified in Section 8.8.  
8.[ADDRESS_884040]s medication diary and study records as 
appropriate.  
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 29 of 53 
PROTOCOL VERSION  5.0 DATE:  [ADDRESS_884041] of care plus  placebo . The brequinar and placebo capsules will be 
provided to each participating institution  in pre -numbered bottles intended for individual subjects to 
be dispensed by [CONTACT_8236]s pharmacist  or designated person . Randomization assignments will be 
provided by [CONTACT_656404] . The pharmacist/designate d 
person will dispense the next number in sequence to the next patient who qualifies for the study at an 
individual site.  
8.7.4 Unblinding/ Expectedness  
Contact [CONTACT_656405] (AE) . Each site will be provided with a sealed envelope containing individual 
sealed envelopes for subject numbers assigned to that site. Each individual subject number sealed 
envelope will have the treatment (brequinar or placebo) randomly assi gned to that subject number. Do 
not open the outer envelope or the individual sealed envelope unless it has been agreed with the 
Medical Monitor and the Sponsor that unblinding is necessary for that particular AE. Unblinding must 
be documented in the study  records. Envelope seals are to be checked to ensure they remain intact 
during drug accountability monitoring.  
If after a discussion with the Medical Monitor, the investigator or treating clinician believes the AE 
leading to unblinding to be related to the  study drug, no further doses of drug should be administered  
to that subject .  
Expectedness will be determined by [CONTACT_656406] -[ADDRESS_884042] . Adequate drug is to be dispensed for the number of subjects expected 
to be treated at each institution.   
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 30 of 53 
PROTOCOL VERSION  5.0 DATE:  [ADDRESS_884043]/ staff member  responsible for drug accountability is to document t he date and time  of 
dispensing  and for what subject the study drug was intended (i.e., record subject initials and birth date 
or other unique identifier). A pharmacy manual will be provided by [CONTACT_1034].   
At the end of the study any unused study drug  will be returned to the Sponsor for destruction or may 
be destroyed locally; disposition of study drug  will be documented .   
The Sponsor will be permitted access to the trial supplies at any time within usual business hours and 
with appropriate notice during or after completion of the study to perform drug accountability 
reconciliation.  Records may be electronic or paper and may be accessed remotel y for monitoring/drug 
accountability purposes.  
Each subject will be provided with one bottle with five brequinar or five placebo capsules for the five 
days of dosing.  
8.8 Prohibited Medications  
Treatment is prohibited with another DHODH inhibitor (e.g., leflun omide and teriflunomide ). 
Treatment is prohibited with agents known to cause bone marrow suppression leading to 
thrombocytopenia.  
8.[ADDRESS_884044] of care is 
expected to change as additional information, such as that from randomized controlled trials, emerges, 
and the Sponsor and the treating clinicians will need to address anticipated off -label use of any other 
drugs, devices, or interventions that might be used to manage COVID -19 (e.g. anticoagulants).  
The Spon sor and treating clinicians are to consider changes in SOC over time, for example, 
overlappi[INVESTIGATOR_656313] a SOC treatment expected to be widely used is to be 
considered. The availability of new standard of care treatment may change over ti me and vary from 
one clinical trial site to another. The Sponsor will discuss these issues with FDA should the need arise.  
 
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 31 of 53 
PROTOCOL VERSION  5.0 DATE:  [ADDRESS_884045] OF THE TRIAL  
9.1 Ethical and Regulatory Considerations  
The trial will be performed in accordance with the Declaration of Helsinki (1964)  as revised in Tokyo 
(1975), Venice (1983), Hong Kong (1989), South Africa (1996), Scotland (2000, Note of Clarification 
2002 & 2004) and Seoul 2008 (Appendix A), and Fortaleza (Brazil) (2013), and with the International 
Counc il on Harmonization ( ICH) Tripartite Guideline on Good Clinical Practice (CPMP/ICH/135/95, 
Jan.97) and [LOCATION_002] ( US) FDA Regulations.  
9.[ADDRESS_884046] be obtained in accordance with US Code of Federal Regulations (21 CFR Part 50) ,  the 
FDA Guidance on Conduct of Clinical Trials of Medical Products  during the COVID -19 Public Health 
Emergency (March 2020, Updated April 16, 2020)  [20], as well as local and national regulations. 
Information should be given in both oral and written form whenever possible and deemed app ropriate 
by [CONTACT_4707] ( IRB). Subjects  and their relatives, if necessary, must be given 
ample opportunity to inquire about details of the study.  
The Investigator  or qualified designated person  will verbally inform subjects as to the nature, expected 
duration and purpose of the trial, the administration of the Investigational Product ( IP), and the hazards 
involved, as well as the potential benefits t hat may come from treatment with this IP. The trial 
procedures will be explained in lay language and any questions will be answered.  The subjects will be 
given an IRB-approved consent form. The subjects will be given appropriate time to consider their 
participation in the trial and have any questions answered prior to signing the consent form. If a subject 
agrees to participate, he/she will sign and date an informed consent form and be provided with a copy 
of the signed consent. All subjects who sign a n inf ormed consent form are to be recorded on the 
applicable screening log . If the subject is unable to consent for any reason, a designated family member 
or healthcare power of attorney or other person may consent per institutional policy.   
The subject will be informed that his/her  medical records will be subject to review by [CONTACT_1034], 
Sponsors representatives , and possibly by a representative of the FDA  and other relevant regulatory 
authorities. Subjects will be informed that they are free to refuse  participation in this clinical 
investigation, and if they should participate, it will be made clear to them that they may withdraw from 
the trial at any time without prejudicing further  medical  care they may require . The subject will receive 
a copy of the  consent form as well as an information sheet about the trial.  
Informed consent must be obtained from every subject  prior to any study -specific procedures . 
Standard procedures carried out prior to completing  the informed consent process but within the tim e 
constraints of the protocol may be used for baseline evaluation; they need not be repeated. 
Documentation of c onsent will be subject to review by [CONTACT_1034]; if in writing, a copy will be given 
to the subject  and a copy will be filed with the subjects medical notes.  Verbal consents will be 
documented by [CONTACT_656360].  
Note that informed consent procedures have been affected by [CONTACT_4113] -19, and the study staff may use 
any consent method that has been approved by [CONTACT_1201]  (e.g., phone consent, verbal consent with 
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 32 of 53 
PROTOCOL VERSION  5.0 DATE:  19 NOV 2020  
 
Clear Creek Bio, Inc.  
CONFIDENTIAL  witness, e -consent, etc.)  of the local institution . In-person consent, w ritten consent signatures and 
providing hard copi[INVESTIGATOR_656329].  
The study should be discussed with the potential participant only after an initial review of his/her 
clinical status and appropriateness for participation have been evaluated to determine if he/she  meets 
the subject selection criteria.  
A sample subject  information sheet and consent form are available from Clear Creek .  The final 
version at each institution may differ  depending on institutional requirement s and standard format s. 
This protocol will not be amended for site specific changes  as such changes are to be made to the sites 
consent when required . 
9.[ADDRESS_884047]  
It is the responsibility of the Investigator to submit the protocol, consent form a nd information sheet 
to the IRB . An IB will be available for review by [CONTACT_1201]. The protocol and informed consent form  
(ICF) must be approved by [CONTACT_656407] . The template consent 
form may be revised in accordance with site -specific requirements with Sponsor review and approval.  
A copy of the IRB written ap proval must be provided  to the Sponsor and investigator before the trial 
may start  at that institution . Written approval from the IRB is also required for substantial protocol 
amendments prior to their implementation.    
A substantial amendment may arise f rom changes to the protocol or from new information relating to 
the scientific documents in support of the trial.  Amendments are substantial  when they are likely to 
have an impact on:  
 the safety or physical or mental integrity of the subjects ; 
 the scien tific value of the trial;  
 the conduct or management of the trial; or  
 the quality or safety of any IP used in the trial.  
If it is necessary to change or deviate from the protocol to eliminate an immediate hazard to the 
subjects, the Investigator will notify  the Sponsor and the IRB of the new events and the measures taken 
as soon as possible.   
The Investigator will report promptly to the Sponsor and IRB any new information that may adversely 
affect the safety of the subjects or the conduct of the trial. On c ompletion of the trial, the Investigator 
will inform the applicable IRB as per local IRB requirements that the trial has ended. If the study is 
terminated for any reason , the investigator will return all clinical supplies and study -related equipment 
supplied by [CONTACT_656362].  
9.[ADDRESS_884048] the saliva sample for viral load testing  and 
perform other study activities such as body temperature, heart rate, respi[INVESTIGATOR_697], SpO2,  and 
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 33 of 53 
PROTOCOL VERSION  5.0 DATE:  [ADDRESS_884049] of study assessments and timings.   
Blood chemistry tests include blood urea nitrogen (BUN), creatinine, alkaline phosphatase (AL K), 
alanine amino transferase (ALT), aspartate amino transferase (AST), total bilirubin, total protein, 
albumin, glucose, serum electrolytes (sodium, potassium, chloride, carbon dioxide/bicarbonate, 
calcium , lactate dehydrogenase (LDH) , and C -reactive prote in (CRP) . Chemistry samples may be 
banked for future analyses.  
Hematology tests include hemoglobin, hematocrit, complete blood count with full differential , and 
platelet count.  
Viral load sampling  is to be carried out on Days [ADDRESS_884050] symptom(s) consistent with SARS -CoV -[ADDRESS_884051] be  [ADDRESS_884052] dose.  
Safety laboratory results (chemistry and hematology) are to be reviewed by [CONTACT_656435] 48 hours of receipt of results.  
Hospi[INVESTIGATOR_656330] -patient with admission > 24 hours.    
As much of the  study as possible will be conducted via telemedicine remote from the site (e.g., consent , 
medical history, concomitant medications may be collected remotely) . Subjects will be visited at home 
(or place of residence) by a home health nurse or come to the s ite for an in -person visit at Screening  
and on study Day [ADDRESS_884053]  
The study visits are to be conducted as shown in the Schedule of Events, Appendix 15.1. 
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 34 of 53 
PROTOCOL VERSION  5.0 DATE:  19 NOV 2020  
 
Clear Creek Bio, Inc.  
CONFIDENTIAL  Study completion or the reason for study discontinuation will be recorded in the source document and 
the eCRF.  
9.5.1 Unscheduled Visits  
Unscheduled visits and tests  are permitted as needed  to asse ss AEs /SAEs  throughout the study. 
Unscheduled visits and tests  are also permitted as needed to assess  AEs/  SAE s with onset within two 
(2) weeks after the final study  visit providing the AE is considered related to study drug  
9.[ADDRESS_884054]s study participation  after discussion 
with the other party if  it is believe d it would be unsafe for the subject to continue in the study .   
Subjects must discontinue study medication  if any of the following events occur:  
 Significant protocol violation or non -compliance, either on the part of the subject or the 
investigator or other site personnel;  
 Decision of the Investigator or Sponsor that removal is in the subject's best interest;  
 Severe unrelated medical illness or complication;  
 Safety reasons/ significant adverse event;  
 Subject request (withdrawal of consent);  
 Sponsor decision.  
Collect/co nduct  all scheduled evaluations  even for subjects who discontinue study medication  prior to 
completing the treatment  period  unless consent is withdrawn . 
9.8 Early Termination of the Study  
If the Sponsor or an Investigator believes it would be unsafe to continue the study, or for any reason 
at the Sponsors request, the study may be terminated  at that site or the entire study terminated after 
discussion with the other part ies. 
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 35 of 53 
PROTOCOL VERSION  5.0 DATE:  19 NOV 2020  
 
Clear Creek Bio, Inc.  
CONFIDENTIAL  The Sponsor will provide a written statement to the IRB and the relevant regulatory authority with the 
reasons for termination of the study. This will be conducted within  15 days of the decision to terminate 
the study.  
If the study is terminated, a close out monitoring visit will be performed and applicable procedures 
will be carried out to close the trial site(s).  
9.[ADDRESS_884055] had a hysterectomy or tubal ligation. A woman is also presumed to be infertile due to natural 
causes if she has been amenorrheic for greater than 12 months and has an FSH greater than 40 IU/L.  
In the absence of such documentation, a negative serum pregnancy test is required for inclusion into 
the study.  
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 36 of 53 
PROTOCOL VERSION  5.0 DATE:  [ADDRESS_884056] a c ausal relationship with this treatment. An 
AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), 
symptom, or disease temporally associated with the use of the medicinal product, whether or not 
considered related to the medicinal product.  
Events that occur prior to  first dose  will be entered as medical history; events  that occur after first dose  
will be ente red as adverse events (AEs)  on the AE form.  
Subjects will be questioned an d observed for evidence of AEs, whether or not judged by [CONTACT_656363] . All AEs will be documented in the 
subject's medical record and CRF. For any pre -existing condition or abnormal laboratory finding th at 
changes in severity after dosing, this change should be recorded as an AE. New abnormal laboratory 
findings that are clinically significant are considered AEs. Investigators and site staff are to elicit from 
the subject and note any signs or symptoms of  mucositis and thrombocytopenia (see Section 10.8). 
Adverse events  will be collected  from the time of first dose  through  Day 29. After Day 29, 
collect/record only Ser ious Adverse Events (SAEs) which are  assessed  by [CONTACT_656449] 14 days of study completion 
(Day 29 or earlier if discontinue prior to Day 29) .  AE details are to be documented including start and 
stop date and times, whether continuous or intermittent, severity, any intervention utilized to correct 
the event  (e.g., medication, surgery , or other therapy) , outcome and the relationship to the study drug.   
AEs identified in the protocol as critical to the evaluation of safety must be reported to the Sponsor by 
[CONTACT_656365].  
AEs determined by [CONTACT_656456] [ADDRESS_884057] results occurring after study enrollment constitute AEs only if they 
induce clinical signs or symptoms, are considered clinically significant, are Grades 3 or 4, or require 
therapy.  
If a death occurs during the SAE reporting period, the cause of death such as pneumonia, ARDS, or 
respi[INVESTIGATOR_1399], is considered as the AE an d the death is considered its outcome. Death should be 
considered an outcome, not an event. The event or condition leading to death should be recorded and 
reported as a single medical concept on the AE eCRF. Generally, only one such event should be 
reporte d. Fatal will be recorded as the outcome of this respective event; death due to an outcome of 
an AE will not be recorded as separate event. If the primary cause of death is disease progression, the 
cause of death should be clearly identified as COVID -19. 
In cases of surgical or diagnostic procedures, the condition leading to the procedure is considered as 
the AE instead of the procedure itself. Each AE will be coded by [CONTACT_656409] a preferred term using a thesaurus based on the M edical Dictionary for Regulatory Activities 
(MedDRA) . For example, record appendicitis, not appendectomy.  
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 37 of 53 
PROTOCOL VERSION  5.0 DATE:  [ADDRESS_884058] dose  are to be recorded in the eCRF using the AE form.  
3. Serious adverse events will be reported to the local IRB according to institutional policy.  
The NIH Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse 
Events, Corrected Version 2.1 (July 2017) 
(https://rsc.niaid.nih.gov/s ites/default/files/daidsgradingcorrectedv21.pdf ) will be used for adverse 
event reporting.    
10.1 Follow Up of Grade 3 or 4 Toxicities  
Grade 3 or 4 toxicities are to be followed by [INVESTIGATOR_1312] -evaluation every 2 days, as feasible, until the toxicity 
returns to Grade  2 severity.  
10.2 Infection Follow Up  
Any new infection that occurs on study regardless of infecting agent (i.e., viral or non -viral) sho uld be 
captured. Additionally, the site of infection and source of culture (BAL, tracheal aspi[INVESTIGATOR_337], sputum, 
blood, urine, etc.) should also be recorded.  
10.3 Classification of Causality  
Attribution is the relationship between an adverse event or serious adverse  event  
and the study treatment. Attribution will be assigned as follows:  
 Definite  The AE is clearly related to the study treatment.  
 Probable  The AE is likely related to the study treatment  
 Possible  The AE may be related to the study treatment.  
 Unlike ly - The AE is doubtfully related to the study treatment.  
 Unrelated - The AE is clearly NOT related to the study treatment  
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 38 of 53 
PROTOCOL VERSION  5.0 DATE:  19 NOV 2020  
 
Clear Creek Bio, Inc.  
CONFIDENTIAL  Guidance for assessing causality:  
The Investigator will need to determine whether an AE is considered related to ( caused by) the 
study drug rather than some underlying condition , for example, COVID -19.   
For the purposes of this study, drug related shall mean Definite, Probable and Possible 
relationship to drug as determined by  [CONTACT_737] . 
10.4 Classification of Severity  
The NIH Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse 
Events, Corrected Version 2.1 (July 2017)  will be utilized for AE reporting. All appropriate treatment 
areas should  have access to a copy of the criteria.  
AEs that are expected are subject to expedited reporting only if the adverse event varies in nature, 
intensity or frequency from the expected toxicity information that is provided in the Investigator 
Brochure . 
10.5 Seriou s Adverse Event (SAE) Reporting  
The regulatory definition of a n SAE  is any untoward medical occurrence or effect that at any dose  
fulfills one or more of these criteria : 
 results in death ; 
 is life threatening (at the time of the event) ; 
 requires in-patient hospi[INVESTIGATOR_1081] ; 
 results in persistent or significant disability / incapacity  
 is a congenital anomaly / birth defect ; 
 or is an  event considered medically serious by [CONTACT_737].  
 
Disability  is defined as a substantial disruption of a persons ability to conduct normal life functions.  
A life -threatening adverse event  is one that places the patient /subject , in the view of the Investigator, 
at immediate risk of death from the event as it occurr ed.  It does not include an event that, had it 
occurred in a more severe form, might have caused death.   
An unexpected adverse event  is any adverse drug event, the nature or severity of which is not 
consistent with the applicable product information (e.g.  IB for an unauthorized  investigational product 
or summary of product characteristics for an authorized  product).  
Enter only one event as the reason for the SAE on the SAE form.  Other non -serious events which did 
not directly result in the SAE should be d etailed in the description section on the SAE form and listed 
separately as AEs if necessary.  For fatal SAEs, report the cause of death as an SAE with a fatal 
outcome rather than reporting death as the SAE term.  
Note that hospi[INVESTIGATOR_656316]:  
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 39 of 53 
PROTOCOL VERSION  5.0 DATE:  19 NOV 2020  
 
Clear Creek Bio, Inc.  
CONFIDENTIAL   Routine treatment or monitoring of COVID -19 infection , not associated with any 
deterioration in condition ;  
 Elective or pre -planned treatment for a pre -existing condition that is unrelated to the 
indication under s tudy and has not worsened since signing the informed consent ;  
 Social reasons and respi[INVESTIGATOR_108999]s general 
condition ; 
 Treatment on an emergency outpatient basis that does not result in hospi[INVESTIGATOR_656317].  
ANY SERIOUS ADVERSE EVENT MUST BE REPORTED IMMEDIATELY (WITHIN 24 
HOURS) BY [CONTACT_656437] .  
ENTER THE SUBJECTS AVAILABLE INFORMATIO N INTO THE  eCRF WITHIN [ADDRESS_884059]s subsequent medical course following a n SAE  must be submitted to 
Covance Patient Safety  until the event has subsided or, in case of permanent impairment, it stabilize s, 
and the overall clinical outcome has been ascertained.  
SAE R EPORTING EMAIL:   SAEIntake@covance .com  
Medical Monitor:  
Norberto Soto, MD  Telephone:  ([PHONE_13587]  
Covance Physician /Medical Monitor  Email:  [EMAIL_12503]  
Sponsor Representative:  
Barbara Powers, MSN, Ph.D.  Telephone:  M: ([PHONE_13588]  
VP, Clinical Operations  Email:  [EMAIL_12502]   
All SAEs will be reported to the IRB  periodically, at the end of the study , or per local institutional 
guidelines.   
10.6 Suspected Unexpected S erious  Adverse Reactions (S[LOCATION_003]Rs)  
Suspected, unexpected, serious adverse reactions ( S[LOCATION_003]Rs ) are SAEs that are both related to the study 
drug (Relationship = Related) and unexpected (not previously described in the investigators 
brochure).  All S[LOCATION_003]Rs will be reported in an expedited manner to the Sponsor or designee  and IRB 
by [CONTACT_656369]. Expectedness will be 
judged by [CONTACT_656370] . It is critical  that all SAEs are reported within 
the 24 -hour guideline so that the expectedness determination can be made . S[LOCATION_003]Rs require immediate 
attention and expedited reporting to relevant regulatory authorities.  
The Sponsor will ensure that all relevant information about fatal  or life -threatening  S[LOCATION_003]R s are 
appropriately recorded and reported  to the concerned Regulator y Authority and to the concerned 
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 40 of 53 
PROTOCOL VERSION  5.0 DATE:  19 NOV 2020  
 
Clear Creek Bio, Inc.  
CONFIDENTIAL  IRB(s)  within seven (7) calendar days of the date of first report to Covance Patient Safety / Sponsor . 
Follow -up information will be communicated to the relevant Regulatory Authorit y within an 
additional eight calendar days . 
All other S[LOCATION_003]Rs will be reported to the Regulatory Authority and to the IRB(s) concerned as soon 
as possible within a maximum of fifteen calendar days of first notification to Covance Patient Safety 
/ Sponsor.  
The Sponsor or designee will also inform al l Investigators studying  the investigational medicinal 
product about S[LOCATION_003]Rs  and ensure that all IRBs have been notified . 
For reported deaths of a subject, the Investigator shall supply the Sponsor and the IRB(s) with 
requested additional information on an expedited basis .   
10.[ADDRESS_884060]s partner during the study period will be 
documented in the subjects source documents and reported to Covance Patient Safety (by [CONTACT_656457] [EMAIL_12505])  and to the IRB by [CONTACT_144300] [ADDRESS_884061]s 
partner will begin at the first dose of study drug and will con tinue through [ADDRESS_884062]s partner has consented to this. Monitoring of the baby [CONTACT_656412] [ADDRESS_884063]s partner has consented to this.  
Pregnancy itself is not an AE; it should be reported for tracking purposes. The Investigator or designee 
will discontinue the pregnant subject from the treatment aspects of the study, continue to follow her 
per protocol for safety outcomes only, and advise her to seek prenatal care and counseling from her 
primary care provider. Data on fetal outcome and breast -feeding will be collected for regulatory 
reporting and drug safety eva luation , if the subject has consented to this . 
If the pregnancy is due to a subjects failure to comply with the contraceptive requirements of this 
protocol, this should be documented as a protocol deviation.  
Complications of pregnancy or congenital abnor malities in the newborn child will be reported 
appropriately as (S)AEs.  
The site clinical staff will request the pregnant subject to notify the site of the outcome of the 
pregnancy (i.e., birth, loss, or termination). To help ensure this, the site clinica l staff will follow the 
subject until the end of pregnancy, with the subjects consent. This request and the subjects response 
will be documented in the subjects source document.  
10.[ADDRESS_884064] to hematologic toxicity. In addition to enhancing safety by 
[CONTACT_459704]:  CCB -CRISIS -02      Page 41 of 53 
PROTOCOL VERSION  5.0 DATE:  19 NOV 2020  
 
Clear Creek Bio, Inc.  
CONFIDENTIAL  selecting a relatively brief 5 -day exposure and a low brequinar dose, all subjects in the clinical trial 
will be under the care of highly q ualified medical personnel. Clinically significant out -of-range 
laboratory  results will be reported as adverse events.  
In addition to real time assessments by [CONTACT_314107], t he Covance  Medical Monitor will 
assess the available hematology data  on a periodic  basis to identify any pathologic trends or safety 
issues. Any apparent increase in the expected rate or severity of hematologic safety events will be 
discussed with the Princip al Investigators  and the Sponsor. In addition, the Data Monitorin g 
Committee (DMC) will assess available hematology data on a periodic  basis to independently assess 
any pathologic trends or safety issues.  If the rate or severity of hematologic toxicities appears to be 
above the expected rate or the severity appears wors e than that expected, the trial enrollment will be 
suspended and no further subjects will be treated while a comprehensive data review is conducted. 
Depending on the outcome of the safety review the study may be stopped , the design adjusted , or the 
study m ay continue as designed . Individual and Study stoppi[INVESTIGATOR_656332] 8.4. 
Safety laboratory results are to be initially assessed in real time by [CONTACT_656439]. Any study drug -related clinically significant out -of-range laboratories  or study 
drug-related adverse events will be followed as needed until resolution or stable.  
The in-clinic  assessments and telemedicine /phone call visits will specifically ask about possible 
hematologic toxicity including any evidence of  the list below. Subjects will be provided with a list of 
the following events in lay terms and will be instructed to call the research team if any of these events 
occur.  
 Ecchymosis /purpura/petechiae  
 Epi[INVESTIGATOR_3940]  
 Hemoptysis  
 Hematuria  
 Gingival bleeding  
 Prolonged bleeding time fr om needle sticks, abrasions or lacerations  
 Hematemesis  
 Rectal bleeding  
 Blood in stool  
 Any other unusual bleeding noted by [CONTACT_656451].  
10.9 Data Monitoring Committee  
A Data Monitoring Committee  (DM C) will be established to provide independent oversight to this 
trial. The primary responsibility of the DMC  will be to review the progress and conduct of the trial in 
order to maintain scientific rigor and to ensure the wellbeing of subjects participating in the trial. The 
specific responsibilities of the DMC  will be detailed in a separate DMC  charter. The DMC  will include 
at a minimum at least one statistician and two clinicians who will perform periodic data review to 
assess whether there are clinically significant differences between treatment arms that could affect 
participant safety.  All adverse events will be reviewed by [CONTACT_656430]. Following 
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 42 of 53 
PROTOCOL VERSION  5.0 DATE:  [ADDRESS_884065] 40 subjects complete the Day 8 visit. 
 
 
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 43 of 53 
PROTOCOL VERSION  5.0 DATE:  19 NOV 2020  
 
Clear Creek Bio, Inc.  
CONFIDENTIAL  11 STATISTICAL CONSIDERATIONS  
A separate, detailed statistical analysis plan (SAP) will be finalized prior to locking the database. All 
analyses will be descriptive in nature and presented by [CONTACT_19313].   
Summaries for quantitative variables will include the mean, median, quartiles, standa rd error, 
minimum, and maximum. For qualitative variables, the summaries will include the number and 
percentage of subjects for each outcome, and 95% confidence interval (CI) , when appropriate. Any 
statistical testing will be considered exploratory and des criptive. All computations will be performed 
using SAS (Version 9.4 or higher).  
Subject disposition, subject demographics and baseline characteristics will be summarized. Subject 
data listings will also be provided. The following sections will briefly sum marize of the planned 
statistical analyses and analysis sets for the primary and secondary endpoints.  
11.[ADDRESS_884066] dose (treatment -emergent) adverse events  will be tabulated by [CONTACT_167546], and by [CONTACT_78621]. All 
laboratory results  and study assessments  will be summarized using appropriate descriptive statistics.  
11.3 Efficacy Analyses  
Efficacy will primarily be assessed via viral load  changes . 
11.4 Sample Size Considerations  
Formal sample size calculations are not applicable for this proof -of-concept study. The s ample size of 
approximately  100 subjects planned to be entered in this trial  is expected to be adequate to provide 
safety and efficacy information to advise future study design . 
11.5 Randomization  
A randomization scheme will be provided by [CONTACT_656376]  + brequinar  or SOC +  placebo  in a 1: 1 
ratio.  
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 44 of 53 
PROTOCOL VERSION  5.0 DATE:  19 NOV 2020  
 
Clear Creek Bio, Inc.  
CONFIDENTIAL  11.6 Pooling of Study Centers  
Not applicable to this small, early phase study.  
11.7 Interim Analysis  
No interim analysis is planned for this trial.  
 
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 45 of 53 
PROTOCOL VERSION  5.0 DATE:  19 NOV 2020  
 
Clear Creek Bio, Inc.  
CONFIDENTIAL  12 INVESTIGATOR RESPONSIBILITIES  
12.1 Investigators Performance  
The Investigator will ensure that all those concerned with conducting the trial are : 
 provided with copi[INVESTIGATOR_656319];  
 trained regarding the conduct of the study and the training has been documented.  
The Investigator will sign the Investigators Statement and Agreement  found in Section 15.[ADDRESS_884067] that his/her identity will be protected and confidentiality will 
be maintained during all audits and inspections of the trial site and documentation. A unique number 
will be assigned to each subject at the start of the trial and this, with the subjects initials, will be used 
to identify the subject . In some cases, a further step may be taken to assign fake initials to the subject, 
per individual site requirements. The subjects  number will be the site number followed by [CONTACT_656458], on all trial correspondence and in the trial database. The Investigator will keep a list of 
identification codes or initials used for  each subject  along with the unique number assigned.  
All information provided to  the Investigator relevant to the investigational product ( IP), as well as 
information obtained during the course of the trial will be regarded as confidential. The Investigator 
and members of his/her research team agree not to disclose or publish such inf ormation in any way to 
any third -party without prior written permission from the Sponsor which will not be unreasonably 
withheld, except as required by [CONTACT_2371], or as permitted by [CONTACT_656417], 
Section  12.7. 
The Investigator will take all measures to ensure subjects  confidentiality will be maintained at all 
times.  
12.[ADDRESS_884068] 
access to the subjects ' medical or clinic records is necessary. The In vestigator will ensure that certain 
information is contained in the medical or clinic written or electronic records of the subject  and that 
the entries are signed and dated, as follows:  
 sufficient data to allow verification of the entry criteria in terms o f past and present medical and 
medication histories;  
 a note on the day the subject entered the trial describing the trial number, the IP being evaluated, 
the trial number assigned to that subject  and a statement that consent was obtained;  
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 46 of 53 
PROTOCOL VERSION  5.0 DATE:  19 NOV 2020  
 
Clear Creek Bio, Inc.  
CONFIDENTIAL   a note of each su bsequent trial visit including any concerns about AEs and their resolution;  
 notes of all concomitant medication taken by [CONTACT_19578] , including start and stop dates;  
 a note of when the subject  terminated from the trial, the reason for termination and the subject s 
general condition at termination;  
 a copy of the signed informed consent form should be kept in the medical records of each subject 
during the clinical phase of the study. A signed copy should also be filed in the investigator file.  
12.[ADDRESS_884069] the research staff with 
any queries. All queries and discrepancies relating to the data collection are to be resolved at the 
completion of the trial . Remote data capture is encouraged whenever possible.  
12.5 Case Report Forms, Investigators Site File and Record Retention  
The Sponsor m ay provide the CRFs in paper, electronic (eCRF), or other media. The forms will be 
reviewed against source documentation at each monitoring visit. All CRFs and supporting source 
documentation must be completed and available to the Sponsor in a timely manne r. Changes or 
corrections due to data clarification and resolutions will be tracked by [CONTACT_656418].  
Prior to review of the case report forms by [CONTACT_1034]s representative, they should be reviewed for 
completeness and accuracy by [CONTACT_29517] a member of the research team.  
The Investigator must maintain an Investigator Site File which include s, but is not limited to, the IB, 
the protocol plus any amendments, all correspondence with the IRB including the approval for the 
trial to proceed, Regulatory Authority approval/ notification (if applicable) including a sample of an 
approved informed consent, IP accountability, Source D ocuments, investigator and staff curricula 
vitae ( CVs, ) trial documentation, and all trial correspondence. The original signed informed consent 
forms and the final report will be kept in the Investigator Site File.  
The Investigator will archive all essenti al documents. The medical files of trial subjects shall be 
retained in accordance with national legislation and in accordance with the maximum period of time 
permitted by [CONTACT_5035][INVESTIGATOR_307], institution or private practice. The Investigator has a responsibility to retain 
essential documents for as long as is required by [CONTACT_656419]. It 
is the responsibility of the Sponsor to inform the Investigator as to when these documents no longer 
need to be retained. Investigators will b e asked to contact [CONTACT_656420]. Any transfer of ownership of the data or of documents will be docu mented in 
writing. The new owner will assume responsibility for data retention and archiving.  
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 47 of 53 
PROTOCOL VERSION  5.0 DATE:  [ADDRESS_884070] 30 days before its submission for any meeting or journal. In addition, if 
deemed necessary by [CONTACT_656421] t filing, the 
Investigator agrees to a further delay of 60 days before any presentation or publication is submitted. 
The Sponsor reserves the right to include the report of this trial in any regulatory documentation or 
submission or in any informational ma terials prepared for the medical profession.  
Authorship determination will be at the discretion of the Sponsor and will include evaluation of the 
following criteria: Investigator must participate in the review of and content of the protocol; review 
and com ment on the study results; participate in the writing, reviewing and commenting of the 
manuscript; and approve the final manuscript for submission.  
 
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 48 of 53 
PROTOCOL VERSION  5.0 DATE:  19 NOV 2020  
 
Clear Creek Bio, Inc.  
CONFIDENTIAL  13 SPONSOR RESPONSIBILITIES  
13.1 General  
The Sponsor agrees to adhere to the ICH Note for Guidance on GCP  (CPMP/ICH /135/95, Jan.97)  and 
US FDA Regulations. It is the Sponsor's responsibility to obtain appropriate regulatory approval to 
perform the trial (if applicable). The Sponsor should notify promptly all concerned investigator(s), 
IRB(s) and the Regulatory Authorit y of findings that could adversely affect the health of the patients/ 
subjects, impact on the conduct of the trial or alter the Regulatory Authoritys authorization  to continue 
the trial. If it is necessary to change or deviate from the protocol to elimina te an immediate hazard to 
the subjects the Sponsor will notify the relevant regulatory authority and relevant IRB of the new 
events, the measures taken and the plan for further action as soon as possible.  This will be by [CONTACT_656422] a written report.   
On completion of the trial, the Sponsor will inform the regulatory authority that the trial has ended.  If 
the study is terminated for any reason the Sponsor will provide a written statement to the relevant 
regulatory authorit y and the IRB with the reasons for termination of the trial. This will be conducted 
within [ADDRESS_884071] (EHR) or conduct remote monitoring visits at regular intervals 
during the trial for monitoring purposes and to assist the research staf f with any queries. CRFs and 
source documentation will be available for review during monitoring visits to the trial site. The 
function of this monitoring is to ensure compliance with the protocol, adherence to regulatory and 
GCP  obligations, proper mainte nance of records including IP accountability records, correct 
administration of IP including storage conditions and accurate reporting of AEs. On-site visits are not 
required for any monitoring visits for this study.    
Once the data from the case report fo rms have been entered onto the database, they will be reviewed , 
and the data verified against the subjects source data. Any discrepancies will be tracked by [CONTACT_656423].  
13.4  Audit  
The Sponsor has an obligation to au dit a proportion of studies.  A department other than the clinical 
department will undertake this obligation.  Therefore , the Sponsor, an independent auditor or a 
regulatory authority may audit the trial site and trial documentation. These audits may take p lace while 
the trial is being conducted or up to several years later.   
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 49 of 53 
PROTOCOL VERSION  5.0 DATE:  [ADDRESS_884072] s name, and subject s 
confidentiality will be maintained at all times.  
13.[ADDRESS_884073] of a separate agreement between the Investigator /Institution  and Sponsor.  
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 50 of 53 
PROTOCOL VERSION  5.0 DATE:  19 NOV 2020  
 
Clear Creek Bio, Inc.  
CONFIDENTIAL  14 REFERENCES   
1. Sykes DB, Kfoury YS, Mercier FE, et al. Inhibition of dihydroorotate dehydrogenase 
overcomes differentiation blockade in acute myeloid leukemia. Cell 2016; 167(1): 171 -186. 
2. Zhou  F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality 
of adult inpatients with COVID -19 in Wuhan, China: a retr ospective cohort study. Published 
online March 9, 2020. https://doi.org/10.1016/S0140 -6736(20)[ZIP_CODE] -3 
3. Phelan  A, Katz R, and Gostin L. The novel coronavirus originating in Wuhan, China. 
Challenge s for global health governance. Jama. 2020;323(8):709 -710.   
4. Handel A, Mille J, Yang G, Fung I. If containment is not possible, how do we minimize 
mortality for COVID -19 and other emerging disease outbreaks.  March 13, 2020. 
https://doi.org/10.1101/2020.03.13.20034892 . 
5. Brequinar Investigators Brochure  
6. Chen S, Ding S, Yin Y, Xu L, Li P, Peppelenbosch MP, et al. Suppression of pyrimidine 
biosynthesis by [CONTACT_656459]. Antiviral 
Res. 2019 Jul;167:35 44.  
7. Mei-Jiao G, Shi -Fang L, Yan -Yan C, Jun -Jun S, Yue -Feng S, Ting -Ting R, et al. Antiviral 
effects of selected IMPDH and DHODH inhibitors against foot and mouth disease virus. 
Biomed Pharmacother. [ADDRESS_884074]; 118:109305.  
8. Wang QY, Bushell S, Qing M, Xu HY, Bonavia A, Nunes S, et al. Inhibition of Dengue 
Virus through Suppression of Host Pyrimidine Biosynthesis. 2011 Jun 9;85(13):6548 56.  
9. Luthra P, Naidoo J, Pi[INVESTIGATOR_656320], De S, Khadka S, Anantpadma M, et al. Inh ibiting 
pyrimidine biosynthesis impairs Ebola virus replication through depletion of nucleoside 
pools and activation of innate immune responses. Antiviral Res. [ADDRESS_884075];158:288 302.  
10. Andersen PI, Krpi[INVESTIGATOR_28947] K, Ianevski A, Shtaida N, Jo E, Yang J, et al. Novel Antiviral Activities 
of Obatoclax, Emetine, Niclosamide, Brequinar, and Homoharringtonine. Viruses. [ADDRESS_884076] 
18;11(10).  
11. Xiong  R, Zhang L , Li S, Sun Y , Ding M , Wang, Y , et al. Novel and potent inhibitors 
targeting DHODH, a rate -limiting enzyme in de novo pyrimidine biosynthesis, are broad -
spectrum antiviral against RNA viruses including newly emerged coronavirus SARS -CoV -2. 
12. Sah R, Rodriguez -Morales AJ, Jha R, Chu DKW, Gu H, Peiris M, et al. Complete Genome 
Sequence of a 2019 Novel Coronavirus (SARS -CoV-2) Strain Isolated in Nepal. Microbiol 
Resour Announc. 2020 Mar 12;9(11).  
13. Liu Q, Gupta A, Okesli -Armlovich A, Qiao W, Fischer C, Smith M, et al. Enhancing the 
Antiviral Efficacy of RNA -Dependent RNA Polymerase Inhibition by [CONTACT_656460]. bioRxiv. 2020 Jan 1;2020.03.24.992230.  
14. Study DUP 785 -001 Clinical Study Report (on file with Clear Creek)  
15. Study DUP 785 -003 Clinical Study Report (on file with Clear Creek)  
16. Study DUP 785 -005 Clinical Study Report (on file with Clear  Creek)  
17. Study DUP 785 -022 Clinical Study Report (on file with Clear Creek)  
18. Study DUP 785 -031 Clinical Study Report (on file with Clear Creek)  
19. Study DUP 785 -034 Clinical Study Report (on file with Clear Creek)  
20. FDA Guidance COVID -19: Developi[INVESTIGATOR_656339] ( https://www.fda.gov/media/137926/download ) 
 
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 51 of 53 
PROTOCOL VERSION  5.0 DATE:  19 NOV 2020  
 
Clear Creek Bio, Inc.  
CONFIDENTIAL  15 APPENDICES  
15.1 Appendix  A:  CCB -CRISIS -[ADDRESS_884077] dose time  
Procedures  Screen  
(D -7 to 
 -1) 
IPVf D1 
IPV 
 D2, 3  
( 8 
hrs) 
TCf D4 
( 8 
hrs) 
TM D5,6,7 
( 8 hrs)  
TC D8 
( 8 hrs ) 
IPV+TM  D12 
( 1 
day)  
TM D15 
( 1 day)  
IPV+TM  D22 
(1 
day)  
TM Final 
Visit   
D29 
( 2 
days)  
IPV+TM  
Informed Consent (note Date and Time)  X          
AE/Concomitant Medications (dose, route, duration 
or ongoing)  X X X X X X X X X X 
Medical history (relevant within one year or 
ongoing)/ History of current illness (date of 
symptom onset or change in baseline co -morbidity 
thought to be due to COVID -19 infection)  X          
Demographics (subject reported height and weight, 
date of birth, gender, race, ethnicity)  X          
Check for Physical Exam abnormalities (subject 
self-reported)  X          
Pregnancy Test (WOCBP)  X 
(serum)          X 
(urine)  
Hematology/Chemistrya X X     X  X   
Vital Signsb X X  X  X X X X X 
Symptom Assessmentc X X  X  X X X X X 
SARS -CoV -[ADDRESS_884078] X          
Viral load  sample (pre -dose Day 1)e  X   X  X X X X X 
Hospi[INVESTIGATOR_656304]       X  X X X 
WHO Ordinal Scale Assessment   X    X  X X X 
Confirm Eligibility   X         
Randomize subject and dispense Study Medication   X         
Study drug administrationf  X X X X 
D5 
Only       
Drug Accountability       X     
aDo not repeat if within 48h of Day 1 visit.  Send to Covance Central Laboratory Services (CCLS) for analysis.  
bVital signs include heart rate, respi[INVESTIGATOR_697], body temperature, and S pO2. Subject will be provided with a thermometer and pulse oximeter 
with hea rt rate monitoring capability. Training will be provided during the first visit. Vital signs parameters will be observed and recorded 
by [CONTACT_656461] (IPV) (at the study site or home visit).  
cSymptom Assessment will capture  symptoms such as sore throat, cough, GI symptoms (vom iting, diarrhea), an osmia, dysgeusia, other 
(specify), etc.  Severity None, Mild, Moderate, or Severe will be collected. Symptom(s) onset date must be within [ADDRESS_884079] using an O mnigene collection system or similar. The 
site staff or home health nurse will train the subject and observe sample collection on Day 1. These samples are to be sent to CCLS for 
analysis.  The viral load sample may also be used to perform viral cultures (sample can be split  by [CONTACT_2237] , no additional sample 
required).  
eSubject will self -administer study drug once daily Days 1  [ADDRESS_884080] doses in a medication diary.  Note that any visits/visit activities 
may be conducted via telephone, telemedicine , or digital media other than serum pregnancy test and chemistry/hematology sample 
collection. These labs may be collected at the clinical site or another d esignated out -patient facility/laboratory or collected via home visit.  
Arrangements for shippi[INVESTIGATOR_656336].  
fIPV = in-person visit (subjects home or at clinical site ; may also include TM or TC if all study visit act ivities cannot be completed by [CONTACT_656454]-person personnel ); TC = Telephone Call with site  and subject ; TM = Telemedicine with site  and subject.  
 
  
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 52 of 53 
PROTOCOL VERSION  5.0 DATE:  19 NOV 2020  
 
Clear Creek Bio, Inc.  
CONFIDENTIAL  15.2 Appendix  B: Investigators Statement and Agreement  
STUDY NUMBER:    CCB -CRISIS -02 
The CRISIS2 Study: A phase 2, randomized , double blind, placebo -controlled, multi -center study 
assessing the safety and anti -coronavirus response of suppression of host nucleotide synthesis in out -
patient adults with SARS -CoV -2.  
INVESTIGATORS STATEMENT AND AGREEMENT  
I (the Investigator ) have read this protocol and hereby [CONTACT_656426].  It is further agreed that the details of this trial and all information provided to me by 
[CONTACT_656388], Inc.  (the Sponsor ) will be held in the strictest confidence and will not be revealed for 
any reason without written authorization from Clear Creek Bio, Inc. except to those who are to 
participate in the conduct of the trial.  
I agree that all data, the case report forms , and all materials provided for the conduct of the trial are 
the property of Clear Creek Bio, Inc.  unless specified otherwise in writing. It is understood that Clear 
Creek Bio, Inc. will utilize the information derived from this trial in various ways, such  as for 
submission to government regulatory agencies, required internal reports , and presentations without 
violating patient/ subject confidentiality in any way.  
I further agree that Clear Creek Bio, Inc.  or its representatives will be permitted access , in accordance 
with current Good Clinical Practice Guidelines , to all data generated by [CONTACT_656427].  
PRINCIPAL INVESTIGATOR  
[INVESTIGATOR_67476]: ____________________________________  
 
Signature: ________________________________ ____________  Date: __________________  
 
  
PROTOCOL NUMBER:  CCB -CRISIS -02      Page 53 of 53 
PROTOCOL VERSION  5.0 DATE:  19 NOV 2020  
 
Clear Creek Bio, Inc.  
CONFIDENTIAL  15.3 Appendix C: WHO Ordinal Scale  
 
Patient State  Descriptor  Score  
Uninfected  Uninfected; no viral RNA detected  0 
Ambulatory mild disease  Asymptomatic; viral RNA detected  1 
Symptomatic; independent  2 
Symptomatic; assistance needed  3 
Hospi[INVESTIGATOR_057]: moderate disease  Hospi[INVESTIGATOR_057]; no oxygen therapy*  4 
Hospi[INVESTIGATOR_057]; oxygen by [CONTACT_88543]  5 
Hospi[INVESTIGATOR_057]: severe disease  Hospi[INVESTIGATOR_057]; oxygen by [CONTACT_656428]  6 
Intubation and mechanical ventilation, pO 2/FiO 2 150 or SpO 2/FiO 2  200  7 
Mechanical ventilation pO 2/FiO 2 <150 (SpO 2/FiO 2 < 200) or vasopressors  8 
Mechanical ventilation pO 2/FiO 2 <150 and vasopressors, dialysis, or ECMO  9 
Dead  Dead  10 
 
WHO clinical progression scale  
 